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1. Inleiding 
 
 
Aanleiding 
 
 
 
NZa beleidsregels  
intramurale 
geneesmiddelen 
(2006-2011) 
 
 
 
 
 
 
 
NZa beleidsregel  
Prestaties en 
tarieven medisch 
specialistische zorg 
(vanaf 2012) 
 
In het kader van de NZa beleidsregels ‘Dure geneesmiddelen’ 
en ‘Weesgeneesmiddelen in academische ziekenhuizen’ 
beoordeelt het CVZ sinds 1 januari 2006 of dure 
geneesmiddelen tijdelijk kunnen worden opgenomen in deze 
beleidsregels en daarmee aanspraak maken op additionele 
financiering. Deze aanspraak is gekoppeld aan het 
verzamelen van gegevens in de klinische praktijk, het 
uitkomstenonderzoek. Op basis van het uitkomstenonderzoek 
vindt na 4 jaar een herbeoordeling plaats, waarin naast de 
therapeutische waarde en het kostenbeslag ook de 
kosteneffectiviteit wordt beoordeeld. Tot 2012 adviseerde  
het CVZ de NZa en VWS op basis van deze herbeoordeling 
over continuering van additionele financiering middels de NZa 
beleidsregels.  
 
Sinds 1 januari 2012 zijn voornoemde beleidsregels 
opgegaan in de NZa beleidsregel ‘Prestaties en tarieven 
medisch specialistische zorg’ . De zogenaamde t=0 en t=4 
beoordelingen voor dure geneesmiddelen vinden nu plaats in 
het kader van deze beleidsregel, waarbij het CVZ een 
uitspraak doet over de toelating van dure geneesmiddelen tot 
het basispakket.  
 
Uitkomsten-
onderzoek 
 
 
 
 
 
 
 
 
Pragmatisch 
Het CVZ beoordeelt dure geneesmiddelen sinds 2006 op 
basis van uitkomstenonderzoek, i.e. het verzamelen van 
gegevens in de klinische praktijk op basis waarvan een 
uitspraak over de kosteneffectiviteit en doeltreffende 
toepassing van dure geneesmiddelen kan worden gedaan.  
In 2006 heeft het CVZ een beoordelingsprocedure voor 
intramurale geneesmiddelen1 en een beoordelingskader 
doelmatigheid2 opgesteld. Daarnaast heeft het CVZ een 
werkgroep ‘Beoordeling doelmatigheid intramurale 
geneesmiddelen’ in het leven geroepen. Deze werkgroep 
heeft in de ‘Leidraad voor uitkomstenonderzoek’3 vastgelegd 
wat we verstaan onder uitkomstenonderzoek; welke gegevens 
we moeten verzamelen; welke bronnen hiervoor gebruikt 
kunnen worden; wie betrokken moeten zijn; wat de gewenste 
studieopzet is en wat de gewenste infrastructuur is. De 
aanbevelingen van de werkgroep zijn samengevat in een 
stroomschema waarin de pragmatische opzet van het 
uitkomstenonderzoek staat weergegeven alsmede het 
bijbehorende stappenplan. 
                                                    
1 Procedure beoordeling intramurale geneesmiddelen 
(http://www.cvz.nl/binaries/content/documents/cvzinternet/nl/documenten/rapporten/2006/rpt0604+intram
urale+geneesmiddelen.pdf) 
2 Beoordelingskader doelmatigheid intramurale geneesmiddelen 
(http://www.cvz.nl/binaries/content/documents/cvzinternet/nl/documenten/rubriek+zorgpakket/cfh/beoorde
ling+doelmatigheid+intramurale+geneesmiddelen.pdf) 
3 Leidraad voor uitkomstenonderzoek 
(http://www.cvz.nl/binaries/content/documents/cvzinternet/nl/documenten/rapporten/2008/rpt0812+leidraa
d+uitkomstenonderzoek.pdf) 
De leidraad vormt een verbijzondering van de ‘Richtlijnen 
voor farmaco-economisch onderzoek’4 en bevat praktische 
informatie voor het verrichten van uitkomstenonderzoek.  
 
Opdracht aan iMTA Het CVZ heeft het iMTA opdracht gegeven om te onderzoeken  
hoe aan de beoordeling van de doelmatigheid van dure 
geneesmiddelen op basis van praktijkgegevens nader 
invulling kon worden gegeven. Specifiek werden de volgende 
vragen gesteld: 
1) Een aantal methodologische vragen met betrekking tot 
uitkomstenonderzoek op basis van een internationale 
literatuurstudie te adresseren; het resultaat is 
meegenomen in de eerste bespreking van de Werkgroep 
‘Beoordeling doelmatigheid intramurale geneesmiddelen’ 
in 2007.  
2) Deze methodologische vragen, vanuit de concept-
leidraad, te toetsen aan praktijkervaringen die gebaseerd 
zijn op een tweetal pilotstudies. Op basis van de 
resultaten van deze pilotstudies wordt de waarde van het 
uitkomstenonderzoek ingeschat en doet het iMTA een 
aantal methodologische aanbevelingen voor het doen van 
uitkomstenonderzoek.  
 
In dit rapport worden de bortezomib en oxaliplatin pilot 
studies besproken alsmede de methodologische 
aanbevelingen die hieruit naar voren zijn gekomen. De 
volledige achtergrondstudies zijn opgenomen als bijlagen bij 
dit rapport.  
 
Begeleidings 
commissie 
 
De voortgang van de pilotstudies is regelmatig door de 
onderzoekers besproken met de begeleidingscommissie 
bestaande uit Prof. Dr. P.C. Huygens (VUMC), Prof. Dr. A. 
Steenhoek (ErasmusMc), Dr. G.O. Delwel (CVZ) en Dr. ir. W.G. 
Goettsch (CVZ). 
 
 
 
2. Pilotstudies 
 
Selectiecriteria 
voor de pilotstudies 
 
Voor het uitvoeren van onderzoek in de praktijk moet onder 
andere rekening gehouden worden met de volgende factoren: 
- De patiëntenpopulatie waarvoor het geneesmiddel is 
geregistreerd 
- Het type geneesmiddel 
- De grootte van de patiëntengroep 
- De effectiviteitsparameters (levensduur; verbetering van 
ziektespecifieke klinische parameters) 
- De behandeling van patiënten binnen of buiten 
studieverband 
- De aanwezigheid van gegevens uit een gerandomiseerd 
                                                                                                                                                           
4 Richtlijnen voor farmacoeconomisch onderzoek, geactualiseerde versie 
(http://www.cvz.nl/binaries/live/cvzinternet/hst_content/nl/documenten/rubriek+zorgpakket/cfh/richtlijnen+f
armaco-economisch+onderzoek.pdf) 
klinisch onderzoek of een patiëntenregister. 
 
Bij de keuze van de pilotstudies is met deze factoren rekening 
gehouden, en wel zodanig dat de pilotstudies veel van elkaar 
verschilden op deze punten, om een zo breed mogelijk palet 
aan praktijkervaringen te toetsen. In overleg met het iMTA is 
gekozen voor de geneesmiddelen bortezomib voor de 
behandeling van recidiverend en refractair multipel myeloom 
en oxaliplatin voor de behandeling van stadium III en 
gemetastaseerd coloncarcinoom.  
 
Bortezomib pilot 
 
Kenmerken van de bortezomib pilot zijn: 
- Indicatie: recidiverend en refractair multiple myeloom 
- Kleinere patiënten aantallen 
- Behandeling grotendeels in onderzoeksverband  
- Veel dynamiek in klinisch handelen 
- Registratie binnen HOVON studies 
- Klinische fase III studies: APEX en HOVON 
 
Oxaliplatin pilot  
 
Kenmerken van de oxaliplatin pilot zijn: 
- Indicatie: stadium III en gemetastaseerd coloncarcinoom 
- Grote patiënten aantallen  
- Behandeling niet in onderzoeksverband 
- Weinig dynamiek in klinisch handelen  
- Registratie in integrale kankerregistratie 
- Klinische fase III studies: MOSAIC en CAIRO  
 
Onderzoeksvragen  
 
 
Bortezomib 
 
 
Studieopzet 
 
 
Het onderzoeksvoorstel van de bortezomib pilot richtte zich 
op de volgende vraag:  
Hoe wordt bortezomib in de praktijk gebruikt bij de tweede- 
en derdelijns behandeling van patiënten met een multipel 
myeloom, wat is het resultaat ervan en welke kosten brengt 
het gebruik van bortezomib met zich mee? 
Voor de bortezomib studie werden de patiënten gerekruteerd 
uit reeds afgesloten studies HOVON 24 en HOVON 50 en uit 
de registraties van integrale kankercentra. Voor deze studie 
worden verschillende vergelijkingsarmen worden 
geconstrueerd 1) de fase III klinische studie APEX; 2) de 
tweede- en/of derde lijnsbehandeling van de HOVON 24 
patiënten; 3) de HOVON 50 studie.  
 
Oxaliplatin  
 
 
Studieopzet 
 
 
 
Het onderzoeksvoorstel van de oxaliplatin pilot richtte zich op 
de volgende vraag:  
Hoe wordt oxaliplatin in de Nederlandse praktijk gebruikt bij 
de behandeling van stadium III en IV colorectaal carcinoom en 
wat is het resultaat ervan. Welke kosten en baten brengt het 
gebruik van oxaliplatin met zich mee, vergeleken met de 
behandeling met 5-FU/LV? 
Hiertoe werden twee afzonderlijke steekproeven verricht:  
1. Een steekproef onder patiënten met een stadium III 
colorectaal carcinoom om de wijze van het gebruik van 
oxaliplatin en de uitkomsten in de praktijk te 
onderzoeken.  
2. Een steekproef onder patiënten met een stadium IV 
colorectaal carcinoom om de wijze van het gebruik van 
oxaliplatin en de uitkomsten in de praktijk te 
onderzoeken.  
De steekproeven werden gebaseerd  op de databases van een 
aantal Integrale Kanker Centra (IKC) en IKA. Daar er in de IKC 
databank slecht basale informatie beschikbaar is zullen 
vervolgens de statussen van deze patiënten worden 
onderzocht om alle detailinformatie te verzamelen. 
 
Gegevens 
 
In beide pilotstudies werden de volgende gegevens verzameld 
in een geplande studieduur van 2,5 jaar.  
1) Patiënt en behandelkenmerken 
2) Kostengegevens - alleen de directe medische kosten 
het is niet goed mogelijk is om retrospectief 
gegevens over indirecte kosten van de patiënten te 
verkrijgen van wie de effectdata wordt gebruikt.  
3) Uitkomstmaten: respons percentage, tijd tot respons, 
tijd tot progressie, progressie vrije overleving, 
overleving, bijwerkingen, en eventueel kwaliteit van 
leven, de wijze van behandeling met bortezomib in 
de praktijk, de kwaliteit van de behandeling 
(gedefinieerd als voorschrijven volgens indicatie 
en/of specificatie gemaakte keuzen), levensjaren en 
progressie-vrije levensjaren. 
 
De kosteneffectiviteitsanalyses werden uitgedrukt in kosten 
per gewonnen levensjaar, kosten per progressievrij levensjaar 
en (indien mogelijk) kosten per voor kwaliteit gecorrigeerd 
gewonnen levensjaar (QALY’s). Daarnaast werden separate 
kosten- en effectiviteitsanalyses uitgevoerd.  
 
Knelpunten 
 
Bij het starten van het onderzoek werden de volgende 
knelpunten gedefinieerd:  
- De kwaliteit van leven gegevens komen uit de literatuur 
en zijn gebaseerd op patiënten die behandeld zijn in 
studieverband. 
- Het verschil tussen de patiëntengroepen in de 
vergelijkingsarmen. Het is waarschijnlijk dat het feit of 
patiënten wel of niet behandeld zijn met bortezomib of 
oxaliplatin niet berust op toeval maar afhangt van 
factoren zoals het ziekenhuis waar zij zijn behandeld, van 
de algemene toestand van de patiënt, eventuele co-
morbiditeit en het inzicht van de behandelaar.  
 
Praktische keuzen  
 
 
 
 
Geen prospectieve 
studieopzet  
 
 
 
Bij het opzetten van de pilotstudies zijn een aantal praktische 
keuzen gemaakt, ten dele ingegeven door de relatief korte 
onderzoeksperiode (2007–medio 2010, waarbij opgemerkt 
wordt dat het eerste jaar de logistieke aanlooptijd betrof, de 
gegevensverzameling liep vanaf 2008). Hierdoor zijn niet alle 
uitgangspunten zoals verwoord in de Leidraad getoetst in de 
praktijk. Zo hadden beide pilots een retrospectieve 
studieopzet i.t.t. de prospectieve opzet zoals aanbevolen in 
de Leidraad. De reden was dat gebruik werd gemaakt van de 
reeds beschikbare gegevens uit de HOVON trials en de 
  
 
 
Perspectief  
 
Kwaliteit van leven 
 
kankeregistratie, waarbij de gegevensverzameling vanuit deze 
retrospectieve databases overigens wel prospectief verliep. 
Voor beide pilots is geen t=0 doelmatigheidsindicatie 
beschikbaar, aangezien geen t=0 model aanwezig was. 
Uiteindelijk is een model ontwikkeld voor de oxaliplatin 
studie, op basis van dit model en de bevindingen uit de 
kankerregistratie is een uitspraak over de kosteneffectiviteit 
gedaan op t=n.  
Het voorstel uitkomstenonderzoek is niet helemaal volgens 
het CVZ beoordelingskader opgezet, zo wordt geen 
maatschappelijk perspectief gehanteerd; en wordt de 
effectiviteitsmaat utiliteiten alleen in de oxaliplatin studie 
meegenomen. De ‘T=4 beoordeling’: doeltreffende toepassing 
en dynamiek klinisch handelen wordt in beide studies 
uitgevoerd, een uitspraak over de  
kosteneffectiviteit is uitsluitend in de oxaliplatin studie 
gedaan. 
 
Resultaten De resultaten vanuit de pilotstudies geven aan het mogelijk is 
op basis van uitkomstenonderzoek een uitspraak te doen over 
de doeltreffende toepassing en de kosteneffectiviteit van dure 
geneesmiddelen.  
 
 
3. Methodologie 
Methodologische 
aanbevelingen  
De belangrijkste methodologische conclusies uit de twee 
pilotstudies zijn samengevat in de rapportage 
‘Methodologische vraagstukken’. In deze rapportage staan 
aanbevelingen voor het doen van uitkomstenonderzoek, 
daarnaast worden kritische succesfactoren en knelpunten 
benoemd.  
 
 
 
 
Kritische 
succesfactoren 
 
 
 
 
 
 
 
 
 
 
 
Knelpunten/Risicof
actoren 
 
 
 
 
Volgens het iMTA waren de meest kritische succesfactoren 
voor het uitvoeren van goed uitkomstenonderzoek: 
- beschikbaarheid van een goed onderzoeksdesign op 
t=0 (start van de voorwaardelijke financiering en het 
uitkomstenonderzoek); 
-  duidelijk uitgewerkte onderzoeksvraag; 
- onderzoek moet gericht zijn op het reduceren van 
onzekerheid over de uitkomsten (effectiviteit en 
kosteneffectiviteit) 
- samenwerking tussen partijen zoals de behandelaren, 
de regulatoire en vergoedings/ HTA organisaties; 
- flexibiliteit en mogelijkheden om het 
uitkomstenonderzoek ‘tailor-made’ op te zetten. 
 
Het iMTA identificeerde ook een aantal knelpunten : 
- Uitkomstenonderzoek kost veel tijd- en financiële 
investering; 
- Observationele studies hebben veel last van ‘bias’ en 
‘confounding’; 
- Bestaande databronnen zijn vaak onvoldoende 
compleet voor uitkomstenonderzoek waardoor 
additionele dataverzameling noodzakelijk is. Zo 
  
 
 
 
 
 
 
 
 
 
Aanbevelingen 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
bevatten patiëntenstatussen vaak onvoldoende 
informatie over prognostische factoren en 
uitkomstmaten. 
- Dynamiek in klinisch handelen kan de 
vergelijkbaarheid met klinische studies verstoren 
waardoor de schatting van een 
kosteneffectiviteitsratio moeilijk wordt. 
 
Het iMTA heeft ook een aantal aanbevelingen geformuleerd: 
- Het onderzoeksdesign van het uitkomstenonderzoek 
moet altijd afhankelijk zijn van het type ziekte en 
geneesmiddel en de verwachte dynamiek in klinisch 
handelen; 
- De duur van het uitkomstenonderzoek is ook 
afhankelijk van de te behandelen ziekte en het 
geneesmiddel; 
- Ziektespecifieke patiëntenregistraties zijn van belang 
om voldoende vergelijkbaar behandelde patiënten te 
verzamelen en op een uniforme manier gegevens te 
kunnen verzamelen; 
- Data uit de dagelijkse praktijk zijn essentieel om te 
achterhalen wie op welke manier deze 
geneesmiddelen ontvangen. Daarvoor moet een 
minimale dataset in de dagelijkse praktijk worden 
verzameld.  
- Het is van belang dat het uitkomstenonderzoek 
zodanig is opgesteld dat veranderingen in klinisch 
handelen kunnen worden meegenomen; 
- Indien nodig, dienen schattingen van de 
kosteneffectiviteit te worden bepaald op basis van 
een synthese van gegevens uit de dagelijkse praktijk 
en gegevens uit mogelijke andere relevante bronnen. 
 
 
4. Vervolgstappen 
 
Per 1-1-2012 
pakketbeoordeling 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Zoals hierboven vermeld zijn per 1 januari 2012 de 
Beleidsregels Dure en Weesgeneesmiddelen komen ter 
vervallen. Vanaf 1 januari 2012 beoordeelt het CVZ 
specialistische geneesmiddelen in het kader van het 
verzekerde basispakket en adviseert hierbij de minister van 
VWS en niet meer de NZa. Details van de procedure van deze 
beoordeling worden beschreven in de ‘Procedure 
pakketbeheer specialistische geneesmiddelen’. Dit betekent 
dat specialistische geneesmiddelen met een therapeutische 
(meer)waarde en die voldoen aan het kostencriterium 
(kostenbeslag meer dan €2,5 miljoen per jaar) op het moment 
van de zogenaamde t=0 beoordeling, in aanmerking kunnen 
komen voor voorwaardelijke financiering in het kader van de 
toelating tot het basispakket van deze dure specialistische 
geneesmiddelen.  De voorwaarde voor deze financiering blijft 
analoog aan de addditionele bekostiging middels de 
opgeheven NZa Beleidsregels dure en weesgeneesmiddelen, 
dat additionele financiering ten behoeve van de toelating tot 
het basispakket gekoppeld is aan het verrichten van 
  
 
 
 
 
 
 
 
Aanpassing 
Leidraad 
Uitkomsten en 
Farmaco-
economische 
richtlijnen 
 
 
uitkomstenonderzoek. Kortom: ook voor dure specialistische  
middelen moet (uitkomsten)onderzoek  worden opgezet om  
gegevens over de kosteneffectiviteit in de dagelijkse praktijk 
te verzamelen.  
 
Het CVZ is van oordeel dat de resultaten van het iMTA 
onderzoek kunnen worden gebruikt om de ‘Leidraad voor 
Uitkomstenonderzoek’ en de ‘Farmaco-economische 
richtlijnen’ aan te passen in het kader van de 
pakketbeoordelingen van deze dure specialistische 
geneesmiddelen. Daarbij stelt het CVZ voor om als onderdeel 
van een grondige herziening van deze richtlijnen ook de 
ervaringen met het uitkomstenonderzoek tussen 2006 en 
2012 als onderdeel van de beoordelingen in het kader van de 
Beleidsregel Dure en weesgeneesmiddelen mee te nemen. 
Tenslotte zal het CVZ ook de resultaten van de verschillende 
onderzoeksprojecten die in het kader van het ZonMW 
programma HTA methodologie meenemen in deze 
herziening.  
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Summary 
Introduction 
Multiple myeloma is a progressive hematologic disease that remains incurable. In 2006, 
bortezomib (Velcade®), a novel first-in-class proteasome inhibitor, was admitted, based on 
APEX (Assessment of Proteasome Inhibition for Extending Remissions) trial results, for 
treatment of relapsed or refractory multiple myeloma under the Dutch policy regulations for 
expensive pharmaceuticals. The APEX clinical trial compared bortezomib to 
dexamethasone and proved bortezomib to be more effective, i.e., increased overall 
survival, response rates and response duration. Hospitals receive additional funding for 
drugs enlisted on the expensive drug list. However, performing outcomes research (i.e. 
evidence development on appropriate drug use and real-world cost effectiveness) is 
required in order to continue financial compensation after three years. Outcomes research 
in this particular context is new in Dutch policy making and therefore experience in the 
application of outcomes research is lacking. This report investigates how bortezomib is 
used in daily practice and explores real-world treatment effects and costs in relapsed or 
refractory multiple myeloma in Dutch daily practice. This pilot outcomes research study 
was conducted as part of a comprehensive study of methodological issues related to 
outcomes research. The pilot study will contribute valuable information on these potential 
methodological issues. To our knowledge, this is the first study assessing both treatment 
effects and costs of bortezomib in relapsed multiple myeloma using patient level data from 
Dutch daily practice.  
 
Method 
The patient population was selected from patients who relapsed from treatment protocol of 
a clinical trial (HOVON50) for upfront therapy that was performed in daily practice. We 
retrospectively collected detailed case reports from hospital medical records available from 
the time of first relapsed or refractory disease until end of follow-up. We researched how 
bortezomib was used in daily clinical practice and investigated treatment regimes and 
dose modifications. To assess clinical effectiveness, the validity of outcome measures was 
explored and different adjustment methods, such as average covariate adjustment, 
regression adjustment by propensity scores and matched analysis, were compared. 
Treatment costs were computed from a hospital perspective and costs for individual 
patients were determined by applying unit costs to individual resource use. 
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Results 
A total of 139 patients relapsing from HOVON50 protocol were included. The majority of 
multiple myeloma patients follow a relapsing disease course requiring subsequent 
treatment lines. All 139 patients were grouped according to the line in which bortezomib 
treatment was first administered, resulting in four groups: patients who never received 
bortezomib (n=67) and patients who received bortezomib for the first time in second 
(n=25), third (n=35) and fourth line or later (n=12).  
 Many patients were treated in more than one hospital, thereby requiring over 1700 
hours for data collection in 42 different hospitals. The real-world data exposed large 
variation in treatment regimes. Compared to the APEX trial, daily practice patients 
received on average lower dosages and fewer treatment cycles. The availability of 
prognostic factors was limited since such information was often not reported in medical 
records and it was not clear whether physicians used universal response criteria. 
The covariate and propensity score adjustment methods were deemed feasible. 
The confounder for assessing the effectiveness of bortezomib in relapsed disease was 
found to be thalidomide treatment of the HOVON50 protocol in the first treatment line. It 
was difficult to determine a valid outcome measure. After exploring the use of various 
outcomes, the use of overall survival (OS) from start of first relapse or refractory disease to 
initial treatment and time to next treatment line or time to progression were concluded to 
be inappropriate outcomes for demonstrating the effectiveness of bortezomib treatment 
compared to patients not receiving bortezomib. The former outcome was biased by the 
effect of previous thalidomide use, and the latter two outcomes revealed contradictory 
results. Due to the bias of previous treatment received in HOVON50, the preferred method 
is to report outcomes for each treatment group stratified by HOVON50 treatment arm (i.e., 
thalidomide versus vincristine). However, this was challenged by the small number of 
observations in each of the eight groups, and instead unadjusted and adjusted OS from 
diagnosis were estimated for all patient groups without stratification. Furthermore, when 
applying methods for adjustment of differences in baseline prognosis, the adjusted OS 
curves revealed minor differences compared to the unadjusted curves for all groups. 
Consequently, only the unadjusted estimates for each of the four treatment groups were 
retained for the final cost-effectiveness estimates. 
The mean and median unadjusted OS from start of bortezomib treatment 
regardless of treatment line were 19.4 and 17.2 months, respectively. The mean 
unadjusted OS from diagnosis for patients treated in second line was 52.2 while the 
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median has not yet been reached. The mean and median unadjusted OS from diagnosis 
for patients treated in third line was 55.5 and 59.3 months compared to 50.1 and 48.5 
months for patients treated in fourth line or later, respectively. Total mean costs from the 
start of first relapse or refractory disease to initial treatment for patients treated with 
bortezomib amounted to €81,626 but varied widely between patients (range €17,793 to 
€229,783), while active pharmaceutical treatment was responsible for 44% of the cost.  
The mean and median unadjusted OS from diagnosis for patients never treated 
with bortezomib, which included both patients eligible and ineligible for bortezomib, was 
45.9 and 56 months, respectively. Total mean costs from the start of first relapse or 
refractory disease to initial treatment for patients never treated with bortezomib were 
€52,760 (range €748 to €179,571), while active pharmaceutical treatment was responsible 
for 30% of the cost. 
 
Discussion 
Outcomes research provides valuable information on the utilisation of bortezomib in daily 
practice. In the last few years, there have been many advances in the treatment of multiple 
myeloma, reflected by the heterogeneity in our data. As a result, our retrospectively 
obtained real-world data challenged the assessment of the incremental cost-effectiveness 
of bortezomib treatment in the indication of relapsed disease in daily practice. The 
dynamics in daily practice, such as changes to the treatment guidelines and practice 
variation, incomparability of pilot patients, restrictive use of outcome measures and small 
patient numbers, severely limited the ability to compare patients treated and never treated 
with bortezomib. Consequently, it was impossible to estimate a valid and precise 
incremental estimate for the comparison between the two different patient groups. 
However, our real-world data provided valuable information on the appropriate use of 
bortezomib in daily practice. We revealed the diffusion of bortezomib, application of 
treatment regimes, dose modifications and treatment related toxicities. Furthermore, it was 
possible to estimate a cost-effectiveness measure (i.e. costs per month of survival) for 
bortezomib use in younger patients in daily practice for relapsed disease.  
Both the bortezomib and oxaliplatin pilot study provide valuable information 
regarding methodological challenges of outcomes research as required by Dutch policy 
regulations for expensive hospital drugs. The pilot studies can be seen as empirical 
addendum to the Guidance for Outcomes Research (i.e. how to develop evidence on 
appropriate use and cost effectiveness in daily practice), more specific information on this 
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is provided in a separate report. The bortezomib pilot study underscores the need for 
refinement of practice and evidence-based professional guidelines for relapsed multiple 
myeloma. Furthermore, prospective observational data using a national and/or 
international registry could facilitate closer follow-up of patients, ensure uniform response 
criteria, enable the selection of comparable groups of similarly treated patients and thereby 
contribute to enhanced value of outcomes research. 
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Samenvatting 
Introductie 
Multipel myeloom is een hematologische ziekte die vooralsnog niet te genezen is. In 2006 
werd de innovatieve proteasoomremmer bortezomib (Velcade®), op basis van de 
resultaten van de APEX studie (Assessment of Proteasome Inhibition for Extending 
Remissions), opgenomen op de beleidsregel dure geneesmiddelen voor de indicatie 
recidief of refractair multipel myeloom. De APEX studie heeft aangetoond dat een 
behandeling met bortezomib effectiever is dan een behandeling met dexamethasone. 
Bortezomib verlengt de algemene overleving, verbetert de respons en verlengt de respons 
tijd. Ziekenhuizen ontvangen additionele vergoeding wanneer zij een geneesmiddel 
gebruiken dat op de beleidsregel is opgenomen. Tevens verplicht opname op de 
beleidsregel tot het uitvoeren van uitkomstenonderzoek. Er is geen ervaring met 
uitkomstenonderzoek in deze context omdat dit nieuw is in het Nederlandse beleid. Dit 
rapport analyseert de effecten en kosten van een behandeling met bortezomib voor 
patiënten met een recidief of refractair multipel myeloom en beschrijft hoe bortezomib in 
Nederland wordt toegepast in de dagelijkse praktijk. Deze pilot studie werd uitgevoerd als 
onderdeel van het onderzoek naar de methodologische aspecten bij het uitvoeren van 
uitkomstenonderzoek. 
 
Methode 
De populatie bestond uit patiënten met een recidief of refractair multipel myeloom, 
gerekruteerd uit een voltooide klinische studie (HOVON50). Voor deze patiënten werden 
retrospectief gedetailleerde gegevens verzameld uit medische dossiers vanaf de eerste 
progressie van de ziekte. De dagelijkse praktijk werd in kaart gebracht en gegevens over 
behandelregimes, doseerschema’s en redenen voor aanpassingen van doseringen 
werden geanalyseerd. Daarnaast werd de validiteit van diverse uitkomstmaten onderzocht 
en werden verschillende correctie methoden vergeleken, waaronder het corrigeren voor 
covariaten, ‘propensity’ score en ‘matching’ methode. De kosten van behandeling werden 
berekend vanuit het ziekenhuis perspectief. Zorggebruik werd gewaardeerd per individuele 
patiënt door middel van microcosting schattingen.  
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Resultaten 
In totaal werden 139 patiënten geïncludeerd in de studie. De meeste multipel myeloom 
patiënten vertonen een terugkerend ziektebeloop waarvoor verschillende elkaar 
opeenvolgende behandelingen worden gegeven. Alle 139 patiënten werden ingedeeld in 
de behandellijn waarin zij bortezomib kregen. Dit resulteerde in vier patiënt groepen: 
patiënten die niet werden behandeld met bortezomib (n=67), patiënten die voor het eerst 
bortezomib kregen in de tweede behandellijn (n=25), derde behandellijn (n=35), en in de 
vierde of latere behandellijn (n=12). 
 Veel patiënten bezochten meerdere ziekenhuizen waardoor het noodzakelijk was 
om data te verzamelen in 42 verschillende ziekenhuizen. Dit vereiste meer dan 1700 uur 
data verzameling. De gegevens toonden aan dat er veel behandelvariatie is in de 
dagelijkse praktijk. Pilot patiënten ontvingen gemiddeld lagere doseringen bortezomib en 
minder behandelcycli vergeleken met patiënten uit de APEX studie. De beschikbaarheid 
van prognostische gegevens was beperkt en bovendien was het niet duidelijk of artsen in 
de dagelijkse praktijk universele uitkomstmaten gebruikten.  
De co-variate en propensity score correctie methode werden uitvoerbaar 
bevonden. De grootste confounder was de inductiebehandeling in de HOVON50 studie, 
waardoor het kiezen van een valide uitkomstmaat werd bemoeilijkt. Nadat diverse 
uitkomstmaten werden onderzocht, werd geconcludeerd dat overleving vanaf start van 
behandeling, tijd tot volgende behandeling en tijd tot progressie geen geschikte 
uitkomstmaten waren. De eerste uitkomstmaat werd beïnvloed door thalidomide 
behandeling in de eerste lijn en beide andere uitkomstmaten gaven tegenstrijdige 
resultaten. Stratificeren naar HOVON50 behandeling (wel of geen thalidomide) zou de 
beste correctie methode zijn, dit werd echter bemoeilijkt door kleine patiënt aantallen per 
groep. Hierdoor werd het noodzakelijk om overleving vanaf diagnose als uitkomstmaat te 
gebruiken. Het corrigeren voor verschillen in baseline prognose had weinig invloed op de 
overlevingscurven. Voor het schatten van de kosteneffectiviteit werd gebruik gemaakt van 
de ongecorrigeerde overleving vanaf de eerste progressie/ recidief van de ziekte. 
De gemiddelde en mediane ongecorrigeerde overlevingsduur vanaf de start van de 
bortezomib behandeling was 19,4 en 17,2 maanden. De gemiddelde ongecorrigeerde 
overlevingsduur vanaf diagnose was voor patiënten die in de tweede lijn werden 
behandeld 52,2 maanden, de mediaan is nog niet bereikt. Voor patiënten die in de derde 
lijn bortezomib kregen was de gemiddelde en mediane ongecorrigeerde overlevingsduur 
55,5 en 59,3 maanden en voor patiënten die in de vierde lijn of later bortezomib kregen 
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50,1 en 48,5 maanden. Voor deze patiënten bedroegen de totale gemiddelde kosten vanaf 
de eerste progressie van de ziekte €81.626, met een grote variatie tussen patiënten 
(€17.793 tot €229.783), 44% van deze kosten zijn gerelateerd aan actieve behandeling. 
Patiënten die niet met bortezomib werden behandeld, ongeacht de reden hiervoor, 
hadden achtereenvolgens een 45,9 en 56,0 maanden gemiddelde en mediane 
ongecorrigeerde overlevingsduur vanaf diagnose. Voor deze patiënten waren de 
gemiddelde kosten vanaf de eerste progressie van de ziekte €52.760 (€748 tot €179.571), 
30% van deze kosten zijn gerelateerd aan actieve behandeling. 
 
Discussie 
Uitkomstenonderzoek levert waardevolle informatie op over het gebruik van bortezomib in 
de dagelijkse praktijk. In de afgelopen jaren zijn er veel veranderingen geweest in de 
behandeling van het multipel myeloom, wat zich uit in de heterogeniteit in onze gegevens. 
Er werd geconstateerd dat het retrospectief verzamelen van gegevens een uitdaging 
vormde voor het bepalen van een incrementele kosteneffectiviteitratio van een 
behandeling met bortezomib voor patiënten met een refractair of recidief multipel 
myeloom. De dynamiek van de dagelijkse praktijk, zoals veranderende professionele 
richtlijnen, behandelvariatie, onvergelijkbaarheid van pilot patiënten, beperkte keuze in 
geschikte uitkomstmaten en het kleine aantal geïncludeerde patiënten, beperkte de 
mogelijkheden om patiënten die met bortezomib werden behandeld te vergelijken met 
patiënten die niet met bortezomib werden behandeld. Hierdoor was het onmogelijk om een 
valide en nauwkeurige schatting te maken van verschillen tussen beide groepen. 
Desalniettemin bieden de pilot gegevens waardevolle informatie over de doeltreffende 
toepassing en het gebruik van bortezomib in de dagelijkse praktijk. Het was mogelijk de 
diffusie van bortezomib aan te tonen, behandel regimes te onderzoeken, dosis 
aanpassingen en behandelingsgerelateerde toxiciteit zichtbaar te maken. Tevens kon een 
schatting worden gemaakt van de kosteneffectiviteit van bortezomib in de dagelijkse 
praktijk (kosten per maand overleving) voor de behandeling van refractair of recidief 
multipel myeloom bij jongere patiënten. 
Zowel de bortezomib als de oxaliplatin pilot studie bieden waardevolle informatie 
met betrekking tot methodologische aspecten bij het uitvoeren van uitkomstenonderzoek 
zoals vereist door de Beleidsregel dure geneesmiddelen. Beide studies zijn te zien als een 
empirische aanvulling op de Leidraad voor Uitkomstenonderzoek, dat wil zeggen hoe 
kunnen gegevens verzameld en gebruikt worden om de doeltreffende toepassing en de 
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kosteneffectiviteit in de dagelijkse praktijk te onderbouwen. Meer specifieke informatie 
wordt beschreven in het methodologie rapport. 
De bortezomib studie toont het belang aan van professionele richtlijnen gebaseerd 
op zowel de dagelijkse praktijk als bewijs uit klinische trials. Bovendien zou prospectieve 
data verzameling in een (inter-)nationaal registratie systeem het volgen van patiënten, het 
gebruik van uniforme uitkomstmaten en de selectie van vergelijkbare groepen 
vereenvoudigen en zodoende een waardevolle bijdrage kunnen leveren aan 
uitkomstenonderzoek. 
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Background 
The Dutch government introduced in 2002 policy regulations (“Beleidsregel dure 
geneesmiddelen”) to relieve the financial burden of hospitals for expensive inpatient drugs. 
These policy regulations were changed in 2006 at the request of the Minister of 
Healthcare, Welfare and Sports. Since 2006, drugs are temporarily admitted on the 
expensive drug or expensive orphan drug list of the Dutch Healthcare Insurance Board 
(NZa), and applicants are required to conduct outcomes research. Outcomes research 
refers to assessing appropriate use (“doeltreffende toepassing”) of a drug and establishing 
real-world cost-effectiveness (“doelmatigheid”) information by means of using data on the 
performance of a drug in daily clinical practice (Delwel 2008). In the reassessment phase, 
the decision whether or not to continue financial compensation for hospitals is based on 
outcomes research.  
 
The institute for Medical Technology Assessment (iMTA) has investigated, by order of the 
Dutch Health Care Insurance Board (CVZ), methodological issues regarding outcomes 
research. Two pilot studies were at the core of this research. Results of the pilot studies 
contribute valuable information on potential methodological issues and provide empirical 
evidence as addendum to the Guidance for Outcomes Research (“Leidraad voor 
Uitkomstenonderzoek”). One of the pilot studies concerns the drug bortezomib (Velcade®). 
In 2006, this drug was added to the expensive drug list for the indication relapsed or 
refractory multiple myeloma. Bortezomib was assessed by the CVZ in 2005, 2007 and 
2008. In 2006, this resulted in the admittance of bortezomib to the expensive drug list of 
the NZa for third line treatment of relapsed or refractory multiple myeloma disease and in 
2007 bortezomib was enlisted under the outpatient drug reimbursement scheme (GVS) on 
Annex 1B and 2 for second line treatment. Finally, in 2008 bortezomib was admitted on the 
expensive drug list of the NZa for first line treatment of multiple myeloma patient ineligible 
for high dose chemotherapy in combination with stem cell transplantation. 
 
This report describes the results of the pilot outcomes research of bortezomib. Information 
on methodological issues is provided in a separate report. The report focuses on the main 
research question for the bortezomib pilot study: 
How is bortezomib used in daily clinical practice of relapsed or refractory multiple myeloma 
and what are the real-world effects and costs of bortezomib? 
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1. Introduction 
Multiple Myeloma 
Multiple myeloma (MM) is a progressive hematologic malignancy characterised by an 
excess amount of abnormal plasma cells producing high levels of monoclonal 
immunoglobulin (M-proteins) or Bence-Jones proteins (Multiple Myeloma Research 
Foundation 2009). Clinically, patients with multiple myeloma present with hypocalcaemia, 
anaemia, renal insufficiency, increased susceptibility to infection, diffuse osteoporosis and/ 
or lytic bone lesions. Worldwide, approximately 0.8% of all cancer diagnoses and 0.9% of 
all cancer deaths were attributable to multiple myeloma (Alexander et al. 2007). The 
disease occurs more frequently among males and incidence rates increase with age, 
particularly after the age 40. 
 In the Netherlands, incidence numbers are only available for all plasma cell 
malignancies, including multiple myeloma, plasma cell cytoma, plasma cell leukaemia and 
extracellular plasmacytomas. Therefore, the available incidence numbers overestimate the 
number of new multiple myeloma patients per year. The incidence from 1996 to 2006 was 
on average 862 new patients per year, fluctuating between the highest incidence of 949 in 
2004 and the lowest incidence of 804 in 1999. These estimates result in, on average, 5.4 
new patients per 100,000 persons per year (range 5.1 to 5.9)1. Dutch prevalence numbers 
were previously estimated to be around 2000 (Commissie Farmaceutische Hulp 2007b). 
 Multiple myeloma remains an incurable disease. Conventional treatments achieved 
a median survival duration of 3 to 4 years; the range, however, varies broadly from less 
than 6 months to more than 10 years (Greipp et al. 2005) . In the last few years, new 
generation therapies, such as thalidomide, bortezomib and lenalidomide, have entered the 
market. Incorporation of these novel agents with conventional treatment regimes offers 
promising opportunities in future treatment of multiple myeloma (Richardson et al. 2007a).  
 At diagnosis, the Durie & Salmon (DS) staging system predicts disease prognosis, 
based on level and type of monoclonal protein, haemoglobin, calcium and number of lytic 
bone lesions (Durie and Salmon 1975). In 2005, a new staging system, the International 
Staging System (ISS), was developed in order to simplify disease staging by only 
incorporating ß2-microglobulin and serum albumin, while maintaining powerful prognostic 
reliability (Greipp et al. 2005). Both staging systems are further clarified in Annex I.  
                                                 
1 Dutch incidence numbers available at: http://www.ikcnet.nl 
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 The majority of patients follow a relapsing disease course, implying that different 
treatment regimes are administered after each instance of disease progression. The 
effectiveness of different treatments can be measured with uniform response criteria 
published by the International Myeloma Working Group (Morgan 2003). Annex II describes 
the interpretation of the different response criteria in more detail.  
 
Bortezomib 
Bortezomib is a novel, first-in-class proteasome inhibitor that was granted accelerated 
approval by the FDA (United States Food and Drug Administration) in 2003 for treatment 
of relapsed or refractory multiple myeloma patients who had received at least two prior 
therapies (Kane et al. 2006). European Market Authorisation by EMEA followed in 2004. In 
2005, bortezomib shifted to an earlier regime and was approved by both the FDA and 
EMEA for patients progressing after at least one previous treatment regime. This approval 
was based on the phase III APEX (Assessment of Proteasome Inhibition for Extending 
Remissions) trial, where bortezomib was compared to dexamethasone treatment in 
patients with relapsed multiple myeloma who received one to three previous treatments 
(Richardson et al. 2005). The APEX trial showed that bortezomib increased overall 
survival (OR), response rates and response duration (Richardson et al. 2007b). Annex III 
provides a systematic literature review on the clinical effectiveness of bortezomib for 
multiple myeloma patients. Many articles published information on the effectiveness of 
bortezomib as mono-therapy or as combination therapy from phase I, II and III studies. 
 
Pilot outcomes research of bortezomib 
Economic evaluations alongside clinical trials are generally seen as the best scientific 
evidence of treatment costs and effects. However, the efficacy results in a clinical trial 
might not accurately present daily practice effectiveness results since trials are conducted 
under ideal circumstances and patients ineligible for trials receive the drug in daily 
practice. In 2006, bortezomib was assessed by the CVZ resulting in admittance to the list 
for expensive inpatient pharmaceuticals mainly based on the results of the APEX trial in 
which bortezomib proved to be superior compared to dexamethasone treatment. In 
accordance with this policy, outcomes research is required in order to determine the 
continuation of financial compensation for hospitals after three years. In outcomes 
research, data on the performance of a drug in daily practice is collected in order to assess 
appropriate use and evaluate real-world cost-effectiveness.  
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For both iMTA pilot studies, different existing patient data sources were used in 
order to compare the applicability of these sources for outcomes research. For the 
bortezomib pilot, we chose to select multiple myeloma patients previously enrolled in a 
clinical trial, whereas the oxaliplatin pilot study for colorectal cancer selected patients from 
the Dutch cancer registry.  
This report describes the utilisation of bortezomib and the related treatment effects 
and costs in relapsed or refractory multiple myeloma in daily clinical practice within the 
Netherlands. The following research questions were investigated: 
• What are the baseline patient and previous treatment-related characteristics of the pilot 
patients? (section 2.1 and 3.1) 
• How is bortezomib used in daily clinical practice in the relapsed/refractory setting? 
(section 2.2 and 3.2) 
• What are the real-world clinical effects for patients treated with bortezomib compared 
to those treated with other therapy? (section 2.3 and 3.3) 
• What are the costs for treating patients in daily practice? (section 2.4 and 3.4) 
• How do the pilot results compare to clinical trial results? (section 2.5 and 3.5) 
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2. Research method 
2.1 Patient population 
Patient selection 
The patient population for the bortezomib pilot was selected from patients previously 
enrolled in the HOVON50 study population. According to the study coordinator, the 
HOVON50 population is a representative sample of Dutch multiple myeloma patients 
younger than 65 years. Generally, around 80% of younger multiple myeloma patients are 
enrolled in HOVON studies; this percentage is lower for the older population 
(Myeloomwerkgroep HOVON 2005).  
The phase III HOVON50 trial enrolled 556 (543 Dutch) patients from November 
2001 to June 2005. The HOVON50 study investigated the treatment effect of thalidomide 
in newly diagnosed DS stage II and III multiple myeloma patients aged 18 – 65 years 
(Lokhorst et al. 2008). The patients were randomly assigned to receive either VAD 
(vincristine, adriamycin and dexamethasone) or TAD (thalidomide, adriamycin and 
dexamethason), both in combination with stem cell mobilisation with CAD 
(cyclophosphamide, adriamycin and dexamethason), followed by high dose melphalan and 
stem cell reinfusion2. 
Patients progressing from the HOVON50 regime no longer receive protocol-based 
therapy. These patients were treated for relapsing disease by physicians in daily practice 
and were, thus, eligible for the pilot study concerning outcomes research of bortezomib in 
progressive, relapsed or refractory multiple myeloma. In order to ensure that the pilot 
patients were a representative sample of the HOVON50 population, (pre-HOVON) 
baseline characteristics were compared between the entire HOVON50 population and the 
selected pilot patients.  
 
Data collection 
Minimal case reports were obtained from the HOVON50 database for all 543 Dutch 
enrolled patients. This database contains information, among other things, about age, 
gender, date of diagnosis, baseline characteristics, HOVON50 treatment and response, 
progression from HOVON50 treatment, off-protocol treatment and survival status. Eligible 
                                                 
2 HOVON50 protocol available at:  
http://www.hovon.nl/studies/studies-per-ziektebeeld/mm.html?action=showstudie&studie_id=40&categorie_id=3 
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pilot patients were selected from the minimal case reports. As stated previously, the 
majority of multiple myeloma patients follow a relapsing disease course, receiving different 
treatment regimes consecutively. Figure 2.1 illustrates the relapsing disease course that 
patients experience from diagnosis until end of follow-up. It is important to note that 
patients receiving many treatments lines are not necessarily the most prognostically 
unfavourable patients. In fact, patients with a more favourable prognosis are more likely to 
survive long enough to receive more treatment lines compared to patients receiving fewer 
treatments. However, this is not always the case and it should be assumed that the 
association between the number of treatment lines received and prognosis is not clear.  
 
Figure 2.1: Patients disease course from diagnosis until end of follow-up 
 
costs line 2 costs subsequent line costs supportive care
(OFF protocol HOVON 50) (subsequent)
DIAGNOSIS relapse/ progression/refractory relapse/ progression/refractory supportive care
end of follow up or
death
Induction second line all subsequent lines
therapy treatment treatment
(HOVON50)
           treatment line                    treatment line            treatment line supportive care
DETAILED DATA COLLECTION PILOT STUDY  
 
All HOVON50 patients progressing to second line therapy were eligible for the pilot; only 
patients with a secondary malignancy and patients receiving bortezomib within an RCT 
setting were excluded. For all pilot patients we retrospectively completed detailed case 
reports using hospital medical records. From diagnosis until the end of follow-up, we 
collected data on treatments and their effects per treatment line. Data for resource use 
was collected in time periods from progression (relapse/refractory) to the next progression 
or end of follow-up. If patients only received supportive care after the last progression, 
data collection was limited to hospital admissions, outpatient visits and radiotherapy. Each 
treatment line can be seen as a treatment regime, starting with the first treatment therapy 
after diagnosis (HOVON50 induction regime) and successive lines beginning after either a 
progression or relapse of the disease or when the patient is refractory to the treatment. 
Detailed data on both costs and effects were collected starting from the time patients went 
off-protocol from the HOVON50 study. Minimal and maximum case report forms that were 
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used for data collection are enclosed in Annex IV and V. The aim was to include a 
minimum of 120 patients, with 60 patients receiving bortezomib and 60 patients never 
receiving bortezomib. The sample sizes were based on the differences in response 
percentages between the bortezomib and the high dexamethasone groups in the APEX 
trial (45% versus 26%). Assuming a similar difference in the pilot study, 96 patients in each 
group were assumed to be sufficient sample sizes for calculating two-sided tests with 95% 
confidence intervals. Anticipating that response might not be evaluated for approximately 
20%, a minimum of 120 patients were required for inclusion in the pilot study. 
 
Baseline characteristics 
As the results of the HOVON50 trial show an advantage in terms of time-to-progression 
(TTP) for the thalidomide arm (Lokhorst et al. 2010), baseline characteristics include 
HOVON50 treatment-related characteristics in addition to patient characteristics. Baseline 
characteristics were stratified by patient groups defined by when the patient was first 
treated with bortezomib: second line, third line, fourth line or later and never. Statistically 
significant differences in means for continuous parameters were tested by the Kruskall-
Wallis test for non-parametric comparisons among three or more groups. For categorical 
variables, differences were tested by the Pearson’s chi square test. Fisher’s exact test was 
used for categorical variables with counts less than five in any category. 
  
Comparison of patient groups 
The extent to which a valid incremental effectiveness estimate can be obtained for 
bortezomib based on the comparator patient group available from retrospective data 
collected in daily practice was taken into account. The validity of the incremental 
effectiveness estimate was suspected to be threatened by the possibility of bias due to 
non-random treatment exposure in observational studies, also called confounding by 
indication. Correction of this bias was explored as a result of the identified differences 
between the patient groups at baseline. 
Confounding by indication can be corrected by a number of techniques. Commonly 
used techniques include adjustment of the treatment effect estimates by including the 
patient characteristics that were found to differ between the groups as covariates in a 
model or by creating comparable groups using propensity score methods. These methods 
require identification of prognostic factors that are predictive of receiving bortezomib at the 
moment of eligibility for treatment with the drug.  
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To identify predictive prognostic factors that can be used for adjustment of 
confounding by indication, all available baseline patient characteristics were first 
considered in a bivariate logistic regression, with the dependent outcome being receipt of 
bortezomib in second line and the independent variable the prognostic factor. A dummy 
variable was also included representing a ‘1’ if the patient progressed to 
relapsed/refractory treatment after the year 2007, at which point the CVZ assessed the 
recommended use of bortezomib in second line and the HOVON guidelines were changed 
to reflect such recommendation (Lokhorst et al. 2008). Second line treatment with 
bortezomib was chosen as the dependent outcome as it represents the start of 
relapsed/refractory treatment, which is the first instance patients are eligible for 
bortezomib. If a prognostic factor was found to be bivariately associated with the 
dependent outcome of treatment with bortezomib in the second line at a significance level 
of α=0.05, the parameter and all possible interactions were considered eligible for 
entrance into a multivariable model with the dependent outcome being receipt of 
bortezomib in second line.  
To assess the validity of the parameters chosen as a result of the bivariate 
analysis, the selected parameters were compared to those identified by soliciting clinical 
opinion. Taking into account clinical opinion, the final set of selected parameters were 
entered in a multivariable logistic model and the final model was chosen by backwards 
selection.  
The multivariable logistic model was used to calculate the conditional probability of 
receiving bortezomib in second line, given the set of identified pre-treatment 
characteristics. This conditional probability is also referred to as the ‘propensity’ to receive 
a particular treatment at a given time, with each patient referred to as having a ‘propensity 
score’ (PS) conditional on his or her values corresponding to the characteristics entered 
into the multivariate model (Rosenbaum and Rubin 1983). The multivariate logistic model 
is, in other words, a prediction model where the propensity is estimated from the identified 
pre-treatment characteristics with statistically significant predictive value of receiving 
bortezomib (D’Agostino 1998). 
The distribution of the propensity to receive bortezomib in second line for patients 
in each treatment group was then compared. The feasibility of making valid comparisons 
between the patient groups was assessed by examining the extent of variation in PS to 
receive bortezomib in second line between the patient groups. Depending on the degree of 
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variation that was revealed, the need for adjustment methods was then explored during 
the effectiveness analysis. 
2.2 Bortezomib usage in clinical practice 
Clinical practice 
There are several treatment options for multiple myeloma patients. Professional guidelines 
were examined in order to establish possible regimes. The treatments that pilot patients 
received in clinical practice were explored by treatment line and combinations of different 
treatments were investigated.  
 
Bortezomib regimes, dose modifications and toxicities 
Bortezomib treatment regimes from the APEX trial were described and compared to 
planned and actual regimes in daily practice. In addition, the proportion of the dose 
actually received by pilot patients was assessed. Dosages are expressed in units of mg 
per square meter of body surface area (mg/m2). The reasons for dose modifications were 
summarised. Toxicities were only reported when resulting in a dose modification. Toxicities 
were distinguished as neurological, gastrointestinal, haematological and renal toxicities or 
any other circumstances related to patient condition. Finally, the proportion of the 
administered versus discarded dose of the total bortezomib dose available in the vial as 
packaged by the manufacturer was assessed. 
 
Diffusion of bortezomib 
The yearly diffusion of bortezomib was explored in the pilot study population. Furthermore, 
the diffusion of bortezomib for all Dutch multiple myeloma patients was researched by 
means of DBC (Diagnosis Treatment Combination) registration data obtained from the 
national DBC information system (DIS). The utilisation of bortezomib by different types of 
hospitals was examined in the years 2006, 2007 and 2008. In addition, SFK (Foundation 
for Pharmaceutical Figures) figures and sales data from the manufacturer (Janssen-Cilag) 
were analyzed in order to evaluate the annual diffusion of bortezomib in the Netherlands. 
To assess accessibility of bortezomib, regional prevalence numbers were estimated from 
available incidence and mortality numbers and compared with sales figures per region. 
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2.3 Clinical effectiveness 
Clinical effectiveness outcomes 
The possible choices of clinically valid effectiveness outcomes within multiple myeloma 
were explored, including OS from diagnosis, OS from start of relapsed/refractory 
treatment, time-to-progression (TTP) and time-to-next-treatment (TTNT) within each line of 
relapsed/refractory treatment, time to first response, time to best response, and duration of 
response (DOR). The pros and cons of using each of these effectiveness outcomes and 
the ability to validly compute each outcome given the restraints of the data was reviewed. 
Unadjusted estimates of the chosen outcome were calculated for each of the four patient 
groups. 
 We compared the baseline characteristics of all patient groups and determined 
whether certain prognostic factors were significantly different between the groups. For 
significantly different prognostic factors, we explored techniques to adjust for such 
differences between the patient groups in order to determine the best method to correct for 
these differences in baseline characteristics. We considered the following techniques that 
are commonly used to adjust crude survival estimates for confounding by indication: 
 
• Average covariate adjustment: Survival analysis that included the mean of all 
covariates associated with the propensity (probability) of receiving bortezomib in 
second line (Nieto and Coresh 1996; Lee et al. 1992; Chang, Gelman, and Pagano 
1982).  
• Regression adjustment by PS: Survival analysis that includes the mean of the PS 
as a covariate (Rosenbaum and Rubin 1983). 
• Survival analysis matched on PS: Survival analysis was conducted after matching 
all patients for the pre-treatment characteristics identified for inclusion in the 
multivariate logistic model (Rosenbaum and Rubin 1983; D’Agostino 1998). This 
method matches patients from each treatment group based on propensity score. 
The feasibility of matching techniques such as local optimal algorithms, as 
described by Gu and Rosenbaum (1993) and Smith and Todd (2005), was 
explored.  
 
To assess the influence of the adjustment methods on the effectiveness estimates, 
unadjusted and adjusted effectiveness estimates were compared. 
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 We reported the median estimates for reference by readers with a clinical 
background. For the economic evaluation of a particular health technology, the mean is 
preferred when looking at the potential effectiveness of any treatment for an entire group 
because it takes into account the shape of the survival curve, i.e., the proportion of short- 
and long-term survivors. With the median method, the shape of the survival curve is not 
taken into account when reporting the survival time at which 50% of the population has 
survived. Therefore, in economic evaluation studies, mean estimates of survival are 
preferred because of incorporation of the overall group distribution of survival. 
 
Analytical technique 
Unadjusted effectiveness estimates were calculated by the Kaplan-Meier estimator to 
estimate the survival function (Kaplan and Meier 1958). For adjusted effectiveness 
estimates, the use of a Cox proportional hazards (PH) model was assessed statistically 
(Cox 1972) for each covariate entered into the model. If found to uphold the PH 
assumption, Cox PH models were calculated firstly with adjustment for the variables 
included in the PS score and secondly for the PS. For both adjustment methods, the mean 
value for the total population was used for either the parameters included in the final model 
or for the PS of each patient group. Total follow-up was censored at the shortest follow-up 
observed in the entire group of patients (N=139).  
 Statistical analyses were conducted with the statistical software program SAS, 
version 9.1 (SAS Institute Inc., Cary, NC).  
2.4 Costs in clinical practice 
This section describes the methods of the cost analyses which were conducted from the 
hospital perspective. The following costs were calculated separately for patients ever and 
patients never receiving bortezomib: 
o Total mean treatment costs 
o Second line treatment costs 
o Third line treatment costs 
o Fourth+ line treatment costs 
 
Total costs for individual patients were determined by the identification of resource use 
and unit costs of the following cost components: inpatient hospital days, intensive care 
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days, outpatient visits, consultations by telephone, day-care treatments, emergency room 
visits, radiotherapy, surgical procedures, laboratory services, medical imaging services, 
concomitant treatment, active treatment, donor leukocyte infusions and stem cell 
transplantations.  
The cost analyses were based on the resource use of the full patient sample 
including patients still treated at the end of data collection. In order to determine whether 
the inclusion of these patients influenced our cost estimates, cost analyses were 
additionally conducted solely for patients whose resource use was collected until the end 
of treatment. 
 
Unit costs 
Table 2.1 presents the unit costs of inpatient hospital days, intensive care days, outpatient 
visits, consultations by telephone, day-care treatments and emergency room visits. The 
unit cost calculations were based on detailed micro costing studies reflecting full hospital 
costs, including overhead costs (Sonneveld et al. 2007; Tan et al. 2008; Tan et al. 2010). 
Some unit costs were weighted for their origin: 67% of the unit costs were based on data 
from the general hospitals and 33% on those from university hospitals. These shares 
reflect the distribution of patients among hospitals in Dutch daily practice. We conducted 
this micro costing study to compute haematological specific unit prices since they are 
known to be slightly higher compared to the average prices in the Dutch Costing Manual 
2004. 
Table 2.1 also presents the unit costs of radiotherapy, medical imaging services 
and laboratory services. The resource use of radiotherapy, surgical procedures and 
medical imaging services was valued using the fees as issued by the Dutch Healthcare 
Authority. Unit costs for laboratory services were based on a detailed inventory of the 
resource use of 12 patients (approximately 1,000 tests). Where necessary, all unit prices 
were inflated to 2009 euros.  
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Table 2.1: Unit costs (Euro 2009) 
Resource Use Unit Price
Haematological inpatient hospital day * € 516
Intensive care day € 2,080
Haematological outpatient visit * € 110
Haematological day-care treatment * € 167
Consultation by telephone € 13
Emergency room visit € 109
Radiotherapy standard € 1,656
Radiotherapy intensive € 7,971
Laboratory (per test) € 53
Cytology testing € 47
X-ray € 52
Skeletal scan € 177
CT scan € 208
MRI € 270
Radionucleide scan € 350
PET scan (total body) € 1,411
Echo (ultrasound) € 86
Bacterial culture € 14
Virale culture € 27
*weighting factor of 67:33 for general and university hospitals
 
 
 Unit costs of concomitant treatment were acquired from the Pharmaceutical 
Advisory Committee (“Farmacotherapeutisch Kompas”). Table 2.2 presents the unit costs 
of concomitant treatment per day. Due to time and feasibility constraints, detailed daily 
concomitant treatment costs were only determined for 18 patients. These daily costs were 
considered representative for the remaining 121 patients. The average daily cost based on 
this sample of patients was applied to the remainder of the patient population if the patient 
had been administered concomitant medication for chronic and ongoing adverse events.  
 Per day unit costs were assumed to last either the entire total follow-up the patient 
spent in a particular line or for a proportion of the total follow-up in that line. Prophylactic 
antibacterials/antifungals/antivirals were assumed to be administered daily while acute 
administration was assumed to last for 10 days. Administration of bisphosphonates, 
analgesics and concomitant medication for gastrointestinal toxicity were assumed to last 
the entire follow-up time a patient spent in that line. Patients requiring erythropoietin for 
anaemia were assumed to have been administered a subcutaneous injection every three 
weeks for which a daily price was corrected for. Resource use was collected for the 
number of transfusion bags of red blood cells and platelets that were administered in a 
given treatment line and unit prices per bag were applied. A daily price for neurotoxicity 
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medication was applied after correction for the average time spent on medication for 
neurotoxicity based on the sample of 18 patients.  
 
Table 2.2: Unit costs of concomitant treatment per day (Euro 2009) 
Indication for use Unit price
Antibacterial / antifungal / antiviral (prophylaxis) 5.56€        
Antibacterial / antifungal / antiviral (acute infection) 211.50€    
Biphosponates 4.45€        
Anaemia (erythropoietin injection) 3.21€        
Anaemia (red blood cells transfusion)* 204.00€    
Thrombocytopenia (platelet transfusion)* 492.80€    
Neurotoxicity 9.57€        
Gastro-intestinal 2.17€        
Analgesics 1.70€        
* cost per bag  
 
For active treatment, unit costs are shown in table 2.3. Unit prices for intravenously 
administered therapies were based on the cost of an entire vial. Unit costs of donor 
lymphocyte infusions, autologous and allogeneic stem cell transplantations were obtained 
from published micro costing studies and corrected for resource use which was 
retrospectively collected through the fully detailed case reports from hospital medical 
records to prevent double counting (Van Agthoven et al. 2001; Van Agthoven, Groot, and 
Uyl-de Groot 2001). Unit prices for thalidomide were taken from hospital pharmacies 
agreements with a health insurer. All other prices for active treatment were acquired from 
the Pharmaceutical Advisory Committee (“Farmacotherapeutisch Kompas”). 
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Table 2.3: Unit costs of active treatment (Euro 2009) 
Treatment Unit  Price  
Thalidomide (oral)  25/50/100 mg € 2.92 
  150 mg  € 4.37 
  200 mg   € 5.83 
  300 mg € 8.75 
  400 mg € 11.66 
Bortezomib (iv) 3.5 mg vial € 954.52 
Dexamethasone (oral) 1 mg € 0.06 
Dexamethasone (iv) 5 mg € 2.66 
  20 mg € 7.81 
Doxorubicin (iv) 1 mg  € 1.48 
Vincristine (iv) 1 mg € 8.82 
Melphalan (iv) 50 mg € 52.25 
Melphalan (oral) 2 mg  € 0.47 
Prednison (iv) 25 mg € 2.42 
Prednison (oral)  5 mg € 0.05 
Cyclophosphamide (oral) 50 mg  € 0.14 
  100 mg  € 0.27 
Cyclophosphamide (iv) 200 mg € 11.21 
  500 mg € 18.15 
  1000 mg € 34.38 
Interferon alpha (subcutaneous) 1.0 x 10^6 IE € 8.89 
Fludarabine (iv) 50 mg  € 266.94 
Lomustine (oral) 40 mg capsule € 23.39 
Lenalidomide (oral) 5 mg € 210.27 
  10 mg € 222.26 
  15 mg € 233.69 
  25 mg € 256.66 
Cytarabine (iv) 1600 mg € 72.31 
Etoposide (iv) 200 mg € 40.25 
Carboplatin (iv) 150 mg vial € 100.65 
DLI related € 2,342.03 
  unrelated € 7,876.64 
Auto SCT PBSCT*   € 7,933.92 
Allo SCT PBSCT*   € 21,315.74 
Allo SCT MUD*   € 64,540.35 
*excludes resource use collected from patient charts 
 
 
Sensitivity analyses 
To determine the uncertainty of the obtained cost estimates, one-way sensitivity analyses 
were carried out by varying the unit cost values of inpatient hospital day, outpatient visit 
and day-care treatment unit costs between 50% and 150%. Unit costs other than those of 
hospital days were considered to be fairly stable or of less influence and were therefore 
not subjected to sensitivity analyses.  
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Statistical analyses 
Statistical analyses were conducted with the statistical software programmes SPSS for 
Windows version 15.0 (SPSS Inc., Chicago, IL). In addition to descriptive statistics, 
differences between treatment groups were assessed by means of the independent 
samples t-test for variables showing a normal distribution, the Mann-Whitney U test for 
variables not normally distributed and the Pearson Chi-square test for variable fractions. 
Whether a normal distribution could be assumed for each cost variable was assessed by 
means of the Kolmogorov-Smirnov test for normality. To adjust for multiple testing, one 
way analyses of variance with post hoc testing (type Bonferroni) were additionally 
performed. In all cases, p = 0.05 was taken as statistically significant. All costs were based 
on Euro 2009 cost data. Where necessary, costs were adjusted to 2009 using the general 
price index from the Dutch Central bureau of Statistics.  
2.5 Clinical practice versus clinical trial 
Comparison of pilot patients to APEX patients 
To assess the extent to which a valid effectiveness measure could be obtained from the 
pilot patients, which were treated under uncontrolled conditions in daily practice, we first 
explored the extent to which the patients were representative of the cases included in the 
APEX trial that influenced the FDA approval in 2005 of bortezomib and subsequently in the 
Netherlands (Richardson et al. 2005). This was conducted by comparisons in terms of 
baseline characteristics, with baseline defined as the start of relapsed/refractory treatment 
with bortezomib conditional on having never received bortezomib in prior treatment lines. If 
demonstrated to be similar patient groups at baseline, the pilot patients treated with 
bortezomib were compared to the cases in the trial in terms of dosage schemes and 
effectiveness outcomes. 
Effectiveness outcomes included 1-year survival and TTP. As many patients in 
daily practice proceed to subsequent treatment lines due to reasons other than 
progression and because the reason being progression was not always visible in the 
patient charts, TTP was calculated until either progression date if available or start of next 
treatment line. Consequently, the estimate for TTP calculated for the pilot patients can be 
interpreted as a combination of TTP and TTNT. 
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Comparison pilot cost analyses with published literature 
The results of our cost analyses were compared with those obtained from published 
economic evaluations of bortezomib in the treatment of multiple myeloma. Published 
economic evaluations were retrieved from a systematic review as described in Annex VI. 
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3. Results 
3.1 Patient population 
3.1.1 Patient selection and data collection 
Figure 3.1 depicts the flowchart describing the selection process of pilot patients. All Dutch 
HOVON50 patients who progressed to second line therapy (n=250) were eligible for 
inclusion; patients with a secondary malignancy (n=7) and patients receiving bortezomib 
within an RCT (n=31) were excluded. For pragmatic reasons, we chose to exclude patients 
who were treated in a hospital that included six or less patients in the HOVON50 trial 
(n=25) and one patient who was both treated in more than three hospitals and was the 
only pilot patient in such hospitals. We started selecting patients in academic hospitals that 
included more than 20 patients in the HOVON50 trial and continued with other 
participating hospitals. Annex VII lists the participating hospitals. We discontinued 
including new patients once the desired study sample size was reached, thus further 
excluding 8 and 36 potential patients never and ever receiving bortezomib, respectively. 
Most patients were treated in more than one hospital, making the data collection 
challenging and time consuming. Consequently, over 1700 hours was needed for data 
collection in 42 different Dutch hospitals in order to collect data for a total of 139 patients. 
Despite this, it was difficult to find patients who never received bortezomib. The intended 
sample size (60 patients receiving bortezomib and 60 patients never receiving bortezomib) 
was increased because several patients initially included as ‘never receiving bortezomib’ 
based on the HOVON50 database actually received bortezomib in a later stage according 
to hospital medical records. In total, 139 patients were included in the pilot study: 67 
patients never treated with bortezomib and 72 patients treated with bortezomib. All data 
were collected by the principal researcher and medical students under the guidance of this 
researcher between April 2008 and May 2009. 
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Figure 3.1: Flowchart of the selection process of pilot patients 
        HOVON50 study population
               543 Dutch patients
(enrolled from November 2001 to June 2005)
 No 2nd treatment line recorded
 in HOVON50 database:
293 patients excluded
 Off protocol HOVON50
 Receiving 2nd line treatment
 (HOVON registration)
 n=250
 Secondary Malignancy:
7 patients excluded
 Received bortezomib
 in an RCT setting
31 patients excluded
 ≤6 HOVON50 patients in hospital:
25 patients excluded
 Patient treated ≥ 3 hospitals:
1 patient excluded
 Medical Records inaccessible:
3 patients excluded
 
 NEVER received EVER received
 bortezomib in daily practice  bortezomib in daily practice
 n=75 n=108
 
 Sufficient sample size:  Sufficient sample size:
 8 patients excluded 36 patients excluded
 NEVER EVER 
 received bortezomib  received bortezomib
 n=67 n=72
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3.1.2 Patient characteristics pilot versus HOVON50 
Table 3.1 describes (pre-HOVON) baseline characteristics of the pilot patients and the 
HOVON50 population, as reported by Lokhorst et al. (2010). A comparison of the groups 
shows widespread similarities. Therefore, it is assumed that the selected pilot patients are 
a representative sample of the HOVON50 population. However, it should be noted that 
bias might have occurred during the selection process. For example, more pilot patients 
were assigned to the VAD treatment arm in the HOVON regime (65 versus 50%). This 
difference is larger for pilot patients never receiving bortezomib (73 versus 58%). 
Furthermore, only patients who progressed to second line therapy were selected because 
the objective of our research was to investigate the costs and effects of bortezomib for 
relapsed or refractory multiple myeloma. Consequently, we may have selected the worst 
off HOVON50 patients by excluding patients for whom the HOVON database did not yet 
report a second treatment line at time of data collection. This could potentially explain the 
discrepancy that more pilot patients were assigned to the HOVON50 VAD arm given that 
Lokhorst et al. (2010) reported that HOVON50 patients receiving thalidomide had a longer 
time to progression. 
 
- 21 - 
Table 3.1: Baseline characteristics HOVON50 and pilot patients 
Characteristic
HOVON 50*** 
(N=536) Pilot Total
EVER 
bortezomib  
(N=72)  
NEVER 
bortezomib 
(N=67)  
P-value 
(EVER vs 
NEVER)
Male Gender 63% 58% 56% 61% 0.6
Age at diagnosis [mean (range)] 56 (30-65) 55 (32-65) 55 (32-65) 56 (34-65) 0.2
HOVON 50 treatment arm 0.1
VAD 50% 65% 58% 73%
TAD 50% 34% 40% 27%
Myeloma Type 0.48
IgA 21% 22% 19% 24%
IgG 60% 57% 63% 51%
IgD 1% 2% 1% 3%
IgM 0%
Light Chain Disease 18% 16% 13% 19%
Stage of disease 0.44
I A/B ** 2% 3% 1%
IIA 20% 21% 19% 22%
IIB 1% 1% 1% 0%
IIIA 67% 66% 69% 63%
IIIB 12% 9% 6% 13%
WHO performance status 0.06*
Asymptomatic NR 41% 50% 31%
Symptomatic but ambulatory NR 40% 35% 46%
In bed < 50% NR 12% 10% 13%
In bed > 50% NR 4% 1% 7%
Bedridden NR 0% 0% 0%
Albumin (g/L) [mean (range)] 36 (4.2-59.1) 36 (16-82) 36 (16-82) 37 (25-55) 0.58
Serum B2 (mg/l) [mean (range)] 3.2 (.0-35.4) 4 (.6-16.5) 4 (1-16) 4.4 (.6-16.5) 0.21
NR=not recorded   *p-value significant at an α=0.1   **12 patients (ineligible HOVON50)   ***Source: Lokhorst et al. 2010  
3.1.3 Baseline characteristics pilot patients 
Baseline characteristics 
Comparison of baseline characteristics of all patients, with baseline being start of 
relapsed/refractory treatment, reveals significant differences (Table 3.2). Differences were 
observed for the proportion of patients presenting with neurotoxicity, whether or not 
bortezomib was recommended for use as second line therapy in the year of progression, 
HOVON50 treatment-related characteristics and mean time until progression from initial 
treatment line. 
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Patients receiving bortezomib were more likely to present with neurotoxicity at 
baseline (p = 0.03). Those receiving bortezomib in second line were more likely to have 
progressed from initial therapy in the years when bortezomib was first recommended for 
use in treatment of initial progression (i.e., 2007 and 2008) (p < 0.001).  
 Treatment-related characteristics also differed among the groups, with patients 
treated with bortezomib in second line being more likely to have been randomised to the 
thalidomide arm of the HOVON50 trial (p = 0.05), to receive more cycles of (V)AD (AD if 
randomised to thalidomide and VAD if randomised to vincristine) (p = 0.015), HDM (p = 
0.005), CAD (p = 0.002), and any maintenance therapy (p = 0.02), especially thalidomide 
maintenance. Due primarily to differences in treatment received during HOVON50, 
baseline comparison also demonstrated that time from diagnosis until first progression is 
significantly longer for patients treated with bortezomib in second and third line (p < 0.001). 
Differences in prognosis at diagnosis may also contribute to the differences in time from 
diagnosis until first progression. For instance, though not statistically significant, the 
baseline comparison also reveals that the patients treated with bortezomib in second line 
were on average younger, presented with a more prognostically favourable WHO 
performance status, lower levels of c-reactive protein, and better responses to initial 
therapy. However, comparisons of known prognostic factors did not reveal striking 
differences between the four groups.  
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Table 3.2: Baseline comparison of all pilot study patients stratified by bortezomib treatment status 
2nd Line (n=25) 3rd Line (n=35) 4th Line+ (n=12)
Patient-related characteristics
Age 54 (42-65) 54 (32-64) 58 (45-65) 56 (34-65) 0.16
Female 40% 46% 50% 39% 0.84
Myeloma Type
IgA 16% 23% 17% 24% 0.92
IgG 68% 57% 67% 51%
IgD 0% 3% 0% 3%
IgE 0% 0% 0% 0%
Light Chain 8% 14% 17% 19%
Unk 8% 3% 0% 3%
WHO performance status 0.17
Asymptomatic 52% 57% 50% 33%
Symptomatic but ambulatory 28% 37% 17% 39%
In bed < 50% 12% 0% 8% 10%
In bed > 50% 0% 0% 0% 6%
Bedridden 4% 0% 0% 4%
Not Reported 4% 6% 25% 7%
Albumin (g/l) [mean (sd)] 39.8 (28-49.4) 40.7 (31-58.9) 38.3 (27-44) 38.4 (16.6-52) 0.92
Serum B2 (mg/l) 4 (1.5-16.7) 4.8 (1.3-13.3) 2.3 (2.1-2.83) 3 (1.1-5.7) 0.66
C-reactive protein (mg/l) 3 (1-5) 10 (1-42) 21.5 (1-67) 31.6 (1-171) 0.08
Creatinine clearance (mmol/l) 9.1 (1.9-16) 5.6 (3.3-8) 6.6 (5.2-8) 7.8 (2.3-16) 0.4
Haemoglobin (mmol/l) 7.5 (5-9.5) 7.7 (5.2-9.5) 7.1 (5.3-8.4) 7.1 (2.1-10) 0.3
Platelet count (x109/l) 182 (10-470) 218.5 (66-657) 264.6 (93-553) 227 (28-828) 0.2
Plasma cell infiltration > 50% 12% 11% 17% 10% 0.82
Present with neurotoxicity 48% 43% 42% 25% 0.03*
Bortezomib recommended for therapy of first 
progression at baseline (2007+) 56% 14% 0% 18% <0.001*
Previous treatment-related characteristics
Thalidomide arm 56% 29% 42% 27% 0.05*
Cycles (V)AD or AD 2.96 (2-3) 3 (3-3) 2.6 (1-3) 2.82 (1-3) 0.015*
Cyles HDM
0 4% 9% 33% 31% 0.005*
1 96% 83% 67% 66%
2 0% 9% 0% 3%
CAD given 100% 97% 75% 78% 0.002*
Received SCT 24% 29% 25% 15% 0.33
Maintenance 0.02*
None 28% 51% 50% 63%
IFNα 20% 20% 25% 24%
Thalidomide 52% 29% 25% 13%
Best response to HOVON50 0.15
Complete response 24% 9% 8% 10%
Partial response 68% 77% 67% 60%
Minor response 8% 0% 8% 10%
No change 0% 6% 0% 4%
Progressive disease 0% 0% 8% 9%
Not Reported 0% 9% 8% 6%
Reason for going off protocol
Normal completion of HOVON protocol 24% 26% 25% 13% 0.34
Excessive Toxicity 32% 14% 17% 28% 0.3
Progression/Relapse 32% 31% 33% 28% 0.97
Mean time until first progression 35.9 (12.9-57.9) 25.6 (6.8-51.1) 16 (2-29.5) 22.4 (1.9-61.4) <0.001*
Characteristic
Bortezomib Ever              
Never (n=67)
P-
value†
†Continuous variables were compared by Kruskall-Wallis test, and either Pearson's chi-sqaure or Fisher's exact test was used to  
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Missing values were common for baseline parameters (Table 3.3). Meaningfully low 
numbers of available data occurred for prognostic factors at baseline, such as WHO 
performance status, albumin and serum β2-microglobulin levels, c-reactive protein 
concentration, creatinine clearance, haemoglobin level, plasma infiltration, and 
assessment of neurotoxicity. Missing data may mask the differences between the four 
groups in terms of known prognostic factors, which contributes to the inability to reveal 
striking differences in baseline prognosis between the four groups.  
 
Table 3.3: Frequency of available data for each baseline characteristic stratified by bortezomib 
treatment line  
Baseline Prognostic Characteristic 2nd Line (n=25) 3rd Line (n=35) 4th Line+ (n=12)  Never (n=67)
Age 100.0% 100.0% 100.0% 100.0%
Gender 100.0% 100.0% 100.0% 100.0%
Type of Myeloma 92.0% 97.1% 100.0% 97.0%
WHO Performance status 96.0% 94.3% 75.0% 92.5%
Albumin 72.0% 68.6% 66.7% 62.7%
Serum β2-microglobulin 40.0% 34.3% 33.3% 20.9%
C-reactive protein 24.0% 25.7% 50.0% 62.7%
Creatinine clearance 24.0% 25.7% 16.7% 11.9%
Haemoglobin 64.0% 68.6% 83.3% 68.7%
Platelet count 100.0% 97.1% 100.0% 98.5%
Plasma infiltration 40.0% 42.9% 58.3% 53.7%
Neurotoxity assessment 80.0% 97.1% 91.7% 97.0%
Treatment arm HOVON 50 100.0% 100.0% 100.0% 100.0%
Cycles (V)AD or AD 100.0% 100.0% 100.0% 100.0%
HDM cycles 100.0% 100.0% 100.0% 97.0%
CAD given 100.0% 100.0% 100.0% 100.0%
Received SCT 100.0% 97.1% 100.0% 100.0%
Type of maintenance 100.0% 100.0% 100.0% 100.0%
Best response to previous regimen 100.0% 91.4% 100.0% 94.0%
Reason discontinuation previous regimen 100.0% 97.1% 100.0% 98.5%
Date of first progression 100.0% 100.0% 100.0% 98.5%
Bortezomib Ever
 
 
Comparison of patient groups 
Table 3.4 reveals the results of the survey regarding clinical opinion concerning relevant 
prognostic factors that would be clinically significant for decision-making in the choice of 
bortezomib treatment at start of refractory treatment and their statistical significance in the 
bivariate logistic regression analysis. Comparison of the clinically significant prognostic 
factors to the statistically significant results of the bivariate analysis reveals many 
similarities, with time from diagnosis until first progression, presence of neurotoxicity, best 
response to initial therapy, HOVON50 treatment arm, and type of maintenance being 
significant in the bivariate analysis and stated to be clinically relevant by at least one of the 
two surveyed leaders in the field of haematology in the Netherlands. The dummy variable 
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for progression in 2007 or later was also significant in the bivariate analysis, indicating 
relevance of taking into account the diffusion of bortezomib in daily practice.  
 Results of the stepwise regression analysis after including all bivariately significant 
variables and their interaction variables revealed the following parameters to be predictive 
of bortezomib in second line in a multivariable model: whether or not patient presented 
with neurotoxicity, patient’s best response to initial therapy, type of maintenance the 
patient received and whether the patient was eligible for treatment of 
progression/refractory disease in the years following recommendation for use of 
bortezomib in second line (Table 3.4). Interaction was also significant for the effect of 
neurotoxicity and best response to initial therapy. 
 
Table 3.4: Clinically and statistically significant baseline prognostic factors predictive of second line 
bortezomib treatment  
Independent predictors of exposure to bortezomin in 2nd treament regimen 
Clinical 
opinion #1
Clinical 
opinion #2
Bivariate 
Model
Multivariable 
Model
Patient-related characteristics
Age
Gender
Myeloma type 9
Time from start of previous treatment until start of next treatement 9 9
Presence of neurotoxicity 9 9 9 9*
Albumin level 
Serum B2 level  
Haemoglobin level  
Platelet count 9 9
C-reactive protein level
Creatinine clearance 9 9
Plasma cell infiltration 
WHO performance status 9 9
Best response to initial treatment regimen 9 9 9 9*
Any reason for discontinuation previous regimen
Reason for discontinuation previous regimen: Normal Discontinuation
Reason for discontinuation previous regimen: Progression/Refractory/Relapse 9
Reason for discontinuation previous regimen: Toxicity 9 9
HOVON 50 treatment-related characteristics
Treatment arm (VAD vs TAD) 9 9 9
# of cycles (V)AD administered
CAD given to the patient
# of cycles HDM patient received
Received allo-SCT (either in or out of HOVON protocol) 9
Type of maintenance 9 9 9
Eligible for bortezomib in 2007+ Not asked Not asked 9 9
Clinically significant Statistically significant 
 
*Interaction variable between neurotoxity and best response was found to be significant in the final multivariable model 
 
The odds ratios (OR) for the parameters retained in the multivariable logistic regression 
model are shown in Table 3.5. The interpretation of the effects of the parameters on the 
odds of getting bortezomib in second line are as follows: patients presenting with 
neurotoxicity are less likely to receive bortezomib (OR = 0.97), patients treated with any 
maintenance are more likely to receive bortezomib compared to those receive no 
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maintenance (OR = 2.22), patients presenting with a less favourable response to initial 
therapy are less likely to receive bortezomib (OR = 0.57), patients progressing in the year 
2007 or later are more likely to receive bortezomib (OR = 7.01), and, as suggested by the 
interaction between the main effect of presenting with neurotoxicity and best response to 
initial therapy, a patient who presents with a less favourable response to initial therapy is 
more likely to receive bortezomib if presenting with no signs of neurotoxicity compared to a 
patient who presents with signs of neurotoxicity with a similar response to initial therapy 
(OR = 1.03). Although the main effects of presenting with neurotoxicity and previous 
maintenance are not significant, they are retained in the model because their interaction is 
statistically significant.  
 
Table 3.5: Logistic regression results when regressing independent predictors on the dependent 
outcome of receiving bortezomib in second line 
Independent predictors of treatment with bortezomib in 2nd line OR (95% CI) P-value
Presence of neurotoxicity (1=yes, 0=no) 0.97 (0.92-1.02) 0.2574
Type of maintenance (0=None, 1=IFNa, 2=Thal) 2.219 (1.15-4.28) 0.0173
Best response to previous treatment regimen (1=CR….5=PD) 0.57 (0.21-1.54) 0.2661
Progression to relapsed/refractory treatment in 2007 or later   (1=yes, 0=no) 7.065 (2.45-20.4) 0.0003
Interaction: Best response to previous treatment * Presence of neurotoxicity 1.03 (1.01-1.06) 0.0536  
 
Comparison of the distribution of propensity scores (probability) across all groups is shown 
in Figure 3.2. Because the propensity scores are essentially probabilities, the range of 
possible values is between 0 and 1. In the bar graph depicted in Figure 3.2, the propensity 
scores have been divided into 10 deciles along the horizontal axis while the proportion of 
patients include in each decile is shown on the vertical axis. 
 It is clear that the patients receiving bortezomib in second line differ from all other 
treatment groups, suggested by a more uniform distribution compared to that of all other 
groups. Though not identical, the left-skewed distributions of all non-second line treatment 
groups largely overlap. Based on the predictive value of the selected prognostic factors, 
patients treated in second line have a mean propensity to receive bortezomib equal to 
0.40, while the mean for all patients not treated in second line was equal to 0.13, 0.124 
and 0.134 for those treated with bortezomib instead in third line, fourth line or greater, or 
never, respectively. In other words, patients treated with bortezomib in second line, third 
line, fourth line or later or never had an average probability of treatment with bortezomib in 
second line equal to 40%, 13%, 12.4% and 13.4% based on their value for significant 
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baseline prognostic factors associated with treatment with bortezomib treatment at this 
time.  
 
Figure 3.2: Comparison of the propensity score distribution by bortezomib treatment line 
 
 
The results seen in Figure 3.2 are not surprising. Patients treated with bortezomib in 
second line are expected to have the highest probability of treatment with bortezomib in 
second line. What is surprising, however, is the similarity in probabilities for bortezomib 
treatment between patients treated in third line, fourth line or later and patients never 
treated with bortezomib. The results are likely to differ when performing a similar analysis 
on the propensity (probability) to get bortezomib in third line or fourth line or later, with 
patients receiving bortezomib in each respective line to be predicted a higher propensity 
compared to all other patient groups not treated in the respective line. Such analyses were 
not conducted but represent a possible extension to the analysis. 
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3.2 Bortezomib usage in clinical practice 
3.2.1 Clinical practice 
Professional guidelines 
There are several treatment options for multiple myeloma patients. The Myeloma Working 
Party of HOVON has developed national guidelines based on both phase II and phase III 
studies and professional expertise (Multiple Myeloma Working Group 2009). It should be 
noted that HOVON has two responsibilities, namely conducting clinical trials and 
developing professional guidelines. The guidelines have been modified over the years as a 
consequence of chances in professional insights due to novel agents entering the market 
and evidence from ongoing trails in the field of haematology. The most important changes 
include recommendation of thalidomide as part of induction therapy and the shift of 
bortezomib and lenalidomide to earlier treatment regimes. This shift is also evident in 
CVZ’s assessment reports of bortezomib regarding the NZa policy for expensive drugs3. 
Initially in October 2005, the CVZ advised that bortezomib was indicated as a third line 
therapy for multiple myeloma patients progressing (or refractory) on a treatment regime of 
thalidomide in combination with dexamethasone or cyclophosphamide, or for patients 
ineligible for this regime. Based on this advice, bortezomib was admitted on the expensive 
drug list from January 2006 onwards. In 2007, based on a GVS application, CVZ advised 
that bortezomib should be added on the outpatient drug reimbursement list (GVS Annex 
1B and Annex 2) and could be administered after at least one multiple myeloma specific 
treatment. Finally, in November 2008 (application for the NZa expensive inpatient drug 
list), patients ineligible for high dose chemotherapy in combination with stem cell 
transplantation are entitled to receive bortezomib in combination with melphalan and 
prednisone as first line therapy. Therefore, bortezomib, alongside specific criteria, has 
shifted within only a few years from third to second to first line therapy in 2005, 2007 and 
2008 respectively.  
 Current HOVON guidelines advise for DS stage I disease a ‘wait-and-see’ 
approach. Patients progressing to an advanced disease stage (DSII or DSIII) are pro-
actively treated according to two different regimes based on the age of the patient (≤65 
years, ≥66 years). Figure 3.3 depicts both treatment regimes. Bortezomib/ dexamethasone 
or lenalidomide/dexamethasone should be administered as second line therapy and is 
                                                 
3 CVZ assessment reports available at: http://www.cvz.nl 
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recommended for subsequent relapses. The professional guideline states that choices 
between the treatment regimes have to be based on individual patient characteristics, 
according to previous treatments and a patient’s side effect profile. Only younger patients 
are eligible for stem cell transplantation after induction therapy. 
  
Figure 3.3: HOVON treatment protocol for multiple myeloma patients 
 
 
(Source: HOVON guidelines4) 
 
Besides professional guidelines for daily practice, multiple myeloma patients eligible and 
willing to participate in a clinical study are enrolled in ongoing trials. The Dutch HOVON 
trials are stratified based on age. Until recently (trial inclusion stopped in 2008), younger 
patients (≤65 years) received induction therapy in the HOVON65 trial (phase III study 
comparing bortezomib mono-therapy versus bortezomib combined with adriamycin and 
dexamethasone followed by high dose melphalan). The HOVON76 is a phase II study 
where younger patients receive lenalidomide as maintenance therapy after (tandem auto 
and allo) stem cell transplantation. Elderly patients, or younger patients ineligible for high 
dose chemotherapy and stem cell transplantation, are treated according the HOVON87 
protocol (phase III trial for previously untreated patients comparing melphalan/ thalidomide 
with melphalan/ lenalidomide). Finally, within the HOVON86 protocol, which is a phase I/II 
                                                 
4 HOVON guidelines available at: http://www.hovon.nl/working-groups/working-groups/myeloma.html 
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trial in elderly patients (60 – 80 years) at first relapse (or primary refractory), patients 
receive combination therapy of lenalidomide, bortezomib and dexamethasone. 
 
Treatments received by pilot patients by line 
Based on constant advances in treatment options, changing professional guidelines and 
the various ongoing clinical trials, it is expected that patients in daily clinical practice might 
receive several treatment regimes. Therefore, the treatments that pilot patients received 
were explored by treatment line. All 139 pilot patients had a second treatment line after the 
HOVON50 protocol, 65% received third line, 40% fourth line, 14% fifth line, 6% sixth line, 
2% seventh line and 1% eighth line therapy. Table 3.6 describes the number of patients 
who received the available treatments by line. At least ten chemical agents were given as 
mono-therapy or in different combinations. Therefore, the sum of each line is higher 
compared to the number of patients treated. We could not identify a general treatment 
pattern because of a large degree of variation in regimes and drug usage often being 
administered in differing and/or reversed order. However, the percentage of patients 
treated with thalidomide decreased over the lines, whereas lenalidomide usage increased. 
Of all patients ever receiving bortezomib, with 79% previously treated with thalidomide. 
Bortezomib was given in all treatment lines, with the exception of line number eight. Six 
patients had bortezomib in more than one treatment line, four patients in two lines and two 
patients in three lines.  
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Table 3.6: Treatments received by pilot patients by line 
Line 2 Line 3 Line 4 Line 5 Line 6 Line 7 Line 8
 Treatment  (N=139) (n=90) (n=55) (n=20) (n=8)  (n=3) (n=2)
 bortezomib 25 35 12 6 1 1 0
 lenalidomide 4 14 21 6 5 1 1
 thalidomide 73 15 8 3 1 0 1
 adriamycin 17 10 4 2 0 2 0
 vincristine 11 6 4 2 0 0 0
 melphalan 21 7 5 2 1 0 0
 high dose melphalan (HDM) 9 4 1 0 0 0 0
 dexamethasone 80 52 32 9 5 2 0
 prednisone 28 12 13 10 4 2 1
 cyclophosphamide 14 9 14 6 1 1 1
 donor lymphocyte infusion (DLI) 19 11 4 2 1 0 0
 stem cell transplantation (allo+auto) 19 7 2 1 0 0 0
 interferon alpha 0 2 0 0 1 0 0
 experimental 1 1 0 0 0 0 0
 other 1 2 3 2 0 0 0
               All pilot patients
 
 
Treatment combinations 
As expected from clinical guidelines and shown in Table 3.6, patients do not only receive 
mono-therapy but a combination of different therapies is common practice. The most 
frequent treatment combinations for all pilot patients from line two onwards are 
combinations of thalidomide/ dexamethasone (n=57), lenalidomide/ dexamethasone 
(n=38), melphalan/prednisone (n=32) and vincristine/ adriamycin/ dexamethasone (n=22). 
In addition, Table 3.7 describes the different treatments that were combined with 
bortezomib within one treatment line.  
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Table 3.7: Treatment combinations of bortezomib 
number of patients
 bortezomib therapy receiving treatment (combination)
 bortezomib treatment (all lines) 80
 bortezomib mono-therapy 23
 bortezomib combination therapy 57
 bortezomib combination therapy (1 other treatment) 46
dexamethasone 33
donor lymphocyte infusion 9
cyclophosphamide 1
thalidomide 1
prednisone 1
dendritic cells 1
 bortezomib combination therapy (2 other treatments) 7
dexamethasone + thalidomide 1
dexamethasone + adriamycin 1
dexamethasone + cyclophosphamide 1
prednisone + ciclosporine 1
thalidomide + donor lymphocyte infusion 1
lenalidomide + donor lymphocyte infusion 1
allo stemcell transplantation + donor lymphocyte infusion 1
 bortezomib combination therapy (3 or more other treatments) 4
dexamethasone + prednisone + cyclophosphamide 1
dexamethasone + high dose melphalan + allo stemcell transplantation 1
dexamethasone + adriamycin + lenalidomide + prednisone 1
dexamethasone + thalidomide + cyclophosphamide + prednisone 1
 
 
As previously mentioned, six patients received bortezomib in more than one treatment line. 
Therefore, a bortezomib regime was administered at 80 instances to 72 pilot patients: 29% 
as mono-therapy and 71% as combination therapy. As expected from professional 
guidelines, bortezomib was most often combined with dexamethasone (58%). However, 
we also found many other treatment combinations. Some combinations are attributable to 
hospital specific guidelines. For example, guidelines of one particular hospital advised 
administration of donor lymphocyte infusion after every second bortezomib cycle, while 
another hospital recommended the combination of bortezomib with cyclophosphamide 
maintenance therapy. Other combinations might be related to the fact that some 
physicians treat patients according to ongoing clinical trials, which demonstrates the 
transition from science to daily practice, such as bortezomib combined with 
dexamethasone and adriamycin (HOVON65) or combining bortezomib with lenalidomide 
(HOVON86). 
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3.2.2 Bortezomib regimes, dose modifications and toxicities 
The previous section described the various treatments and treatment combinations pilot 
patients received. This section further explores the applied bortezomib regimes, dose 
modifications and toxicities. In the APEX trial, a bolus of bortezomib (1.3 mg per square 
meter of body surface area) was administered four times per cycle on days 1, 4, 8 and 11 
for eight three-week cycles, followed by three five-week treatment cycles on days 1, 8, 15 
and 22. The median length of bortezomib therapy was six cycles; 39% of patients received 
the planned eight cycles (Richardson et al. 2007b). Richardson et al. (2005) reported that 
37% of the APEX patients had adverse events requiring discontinuation of bortezomib 
treatment but did not report dose modifications. In the CREST study, in which bortezomib 
was administered in two different dose regimes (1.0 mg and 1.3 mg/m2), 11% of the 
patients receiving the lower doses required a dose modification compared to 35% in the 
higher dose group (Jagannath et al. 2008). 
 Table 3.8 reports the actual and planned bortezomib dose regimes of the pilot 
patients compared to the planned dose regimens of APEX trial by total cycle numbers 
received. The comparison reveals that 50% of the pilot patients received one to three 
treatment cycles, 29% received six or more cycles and only 17% received seven or more 
cycles. Bortezomib treatment for pilot patients was generally planned at lower dosages 
than those in the APEX trial. Most of the pilot patients were treated in comparable cycle 
regimes as the APEX trial. However, pilot patients received both fewer treatments per 
cycle as well as lower dosages per treatment. It should be noted that one patient did not 
receive a cycle based regime but received bortezomib twice per week for 16 weeks, which 
is illustrated by the maximum dosage of 42.2 mg/m2 in the first cycle.  
  
Table 3.8: Actual and planned bortezomib dose regimes stratified by total cycle numbers 
APEX trial
planned dose
Total Cycles (mg/m 2 ) planned
1 9 (11.2%) 9.8   (5.0-42.2) 5.2 9.5   (2.5-42.2)** 0.88 (0.50-1.0)    1.83**
2 8 (10.0%) 10.2   (9.2-10.6) 10.4 9.4   (6.6-10.5) 0.92 (0.63-1.0) 0.90
3 23 (28.8%) 15.0 (13.4-16.0) 15.6 14.2 (10.8-16.0) 0.94 (0.69-1.0) 0.91
4 10 (12.5%) 18.9 (11.8-21.1) 20.8 17.5 (11.5-21.1) 0.93 (0.77-1.0) 0.84
5 7   (8.8%) 21.8 (16.1-26.2) 26.0 20.8 (16.1-26.0) 0.96 (0.85-1.0) 0.80
6 9 (11.2%) 28.5 (19.6-31.6) 31.2 27.4 (16.6-31.6) 0.96 (0.84-1.0) 0.88
7+ 14 (17.5%) 38.7 (21.0-44.3) 42.3 37.9 (30.0-44.3) 0.98 (0.88-1.0) 0.90
* Estimates are presented as the mean (min-max) ** One patient did not receive a cycle based regime
   bortezomib  (mg/m2) APEX trial(mg/m2)
     administrations
Planned Dose* Actual/
Patients treated with bortezomib (n=72)
   n (%) Actual/
 Planned*
Actual Dose*
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On average, over all cycles, 94% of planned dosages were actually administered to pilot 
patients. It is important to realize that physicians often plan the dosage after a previous 
cycle. Thus, the 94% of the actual dose received must be interpreted carefully. 
Comparison of actual dosages in daily practice with planned APEX trial dosages per cycle 
shows that pilot patients received, on average, 87% of trial-planned bortezomib dosage 
over all cycles (excluding the first cycle because of one different regime). Interestingly, the 
CREST study also reported a median dose intensity of 86.9% for the patients receiving the 
1.3 mg/m2 dosage (Jagannath et al. 2008). 
 Based on the available data, it was not feasible to establish a pattern for dose 
modifications according to toxicities in different treatment lines. Therefore, we summarized 
the reasons for dose modifications and toxicities. Table 3.9 depicts the reasons for dose 
modifications. In total, 53% of all 80 bortezomib regimes for the 72 pilot patients required a 
dose modification, including any increase or decrease in dose as well as a delay in receipt 
of dosage or withholding a dosage within a cycle. The dose modification could occur in any 
cycle within the regime. Toxicities were only reported when they resulted in a dose 
modification. As expected, the most common reported toxicity was neurotoxicity. Often 
physicians only reported that the condition of the patient required a dose modification 
without describing the reason for poorer condition. It is remarkable that for one patient the 
physician lowered the dose due to good response on the previous bortezomib cycle.  
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Table 3.9: Reasons for dose modifications when administering bortezomib  
Reason for Dose Modification
Frequency     
(n=80) (%)
Total bortezomib regimes (72 patients) 80
Total number of regimes requiring dose modification 42 (52.5%)
Toxicity/AE 33 (79%)
Gastrointestinal 10
Neurological 20
Haematological 7
Patient condition 11
Renal 2
Other* 6
Progressive disease 1
Treat and observe tolaration 1
Good response to previous regimen 1
Related to tox/AE from previous regime 3
Weight adjustment 1
Unknown 6
*1 had infection due to pneumonia, 1 became progressively deaf, 1 had 
herpes infection, 3 unknown  
 
3.2.3 Proportion of bortezomib vial dose administered versus discarded  
There is a debate in the Netherlands whether hospitals should receive additional funding 
per vial of the drug used as it is in the current situation or whether funding should be based 
on the actual milligram given to patients. The size of one bortezomib vial is 3.5 mg and 
costs €954.52, whereas the normal dosage is 1.3mg/ m2, implying that the vial contains an 
excess of bortezomib for the fast majority of patients. In our pilot study, on average, 66% 
of the vial was used for the administration of bortezomib to patients and the remaining 
34% was thus not used and might be called ‘waste’. However, it is questionable to what 
extent this is actual ‘waste’ of the drug or ‘waste’ of money. It is important to realise that 
most hospitals and/or hospital pharmacies have protocols stating that for safety reasons 
vials are not supposed to be pooled among patients. Furthermore, after preparation, 
bortezomib is only stable for a short period of time. The relatively low prevalence of 
multiple myeloma and thus the small amount of patients eligible for bortezomib treatment 
means that it would be difficult to pool patients by sharing vials and thus administer 
bortezomib at the same day in the same hospital to two, three or more patients.  
 It should be realised that decreasing the amount of mg of bortezomib in a vial will 
not be related to a similar proportional decrease of the price of one vial. However, we 
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assume that there might be possibilities to improve efficiency, for example by stimulating 
the manufacturer to supply bortezomib in smaller vial sizes with varying dosages. 
Nevertheless, it is important to realise that this might provoke an incentive to give a 
(slightly) lower dose (per m2) to patients in order to save money at the cost of potentially 
lower effectiveness of the drug. 
3.2.4 Diffusion of bortezomib  
In 2006, the Dutch policy regulations for expensive inpatient drugs were revised after 
signals of ‘postal code’ prescribing of trastuzumab. Therefore, we examined national and 
regional diffusion of bortezomib to investigate whether or not accessibility issues exist. The 
yearly diffusion of bortezomib within the HOVON50 population is illustrated in Figure 3.4. 
This figure shows the cumulative percentage of all Dutch HOVON50 patients who received 
bortezomib in daily practice (n=108) or within an RCT setting (n=31) from 2004 onwards. 
The sharpest increase was seen in 2006 and 2007, possibly related to the fact that in 2006 
bortezomib was admitted to the list for expensive pharmaceuticals. In total, 25% of all 
Dutch patients included in the HOVON50 study were treated with bortezomib. The 
diffusion pattern could be due to the time period of our data collection and pilot patient 
population. It is expected that the proportion of HOVON50 patients eventually treated with 
bortezomib will increase as more patients relapse from treatment protocol.  
 
Figure 3.4: Diffusion of bortezomib 
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Subsequently, we investigated the diffusion of bortezomib within the entire population of 
Dutch multiple myeloma patients. The independent national DBC (Diagnosis Treatment 
Combination) registration information system (DIS) records DBC data of Dutch hospitals. 
Table 3.10 shows DIS data on national bortezomib utilisation for 2006, 2007 and 2008. Per 
hospital type, the number of bortezomib care track registrations, performance registrations, 
average bortezomib administrations per patient, and hospitals registering bortezomib are 
described. A bortezomib care track registration indicates the number of patients receiving 
bortezomib, whereas the bortezomib performance registration indicates how often these 
patients received bortezomib. The table shows that the number of patients treated with 
bortezomib and the average number of administrations per patient increased over the 
years for most hospital types. In addition, each of the different types of hospitals registered 
bortezomib treatment. However, the table also indicates that the DBC data is incomplete. 
For example, according to the DBC data, only two academic hospitals used bortezomib. 
We collected data from patients receiving bortezomib in six different academic hospitals, 
thus revealing that not all (academic) hospitals register bortezomib utilisation. Additionally, 
dividing performance registrations by the care track registrations indicates the average 
number of bortezomib administrations per patient. According to the DIS data, patients 
receive on average 6 to 13 prescriptions, while pilot patients received on average 17.26 
bortezomib administrations. Therefore, the results must be interpreted cautiously and the 
DIS data can only be used to indicate an increased usage over the years and to show that 
all types of hospitals administer bortezomib.  
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Table 3.10: DIS registration of hospitals using bortezomib 
Year 2006 2007 2008 Total
Type of hospital
General hospital small (n=37)
bortezomib care track registrations 10 25 33 68
bortezomib performance registrations 77 288 435 800
average number of administrations per patient 7.7 11.5 13.2 11.8
number of hospitals registering  bortezomib 7 12 13
General hospital medium (n=28)
bortezomib care track registrations 15 27 45 87
bortezomib performance registrations 90 273 452 815
average number of administrations per patient 6.0 10.1 10.0 9.4
number of hospitals registering  bortezomib 7 11 12
General hospital large (n=10)
bortezomib care track registrations 8 7 17 32
bortezomib performance registrations 85 82 155 322
average number of administrations per patient 10.6 11.7 9.1 10.1
number of hospitals registering  bortezomib 2 3 4
General hospital topclinical (n=20)
bortezomib care track registrations 27 48 74 149
bortezomib performance registrations 241 608 757 1606
average number of administrations per patient 8.9 12.7 10.2 10.8
number of hospitals registering  bortezomib 5 11 14
Academic hospital (n=8)
bortezomib care track registrations 6 6 8 20
bortezomib performance registrations 43 78 62 183
average number of administrations per patient 7.1 13.0 7.75 9.15
number of hospitals registering  bortezomib 1 1 2
Unknown
bortezomib care track registrations 8 8
bortezomib performance registrations 51 51
average number of administrations per patient 6.4 6.4
number of hospitals registering  bortezomib 2
Total
bortezomib care track registrations 66 113 185 364
bortezomib performance registrations 536 1329 1912 3777
average number of administrations per patient 8.1 11.8 10.3 10.4
number of hospitals registering  bortezomib 22 38 47  
 
The Dutch Foundation for Pharmaceutical Figures (SFK) monitors expenditure for 
expensive inpatients pharmaceuticals. Their report shows a similar trend in the diffusion of 
bortezomib according to the DBC data. In 2006, national bortezomib expenditure was €3.3 
million, and this increased to €5.7 million in 2007 (Stichting Farmaceutische Kengetallen 
2009). 
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 Finally, sales data provided by the manufacturer (Janssen-Cilag) shows a similar 
diffusion pattern over the years. Figure 3.5 depicts the number of packages delivered to 
Dutch hospitals from 2004 to 2009, excluding bortezomib used in clinical trials.  
 
Figure 3.5: Bortezomib sales figures 
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Source: Janssen-Cilag 
 
Furthermore, we compared the estimated prevalence of multiple myeloma with sales data 
from the manufacturer. Figure 3.6 presents the percentage of multiple myeloma patients 
treated in daily practice with bortezomib per cancer registration region from 2006 to 2009. 
The figure shows a similar increasing trend of bortezomib utilisation over the years and 
indicates a long adjustment period. Although several assumptions were made to calculate 
the prevalence, there appears to be a residual regional difference in 2009. These results 
indicate that while the policy for expensive pharmaceuticals might have had a positive 
effect on bortezomib utilisation over the years, residual regional variation may exist which 
might point towards residual accessibility issues despite the revision of the policy 
regulations. It should be noted that the estimations are based on sales data and must be 
carefully interpreted since bortezomib usage in clinical trials is not included. For example, 
our data revealed that 31 of the 543 HOVON50 patients received bortezomib in a clinical 
trial (see Figure 3.1). Further investigation is required to reveal if these differences are 
caused by regional variation in trial participation or related to accessibility issues or due to 
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assumptions made for calculations, such as incidence fluctuations over time, regional 
variation in patient characteristics, or due to chance. 
 
Figure 3.6: Percentage of patients treated with bortezomib per cancer registration region 
Percentage of patients treated with bortezomib per region
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3.3 Clinical effectiveness 
We explored the feasibility and validity of the possible outcomes available to demonstrate 
effectiveness of bortezomib in daily clinical practice. 
 
Overall survival (OS) 
OS can be measured in this patient population either from diagnosis or start of treatment 
for relapsed/refractory disease. We first considered the outcome OS from start of 
relapsed/refractory treatment, as this is the relevant survival measure reported in the 
literature when assessing effectiveness of relapsed/refractory treatment for multiple 
myeloma. Figure 3.7 reveals bortezomib to have no statistically significant advantage in 
OS from start of relapsed/refractory (mean: 29.5; median: 33.2) compared to those who 
never received bortezomib (mean: 28; median: 21.6), despite a longer mean and median 
survival (logrank p = 0.308). However, the Wilcoxan statistic, which is a non-parametric 
test statistic that is more sensitive to the differences in survival at early points in time, was 
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significant (p = 0.01). Therefore, the survival curves for both groups are significantly 
different when considering the ratio of hazards at the early points in times rather than 
equally throughout time. This is not a surprising result as we see that the curves are far 
apart at early points in time and eventually cross around 40 months of survival (Figure 
3.7). The crossing of the curves is likely due to the low number of patients still in follow-up 
after approximately 36 months. That is, 14 patients remain after 36 months in each group, 
accounting for 19% and 21% of the patient population in the group of patients ever versus 
never receiving bortezomib, respectively. 
 
Figure 3.7: Kaplan-Meier curves of overall survival from start of relapsed/refractory treatment 
stratified by receipt of bortezomib  
 
 
Due to the relevance of previous treatment to the effectiveness of subsequent treatment, 
we further stratified the outcome based on HOVON50 treatment arm and found a 
marginally insignificant logrank statistic (p = 0.056) but a significant Wilcoxan statistic (p = 
0.015) (Figure 3.8). It is reasonable to conclude that the patient groups when defined by 
never versus ever receiving bortezomib have statistically significant differences in OS in 
the early months following relapsed/refractory treatment but that the difference is not 
carried over throughout the remaining survival due to low number of observations. It is also 
reasonable to conclude that HOVON50 treatment has a further effect on survival in 
addition to that of receipt of bortezomib, with patients receiving no thalidomide prior to 
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bortezomib treatment doing better in terms of OS from start of relapsed/refractory 
treatment compared to those receiving thalidomide. 
 
Figure 3.8: Kaplan-Meier curves of overall survival from start of relapsed/refractory treatment 
stratified by receipt of bortezomib and HOVON50 treatment randomization 
 
 
To assess whether patients who received bortezomib at the earliest moment of eligibility, 
i.e., second line, OS from start of relapsed/refractory treatment was compared between 
patients receiving bortezomib in second line to those not receiving it in second line. A 
statistically significant advantage for bortezomib treatment was absent when comparing 
patients who received bortezomib in second line compared those who either never 
received bortezomib or received it in third line or later (logrank p = 0.791; Wilcoxan p: 0.83) 
and when further stratifying by HOVON50 treatment arm (logrank p = 0.328; Wilcoxan: 
0.58) (Figures 3.9 and 3.10). These results suggest no advantage in OS from start of 
relapsed/refractory treatment for patients receiving bortezomib in second line compared to 
those either never receiving it or receiving it at a later point in relapsed/refractory 
treatment. 
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Figure 3.9: Kaplan-Meier curves of overall survival from start of relapsed/refractory treatment 
stratified by receipt of bortezomib in 2nd line 
 
 
Figure 3.10: Kaplan-Meier curves of overall survival from start of relapsed/refractory treatment 
stratified by receipt of bortezomib in 2nd line and HOVON50 treatment arm 
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We explored the difference in survival between all four groups defined by treatment line of 
bortezomib from start of relapsed/refractory treatment (Figure 3.11). When examining OS 
from start of relapsed/refractory treatment for the four patient groups, again the difference 
in survival was significant only when weighted by the proportion of events occurring at 
early points in time (logrank p = 0.41; Wilcoxan p = 0.04). Mean and median OS favoured 
receipt of bortezomib in third line (mean: 31; median: 35.4) followed by receipt in fourth 
line or later (mean: 31.6; median: 32.5). Patients receiving bortezomib in second line were 
the worse off when comparing mean estimates (mean: 18.8; median: 24); and patients 
never receiving bortezomib were worse off when comparing medians (mean: 28; median: 
21.6). Considering the significant results of the Wilcoxan test, it is reasonable to conclude 
that the four patient groups are distinct and should be assessed individually.  
 
Figure 3.11: Kaplan-Meier curves of overall survival from start of relapsed/refractory treatment 
stratified by line of bortezomib treatment  
 
 
Further stratification by HOVON50 treatment resulted in a statistically insignificant effect 
on OS from start of relapsed/refractory treatment between the four groups (logrank p = 
0.16; Wilcoxan: p = 0.08) (Figure 3.12). However, a pattern favouring an advantage for 
bortezomib patients receiving no thalidomide in HOVON50 as demonstrated previously 
was difficult to discern due to the small number of observations in each of the 8 groups. 
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Therefore, the effect of HOVON50 treatment was no longer considered when comparing 
the 4 patient groups. 
 
Figure 3.12: Kaplan-Meier curves of overall survival from start of relapsed/refractory treatment 
stratified by line of bortezomib treatment and HOVON50 treatment arm 
 
 
As many studies report the OS from start of treatment with the baseline being start of 
bortezomib treatment, regardless of the treatment line it is received in, the mean and 
median OS from start of bortezomib treatment for all bortezomib patients was also 
calculated to facilitate comparisons to previous studies. The mean and median OS 
estimates from the start of bortezomib treatment were 19.4 and 17.2 months, respectively. 
 It is also relevant to report the OS from start of bortezomib treatment for the 
respective line when bortezomib was administered. This outcome would be useful in 
assessing how the cost-effectiveness of bortezomib changes when administered farther 
along in relapsed/refractory treatment. Mean and median OS estimates from start of 
respective line when bortezomib was administered in second line are discussed above 
(mean: 18.8; median: 24). Mean and median OS estimates from start of third line for 
patients treated with bortezomib in third line was 21.5 and 24.2 months, respectively 
(curves not shown). For patients receiving bortezomib in fourth line or later, mean and 
median OS estimates from fourth line was 10.4 and 11.6 months, respectively (curves not 
shown). 
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Time-to-next-treatment (TTNT) and time-to-progression (TTP) 
Time-to-event curves when examining the outcomes TTNT and TTP within each line 
stratified on receipt of bortezomib versus any other treatment revealed counterintuitive 
results which also suggested no advantage to bortezomib treatment (data not shown). 
Patients treated with bortezomib either progressed or started subsequent treatment lines 
sooner compared to patients who received other treatment during each line conditional on 
no history of receiving bortezomib in previous lines. For example, in second line, median 
TTNT for bortezomib patients was 11.7 months compared to 13.9 for patients not treated 
with bortezomib in second line. Similarly, in third line, median TTNT for bortezomib 
patients was 10.8 months compared to 11.4 for patients not treated with bortezomib in 
third line conditional on never having received bortezomib previously. Consequently, TTP 
and TTNT were decided to be inappropriate for outcomes for demonstrating the 
incremental effectiveness of bortezomib in daily practice. As progression-free survival 
(PFS) is correlated with both TTP and TTNT, its use as an outcome was assumed to be 
inappropriate as well and, consequently, was not assessed. 
 The primary outcome measures of time to first response, time to best response, 
and DOR are not possible with the pilot data because detailed follow-up regarding 
response to treatment was not collected, as it was not available in patient charts; only best 
response was recorded by treatment line. 
 
Selected effectiveness outcome 
After an exploration of the possible outcomes available to demonstrate the effectiveness of 
bortezomib in daily clinical practice, it was decided that clinical effectiveness would be 
calculated in terms of overall survival (OS), with baseline being diagnosis. This decision 
was based on the inconclusive results obtained when examining the outcome of OS from 
start of relapsed/refractory treatment and the counterintuitive results obtained when 
examining either TTP or TTNT within each line. 
As mentioned previously, the validity of an incremental effectiveness estimate 
depends on the extent to which confounding by indication is present. To explore the extent 
to which we could correct confounding by indication, adjustment of survival curves was 
attempted by the following methods: average covariate adjustment, PS adjustment and 
matched survival analysis. The methods of average covariate and PS adjustment were 
feasible. The method of matched survival analysis was deemed uninformative after 
exploration of the feasibility of creating matched groups. The limitation to conducting the 
- 47 - 
matched method was primarily due to low numbers of eligible matches. A total of 4 
matches were found to be possible, with 1 patient from each of the 4 groups being 
matched to one another on the basis of PS. A total population of 16 was deemed 
insufficient to gather informative results. Therefore, only the results of the covariate and 
PS adjusted survival analysis are presented. 
 Clinical effectiveness is shown separately for patients treated with bortezomib from 
those never treated with bortezomib. The rationale for presenting the patients treated with 
bortezomib from those not treated with bortezomib is to discourage comparison of the 
groups and instead to first objectively examine the OS for both groups without forcing 
comparison of groups for which may be inappropriate.  
3.3.1 Clinical effectiveness for patients treated with bortezomib 
To ensure equal follow-up between all four groups, OS estimates from diagnosis were 
censored after the last available follow-up estimate for the group of patients with the 
shortest total follow-up. The group of patients with the shortest available follow-up was the 
group of patients treated with bortezomib in second line because this group was still 
treated at the time data collection. Accordingly, patients in all four groups with follow-up 
available after 76 months were censored. 
 
No adjustment 
The unadjusted curves for the patient groups treated with bortezomib reveal that the 
median OS from diagnosis for patients exposed in the second line has not been reached, 
while the median OS from diagnosis for patients exposed in third line and fourth line or 
later is 59.3 and 48.5, respectively (Figure 3.13). Estimates of mean unadjusted estimates 
for such patient groups reveals that patients exposed in third line have the longest OS 
(mean OS = 55.5), followed by patients exposed in second line (mean OS = 52.2), while 
patients exposed in fourth line survive from diagnosis on average for the shortest duration 
(mean OS = 50.1). The logrank statistic is significant (p = 0.01), suggesting that the 
difference in survival between the three groups is statistically significant.  
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Figure 3.13: Kaplan-Meier curves for overall survival of patients treated with bortezomib stratified by 
line of treatment 
 
 
Adjusted survival curves 
Adjusted OS curves reveal minor changes in the overall shape of the graph. However, with 
covariate adjustment, the survival estimates are slightly increased compared to estimates 
resulting with PS adjustment (Figure 3.14). 
As a result of the increase, the median OS estimates for patients exposed in 
second or third line were not available, while patients exposed in fourth line or later 
survived from diagnosis at a median of 50.7 months. Comparison of the mean estimates of 
OS after covariate adjustment reveals a similar pattern as that of the unadjusted analysis, 
with patients exposed in third line having the longest OS (mean OS = 63.3), followed by 
patients exposed in second line (mean OS = 59.3), while patients exposed in fourth line 
survive from diagnosis on average for the shortest duration (mean OS = 52.1). The 
absolute difference between the mean OS estimates of all three groups is more spread out 
after covariate adjustment in comparison to the unadjusted estimates. 
When comparing the mean OS estimates resulting after PS adjustment to the 
mean unadjusted and covariate adjusted estimates, again a similar pattern is revealed, 
with patients exposed in third line have the longest OS (mean = 58.8; median = 63.5), 
followed by patients exposed in second line (mean OS = 57.9; median = 59.9), while 
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patients exposed in fourth line survive from diagnosis on average for the shortest duration 
(mean OS = 44.1; median = 49). In contrast, the difference between mean OS estimates 
after PS adjustment for patients treated in second line to patients treated in third line is 
compressed to the largest degree out of all three analytical methods with the difference 
being less than 1 month. Lastly, the PS adjusted method produces the shortest mean 
estimate for survival from diagnosis for patients exposed in fourth line or later. 
 
Figure 3.14: Adjusted overall survival for patients treated with bortezomib stratified by line of 
treatment 
 
 
Comparison of estimates 
Patients treated with bortezomib in second and third line in this pilot study appear to live 
the longest. It is interesting to note that the method of average PS adjustment results in a 
longer median OS compared to the mean OS for patients treated in fourth line or later, 
which is in contrast to a longer mean OS compared to the median as observed from the 
unadjusted and average covariate adjusted analyses. 
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Table 3.11: Comparison of mean and median OS estimated with and without adjustment in patients 
receiving bortezomib 
Bortezomib 
treatment 
status
% 
Censored
Mean Median Mean Median Mean Median
2 68% 52.2 NA 59.3 NA 57.9 59.9
3 54% 55.5 59.3 63.3 NA 58.8 63.5
4+ 8% 50.1 48.5 52.1 50.7 44.1 49.0
No Adjustment
Average covariate 
adjustment
Average PS 
adjustment
 
 
3.3.2 Clinical effectiveness for patients not treated with bortezomib 
No adjustment 
The unadjusted survival curve for patients never treated with bortezomib reveals a mean 
OS estimate of 45.9 months and a median of 56 months (Figure 3.15). When disregarding 
censoring patients with follow-up longer than 76 months, follow-up estimates for patients 
never receiving bortezomib ranged between 2.5 and 84.8 months, suggesting extensive 
variation in survival within this group.  
 
Figure 3.15: Kaplan-Meier curves for overall survival of patients never treated with bortezomib 
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Adjusted survival curves 
Adjustment of the OS for patients never treated with bortezomib by means of the covariate 
adjustment method reveals an extended mean and median OS estimate of 59.3 and 67.1, 
respectively, compared to the unadjusted estimates (Figure 3.16). Mean and median OS 
estimates after PS adjustment were 57.6 and 60.1, respectively, which are similarly higher 
compared to the unadjusted estimates but lower than that after covariate adjustment. 
 
Figure 3.16: Adjusted overall survival for patients never treated with bortezomib 
 
 
Comparison of estimates 
The OS for patients never receiving bortezomib is greatly extended by the average 
covariate method, regardless of reporting the mean or median (Table 3.12). 
 
Table 3.12: Comparison of mean and median OS estimated with and without adjustment in patients 
never receiving bortezomib 
Bortezomib 
treatment 
status
% 
Censored
Mean Median Mean Median Mean Median
Never 46% 45.9 56.0 59.3 67.1 57.6 60.1
No Adjustment
Average covariate 
adjustment
Average PS 
adjustment
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3.3.3 Summary of clinical effectiveness for all patient groups 
Patients that appear to have the most survival gain from bortezomib treatment are those 
treated in second and third line. In general, the adjusted survival curves do not differ in 
overall shape from their unadjusted counterparts. Comparison of the adjusted OS 
estimates reveals two consistent results (Table 3.11 and 3.12): (1) both methods lead to 
extended mean and median OS estimates compared to the crude, with the exception of 
adjustment for the group exposed in fourth line or greater for which the OS estimates 
adjusted by means of the PS are reduced; (2) adjustment by means of covariates results 
in the most extended mean and median estimates of all three analyses. 
3.4 Costs in clinical practice 
3.4.1 Costs in clinical practice for patients treated with bortezomib 
Table 3.13 presents the total mean treatment costs for all patients ever receiving 
bortezomib (n=72). These cost analyses were based on the resource use of the full patient 
sample including patients still treated at the end of the data collection.  
The mean follow-up duration was 26 (SD 14.4) months. Total mean treatment costs 
amounted to €81,626 but varied widely between patients. Treatment costs ranged from 
€17,793 to €229,783, with the most expensive patient receiving lenalidomide in line 6 for 
approximately one year. Inpatient hospital days and active treatment were the most 
important cost drivers.  
With total mean costs of €30,733 (SD 24,654), active treatment (excluding stem 
cell transplantation) was responsible for 38% of the total mean treatment costs. 
Bortezomib accounted for 57% and lenalidomide for 35% of the active treatment costs.  
 Inpatient hospital day costs amounted to a mean €12,294 (SD 13,769). Patients 
were admitted for an average of 23.4 (SD 26.7) inpatient days. As expected, inpatient 
hospital days were especially important in patients receiving stem cell transplantation.  
Table 3.13 also presents the total mean treatment costs separately for patients receiving 
bortezomib in the second (n=25), third (n=35) and fourth+ (n=12) treatment line. 
Compared with patients receiving bortezomib in the second line, total costs were 
substantially higher for patients receiving bortezomib in the third line (€53,726 versus 
€95,962; Mann-Whitney U test: p = 0.002). A similar trend was observed when comparing 
- 53 - 
patients receiving bortezomib in second line to those receiving the drug in fourth line or 
later (€53,726versus €97,937; Mann-Whitney U test: p = 0.027). The significantly lower 
results for patients treated with bortezomib in second line are not surprising since the 
majority of patients (68%) treated in second line were still in follow-up at the time of data 
collection compared to 54% and 8% of patients in third line and fourth+ line, respectively.  
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Table 3.13: Total mean costs per patient treated with bortezomib 
Resource Use (numbers) Mean SD Mean SD Mean SD Mean SD
Inpatient hospital days 23.4 26.7 13.4 18.7 26.2 30.4 36.1 23.5
Intensive care days 0.3 1.4 0.4 2.0 0.3 1.1 0.2 0.6
Outpatient visits 51.6 35.5 32.6 29.4 55.4 30.4 79.9 40.6
Consultations by telephone 3.9 5.0 3.3 4.5 4.0 2.9 5.1 9.5
Day-care treatments 28.7 17.9 23.3 14.4 30.1 17.2 36.1 24.0
Emergency room visits 1.5 2.0 1.2 2.1 1.4 1.7 2.3 2.3
Costs (Euro 2009)
Inpatient hospital days € 12,294 € 13,750 € 6,708 € 9,767 € 14,115 € 15,476 € 18,619 € 12,112
Intensive care unit days € 607 € 2,909 € 832 € 4,160 € 535 € 2,219 € 347 € 1,201
Outpatient visits € 5,676 € 3,902 € 3,590 € 3,234 € 6,097 € 3,343 € 8,791 € 4,461
Consultations by telephone € 51 € 65 € 43 € 59 € 52 € 38 € 66 € 124
Day-care treatments € 4,799 € 2,993 € 3,894 € 2,402 € 5,024 € 2,872 € 6,026 € 4,010
Emergency room visits € 160 € 216 € 131 € 231 € 153 € 189 € 245 € 251
Radiotherapy € 1,971 € 3,139 € 398 € 722 € 2,511 € 3,574 € 3,675 € 3,640
Surgical procedures € 766 € 2,058 € 262 € 1,070 € 905 € 2,495 € 1,407 € 2,127
Other diagnostic procedures € 172 € 286 € 85 € 166 € 187 € 301 € 308 € 387
Laboratory € 4,642 € 3,466 € 2,593 € 1,963 € 5,356 € 3,773 € 6,832 € 2,955
Pathology € 114 € 122 € 47 € 81 € 140 € 112 € 182 € 160
Bacterial cultures € 190 € 288 € 74 € 119 € 221 € 343 € 342 € 285
Viral cultures € 71 € 207 € 11 € 31 € 80 € 237 € 171 € 287
Xrays € 897 € 584 € 521 € 486 € 1,000 € 528 € 1,385 € 455
CT scans € 277 € 421 € 158 € 330 € 338 € 496 € 346 € 311
MRIs € 315 € 441 € 173 € 290 € 409 € 521 € 337 € 401
Radionucleide scans € 10 € 58 € 0 € 0 € 10 € 59 € 29 € 101
PET scans € 745 € 2,009 € 564 € 1,822 € 1,008 € 2,385 € 353 € 877
Ultrasounds € 65 € 140 € 34 € 66 € 86 € 177 € 65 € 128
Antibacterial medication (prophylaxis) € 2,560 € 2,413 € 1,793 € 1,770 € 2,505 € 2,428 € 4,320 € 2,793
Antibacterial medication (acute infection) € 238 € 213 € 178 € 180 € 296 € 236 € 194 € 168
Biphosponates (prophylaxis) € 2,776 € 2,044 € 1,434 € 1,454 € 3,541 € 2,017 € 3,342 € 1,867
Transfusion of ery’s € 1,298 € 3,141 € 539 € 1,702 € 1,381 € 3,628 € 2,635 € 3,660
Erythropoietin € 166 € 388 € 75 € 183 € 206 € 449 € 238 € 496
Transfusion of platelets € 986 € 2,553 € 572 € 1,990 € 1,056 € 2,998 € 1,643 € 2,187
Chronic neurotoxicity medication € 745 € 1,915 € 831 € 1,615 € 735 € 2,104 € 595 € 2,061
Chronic gastro-intestinal medication € 3,670 € 3,887 € 1,929 € 2,065 € 4,513 € 4,457 € 4,838 € 4,021
Chronic analgesics € 664 € 671 € 371 € 376 € 853 € 767 € 725 € 684
Thalidomide € 514 € 708 € 84 € 239 € 776 € 846 € 643 € 489
Bortezomib € 17,407 € 11,143 € 16,914 € 9,563 € 18,927 € 12,536 € 13,999 € 9,779
Dexamethasone € 103 € 127 € 67 € 88 € 100 € 89 € 188 € 228
Adriamycin € 133 € 268 € 101 € 248 € 92 € 162 € 320 € 451
Vincristine € 25 € 61 € 12 € 43 € 18 € 48 € 75 € 96
Lenalidomide € 10,769 € 18,062 € 7,550 € 14,487 € 15,629 € 21,551 € 3,298 € 7,258
Melphalan € 76 € 202 € 0 € 0 € 65 € 148 € 266 € 377
Prednisone € 21 € 78 € 2 € 5 € 32 € 110 € 29 € 23
Cyclophosphamide € 17 € 40 € 6 € 16 € 23 € 53 € 24 € 31
Donor leukocyte infusions € 1,594 € 3,015 € 1,124 € 2,354 € 1,941 € 3,431 € 1,561 € 3,051
Interferon alpha € 22 € 134 € 27 € 133 € 27 € 158 € 0 € 0
Stem cell transplantation € 3,969 € 13,313 € 0 € 0 € 4,960 € 15,399 € 9,345 € 18,456
Other active treatment € 52 € 269 € 0 € 0 € 61 € 278 € 134 € 462
Total global costs € 81,626 € 47,246 € 53,726 € 27,956 € 95,962 € 51,484 € 97,937 € 42,382
Median € 72,182 € 47,906 € 78,788 € 85,051
Minimum € 17,793 € 17,793 € 37,567 € 30,234
Maximum € 229,783 € 115,793 € 229,783 € 186,372
 All bmib patients 
(n=72) 
 Bmib 2nd line 
(n=25) 
 Bmib 4th+ line 
(n=12) 
 Bmib 3rd line 
(n=35) 
 
 
Table 3.14 presents the proportion of the total costs for the most costly individual cost 
components that explain the majority of the total global costs for patients treated with 
bortezomib. The share of total global costs explained by costs for hospital days, 
concomitant medication, resource use and active treatment is also shown. The top three 
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individual cost components that explain the largest of proportion of total global costs 
include bortezomib treatment (21%), inpatient hospital stays (15%) and lenalidomide 
treatment (13%). Furthermore, costs for active treatment accounted for almost half of total 
global costs for bortezomib patients, followed by costs for all other resource use excluding 
costs for inpatient and intensive care unit hospital days, which accounted for one-fourth of 
total global costs.  
 
Table 3.14 Proportion of total costs explained by cost components 
Cost components (Euro 2009)
 All bmib 
patients (n=72) 
Inpatient hospital days 15%
Intensive care unit days 1%
Outpatient visits 7%
Day-care treatments 6%
Laboratory 6%
Bortezomib 21%
Lenalidomide 13%
Stem cell transplantation 5%
Total % explained by above components 72%
Total hospital day costs* 15%
Total concomitant medication costs 16%
Total resources use costs** 25%
Total active treatment costs 44%
*includes inpatient and intensive care unit days  
**excludes hospital day costs  
3.4.2 Costs in clinical practice for patients not treated with bortezomib 
Table 3.15 presents the total mean treatment costs for patients never receiving bortezomib 
(n=67). These cost analyses were based on the resource use of the full patient sample 
including patients still treated at the end of the data collection. The mean follow up 
duration was 21.5 (SD 16) months. Total mean treatment costs amounted to €52,760 but 
varied widely between patients. Treatment costs ranged from €748 to €179,571, with the 
most expensive patients consuming substantial high proportions of their total costs for 
hospital stays, resource use and active treatment. Inpatient hospital days and cost of 
lenalidomide therapy were the most important cost drivers for the entire group.  
With total costs of €10,409 (SD 24,340), active treatment (excluding stem cell 
transplantation) was responsible for 20% of the total mean treatment costs. Lenalidomide 
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accounted for 86% of the total active treatment costs and stem cell transplant accounted 
for 8% of total costs.  
Inpatient hospital days amounted to €12,168 (SD 13,843) and stem cell 
transplantations to €4,412 (SD 10,937). Patients were admitted for an average of 23.6 (SD 
26.8) inpatient days. Inpatient hospital days were especially important in patients receiving 
stem cell transplantation.  
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Table 3.15: Total mean costs for all patients never receiving bortezomib 
Resource Use (numbers) Mean SD
Inpatient hospital days 23.6 26.8
Intensive care days 1.1 2.9
Outpatient visits 33.9 36.6
Consultations by telephone 2.3 4.0
Day-care treatments 6.8 9.9
Emergency room visits 0.6 1.0
Costs (Euro 2009)
Inpatient hospital days € 12,168 € 13,843
Intensive care unit days € 2,297 € 6,071
Outpatient visits € 3,732 € 4,023
Consultations by telephone € 30 € 53
Day-care treatments € 1,132 € 1,653
Emergency room visits € 65 € 111
Radiotherapy € 1,698 € 2,623
Surgical procedures € 1,383 € 3,035
Other diagnostic procedures € 265 € 1,255
Laboratory € 4,106 € 4,899
Pathology € 97 € 113
Bacterial cultures € 192 € 276
Viral cultures € 91 € 262
Xrays € 762 € 789
CT scans € 245 € 308
MRIs € 290 € 459
Radionucleide scans € 21 € 83
PET scans € 274 € 894
Ultrasounds € 75 € 113
Antibacterial medication (prophylaxis) € 1,869 € 2,802
Antibacterial medication (acute infection) € 139 € 120
Biphosponates (prophylaxis) € 2,440 € 2,249
Transfusion of ery’s € 368 € 867
Erythropoietin € 296 € 867
Transfusion of platelets € 294 € 1,170
Chronic neurotoxicity medication € 118 € 962
Chronic gastro-intestinal medication € 2,970 € 3,960
Chronic analgesics € 522 € 690
Thalidomide € 818 € 957
Bortezomib € 0 € 0
Dexamethasone € 67 € 69
Adriamycin € 39 € 105
Vincristine € 6 € 20
Lenalidomide € 8,923 € 24,282
Melphalan € 67 € 124
Prednisone € 7 € 15
Cyclophosphamide € 9 € 23
Donor leukocyte infusions € 467 € 1,310
Interferon alpha € 6 € 49
Stem cell transplantation € 4,412 € 10,937
Other active treatment € 0 € 0
Total global costs € 52,760 € 45,865
Median € 36,882
Minimum € 748
Maximum € 179,571
Never Bmib (n=67)
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Table 3.16 presents the proportion of the total costs for the most costly individual cost 
components that explain the majority of the total global costs for patient never treated with 
bortezomib. The share of total global costs explained by costs for hospital days, 
concomitant medication, resource use and active treatment is also shown. The individual 
cost components that explain the largest of proportion of total global costs include inpatient 
hospital stays (22%) and lenalidomide treatment (16%), followed by costs for laboratory 
tests (8%) and stem cell transplant (8%). Costs for active treatment costs consume nearly 
one-third of total global costs for patients never treated with bortezomib, followed by costs 
for all other resource use excluding costs for inpatient and intensive care unit hospital days 
and total hospital day costs, each accounting for 27% of total global costs.  
 
Table 3.16: Proportion of total costs explained by cost components 
Cost components (Euro 2009)
 Never 
Bmib (n=67) 
Inpatient hospital days 22%
Intensive care unit days 4%
Outpatient visits 7%
Day-care treatments 2%
Laboratory 8%
Bortezomib 0%
Lenalidomide 16%
Stem cell transplantation 8%
Total % explained by above components 68%
Total hospital day costs* 27%
Total concomitant medication costs 17%
Total resources use costs** 27%
Total active treatment costs 30%
*includes inpatient and intensive care unit days  
**excludes hospital day costs  
3.4.3 Overview treatment costs within treatment lines 
Figure 3.17 presents an overview of total mean costs and costs per treatment line for both 
patients receiving bortezomib and patients never treated with bortezomib. These cost 
analyses were based on the resource use of the full patient sample including patients still 
treated at the end of the data collection. In order to determine whether the inclusion of 
these patients influenced our cost estimates, cost analyses were additionally conducted 
solely for patients whose resource use was collected until the end of treatment. P-values 
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shown are for comparison of the differences between total costs when including versus 
excluding patients still treated at the end of the data collection. 
 
Figure 3.17: Overview treatment costs (including patients still treated at the end of data collection) 
Patients receiving 
bortezomib
Patients never 
receiving 
bortezomib
€81,626 
n=72
(p=0.54)
MEAN TOTAL COSTS 
ALL LINES
Bmib €36,068 
n=25
(p=0.13)
No bmib  €20,189 
n=47
(p=0.966)
No bmib  €32,877 
n=6
(p=0.53)
No bmib  €18,111 
n=13
(p=1)
Bmib  €38,213
n=35
(p=0.6)
No bmib  €20,481 
n=12
(p=0.83)
Bmib      €23,225 
n=12
(p=0.5)
No bmib  €30,828 
n=21
(p=0.82)
Bmib  €28,465
n=5
(p=1)
€51,280 
n=10
(p=0.257)
€35,057 
n=30
(p=0.09)
€28,239 
n=67
(p=0.044)
€52,760 
n=67 
(p=0.02)
MEAN COSTS 2nd line MEAN COSTS 3rd line MEAN COSTS ≥4
th
line 
 
P-values shown for comparison of the differences between total costs when including versus excluding 
patients still treated at the end of the data collection. 
 
For patients treated with bortezomib, the cost difference between patients whose resource 
use was collected until the end of treatment and patients still treated at the end of the data 
collection was not significant (Mann-Whitney U test: p = 0.54). For patients never receiving 
bortezomib, this cost difference was significantly greater (Mann-Whitney U test: p = 0.02). 
This cost differences was predominantly owing to the substantially higher costs for 
lenalidomide (Mann-Whitney U test: p = 0.004), donor leukocyte infusions (Mann-Whitney 
U test: p = 0.02) and stem cell transplants (Mann-Whitney U test: p = 0.056) among 
patients who were still treated at the end of data collection.  
 Figure 3.17 presents the by-line line treatment costs for patients ever receiving 
bortezomib (n=72) including patients still being treated at follow-up. The mean follow-up 
duration was 10.4 (SD 5.33) months versus 13.3 (SD 9.6) months for bortezomib patients 
receiving bortezomib in second line versus those receiving other. Mean costs were 
€15,879 higher for patients receiving bortezomib (n=25/72) compared with patients not 
receiving bortezomib (n=47/72; Mann-Whitney U test: p = 0.000).  
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 Figure 3.17 presents the third line treatment costs for patients ever receiving 
bortezomib (n=60). The mean total costs of third line and follow up duration for all 
bortezomib patients receiving third line was €30,311 (SD 25,831) and 7.6 (SD 4.9) months. 
Twelve of the 25 patients receiving bortezomib in the second line did not receive any 
treatment in the third line because they were either still treated in the second line at the 
end of the data collection (8/12), experienced no further benefit from treatment (3/12) or 
died (1/12). The remaining 13/25 patients received any treatment in the third line at a total 
cost of third line treatment equal to €18,111 (SD 16,521) and a mean total follow-up of 6.2 
(SD 5.1) months.  
 All of the 47 patients who did not receive bortezomib in the second line treatment 
received some sort of treatment in the third line, with 35 receiving bortezomib. Mean total 
follow-up for the 35 bortezomib patients was 7.3 (SD 4.3) months compared to 10.1 (SD 
5.9) among patients not receiving bortezomib (n=12). Third line costs were €18,964 higher 
for patients receiving bortezomib (n=35/47) compared with all patients not receiving 
bortezomib in third line irrespective of receiving bortezomib in second line (n=25/47; Mann-
Whitney U test: p = 0.01).  
 Figure 3.17 presents the fourth+ line treatment costs for patients ever receiving 
bortezomib (n=44). Seven of the 13 patients receiving bortezomib in the second line but 
not in the third line did not receive any treatment in the fourth+ line because they were 
either still treated in the third line at the end of the data collection (5/7) or died (2/7). The 
remaining 6/13 patients received some sort of treatment in the fourth+ line at a total mean 
cost for fourth+ line equal to €32,877 (SD 12,915) and a total mean follow-up of 9.25 (SD 
4.6) months. None of these patients received bortezomib. 
 Nine of the 35 patients receiving bortezomib in the third line but not in the second 
line did not receive any treatment in the fourth+ line because they were either still treated 
in the third line at the end of the data collection (5/9) or died (4/9). The remaining 26/35 
patients received some sort of treatment in the fourth+ line, with 5 receiving bortezomib. 
Mean total costs for fourth+ line for patients receiving bortezomib (n=5/26) compared with 
patients not receiving bortezomib were not found to be significantly different (n=21/26; 
Mann-Whitney U test: p = 0.18). Mean total follow-up in fourth+ line was 20.8 (SD 18.2) 
and 11.8 (SD 9) for patients receiving bortezomib compared to those not receiving 
bortezomib. The longer follow-up in patients receiving bortezomib in third and fourth line or 
later contributes greatly to the higher costs in fourth+ line seen in these patients. The 
higher costs are also attributable to two unique patients: one patient who received 
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bortezomib in third, fifth and sixth line and to a second patient who received bortezomib in 
third, fourth, fifth and sixth line. 
Twelve of the 12 patients who neither received bortezomib in the second nor third 
line treatment received bortezomib in the fourth line or later. Mean total costs for fourth+ 
line for these patients amounted to €23,225 (SD 21,312) and a total mean follow of 11.7 
(SD 6) months. 
Finally, Figure 3.17 also presents the mean total costs by-line for patients never 
treated with bortezomib. The mean total costs for second, third and fourth+ line were 
€28,239 (SD 31,146), €35,057 (SD 36,263) and €51,280 (SD 45,541), respectively. Total 
mean follow-up for each respective line were 15.7 (SD 14.4), 10.6 (SD 10.4) and 7.3 (SD 
5.5) months. The substantially higher costs in the fourth+ line were mainly attributable to 
costs of lenalidomide treatment, stem cell transplants and inpatient hospital stays.  
3.4.4 Sensitivity analyses 
Varying the unit costs of inpatient hospital days, day-care treatments and outpatient visits 
between 50% and 150% appeared to have a rather modest influence on the total mean 
costs with the greatest influence when varying the unit price for inpatient hospital days.  
 For patients treated with bortezomib, total mean costs varied from €75,176 to 
€88,076 when inpatient hospital day unit costs were varied, from €79,227 to €84,026 when 
day-care treatment unit costs were varied and from €78,788 to €84,464 when outpatient 
visit unit costs were varied. The results of the sensitivity analyses on total mean costs for 
patients treated with bortezomib are presented in Figure 3.18. 
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Figure 3.18: Results of sensitivity analysis on total mean costs for bortezomib patients 
 
 
For patients never treated with bortezomib, total mean costs varied from €45,527 to 
€59,993 when inpatient hospital day unit costs were varied, from €52,194 to €53,326 when 
day-care treatment unit costs were varied and from €50,894 to €54,626 when outpatient 
visit unit costs were varied. The results of the sensitivity analyses on total mean costs for 
patients never treated with bortezomib are presented in Figure 3.19. 
 
Figure 3.19: Results of sensitivity analysis on total mean costs for patients never treated with 
bortezomib 
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3.5 Clinical practice versus clinical trial 
3.5.1 Effectiveness 
Baseline characteristics 
The majority of the baseline characteristics of patients treated with bortezomib in the pilot 
study do not differ significantly from those included in the APEX trials (Table 3.17). Slight 
differences were observed. For instance, the pilot patients were slightly younger than the 
APEX patients and presented on average with lower levels of serum β2-microglobulin and 
higher levels of c-reactive protein. As a result of restricting the selection of patients for the 
pilot study to those relapsing from or becoming refractory to the HOVON50 trial, which 
restricts the eligible patient population to those aged less than 65, the pilot study patients 
were younger than the patients included in the APEX trial. However, valid comparisons of 
prognostic biomarkers were difficult due to the high frequency of missing values in the pilot 
study. From the baseline comparisons it is also revealed that receipt of combination 
treatment during the initial treatment was more common among the pilot patients in 
comparison to that of the patients included in the APEX trial, but this result is explained by 
the many combinations of treatment administered during the HOVON50 trial and 
subsequent treatment in daily practice. 
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Table 3.17: Comparison of baseline characteristics between pilot and APEX patients receiving 
bortezomib 
Baseline Characteristic Pilot (n=72)  APEX (n=333)
Male 56% 56%
Age* 59 (47, 67) 62 (48, 74)
Type of myeloma
IgG 63% 60%
IgA 19% 23%
IgD 1% 2%
Light Chain 13% 12%
Nonsecretory NR 1%
NR 4% 0%
Median time since diagnosis (yr)* 3 (1, 4) 3.5 (1.3, 7.8)
NR 2.8% 0.6%
Median serum B2 (mg/liter)* 2.7 (1.7, 5.1) 3.7 (2.0, 8.8)
NR 85% 3%
C-reactive protein (mg/liter)* 7 (1.5, 41) 4 (4, 23.1)
NR 72% 10%
Hemoglobin (g/liter)* 119 (97, 143) 108 (86, 132)
NR 67% 1%
Platelet count (cells/mm3 x 105)* 1.76 (0.7, 2.86) 1.93 (0.88, 3.16)
NR 65% 1%
Number of previous lines
1 35% 40%
2 or 3 58% 56%
≥4 7% 4%
Type of previous therapy
Corticosteriods 100% 98%
Alkylating agents 100% 91%
Anthracyclines 100% 77%
Thalidomide 79% 48%
Vinca alkaloids 100% 75%
SCT or other high-dose therapy 93% 67%
*Estimates presented as the median (10th and 90th percentile)  
 
Treatment-related outcomes 
Comparisons of treatment-related outcomes between pilot and APEX patients receiving 
bortezomib are presented in Table 3.18. In support of previous results revealing pilot 
patients to be more likely to receive lower total doses of bortezomib compared to APEX 
patients (Table 3.8), pilot patients also discontinue treatment earlier compared to APEX 
patients, with a median total number of cycles equal to 4 and 6 in the pilot versus APEX 
patients, respectively. Despite these findings, the proportion of patients in both groups 
experiencing a favourable response (i.e., complete response (CR), very good partial 
response (VGPR), partial response (PR), and minor response (MR)) during bortezomib 
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treatment were similar. However, the pilot patients were less likely to experience a 
response of ‘no change’ and were more likely to experience ‘progressive disease’. As for 
time-to-event outcomes, pilot patients treated with bortezomib were less likely to survive 
the first year following relapsed/refractory treatment compared to those in the APEX trial. 
This difference may be due to reduced sensitivity to bortezomib resulting from previous 
thalidomide treatment, as many pilot patients receiving bortezomib had previously received 
thalidomide. TTP is longer for the pilot patients, especially those treated with bortezomib 
as first refractory treatment. This is likely due to the more stringent criteria for progression 
used in clinical trials compared to that in daily practice. 
 
Table 3.18: Comparison of treatment-related outcomes between pilot and APEX patients receiving 
bortezomib 
Treatment-related outcomes
Bortezomib 
(Pilot)
Bortezomib 
(APEX)
Cycles of bortezomib
≥5 40% 56%
≥8 15% 29% (39%*)
11 1% 9%
 Median   4 6
Response to treatment
Complete 8% 6%
VGPR/PR/MR 55% 41%
No change 3% 43%
Progressive disease 19% 7%
Not evaluated 15% 3%
1-year survival rate (%) 66% 80%
Median TTP (mos) All Pts
All patients 6.8 6.22
One previous treatment 8.9 7
More than one previous treatment 4.7 4.9
All estimates were taken from Richardson, et al. (2005) unless denoted by (*). 
*Estimate taken from extended follow-up reported by Richardson, et al. (2007b)  
3.5.2 Costs 
Annex VI describes the results of the systematic review carried out to provide, as 
comprehensive as possible, a retrieval of economic evaluations of bortezomib in the 
treatment of multiple myeloma. Only one publication was identified. Mehta, Duff, and 
Gupta (2004) compared bortezomib treatment to best supportive care and thalidomide in 
advanced multiple myeloma based on resource use of the SUMMIT trial based on the 
perspective of the United States healthcare payer (costs reported in 2003 US dollars). 
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Mehta, Duff, and Gupta (2004) found chemotherapy costs for patients receiving 
bortezomib to be fairly similar to those found in our cost analyses (mean costs of 
bortezomib per patient ever treated with bortezomib of $22,059 versus our estimate of 
€17,407). However, total mean costs were substantially lower than in our cost analyses 
($65,222 per patient versus €81,626). This difference was predominantly explained by the 
difference in median overall survival from start of relapsed/refractory treatment (15.7 
months versus our estimate of 33.2 months). The authors themselves commented that 
their unit costs based on (Medicare) reimbursement fees may not necessarily reflect the 
actual purchase price. They found an incremental cost-effectiveness ratio of $45,356 per 
additional life-year for bortezomib compared with best supportive care (Mehta, Duff, and 
Gupta 2004).  
It should be mentioned that NICE (National Institute for Health and Clinical 
Excellence) conducted a single technology appraisal on bortezomib for multiple myeloma 
patients at first relapse in 2007. They estimated an incremental cost-effectiveness of 
bortezomib versus high dose dexamethason to be around £28,000 - £31,000 per life year 
gained (NICE 2007). Additionally they stated that using bortezomib in later lines reduces 
treatment benefits and thus results in a higher ICER. 
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4. Discussion 
4.1 Dynamics in daily clinical practice 
The pilot study shows that daily practice dynamics complicate outcomes research of 
bortezomib. In the last few years, there have been great advances in treatment for multiple 
myeloma which resulted in changes to the professional guidelines. Bortezomib was initially 
recommended as third line therapy but was subsequently shifted to use in second line. 
More recently, it was recommended for use as first line therapy. Current national 
guidelines for any relapsed or refractory disease advise two different treatment options: 
namely, bortezomib combined with dexamethasone or lenalidomide with dexamethasone. 
If thalidomide was not used upfront, the guidelines advise thalidomide with 
dexamethasone as a third option. However, most patients follow a relapsing disease 
course, implying that physicians must decide on new regimes after every subsequent 
relapse. Possibly as result of changes to the professional guidelines, our real-world data 
exposes large variation in treatment regimes and treatment order, creating significant 
hurdles in identifying a treatment comparator. It seems unfeasible with small patient 
numbers to compare bortezomib with many different comparators. Moreover, these 
treatments were often combined in various ways. Our data reveals that it is essential to 
select appropriate outcome measures since effects from previous treatment regimes 
cannot be ignored. 
We illustrated that physicians needed several years before bortezomib 
administration was common practice. In addition, pilot patients received lower bortezomib 
dosages and fewer treatment cycles compared to the APEX trial, of which is unclear how it 
affects treatment effectiveness. It could indicate that pilot patients had lower tolerance or 
more frequently experienced side-effects of bortezomib treatment, especially when taking 
into account the fact that patients who are not eligible for trials receive it in daily practice. 
However, these results might also suggest that physicians are more cautious and reluctant 
to new novel pharmaceuticals. The results of these dynamics in daily practice underscore 
the need for refinement of practice and evidenced-based professional guidelines and the 
necessity of an active professional association advocating appropriate use. 
 Data for the pilot study was retrospectively collected from hospital medical records 
which restricted the availability of data compared to that collected in a clinical trial. In daily 
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practice, physicians do not have to follow a strict trial protocol. Patient files were often 
incomplete, suggestive of seemingly less strict criteria being used in maintaining patient 
charts. For example, clinical trials dictate response and outcome measures, whereas we 
often found that physicians used various outcome definitions and reported response in 
more subjective terms, such as “patient is responding well” or “patient has a good 
response on the treatment”. Furthermore, it was not always possible to determine via the 
physician’s notes the reason a patient progressed to a new treatment line or the reasons 
for selecting a specific treatment regime. The absence of such information limited the 
ability to analyse and interpret certain treatment outcomes. A prospective research design 
might tackle some of the above described drawbacks, but it cannot resolve all issues. 
However, it does signify the importance of active cooperation of physicians in outcomes 
research. 
4.2 Clinical effectiveness 
Interpretation of results 
Patients treated with bortezomib 
Regardless of adjustment, patients in second and third line appear to do better compared 
to patients treated in fourth line or later when examining OS from diagnosis. This also 
holds when examining OS from start of second line. Contradictory to what would be 
expected, patients receiving bortezomib in third line seem to do better compared to 
patients who receive it in second line. This is not surprising given that the median survival 
has yet to be reached for patients treated in second line, indicating that the patients 
treated in second line represent the later stages of diffusion of bortezomib use in daily 
practice and that patients in third line represent the early stages of diffusion. This 
difference is illustrated by the difference in the proportion of patients treated with 
bortezomib prior to 2007 for the group of patients treated in second line versus those 
treated in third line (44% and 86%, respectively; Table 3.2). Further, because the patients 
treated in second line were more likely to have been treated with thalidomide in the 
HOVON50 trial compared to patients treated with bortezomib in third line (56% and 29%, 
respectively; Table 3.2) and response to thalidomide is associated with reduced 
progression-free and overall survival after relapse treatment ( Lokhorst et al. 2010; Vogl et 
al. 2009), the group of patients treated in second line selected for this pilot study may also 
have had a reduced capacity to benefit from bortezomib in terms of OS. An additional 
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reason for this difference may be due to the possibility that patients treated in third line 
were prognostically more favourable compared to the second line patients suggested by 
the fact that they lived long enough to receive three lines of therapy. The limitation in 
adequate follow-up reflects the well-known difficulty with assessing the effectiveness of 
new therapies for multiple myeloma during the current era of constant advances in 
treatment. In other words, the assessment of the effectiveness of one therapy is soon 
replaced and made less relevant by the need for an assessment of its successor, while the 
assessment of the successor is difficult due to incomplete follow-up. Given this limitation, 
the results presented here by this study demonstrate that third line usage of bortezomib is 
effective in daily practice and that its usage in second line is likely to be demonstrated as 
similarly effective once complete full follow-up is available for patients treated in second 
line. 
 
Patients never treated with bortezomib 
This group of patients is suspected to be a mixture of patients with extremely poor 
prognosis and patients with extremely favourable prognosis, as the OS in this group 
ranged from a few months to greater than the last available follow-up for patients in 
second line (i.e., 76 months). Therefore, the median and mean overall survival for this 
group as a whole is considerably long (mean = 45; median = 56). Due to such variation 
within this group, the mean OS should be assumed to most accurately reflect the average 
survival within this group, as the median does not take into account the distribution of 
survival estimates. 
 
Adjustment methods 
The use of adjustment by the propensity score and mean covariate methods did not result 
in strikingly different survival curves compared to the unadjusted curves. If prognostic 
factors fully explain the decision to administer bortezomib, one would expect that 
correction for such prognostic factors would result in curves that are more similar to one 
another with the remaining difference to be solely explained by the treatment effect instead 
of differences in prognosis. However, the curves appear to be of similar form with a slight 
extension of the mean and median estimates. Such results suggest that prognostic factors 
either do not fully explain the decision to receive bortezomib, i.e., no confounding by 
indication exists, or residual confounding by indication exists on account of missing 
information not available in the data.  
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 Adjustment for the propensity to receive bortezomib in third line, fourth line or later 
could also have been used to adjust the survival curves for prognostic factors on the 
decision to receive bortezomib at different points in relapsed/refractory treatment. 
However, it is unlikely that the prognostic factors that are related to the decision to 
administer bortezomib in second line have a differential effect in later treatment lines. 
Therefore, one would expect correction of OS by the propensity to receive bortezomib in 
later lines to produce survival graphs similar to that of the unadjusted. 
 
Comparison to previous studies  
A number of studies have reported outcomes for bortezomib use in daily practice (Wu et 
al. 2005; Freimann et al. 2007; Onitilo et al. 2007; Knauf et al. 2009). Each of these 
studies report response rates and toxicity profiles comparable to that seen in large-scale 
clinical trials, which is also consistent with the response rates observed in the pilot 
patients. Only one study reported the median OS from start of bortezomib treatment (Wu 
et al. 2005). Wu et al. (2005) reported a median OS from start of bortezomib to be 15 
months, which is slightly shorter compared to the estimate of 17.2 reported here for the 
pilot patients. Comparison of OS from diagnosis could not be evaluated because no 
studies reported the OS from diagnosis.  
 
Strengths and weaknesses of the analysis 
Adjustment methods 
There are notable drawbacks to the chosen adjustment methods. Regarding the average 
covariate adjustment method, the obvious drawback is the use of the mean estimate for 
nominal variables, which is the situation for all variables included in the prediction model. 
The central issue is how to interpret the mean effect of a prognostic factor at the individual 
level (Chang, Gelman, and Pagano 1982). Furthermore, the adjusted regression model 
computes an average hazard rate, as opposed to the average survival. In other words, the 
method neither accounts for heterogeneity in survival within the group nor the effect of 
time-dependency on the individual’s survival (Nieto and Coresh 1996).  
Adjustment by means of the average PS is susceptible to the same drawbacks as 
that mentioned above for the average covariate method. In addition, the use of the 
average PS method is further limited by the drawbacks of using the logistic regression to 
identify factors that are predictive of getting a particular treatment, including missing 
predictors or confounders in the available data, selecting predictors solely on statistical 
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significance and the inappropriate inclusion/exclusion of interaction terms (Weitzen et al. 
2004). 
Despite the advantages of goodness of fit and good discrimination of the outcome 
(i.e., treatment with bortezomib in second line) for the predictive model in this study, the 
ability to define such a highly predictive model has in this case resulted in largely non-
overlapping distributions of the PS within the groups. The overlap in distribution results in 
difficulty to apply the ideal PS adjustment method. The ideal method would be to stratify 
outcomes for patients groups by propensity score percentiles where the distribution of 
patients within each group is divided into equal groups (i.e., terciles, quartiles, quintiles, 
etc.). This would allow the more robust method of comparing across groups based on 
similar percentile groups. However, due to the low number of patients represented in each 
PS decile as a result of not only the small number of observations in the patient population 
but also a highly discriminative model, we were unable to use the more robust methods to 
incorporating the PS in the analysis. 
A final drawback of using the PS method in this analysis was the correction for a 
propensity to receive a treatment at one point in time when in reality the patient is eligible 
to receive the treatment at multiple points in time. This method should further be applied 
separately for each line. Namely, a separate effectiveness outcome estimate should be 
adjusted for the propensity to receive bortezomib not only in second line, but also in third 
line, fourth line and later. This would require three different propensity estimates for each 
patient. Similarly, due to the small number of observations within each patient group, this 
method is not feasible.  
The strength of the adjustment analyses is the added information regarding 
statistically significant factors that are predictive of receipt of bortezomib in daily practice. 
Greater overlap between the clinically and statistically significant factors would be 
expected; however, small numbers within patient groups may have resulted in rejected 
parameters due to statistical insignificance. Consequently, there remains the possibility of 
residual confounding not accounted for by the final prediction model. The method of 
selecting parameters for the predictive model as that employed here may have been 
inappropriate and could have been replaced by a more appropriate method. Unfortunately, 
many studies in the literature vary with regard to methods, indicating uncertainty in the 
guidelines/recommendations to estimation of a useful PS (Weitzen et al. 2004). 
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Choice of outcome 
The choice of outcome here was restricted for many reasons. The availability of data in 
patient charts restricted the analysis to the use of OS, TTNT and TTP. The use of the 
outcome TTNT resulted in bortezomib patients receiving subsequent treatment lines 
earlier than patients receiving other therapies, suggesting that bortezomib is ineffective 
when using this outcome. Similar results were obtained when using the outcome TTP. The 
counterintuitive results seen with the outcome TTNT are suspected to be due to the 
diffusion phenomenon in daily practice, where patients given a new drug for which 
clinicians have little experience with are followed more carefully. The outcome TTNT, 
therefore, is not preferred when assessing the effective of a new drug in daily practice for 
multiple myeloma. The counterintuitive results for the outcome TTP is also suspected to be 
due to the diffusion phenomenon but additionally due to variation in either definitions or 
routine diagnostics for determining progression in daily practice. The outcome TTP, 
therefore, is not preferred for indications where the definition of progression is subjective 
and/or not defined by strict criteria used by all clinicians in daily practice, such as is the 
case for multiple myeloma. 
The outcome OS was feasible within the restraints of the data. The most difficult 
decision was to determine the baseline from which OS would be computed due to 
confounding of initial therapy. Due to the inclusion of a ‘control’ arm consisting of patients 
who never received bortezomib, the largest confounder of the effect of bortezomib on the 
outcome OS, regardless of examining OS from diagnosis or start of relapsed/refractory 
treatment, was the HOVON50 treatment received in first line therapy. The reason for this is 
that treatment received by a patient at initial therapy is not only related to OS from 
diagnosis but also to the decision to receive bortezomib in subsequent lines. Treatment 
received in subsequent lines after HOVON50 is also related to OS from start of 
relapsed/refractory therapy. Most importantly, treatment with thalidomide is standard in 
many cases prior to receiving bortezomib. Therefore, the OS estimates should be further 
stratified by HOVON50 treatment arm, regardless of baseline being diagnosis or start of 
relapsed/refractory treatment. However, the differential effect of HOVON50 treatment on 
the treatment effect of bortezomib is concealed by the limitation of small numbers (Figure 
3.12). This limitation is visible by the insignificant logrank and Wilcoxan statistic (refer to 
section 3.3) when further stratifying by HOVON50 treatment, as this created 8 comparator 
groups with small numbers of observations resulting in estimates lacking the precision to 
reveal a significant effect of HOVON50 treatment. If an adequate sample size were 
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available, the stratification of effectiveness results by initial therapy received would be 
necessary.  
4.3 Clinical costs 
To our knowledge, our cost analyses of multiple myeloma treatment are the first based on 
real-world resource use. For patients ever receiving bortezomib, total mean treatment 
costs amounted to €81,626. Treatment costs during bortezomib regimens were slightly 
more expensive in the third line (€ 38,213) than in the second line (€36,068). The average 
cost of a patient treated with bortezomib in third and fourth line or later was more 
expensive (€95,962 and €97,937) compared to patients treated during second line 
(€53,726) mainly due longer follow-up available for these patients which resulted in greater 
resource use and administration of further active or palliative treatment.  
 For patients never receiving bortezomib, total mean treatment costs amounted to 
€52,760. Although total mean treatment costs were lower for patients never receiving 
bortezomib, the treatment line costs were structurally higher for patients never receiving 
bortezomib compared with those for patients ever receiving bortezomib in another 
treatment line than the one under consideration. Treatment line costs for patients never 
receiving bortezomib were €28,239 (versus €20,189) in the second line, €35,057 (versus 
€18,111 and €20,481) in the third line and €51,280 (versus €32,877 and €30,828) in the 
fourth+ line. 
The inclusion of patients still treated at the end of the data collection influenced our 
cost estimates only slightly. For patients treated with bortezomib, the cost difference 
between patients whose resource use was collected until the end of treatment and patients 
still treated at the end of the data collection was not significant (Mann-Whitney U test: p = 
0.54). For patients never receiving bortezomib, the substantially higher costs of two of the 
four excluded patients who were mainly attributable to costs from fourth line onwards for 
lenalidomide treatment, stem cell transplant and inpatient hospital stays. 
In general, it is known that treatment costs are skewed and few patients with high 
or expensive resource use may have a considerable impact on the average costs per 
patient. From our patient sample, it can be concluded that total mean treatment costs 
varied widely between patients, with the most expensive patients more likely to receive 
lenalidomide treatment and stem cell transplantations. 
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The robustness of our results was tested in sensitivity analyses. Our sensitivity 
analyses show that the total mean treatment costs are maintained over a wide variation in 
unit costs of inpatient hospital days, day-care treatments and outpatient visits. 
Furthermore, the conclusions drawn from our cost analyses still hold, even if unit costs 
were 0.5 or 1.5 times the current costs.  
 Costs are preferably determined from a societal perspective in which all relevant 
costs are included (Drummond et al. 2005). However, considering limited time and 
information, it was impossible to collect retrospective data on societal costs for our cost 
analyses. Therefore, our cost analyses were conducted from the hospital perspective. 
Disregarding productivity costs is expected to have influenced our results, as this study 
included younger (< 65 years of age) working multiple myeloma patients. Furthermore, 
disregarding patients’ out of pocket expenses (e.g. expenses for travel, time and home 
modifications) may have influenced the treatment costs of patients who consumed more 
inpatient hospital days and day-care treatments. 
4.4 Cost-effectiveness of bortezomib 
Economic evaluations compare costs of a treatment with the effects of the treatment. 
Although safety and efficacy are still the primary research parameters used to assess the 
value of alternative treatment strategies, as illustrated by the high number of published 
articles in the effectiveness review, cost-effectiveness has become increasingly important 
in current health care decision making (Drummond et al. 2005; Moeremans and 
Annemans 2006). Nevertheless, only one study assessed the costs of bortezomib 
treatment in multiple myeloma. Mehta et al. (2004) concluded that bortezomib provides a 
cost-effective option in the treatment of relapsed multiple myeloma and provides the best 
value among currently available therapeutic options in terms of cost per life-year gained. 
However, the review of Moeremans et al. (2006) demonstrated that more evidence is 
required to confirm the cost-effectiveness of novel as well as established treatment 
strategies for multiple myeloma at different stages of the disease. Moreover, NICE 
concluded in their bortezomib technology appraisal that using bortezomib in later lines 
could reduce treatment benefits and thus result in a higher ICER (NICE 2007). 
Estimating real-world cost-effectiveness of bortezomib in relapsed multiple 
myeloma requires comprehensive data on both treatment effects and costs. Generally, 
outcomes measures such as DOR, TTP, TTNT and OS are essential in determining cost-
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effectiveness. However, as previously mentioned, our pilot data only allows the 
assessment of TTNT, OS and survival from start of a new treatment line, whereas the 
other outcomes are either frequently missing or the validity of which is questionable. The 
effectiveness outcome measures TTNT and OS are expected to be valid estimates of 
bortezomib in the selected patient group from daily clinical practice in the Netherlands. 
Nevertheless, it is not possible to compute cost-effectiveness from start of diagnosis, since 
we did not collect cost data from the first treatment regime. It is, however, feasible to 
assess cost-effectiveness of bortezomib for relapsed multiple myeloma.  
 We were able to estimate the real-world cost-effectiveness of bortezomib for 
relapsed multiple myeloma. In cost-effectiveness analyses, it is preferred to report costs 
per QALY. As no data was available regarding quality of life, we estimated cost-
effectiveness by means of the outcomes OS from start of relapsed/refractory treatment for 
all patients treated with bortezomib and for OS from start of respective treatment lines 
when bortezomib was administered. The cost from the start of second line for all patients 
treated with bortezomib was €2,767 (mean costs: €81,626; mean OS: 29.5 months) per 
month of survival. Similarly, for patients treated in second line only, the cost-effectiveness 
of bortezomib from start of relapsed or refractory treatment was €2,858 (mean costs: 
€53,726; mean OS: 18.8 months) per month of survival. As for patients receiving 
bortezomib in third line and fourth line or later, the cost-effectiveness of bortezomib from 
the start of relapsed or refractory treatment was €3,096 (mean costs: €95,962; mean OS: 
31 months) and €3,099 (mean costs: €97,937; mean OS: 31.6 months) per month of 
survival, respectively. It should be noted that these estimates must be interpreted 
cautiously since the costs are based on all patients including the patients still treated at the 
time of data collection and we ignored treatment costs and effects from the first treatment 
regime and disregarded effects from treatment combinations, which could bias the validity 
of these cost-effectiveness estimates as previously described.  
4.5 Incremental analysis 
The dynamics in daily clinical practice as described in this report compromise the ability to 
compute a valid and precise real-world incremental cost-effectiveness measure. Mainly as 
a result of the study design chosen for collecting the bortezomib pilot data, it is impossible 
to perform an incremental analysis. Firstly, prognosis varied greatly within the group of 
patients never receiving bortezomib as well as that between the patients receiving 
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bortezomib in second and third line, of which could not be differentiated merely on 
differences in baseline characteristics. The incomparability of the patient groups could not 
be corrected for due to missing values and other missing information on seemingly clinical 
significant important decision-making criteria that appeared to be absent in patient charts. 
Secondly, extensive treatment variation and different treatment combinations in daily 
practice of multiple myeloma complicate the identification of a treatment comparator. 
Finally, only 139 patients were included in the pilot study. It is impossible to overcome the 
majority of the limitations of the data with small patient numbers, whereas the availability of 
large numbers could have offered more opportunities to carry out incremental analysis by 
using comprehensive modelling techniques. Accordingly, incremental analyses were not 
performed since it was not expected that they would provide valid and precise estimates. 
4.6 Pilot outcomes research of bortezomib 
The Dutch policy regulations for expensive hospital medicines (“Beleidsregel dure 
geneesmiddelen”) aim to relieve the financial burden of hospitals. However, it also 
stipulates that outcomes research needs to be conducted in order to be entitled to the 
continuation of financial compensation after three years. By order of CVZ, iMTA has 
researched methodological aspects of outcomes research to provide empirical experience 
additional to the Guidance for Outcomes Research (“Leidraad voor 
Uitkomstenonderzoek”). Two pilot studies were at the core of this research. The results of 
the research regarding methodological issues related to outcomes research are reported 
separately. This report describes the results of the bortezomib pilot study, investigates how 
bortezomib is used in the Dutch daily practice and explores real-world treatment effects 
and costs of bortezomib in relapsed or refractory multiple myeloma. To our knowledge, this 
is the first study assessing both the effects and the costs of bortezomib in relapsed 
multiple myeloma using real-world patient level data in the Dutch setting. 
 
Outcomes research: Knowledge at time T=0 
In 2006, at time T=0 for this indication, bortezomib was assessed by CVZ and as a result 
was admitted to the Dutch policy list for expensive drugs based on the phase III APEX 
trial. The APEX trial showed that bortezomib was superior to high dose dexamethasone in 
terms of increased overall survival, response rates and response duration in relapsed 
multiple myeloma patients (Richardson et al. 2005). In the CVZ assessment report, the 
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expected costs for bortezomib treatment were based on the claim of the manufacturer, 
which was estimated at €27,432 per treated patient (Commissie Farmaceutische Hulp 
2005). These costs were computed based on the price of bortezomib vials assuming that 
patients receive on average six cycles; no other costs were included in the T=0 
assessment. 
 In the following years, outcomes research needs to be conducted in order to 
assess appropriate use and to evaluate real-world cost-effectiveness. The flowchart for 
pragmatic outcomes research design, available in the Guidance for Outcomes Research, 
advises collection of detailed patient data if there is no indication for a cost-effectiveness 
measure at T=0 (Delwel 2008). Additionally, if there would have been a T=0 model, a 
Value of Information (VOI) analysis would have been of limited use since treatment of 
multiple myeloma in the current era is known for constant advances in treatment and, thus, 
expected to reveal high variation in daily practice. Consequently, the flowchart would again 
advise collection of detailed data. In the following years, we retrospectively collected 
detailed patient level data from hospital medical records. In contrast to CVZ’s 
recommendation in the Guidance for Outcomes Research, we did not collect data on 
disease- and treatment-related Quality of Life, since this was not possible with a 
retrospective study design. To date, there is no evidence in the literature for a significant 
difference in utilities between treatment strategies administered to relapsed/refractory 
multiple myeloma patients. One study did demonstrate a utility value for 
relapsed/refractory multiple myeloma patients while receiving bortezomib (Mujica-Mota et 
al. 2004).  
 
Outcomes research: Knowledge from literature at time T=3  
Only very limited information on costs of bortezomib became available in these years (see 
literature review in Annex VI). Mehta et al. published in 2004 information on costs for 
bortezomib therapy prior to T=0; however, their resource use data was partly derived from 
a clinical trial but also partly estimated by an expert panel. The manufacturer submitted in 
2007 an application for bortezomib to the (outpatient) drug reimbursement system. The 
pharmaco-economic assessment and budget impact reports incorporated costs for the 
administration of bortezomib in an outpatient clinic (Commissie Farmaceutische Hulp 
2007a; Commissie Farmaceutische Hulp 2007c). However, the calculations were based on 
the assumption that bortezomib would mainly be administered outside a hospital, which is 
not in accordance with our daily practice data. 
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On the contrary, many articles concerning the effectiveness of bortezomib were 
published (see literature review Annex III). These articles provide updated effectiveness 
information on bortezomib mono-therapy or combination therapy (e.g. dexamethasone, 
melphalan, adriamycin and thalidomide) from phase I, II and III studies on various outcome 
measures such as PFS, TTP, DOR and OS.  
 
Outcomes research: Insight gained from the pilot study at time T=3 
We investigated both the treatment effects and costs of bortezomib in relapsed multiple 
myeloma using real-world patient level data taken from daily clinical practice. The data 
collection challenged the feasibility of outcomes research for bortezomib since many 
patients were treated in more than one hospital, thereby requiring over 1700 hours for data 
collection in 42 different hospitals. This report illustrates the impact of daily practice 
dynamics for outcomes research. It is achievable with real-world data to investigate daily 
practice utilisation of bortezomib in relapsed multiple myeloma. The diffusion of 
bortezomib, the application of bortezomib regimes, dose modifications, actual received 
dosages and related toxicities were explored. Our data reveals that, in daily practice within 
the hospitals where data was collected, relapsed multiple myeloma patients are treated 
with many different drugs in various combinations and in a diverse treatment order. 
However, analysing treatment effects with real-world data is far more challenging. 
Retrospective observational studies are susceptible to several limitations related to bias 
and validity. Patients are not randomised to a specific treatment and physicians decide 
which treatment to use based on patient characteristics. Based on our data, it was only 
possible to correct for available prognostic factors. However, prognostic factors were often 
not reported, resulting in missing values. Although we suspect that we collected insufficient 
information on other important clinical decision-making criteria, we do consider the 
possibility that it might be unachievable to reveal all medical decision making criteria by 
review of medical records. Consequently, outcomes research with retrospective 
observational data will always be challenged by residual confounding issues. Furthermore, 
selecting appropriate outcome measures is more complicated with real-world data. As 
illustrated in this report, it is not clear whether physicians use universal response criteria. 
In addition, physicians’ notes seem to provide insufficient information on decision criteria 
for a specific treatment regime. Moreover, in any retrospective study, it is impossible to 
obtain quality of life information and thus establish a relationship between a treatment 
response and a quality of life measurement. These issues challenge the selection of 
- 79 - 
appropriate outcome measures, such as the preferred quality-adjusted survival for 
conducting cost-effectiveness analyses, and have an impact on the validity of estimated 
outcomes. 
As previously mentioned, it was possible to compute real-world costs and estimate 
real-world cost-effectiveness of bortezomib for relapsed multiple myeloma. However, these 
estimates have to be interpreted cautiously in light of the fact that we were restricted to 
select outcomes measures, we ignored treatment costs and effects from the first treatment 
line and we disregarded the effects of treatment combinations, thereby resulting in 
potentially biased real-world cost-effectiveness estimates. Furthermore, only 72 patients 
who received bortezomib were included in the pilot study. Such small numbers hinders the 
ability to correct for differences and constrains the value of a cost-effectiveness measure, 
since small numbers will result in wide confidence intervals and, thus, challenge precision 
of the estimate. 
 On the contrary, it is impossible with this pilot data to estimate a valid and precise 
real-world incremental cost-effectiveness ratio for bortezomib in relapsed multiple 
myeloma. Extensive treatment variation, incomparability of the patient groups and small 
patient numbers severely complicate performing an incremental analysis. 
4.7 Conclusion  
Bortezomib was admitted under the policy regulations for expensive drugs based on the 
results of the APEX trial. This clinical trial compared bortezomib to dexamethasone and 
proved bortezomib to be effective, i.e., increased overall survival, response rates and 
response duration. We performed a pilot outcomes research study and assessed the 
appropriate use and explored real-world effects and costs of bortezomib in relapsed or 
refractory multiple myeloma. The generalisability of the pilot results to other expensive 
drugs and the conclusions regarding methodological issues related to outcomes research 
are described in a separate report. 
In the last years, there have been many advances in treatment of multiple 
myeloma, which is reflected by the heterogeneity in our data. Consequently, our real-world 
data challenged the assessment of cost-effectiveness of bortezomib treatment in the 
indication of relapsed disease. We showed that the dynamics within daily practice resulted 
in incomparability of pilot patients. Additionally, restrictive appropriate outcome measures 
and small patient numbers compromised the ability to estimate a valid and precise 
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incremental outcome comparing patients treated with and not treated with bortezomib. 
Outcomes research with retrospective observational data will always be challenged by 
residual confounding issues, however, we believe that a prospective research design will 
not overcome all above described issues. 
Nevertheless, we demonstrated that outcomes research provides valuable 
information on drug usage in daily practice. We explored the diffusion of bortezomib, 
application of treatment regimes, dose modifications, actual dosages received and 
treatment-related toxicities. Compiling different data sources, such as daily practice data 
on more patients, information from extended follow up and other research studies, might 
offer opportunities to estimate more valid outcomes by data synthesis using 
comprehensive and advanced modelling techniques. Outcomes research performed in 
areas with constant advances in treatment should take heterogeneity of patient level data 
into account as a result of the rapid developments in that specific medical field. It should 
be noted that these advances in treatment for multiple myeloma in the last few years have 
extended overall disease survival. 
Furthermore, this pilot study underscores the need for refinement of practice and 
evidence-based professional guidelines for relapsed multiple myeloma advocated by an 
active professional association as a means to reduce practice variation, support 
appropriate clinical decision-making and, ultimately, improve the treatment of individual 
patients. Moreover, active physician participation and prospective observational data using 
national and/or international registries could facilitate closer follow-up of patients, ensure 
uniform response criteria, enable the selection of groups of similarly treated patients and 
thus contribute to enhanced value of outcomes research. 
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Annex I: Disease staging systems 
Durie & Salmon staging system 
 
Source: Durie and Salmon 1975 
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International Staging System 
 
New International Staging System
Median
Stage Criteria Survival
(months)
I Serum β2-microglobulin < 3.5 mg/L 62
Serum albumin ≥ 3.5 g/dL
II Not stage I or III* 44
III Serum β2-microglobulin ≥ 6.5 mg/L 29
* There are two categories for stage II: serum β2-microglobulin < 3.5 mg/L
but serum albumin < 3.5 g/dL; or serum β2-microglobulin 3.5 to < 5.5 mg/L
irrespectie of the serum albumin level  
Source:Greipp et al. 2005 
 
 
 
Comparison between Durie & Salmon and International Staging System 
 
    Comparison between Durie & Salmon and ISS Staging System: survival duration by stage in months
Durie & Salmon International Staging System
 Stage % of patients* Median survival  Stage % of patients* Median survival
       (months)        (months)
 IA  7.5 62   I 29 62
 IB  0.5 22
 IIA 22 58  II 33 44
 IIB 4 34
 IIIA 49 45  III 39  29
 IIIB 17 24 
* Percentage of patients falling into each staging category  
Source: Greipp et al. 2005 
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Annex II: Response criteria for multiple myeloma 
EBMT, IBMTR and ABMT criteria for definition of response, relapse and progression with 
multiple myeloma patients (Blade et al. 1998): 
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Annex III: Literature review of effectiveness of bortezomib 
Identification of studies 
The aim of the search was to provide, as comprehensive as possible, a retrieval of the 
available evidence concerning the clinical effectiveness of bortezomib in the treatment of 
previously treated multiple myeloma. 
 
Sources searched 
Three electronic databases were searched. The literature search was performed in March 
2009 via the PubMed, Cochrane Library and EMBASE databases.  
 
Keyword strategies 
The following search strategies were used:  
PubMed 
(“bortezomib” [Title/Abstract]) OR (“velcade” [Title/Abstract]) AND “multiple myeloma” 
[Title/Abstract] AND (English [lang] OR Dutch [lang])  
Cochrane 
(bortezomib):ti,ab,kw or (velcade):ti,ab,kw and (multiple myeloma):ti,ab,kw 
Embase 
'bortezomib':ab,ti OR 'velcade':ab,ti AND 'multiple myeloma':ab,ti  
 
Inclusion and exclusion criteria 
The following inclusion and exclusion criteria were used: (1) articles were considered if 
they concern adult patients with multiple myeloma, (2) bortezomib in the first-, second- or 
third-line treatment was one of the main topics of the article (3) studies evaluated 
bortezomib as a single agent or in combination with other regimens, (4) the title contained 
a word or words referring to the effectiveness of bortezomib, such as response, length of 
remissions, survival or progression-free survival, articles should not primary deal with the 
adverse events of bortezomib, (5) only research articles were considered (editorials, 
letters, comments, guidelines, reviews, case reports etc. are excluded as well as phase I 
trials), (6) studies were considered if they included more than 20 patients and (7) only 
papers using the English or Dutch language were considered. Full papers were obtained 
for any titles or abstracts that were considered relevant or where the title or abstract 
information was not sufficient to make a decision. 
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Results of clinical effectiveness review 
The database search identified 1650 articles, with 679 found via PubMed, 113 via the 
Cochrane Library and 858 via the EMBASE database. Out of the 1650 articles, 709 
articles appeared in more than one database. After exclusion of redundant articles, a total 
of 941 unique articles were considered. Based on title alone, a total of 801 articles were 
excluded. The abstracts and/ or full texts of the remaining 140 articles were considered. 
Finally, 38 publications met the inclusion criteria, with a total of 25 focusing on bortezomib 
for the treatment refractory/relapsed multiple myeloma. 
 
 
 
Potentially relevant citations 
identified through electronic 
searches
n = 1650 
Papers rejected because they
appeared in more than one
database
n = 709
Titles screened and inspected 
n = 941
Papers rejected at the title stage
n = 801
  
Abstracts and/ or full copies 
screened and inspected 
n = 140
Papers rejected at the abstract/
full text stage
n = 101
Publications meeting inclusion 
criteria 
n = 38
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Results: bortezomib 
A final total of 38 studies were suitable for inclusion in this systematic review. Studies of 
bortezomib for previously treated multiple myeloma were distinguished from studies of 
bortezomib in patients with previously untreated multiple myeloma. The first section of this 
review concerns studies of bortezomib for relapsed or refractory multiple myeloma. Table 
1 presents the main characteristics of the study as well as the most important outcomes 
and toxicities. Table 2 presents the same data for studies concerning bortezomib in 
patients with previously untreated multiple myeloma.  
The primary outcome for most studies was response rate. The majority of studies 
used the European Group for Blood and Marrow Transplantation (EBMT) criteria for 
defining response rate. The first criterion was based on reduction in serum M-protein by at 
least 50% from baseline (i.e., those patients who had a complete response or a partial 
response). Beside this criterion, the EBMT response criteria take additional clinically 
relevant information into account. 
 
Evidence about the effectiveness of bortezomib in relapsed and/or refractory 
multiple myeloma 
In May 2003, bortezomib received accelerated approval from the U.S. Food and Drug 
Administration (FDA) for the treatment of progressive multiple myeloma in patients who 
had received at least two prior therapies (Kane et al. 2006, 2955-2960). That approval was 
based on FDA analysis of evidence of durable responses, including complete responses, 
in heavily pretreated patients in two phase II studies. The first study is the Study of 
Uncontrolled Multiple Myeloma managed with proteasome Inhibition Therapy (SUMMIT), a 
multicenter, open-label, non-randomised trial. The second study is the Clinical Response 
and Efficacy study of bortezomib in the Treatment of relapsing multiple myeloma (CREST), 
which was a small, open-label, randomised phase II dose finding study.  
A group of 202 patients with relapsed, refractory myeloma were enrolled in the 
SUMMIT. The mean age of the patient population was 60 years and 72% presented with 
Durie-Salmon stage III multiple myeloma. Of the 193 patients who could be evaluated, 178 
had previously been treated with three or more of the major classes of agents for 
myeloma, with the median number of previous therapies being six (range: 2 - 15) 
(Richardson et al. 2003, 2609-2617).  
The patients in the study received bortezomib (1.3 mg/m² on days 1, 4, 8 and 11) in 
a three-week cycle up to eight cycles. Of the 193 evaluable patients, 67 patients (35%) 
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had a complete, partial, or minimal response to bortezomib alone, 19 patients (10%) 
achieved complete or near-complete response. Only age and percentage of plasma cells 
in bone marrow were prognostic factors of responses to bortezomib. The median time to 
progression of disease was seven months compared to three months during the last 
treatment before enrolment. The median overall survival was 16 months (Richardson et al. 
2003, 2609-2617).  
The CREST evaluated two doses of bortezomib (1.0 and 1.3 mg/m²) in patients 
with relapsed or refractory multiple myeloma who had received only front-line therapy 
(Jagannath et al. 2004, 165-172). Patients were randomised to receive one of the two 
doses of bortezomib, on days 1, 4, 8 and 11 up to eight three-week cycles. A group of 54 
patients with a median age of 63 years were enrolled. Fifty-six and sixty-two percent of 
patients in the 1.0 and 1.3 mg/m² dose groups, respectively, were Durie-Salmon stage III 
multiple myeloma at diagnosis. The median number of prior therapies was three (range: 1 
- 7) in both groups. The ORR (CR/nCR + PR + MR) was 33% in the 1.0 mg/m² dose group 
and 50% in the 1.3 mg/m² dose group. Eleven and four percent of the patients, 
respectively, achieved a complete or near complete response. Dexamethasone (20 mg on 
the day of and the day following each bortezomib dose) was given to patients with 
progressive disease after two cycles or stable disease after the first four cycles. Forty-four 
percent of the patients who received bortezomib alone or in combination with 
dexamethasone in the 1.0 mg/m² dose group achieved ORR, 19% achieved complete or 
near-complete response. In the 1.3 mg/m² dose group 62% of the patients who received 
bortezomib alone or in combination with dexamethasone achieved ORR, 4% achieved 
complete or near-complete response. Updated survival analysis after prolonged survival 
showed a median overall survival of 26.8 months in the 1.0 mg/m² group and a median 
overall survival of 60.0 months in the 1.3 mg/m² group. Administration of bortezomib ± 
dexamethasone for first relapse has been associated with longer overall survival 
(Jagannath et al. 2008, 537-540).  
The full approval in 2005 of bortezomib from the U.S. FDA for the treatment of 
patients who have received at least one prior therapy was based on findings of an 
international, randomised phase III Assessment of Proteasome Inhibition for Extending 
Remissions (APEX) trial (Kane et al. 2006, 2955-2960), in which single-agent bortezomib 
was compared to high-dose dexamethasone in patients with multiple myeloma progressing 
after at least one prior therapy. In this study, a total of 669 patients were randomly 
assigned to receive bortezomib (333) or high-dose dexamethasone (336) (Richardson et 
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al. 2005, 2487-2498). The median age was 62 and 61 years in the bortezomib group and 
dexamethasone group, respectively. The median number of previous therapies was two in 
both groups. Responses (CR + PR) were achieved in 38% of the patients in the 
bortezomib group and in 18% of the patients in the dexamethasone group. In 13% and 2% 
of the patients who received bortezomib or dexamethasone, respectively, complete or 
near-complete response was observed. Patients who received bortezomib as second-line 
therapy had a higher response rate than did those who received dexamethasone (45% vs. 
26%), as did those who had received two or more previous treatments (34% vs. 13%) 
(Richardson et al. 2005, 2487-2498). In comparison with treatment with dexamethasone, 
treatment with bortezomib also resulted in a significantly longer time to progression and 
superior survival.  
Extended follow-up of the patients in the phase III trial showed a median overall 
survival of 29.8 months in the bortezomib arm and a median overall survival of 23.7 
months in the dexamethasone arm, despite more than 62% of dexamethasone patients 
crossing over to receive bortezomib (Richardson et al. 2007, 3557-3560). Responses in 
the bortezomib arm improved from 38% to 43% and the complete or near-complete 
response rate improved from 13% to 16%.  
To summarize, two phase II studies showed the benefits of bortezomib. Moreover, 
the APEX trial demonstrated that bortezomib is superior to dexamethasone in the 
treatment of relapsed or refractory multiple myeloma. In addition to the SUMMIT, CREST 
and APEX trial, other clinical trials have evaluated bortezomib as single-agent for patients 
with multiple myeloma. Furthermore, clinical trials have also evaluated bortezomib in 
combination with other agents for relapsed or refractory multiple myeloma, such as 
dexamethasone, melphalan, doxorubicin, and thalidomide. The following section will 
review the evidence for the various regimens of bortezomib. 
 
Single-agent bortezomib 
In a multi-institutional analysis of the efficacy and toxicity of bortezomib in patients who 
were treated in community centers in a compassionate needs program, a total of 50 Dutch 
patients were enrolled with a median age of 59 years (Wu, Van Wieringen et al. 2005). 
The median number of prior treatments was three (range: 1-5). Forty-six percent 
responded to the bortezomib treatment (CR + PR + MR). Results of this study were 
comparable with the results of SUMMIT and CREST, which reported similarly defined 
response rates of 35-50%.  
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In a phase I/II trial, 34 Japanese patients with relapsed or refractory multiple 
myeloma received single-agent bortezomib (0.7, 1.0 or 1.3 mg/m²) (Ogawa, Tobinai et al. 
2008). The median age of the patients was 60 years. Forty-four percent of the patients 
were Durie-Salmon stage II and 56% of the patients were Durie-Salmon stage III. The 
median number of lines of prior therapy was two (range: 1-8) The overall response rate 
was 30% (CR + PR). Of the ten responders, five patients had one line of prior therapy, two 
patients had three lines of prior therapy and three patients had four or more lines of prior 
therapy.  
A phase II trial evaluated the efficacy and toxicity of bortezomib (1.6 mg/m²) in a 
total of 40 patients who had received either one or two previous treatment regimens 
(Hainsworth, Spigel et al. 2008). Median age of the patients was 69 years. An objective 
responses to treatment was achieved in 55% (CR + PR) of the patients. 
A single institution, phase II study evaluated bortezomib as pre-auto-SCT and as 
maintenance therapy post auto-SCT in 40 patients (Uy, Goyal et al. 2008). The median 
age of these patients was 56 years. 68% and 30% of the patients had Durie-Salmon stage 
III and stage II multiple myeloma respectively. The median number of prior therapies was 
one (range: 0-3). Response evaluation immediately before stem cell mobilization showed a 
ORR of 70% (CR + VGPR + PR). Post transplant, the ORR was 78%. 
 
Bortezomib and dexamethasone 
The SUMMIT and CREST evaluated bortezomib alone and in combination with 
dexamethasone for patients with suboptimal response. The SUMMIT concluded that 18% 
of the patients had a minimal or partial response to this combination. However, just 
patients with progressive disease after two cycles or stable disease after four cycles 
received dexamethasone which also counted for CREST. CREST showed an ORR (CR + 
PR + MR) for patients who received a combination of bortezomib and dexamethasone of 
11% in the 1.0 mg/m2 dose group and 12% in the 1.3 mg/m2 dose group (Jagannath, 
Barlogie et al. 2004).  
Bruno and colleagues (2006) retrospectively evaluated bortezomib in 23 patients 
who had relapsed after allografting (Bruno, Patriarca et al. 2006). The median age of the 
patients at transplant was 53 years. The overall response rate (CR + EN-PR + PR + MR) 
was 61%. No significant differences in toxicity and response rates were seen between 
patients treated with bortezomib plus steroids and bortezomib alone. 
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Freimann and colleagues (2007) determined the safety and efficacy results of daily 
practice use of bortezomib in Switzerland (Freimann, Calderoni et al. 2007). Addition of 
oral dexamethasone (20 mg the day of and the day after bortezomib administration) was 
recommended after 2 or 4 cycles in case of progressive or stable disease, respectively. A 
total of 88 patients entered the program. The median age was 66 years and the median 
number of previous treatments was three (range: 2-6). Of the 83 evaluable patients, the 
overall intent-to-treat response rate (≥ MR) was 61%.  
A retrospective study under 37 patients evaluated two different doses of 
bortezomib (1.0 or 1.3 mg/m²) following reduced intensity allogeneic stem-cell 
transplantation (El-Cheikh, Michallet et al. 2008). The median age of the patients was 49 
years, which is relatively young compared to the median age of the patients in most trials. 
The myeloma stage at diagnosis according to the Durie-Salmon classification was III for 
86% of the patients. The median time between allo-SCT and initiation of bortezomib was 
20 (range: 1-65) months. Seventy-three percent (CR + VGPR + PR) of the patients 
achieved an objective disease response after bortezomib. Differences were not found in 
disease response among patients receiving prior thalidomide and/or donor lymphocyte. 
Moreover using bortezomib in combination or without dexamethasone did not influence the 
response rates.  
In 2009, a multicenter, phase IIIb trial was conducted to assess the response rates 
of bortezomib (1.3 mg/m²) with or without dexamethasone in 635 patients (Mikhael, Belch 
et al. 2009). Dexamethasone (20 mg/d) was added to bortezomib for patients who 
experienced progressive disease after ≥ 2 cycles or for stable disease after ≥ 4 cycles. The 
median age of the patients was 63 years and the patients received a median number of 
three (range: 0-11) prior therapies. The best ORR (CR + VGPR + PR + MR) rate in 635 
evaluable patients was 67%. Of the 141 patients who had progressive disease or stable 
disease before dexamethasone was added to their regimen, the ORR with added 
dexamethasone was 33%. A total of 169 (27%) patients received stem-cell transplantation 
prior to bortezomib ± dexamethasone. The ORR in this group was 63%. Among the 397 
(63%) patients who had received prior thalidomide, 64% achieved ORR. 
 
Bortezomib and melphalan combination regimens 
Bortezomib has also been studied in combination with melphalan. In 2006, the results of a 
phase I/II trial assessing bortezomib (0.7 to 1.3 mg/m²) in a 4-wk cycle and melphalan 
(0.025 to 0.25 mg/kg) combination therapy were published (Berenson, Yang et al. 2006). 
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Thirty-five patients with a median age of 60 years were enrolled in this study. The median 
number of prior treatments was three (range: 2-7). Responses were observed in 23 of 34 
(69%) evaluable patients. Fifty-eight percent of the patients receiving the higher dose of 
bortezomib (1.0 mg/m²) achieved ≥ PR, in comparison with 33% of the patients in the 
lower dose group (0.7 mg/m²). The results of this trial suggest that the combination of low-
dose melphalan with a higher dose of bortezomib (1.3 mg/m²) could improve response 
rates while minimizing toxicities.  
In 2008, updated results of the phase I/II trial after longer follow-up were published 
(Berenson, Yang et al. 2008). Forty-eight patients were enrolled with a median age of 62 
years. Responses occurred in 32/46 (70%) evaluable patients. The CRs, nCRs and 
VGPRs were all observed in the higher dose cohorts (1.0 or 1.3 mg/m² bortezomib). This 
phase I/II study showed that the combination of lower doses of melphalan and a longer 
and more convenient 4-wk cycle of bortezomib results in high response rates. 
The addition of prednisone and thalidomide to bortezomib and melphalan 
increased the activity of the combination regimen, with response rates (CR + VGPR + PR) 
of 67% (Palumbo, Ambrosini et al. 2007). Fourteen patients received bortezomib, 
melphalan, prednisone and thalidomide (VMPT) as second-line therapy. The response 
rate in this group was 79%. All of the patients who received VMPT as second-line therapy 
had a 1-year progression-free survival in comparison with 27% of the patients who 
received VMPT as third-line. However, subgroup analysis did not show any statistical or 
clinical difference between responses and either age, line of treatment or dosage of 
bortezomib. 
In a phase I/II trial the ORR of bortezomib in combination with low-dose melphalan 
and dexamethasone was assessed (Popat, Oakervee et al. 2009). Fifty-three patients 
were included in this study with a median age of 61 years. The median number of prior 
therapies was three (range: 1-5). The ORR (CR + nCR + VGPR + PR) was 68% compared 
with an ORR of 64% prior to the addition of dexamethasone. In the 33 patients who were 
treated at the maximum tolerated dose (melphalan, 7.5 mg/m²), the ORR was 76%, which 
was significantly higher than for those not treated at the maximum tolerated dose.  
 
Bortezomib, thalidomide and dexamethasone 
In a phase I/II study clinical activity was determined for bortezomib (1.0 or 1.3 mg/m²) in 
combination with thalidomide and dexamethasone (Pineda-Roman, Zangari et al. 2008). 
Eighty-five patients participated in this study. The median age was 60 years and 27% of 
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the patients were older than 65. In total, 92% and 65% had received one or two prior 
autotransplants, respectively. Seventy-four percent of the patients had received prior 
thalidomide. For the intention-to-treat population, 79% (CR + nCR + PR + MR) responded 
to bortezomib. This study did not show a significant difference in highest response rates 
for patients who did or did not receive dexamethasone. Prior thalidomide seems to be 
significantly associated with lower PR and nCR rates. 
 
Bortezomib and pegylated liposomal doxorubicin (PLD) or doxorubicin combination 
regimens 
In a phase III study 646 patients were randomly assigned to receive either bortezomib (1.3 
mg/m²) or bortezomib in combination with PLD (Orlowski, Nagler et al. 2007). The median 
age of the patients was 61 years. Thirty-four percent of the patients had one prior therapy 
and 66% had two or more prior therapies. The overall response rate (CR + PR) in the 
intention-to-treat population was 41% for the patients who received bortezomib and 44% 
for the patients who received bortezomib in combination with PLD. Moreover, the median 
time to progression was improved from 6.5 months to 9.3 months for patients who 
received bortezomib in combination with PLD instead of bortezomib alone. The improved 
efficacy of bortezomib in combination with PLD was also seen across a variety of 
subgroups, such as patients aged ≥ 65 years old. In addition, patients treated with prior 
immunomodulatory drugs, anthracycline-based therapies and stem-cell transplantation 
benefited from the combination. The results of the above phase III study were stratified on 
the basis of whether patients had received prior thalidomide/lenalidomide (Sonneveld, 
Hajek et al. 2008). The analysis showed no statistical difference with respect to the 
prolonged time to progression attributed to the combination of PLD and bortezomib, 
compared with bortezomib alone between the subgroups.  
The addition of doxorubicin (20 mg/m²) or pegylated liposomal doxorubicin (30 
mg/m²) and dexamethasone to bortezomib (PAD) was also investigated in a multicenter 
trial (Palumbo, Gay et al. 2008). Data was available of 64 patients with relapsed/ refractory 
myeloma. The median age of the patients was 65 years and the median number of prior 
therapy lines was two (range: 1-7). 67% of the patients achieved at least PR. Fifteen 
patients (23%) achieved PAD as second-line therapy, of which 80% had at least a PR 
compared to 63% and 64% of the patients who received PAD as third-line or fourth- to 
eight-line therapy. Thirty-four patients received doxorubicin, of which 79% achieved at 
least PR in comparison with 30 patients who received PLD, of which 53% had at least PR. 
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A retrospective study of 57 patients with relapsed/ refractory myeloma determined 
the efficacy of bortezomib in combination with conventional chemotherapeutic agents for 
multiple myeloma compared with bortezomib alone (Min, Lee et al. 2007). This study 
resulted in observable improvements in response when bortezomib was combined with 
common chemotherapeutic agents. 
 
Bortezomib and other agents for multiple myeloma 
There are several other studies which evaluated bortezomib with other agents that are not 
mentioned above. Suvannasankha and colleagues reported a response rate (CR + nCR + 
PR) of 62% as a consequence of bortezomib in combination with methylprednisolone in 
the treatment of multiple myeloma (Suvannasankha, Smith et al. 2006). 
A phase I/II study evaluated arsenic trioxide/ bortezomib/ ascorbic acid 
combination therapy (Berenson, Matous et al. 2007). In this study, 22 patients were 
enrolled with a median age of 63 years. The patients had received a median of four 
(range: 3-9) prior failed therapies. Objective responses (PR + MR) were observed in 27% 
of the patients.  
Another phase I/II study tested bortezomib in combination with cyclophosphamide 
in combination with prednisone in relapsed/ refractory multiple myeloma (Reece, 
Rodriguez et al. 2008). Thirty-seven patients were enrolled in this trial. They had a median 
age of 60 years and their median number of prior regimens was two (range: 1-6). At the 
highest dose levels, the overall response rate was 95% (CR + PR + MR), with CR 
observed in more than 50% of patients.  
The following figure presents the response rates of bortezomib monotherapy or 
bortezomib combination therapy that resulted from the different studies that are included in 
this review. The response rates include a partial response or higher. 
 
- 99 - 
Figure 1: Response rates of bortezomib monotherapy or combination therapy for previously treated 
multiple myeloma 
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Evidence about the effectiveness of bortezomib in previously untreated 
multiple myeloma 
A number of studies showed that bortezomib in combination with other agents is also 
active in previously untreated multiple myeloma. These studies are discussed below.  
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Bortezomib and dexamethasone 
SUMMIT and CREST showed improved outcomes after the addition of dexamethasone to 
bortezomib in relapsed or refractory multiple myeloma. A phase II study assessed the 
response of bortezomib therapy alone and in combination with dexamethasone for 
previously untreated multiple myeloma (Jagannath et al. 2005, 776-783). Thirty-two 
patients entered the trial with a median age of 60 years. Fifty-six percent of the patients 
had a diagnosis of Durie-Salmon stage IIIA and IIIB multiple myeloma. Dexamethasone 
was added to the regimen in 22 patients. The overall response (CR + nCR + PR) of 
bortezomib with or without dexamethasone was 88%.  
A separate phase II study determined the CR rate achieved after four cycles of 
bortezomib plus dexamethasone combination therapy in patients with newly diagnosed 
multiple myeloma who were candidates for autologous stem-cell transplantation (ASCT) 
(Harousseau et al. 2006, 1498-1505). In total, 50 patients entered the trial of which 48 
patients were evaluable. The median age of the patients was 55 years. The Durie-Salmon 
stage was I in 4 patients, II in 14 patients and III in 32 patients. The overall response was 
66% (CR + VGPR + PR). No relationship was found between the CR or VGPR rate and 
the Durie-Salmon stage. Forty-two patients proceeded to stem-cell transplantation. After 
ASCT, the overall response was 90%.  
The results of a phase II trial investigating the efficacy of bortezomib and 
dexamethasone as up-front therapy in multiple myeloma were comparable (Rosinol et al. 
2007, 4452-4458). 40 patients entered the trial with a median age of 54 years. Twenty-six 
patients (65%) achieved at least PR (on an intent-to-treat basis). At the end of induction 
treatment 60% of the patients achieved at least PR. Of the 37 patients who underwent 
ASCT, 88% achieved at least PR (Rosinol et al. 2007, 4452-4458).  
 
Bortezomib, melphalan and prednisone  
A multicenter phase I/II study evaluated bortezomib in combination with melphalan and 
prednisone in elderly untreated patients with multiple myeloma (Mateos et al. 2006, 2165-
2172). In total, 60 patients entered the trial and 53 patients were evaluable for response. 
The median age of the patients was 75 years. The response rate (CR + nCR + PR) was 
89%. Updated time-to-events data evaluated the influence of known prognostic factors on 
the time to progression (Mateos et al. 2008, 560-565). A univariate analysis showed that 
the time to progression was not significantly influenced by advanced age.  
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A phase 3 study compared the use of melphalan and prednisone with or without 
bortezomib in previously untreated patients with multiple myeloma who were ineligible for 
high-dose therapy (San Miguel et. al. 2008, 906-917). A group of 682 patients entered the 
trial. Partial response or better were observed in 71% of the patients in the bortezomib 
group compared to 35% in the control group. 
 
Bortezomib, thalidomide and dexamethasone 
Bortezomib has also been studied in combination with thalidomide and dexamethasone. A 
study in 38 newly diagnosed patients with multiple myeloma showed rapid onset of 
remission in 33 patients (87%) including 6 patients with complete remission (16%) (Wang 
et. al. 2007, 235-239).  
A large phase II study evaluated the addition of VTD (bortezomib, thalidomide and 
dexamethasone) to PACE (cisplatin, doxorubicin, cyclophosphamide and etoposide) 
combination chemotherapy as induction therapy prior to and as consolidation therapy after 
high-dose melphalan-based tandem transplants (Barlogie et al. 2007, 176-185). In total, 
303 newly diagnosed patients with multiple myeloma were enrolled in total therapy 3 
(TT3). The median age was 59 years. The cumulative frequency of nCR reached 83% at 
24 months and CR reached 56% at 24 months (Barlogie et al. 2007, 176-185). Follow-up 
results were published of TT3, which were compared with TT2 outcomes in the context of 
both standard prognostic factors (SPF) and of gene expression profiling (GEP) data, 
available in 351 of 668 patients enrolled in TT2 and in 275 of 303 patients accrued to TT3 
(Pineda-Roman et al. 2008, 625-634). The 2-year sustained CR rate with TT3 was 92% 
compared to 81% for TT2 with thalidomide and 79% for TT2 without thalidomide. 
 
Bortezomib, doxorubicin and dexamethasone 
A phase I/II trial tested PAD combination therapy which included bortezomib, doxorubicin 
and dexamethasone (Oakervee et al. 2005, 755-762). In total, 21 newly diagnosed 
multiple myeloma patients with a median age of 55 years entered the trial. The Durie-
Salmon stage was IIA in 13 patients. The bortezomib dose was 1.3 mg/m² which was 
given on days 1, 4, 8 and 11. 95% of the patients achieved a PR or greater (all treatment 
levels included). After completion of PAD induction, patients underwent peripheral blood 
stem cell (PBSC) harvesting. Thereafter, high-dose melphalan was administered with 
forced diuresis. Eighteen patients received high-dose melphalan with stem-cell 
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transplantation. On the basis of an intent-to-treat analysis, the ORR rate was 95% (CR + 
nCR + VGPR + PR) at 3 months post-transplantation. 
In 2007 updated results after long-term follow-up were published (Popat et al. 
2008, 512-516). In this follow-up study a second cohort was evaluated. Patients in this 
cohort received bortezomib (1.0 mg/m²) and doxorubicin (9 mg/m²). In this cohort 89% 
achieved a PR or greater. The post-transplantation overall response rate was 89%. The 
CR and nCR rates appeared higher in the first cohort compared to the second cohort both 
pre- and post-HDT-PBSCT, however these differences were not statistically significant 
(Popat et al. 2008, 512-516). 
 
Bortezomib and other agents for multiple myeloma 
Berenson and colleagues evaluated bortezomib in combination with ascorbic acid and 
melphalan in 35 patients with newly diagnosed multiple myeloma (Berenson et al. 2009). 
Median age was 70 years. In 23 of 31 evaluable patients (74%), responses (≥ MR) were 
observed.  
A phase II clinical trial determined the response rates of bortezomib in combination 
with cyclophosphamide and dexamethasone (Reeder et al. 2009). In total, 33 newly 
diagnosed patients with multiple myeloma entered the trial. The mean age was 60 years. 
All patients had symptomatic disease (Durie-Salmon stage II or III). The overall intent-to-
treat response rate in this study (≥ PR) was 88%. 
The following figure presents the response rates of bortezomib combination 
therapy for patients with previously untreated multiple myeloma that resulted from the 
different studies that are included in this review. 
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Figure 2: Response rates of bortezomib combination therapy in patients with previously untreated 
multiple myeloma 
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Conclusion 
The response rates for bortezomib in patients with relapsed or refractory multiple myeloma 
were greater compared to the response rates of dexamethasone alone (Richardson, 
Sonneveld et al. 2005). The response rates increased with the addition of dexamethasone 
to bortezomib treatment (Richardson, Barlogie et al. 2003; Jagannath, Barlogie et al. 
2004). Chemotherapy agents that have been combined successfully with bortezomib 
include melphalan, doxorubicin and thalidomide. 
Given the excellent efficacy and safety profile of bortezomib in relapsed and 
refractory multiple myeloma, questions were raised regarding use as a first-line treatment 
in newly diagnosed disease (Dicato et al. 2006, 474-482). The second section of this 
review gave an overview of the evidence of bortezomib in patients with previously 
untreated multiple myeloma. For this group of patients bortezomib is also promising, with 
primarily the bortezomib-based combinations resulting in high response rates. The optimal 
bortezomib-based combination has not been determined, as such depends in part on 
individual patient characteristics (Manochakian, Miller, and Chanan-Khan 2007, 978-990). 
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Annex IV: Minimal Case Report Form 
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Annex V: Maximal Case Report Form 
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Annex VI: Literature review of cost-effectiveness of 
bortezomib 
 
Identification of studies 
The aim of the search was to provide, as comprehensive as possible, a retrieval of 
economic evaluations of bortezomib in the treatment of multiple myeloma. 
 
Sources searched 
Three electronic databases were searched. The literature search was performed in March 
2009 via the PubMed, Cochrane Library and EMBASE databases.  
 
Keyword strategies 
The queries used for the review were “bortezomib or velcade” and “cost or costs or 
economic”.  
 
Inclusion and exclusion criteria 
The following inclusion and exclusion criteria were used: (1) articles were included if ‘costs’ 
or ‘cost-effectiveness’ of bortezomib for multiple myeloma was one of the main topics of 
the article, (2) only research articles were considered, reviews were excluded with the 
exception of hand-screening reference lists for additional publications, and (3) only articles 
using the English or Dutch language were considered. Full papers were obtained for any 
titles or abstracts that were considered relevant or where the title or abstract information 
was not sufficient to make a decision. 
 
Results of cost-effectiveness review 
The database-search identified 138 articles for potential inclusion in the review. Ten 
articles were excluded because they appeared more than once. A total of 122 articles 
were further rejected based on the title or abstract stage. Full copies were retrieved and 
inspected from a final selection of six articles. Of these, four articles were not research 
articles. One article included a review of recent health economic evidence in published 
literature relating to the management of multiple myeloma. In total, one publication met the 
inclusion criteria (Mehta, Duff, and Gupta 2004, 52-61). 
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Potentially relevant citations 
identified through electronic 
searches
n = 138
Papers rejected because they
appeared in more than one
database
n = 10
Titles and/ or abstracts 
screened and inspected
n = 128
Papers rejected at the title/ 
abstract stage
n = 122
 
Full copies retrieved and 
inspected
n = 6
Full papers excluded
n = 5
Publications meeting inclusion 
criteria
n = 1
 
 
 
Cost-effectiveness review 
Mehta and colleagues (2004) report a cost-effectiveness study of bortezomib in the 
treatment of advanced multiple myeloma in comparison to best supportive care (BSC) and 
thalidomide. The economic analysis was undertaken from a payer’s perspective. 
 
Summary of effectiveness data 
Evidence on the effectiveness of bortezomib was obtained from the Study of Uncontrolled 
Multiple Myeloma managed with proteasome Inhibition Therapy (SUMMIT), a single-arm, 
multicenter, phase II pivotal study (Richardson et. al. 2003). Decision analysis was 
employed to make three comparisons: (1) the full-cohort model that included all 
bortezomib patients from the SUMMIT versus BSC patients; (2) the first of two stratified 
models comparing bortezomib patients who were previous thalidomide users versus BSC 
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patients; and (3) the second stratified model comparing bortezomib patients who had not 
used thalidomide versus thalidomide patients.  
The published data available from the SUMMIT did not include direct comparisons 
with the other treatment options (BSC and thalidomide). Therefore, a Delphi panel 
composed of six experts in MM was surveyed to obtain demographic, clinical, and medical 
resource-utilisation estimates. The median overall survival served as the measure of 
efficacy to evaluate cost-effectiveness. 
 
Cost analysis 
Only the direct medical costs associated with each therapy were included in the analyses. 
The total medical costs were a combination of costs related to three primary medical 
resource-utilisation components: (1) pharmacotherapy (i.e., primary therapy used to delay 
disease progression); (2) disease management (i.e., concomitant medications, office/clinic 
visits, diagnostic tests), and (3) adverse events. The resource use data were derived from 
the SUMMIT and the Delphi panel. Cost estimates obtained from objective, published 
sources were used to retrospectively assign unit costs to medical resource-utilisation. The 
price year was 2003. 
 
Sensitivity analysis 
Sensitivity analysis was performed by allowing the estimates for a number of key variables 
within a range of plus/minus 25%. The following variables were varied: (1) the prices of 
bortezomib and thalidomide, (2) the proportion of patients using bisphosphonates, (3) the 
frequency of chronic events, (4) the frequency of skeletal complications and (5) median 
survival. 
 
Summary 
The median overall survival for the bortezomib group was 16.0 months and 2.5 months in 
the BSC cohort. An estimated 62% and 7% of the patients in the bortezomib and BSC 
cohort, respectively, were assumed to survive for one year. In the first stratified model, the 
median overall survival for bortezomib patients with previous thalidomide use was 15.7 
months compared to 2.5 months for the BSC cohort. One-year survival was 60% and 7%, 
respectively. In the second stratified model, bortezomib patients (without previous 
thalidomide use) had a median overall survival of 26.0 months, whereas the thalidomide 
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patients had an estimated median survival of 8.6 months. The one-year survival rates were 
83% and 46%, respectively.  
For the base-case analysis, the total costs of bortezomib therapy for multiple 
myeloma were $65.220 (€51.025) per patient, compared with $14.423 (€11.284) for BSC 
therapy. The total costs were based on the median duration of survival. The total costs of 
thalidomide therapy were $37.265 (€29.154) per patient.  
The base-case scenario of the full-cohort model revealed an ICER of $45.356 
(€35.484) per additional life-year for treatment with bortezomib compared with BSC. The 
ICER for treatment with bortezomib among patients previously treated with thalidomide 
relative to those managed with BSC resulted in an additional $49.797 (€38.959) per life-
year gained. Conversely, the ICER for treatment with bortezomib among those without 
previous thalidomide use relative to those treated with thalidomide resulted in an additional 
$21.483 (€16.807) per life-year gained. The modified estimates used in the sensitivity 
analysis did not alter the direction of the results. The authors concluded that bortezomib 
provides a cost-effective option in the treatment of multiple myeloma and provides the best 
value among the currently available therapeutic options in terms of cost per life-year 
gained.  
This study was associated with a few limitations. Firstly, only direct costs were 
included in the economic analysis, whereas the societal perspective is preferred in 
economic evaluations, of which requires the incorporation of all costs and effects. 
Secondly, the unit cost estimates may not be identical to the true costs. Finally, the ideal 
data source would have been a randomised clinical trial as opposed to the combination of 
clinical trial data, expert judgment and published data. 
 
Conclusion 
This systematic review contains just one cost-effectiveness analysis. Due to the weakness 
of the underlying data, it is too early to draw conclusions from this one assessment. 
Further research is necessary to assess the cost-effectiveness of bortezomib. 
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Annex VII: Overview participating hospitals 
The following hospitals participated in the pilot study: 
 
Participating hospitals
Alkmaar, Medisch Centrum Alkmaar
Almere, Flevo ziekenhuis
Amersfoort, Meander Medisch Centrum
Amstelveen, Ziekenhuis Amstelland
Amsterdam, Academisch medisch centrum
Amsterdam, VU Medisch Centrum
Apeldoorn, Gelre ziekenhuis, locatie Apeldoorn
Arnhem, Alysis Zorggroep, locatie Rijnstate
Beverwijk, Rode Kruis Ziekenhuis
Capelle aan den IJssel, IJsselland ziekenhuis
Delft, Reinier de Graaf Gasthuis
Den Bosch, Jeroen Bosch Ziekenhuis, locatie Groot Ziekengasthuis
Den Haag, Haga ziekenhuis, locatie Leyweg
Den Helder, Gemini ziekenhuis
Deventer, Deventer ziekenhuis
Dirksland, Dirskland ziekenhuis
Dordrecht, Albert Schweitzer ziekenhuis
Ede, Ziekenhuis Gelderse Vallei
Enschede, Medisch Spectrum Twente
Goes, Oosterschelde ziekenhuis
Gorinchem, Rivas Zorggroep, locatie Beatrix ziekenhuis
Groningen, Universitair Medisch Centrum Groningen
Heemstede, Spaarne ziekenhuis, locatie Heemstede
Heerlen, Atrium Medisch Centrum, locatie Heerlen
Hoorn, Westfriesgasthuis
Leiden, Leids Universitair Medisch Centrum
Lelystad, IJsselmeerziekenhuizen, Zuiderzeeziekenhuis, locatie Lelystad
Nieuwegein, St Antonius ziekenhuis
Nijmegen, Universitair Medisch Centrum Sint Radboud
Roosendaal, Franciscus Ziekenhuis Roosendaal
Rotterdam, Erasmus MC, centrum locatie
Rotterdam, Erasmus MC, Daniel den Hoed
Rotterdam, Maasstad Ziekenhuis, locatie Clara
Rotterdam, Sint Franciscus Gasthuis
Terneuzen, ZorgSaam Ziekenhuis Terneuzen
Tilburg, Sint Elisabeth Ziekenhuis
Tilburg, TweeSteden Ziekenhuis, locatie Tilburg
Utrecht, Universitair Medisch Centrum Utrecht
Vlissingen, Ziekenhuis Walcheren
Woerden, Zuwe Hofpoort Ziekenhuis
Zutphen, Gelre Ziekenhuizen, locatie Het Spittaal
Zwolle, Isala Klinieken, locatie Sophia
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Summary 
Introduction 
Colorectal cancer is one of the most common causes of cancer in the western world with 
more than 200,000 deaths in Europe in 2006. Over the past decade, significant progress 
has been achieved in the treatment of colorectal cancer by advances in, among others, 
systemic chemotherapy. Oxaliplatin, a third-generation chemotherapeutic agent, became 
available for the palliative treatment of metastatic colorectal cancer in 2000 and was 
subsequently approved for the adjuvant treatment of stage III colon cancer in 2005. 
Oxaliplatin is an expensive medicine and was admitted under the Dutch ‘expensive 
medicines’ policy regulation in order to allow hospitals to obtain additional funding for this 
drug. Since 2006, the Dutch policy regulation for expensive hospital medicines requires 
evidence about the real world utilization, effectiveness and cost-effectiveness after three 
years of temporary supplemental funding. Outcomes research in this particular context is 
new in Dutch policymaking and experience in the application of outcomes research is 
therefore lacking. This paper investigates how oxaliplatin is used in daily practice and 
explores its real-world treatment effects and costs in stage III colon and metastatic 
colorectal cancer in Dutch daily practice. This pilot outcomes research study was 
conducted as part of a comprehensive study of methodological issues related to outcomes 
research. 
 
Methods 
The oxaliplatin pilot study examined the appropriate use and cost-effectiveness of 
oxaliplatin by exploring how it was used in Dutch daily practice for a) the treatment of 
stage III colon cancer; and b) the treatment of metastatic colorectal cancer. Real-world 
effects and costs of oxaliplatin treatment were investigated. The pilot study population was 
identified via the database of the Dutch Cancer Registry and comprised patients 
diagnosed with stage III colon or stage IV colorectal cancer. Of note, stage IV concerns 
patients who present with distant metastases (synchronous disease), as opposed to 
patients who develop distant metastases during follow-up (metachronous disease). Since 
patients with metachronous disease are not registered by the Dutch Cancer registry, this 
analysis is restricted to stage IV synchronous patients. First, minimal Case Report Forms 
were retrospectively completed using hospital medical records. Second, maximal Case 
Report Forms were used to collect additional detailed data for a representative sub-group. 
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We investigated how oxaliplatin was used in daily practice and analysed application of 
treatment regimes, dose modifications and treatment-related toxicities. Survival curves 
were visualised using Kaplan-Meier methods to analyse the effect of oxaliplatin on 
disease-free survival (stage III) and overall survival (stage IV). Treatment costs were 
calculated using the hospital perspective and resource use was assessed per individual 
patient by means of micro-costing estimates. Results of stage III colon cancer were 
compared to the pivotal clinical registration trial (MOSAIC trial). Results of stage IV 
colorectal cancer were compared to the post-registration trial (CAIRO trial) that took place 
in the Netherlands during the same time period used in the pilot study. Our retrospective 
study design made it impossible to collect data on Health Related Quality of Life (HRQOL). 
However, the CAIRO study measured the disease specific quality of life using the QLQ-
C30 questionnaire of the European Organisation for Research and Treatment of Cancer 
(EORTC). We used a recently developed model to convert these QLQ-C30 values into 
health utilities to allow comparisons of Quality adjusted life years (QALYs) between the 
treatment groups in metastatic colorectal cancer. Lastly, the incremental cost-effectiveness 
of oxaliplatin in stage III colon cancer was determined using a probabilistic Markov model, 
synthesising evidence from the pilot study and the pivotal clinical registration trial 
(MOSAIC). 
 
Results 
Oxaliplatin in stage III colon cancer 
In total 463 patients were treated in 19 selected hospitals. 391 of these patients were 
included. The most frequently used treatment regimens in the Netherlands during the 
study period were capecitabine combined with oxaliplatin (CAPOX, 37%), 5FU/LV 
combined with oxaliplatin (FOLFOX, 35%), capecitabine monotherapy (24%), and different 
5-FU/LV regimens (4%). There was a quick diffusion of oxaliplatin in the time period 
examined in the pilot study. The planned dose for each regimen was equal to the dosing 
recommendations found in the Dutch guidelines. The mean administered dosage per week 
across all cycles was only slightly lower than the planned dosage. However, oxaliplatin 
seemed to be less well tolerated when given in the CAPOX schedule than in the FOLFOX 
schedule. Patients who did not receive oxaliplatin were significantly older and more often 
had comorbidities than patients who received oxaliplatin. There were clear reasons why 
patients did not receive oxaliplatin. These observations provided evidence to conclude that 
the prognosis of patients who received oxaliplatin was not comparable with the prognosis 
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of other patients, and that a direct comparison of disease-free survival was not justified. 
However we were able to compare our findings to the results of the MOSAIC trial. In total 
82% of the pilot patients who received oxaliplatin fulfilled the inclusion criteria of the 
MOSAIC trial. Baseline characteristics, FOLFOX schedules, total cumulative dosages and 
disease free survival outcomes were comparable between the MOSAIC trial patients and 
the pilot study patients who fulfilled the eligibility criteria used in the MOSAIC study and 
also received oxaliplatin. The average costs per patient were € 9,114 for 5FU/LV, € 9,220 
for capecitabine monotherapy, € 30,873 for FOLFOX and € 17,212 for CAPOX. 
Differences in baseline characteristics did not seem to be associated with total costs. The 
incremental cost-effectiveness per QALY gained varied between € 15,491 and € 22,836, 
depending on the chosen population and scenario.  
 
Oxaliplatin in metastatic colorectal cancer 
In total 433 patients diagnosed with stage IV colorectal cancer were treated in 29 selected 
hospitals; 312 of these patients were included for further analyses. Sixty-three percent of 
the patients received first-line monotherapy with fluoropyrimidines, and 37% received 
combination therapy with either oxaliplatin or irinotecan. When the CAIRO eligibility criteria 
were applied to the pilot study population, 71% (224/314) of them fulfilled all criteria. Most 
patients with metastatic colorectal cancer received several treatment lines. At least half of 
the patients receiving monotherapy as first-line treatment received combination therapy 
with either oxaliplatin or irinotecan in the second line. In the third line 22% of the patients 
still received chemotherapy. The types of second-line and third-line therapy given to 
patients receiving first-line combination therapy were very similar to these results, although 
a larger proportion of these patients received both oxaliplatin and irinotecan during the 
course of their disease compared to patients receiving first-line monotherapy. In general, 
our findings were in line with the recommendations found in the Dutch guidelines. The 
prognosis of the pilot study patients who fulfilled the CAIRO study eligibility criteria was 
comparable with the prognosis of the patients in the CAIRO study. This was reflected in 
the overall survival outcomes. Among eligible pilot patients, median overall survival was 
15.1 (95% CI 12.8 – 19.0) months for the patients who received first-line combination 
therapy and 11.2 (95% CI 9.5 – 13.3) months for patients receiving first-line monotherapy. 
In the CAIRO study, the median overall survival was 15.9 (95% CI 14.3 – 18.0) months for 
patients receiving first-line combination therapy and 13.4 (95% CI 11.5 – 15.2) months for 
the patients who received first-line monotherapy. No significant differences were found 
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between the CAIRO study and the pilot patients treated in Dutch clinical practice. 
However, patients receiving monotherapy in the pilot study tended to have a slightly worse 
outcome compared to the CAIRO patients receiving first-line monotherapy and compared 
to patients receiving combination therapy. This can be explained by the non-random 
assignment of treatments in the pilot population. The proportion of patients older than 70 
years of age was greater amongst the pilot study patients receiving monotherapy than 
amongst the pilot study patients receiving combination therapy and the CAIRO patients. 
Besides this we found that these patients were significantly less often treated with a third-
line therapy than patients in the CAIRO sequential (first-line monotherapy) treatment arm. 
This may reflect a tendency towards a higher motivation for treatment in trial versus non-
trial patients. Regarding quality of life, the CAIRO study found that patients randomised to 
first-line monotherapy and patients receiving combination therapy had a comparable 
overall mean utility (0.77 vs. 0.76). Total mean costs in eligible pilot patients amounted to € 
19,812 for monotherapy, € 28,200 for oxaliplatin combination therapy and € 44,664 for 
irinotecan combination therapy. Mean costs for monotherapy and oxaliplatin combination 
therapy were significantly different. A substantial cost variation was found in the total costs 
obtained for individual patients within treatment groups as well as in each individual cost 
component. Inpatient hospital days and chemotherapy (leucovorin, capecitabine, 
oxaliplatin and irinotecan) were the most important cost drivers. 
 
Discussion 
Outcomes research provides valuable information on the utilisation of oxaliplatin in daily 
practice. In stage III colon cancer, insight into patient baseline characteristics, use of 
oxaliplatin, toxicities and effectiveness demonstrated that treatment with oxaliplatin in 
clinical practice corresponds well with the requirements for registering oxaliplatin at T = 0.  
However, a valid comparison between patients who did and did not receive oxaliplatin was 
not possible. As a result, MOSAIC patients randomised to receive the control treatment 
without oxaliplatin were used as a comparator group in the cost-effectiveness model to 
calculate the incremental cost-effectiveness of oxaliplatin. In our opinion, this approach led 
to a sufficiently precise and valid estimate of the cost-effectiveness of oxaliplatin in daily 
clinical practice. In conclusion, both the cost-effectiveness and the appropriate use of 
oxaliplatin in the treatment of stage III colon cancer in daily practice could be sufficiently 
substantiated. In metastatic colorectal cancer we were able to make use of the CAIRO 
post-registration trial and the pilot patients were selected from the same underlying source 
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population as part of the CAIRO patients. This allowed valid comparisons to be made 
between the eligible pilot population and the CAIRO patients. The results of the studies 
were comparable and led us to conclude that it was feasible to make a sufficiently precise 
and valid estimate of the cost-effectiveness of oxaliplatin. Also, the appropriate use of 
oxaliplatin for the indication of metastatic colorectal cancer could be sufficiently 
substantiated.  
However it is important to realise that a crucial factor in this pilot study was the ability to 
use data and results from trials such as the MOSAIC and CAIRO, combined with a limited 
dynamics in daily practice (i.e., a limited amount of treatment variation). The combination 
of data sources used in this study is a cogent reminder that the assessment of the real-
world effectiveness and cost-effectiveness of a medicine will make use of all available 
data. The actual approach to be taken will have to depend on the types of data and 
evidence available at the time of the final assessment (i.e., 3-4 years of use in daily 
practice). 
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Samenvatting 
Introductie 
Colorectaal kanker is één van de meest voorkomende vormen van kanker in de westerse 
wereld. Er stierven meer dan 200.000 personen ten gevolge van colorectaal kanker in 
Europa in 2006. De afgelopen tien jaar is er belangrijke vooruitgang geboekt in de 
behandeling van colorectaal kanker door verbetering van onder andere systemische 
chemotherapie. Oxaliplatin is sinds 2000 beschikbaar voor het palliatief behandelen van 
gemetastaseerd colorectaal kanker en werd in 2005 goedgekeurd voor de adjuvante 
behandeling van stadium III colon kanker. Oxaliplatin is een duur medicijn en is daarom op 
de beleidsregel ‘Dure geneesmiddelen’ geplaatst, zodat ziekenhuizen aanvullende 
financiering krijgen. Uit deze beleidsregel vloeit sinds 2006 voort dat na drie jaar tijdelijke 
aanvullende financiering, bewijs over het gebruik, het effect en de kosten-effectiviteit van 
de dure geneesmiddelen in de dagelijkse, klinische praktijk verzameld wordt. 
Uitkomstenonderzoek voor dit doeleinde is nieuw in Nederland. Er is daarom weinig 
ervaring met de toepassing ervan. Het doel van deze studie is onderzoeken hoe oxaliplatin 
wordt gebruikt in dagelijkse, klinische praktijk. Daarnaast worden de werkelijke 
behandeleffecten en kosten in stadium III colon kanker en gemetastaseerd colorectaal 
kanker in de dagelijkse, klinische praktijk onderzocht. Deze pilot studie is uitgevoerd als 
onderdeel van een uitgebreide studie naar methodologische aspecten bij 
uitkomstenonderzoek.  
 
Methoden 
De oxaliplatin pilot studie onderzoekt hoe oxaliplatin in de dagelijkse, klinische praktijk 
gebruikt wordt. Tevens wordt de kosteneffectiviteit van oxaliplatin onderzocht voor a) de 
behandeling van stadium III colon kanker; en b) de behandeling van gemetastaseerd 
colorectaal kanker. De onderzoekspopulatie is vastgesteld door middel van de database 
van de Nederlandse Kankerregistratie (NKR) en bestaat uit patiënten die gediagnosticeerd 
zijn met stadium III colon kanker of stadium IV colorectaal kanker. Stadium IV colorectaal 
kanker patiënten betreft patiënten die zich presenteerden met afstandsmetastasen 
(synchrone metastasen), in tegenstelling tot patiënten die afstandsmetastasen 
ontwikkelden gedurende follow-up (metachrone metastasen). Omdat patiënten met 
metachrone metastasen niet geregistreerd zijn door de NKR is deze studie alleen gericht 
op patiënten met stadium IV colorectaal kanker (synchrone metastasen). Eerst werden 
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minimale Case Report Forms retrospectief ingevuld met behulp van de medische dossiers 
van de patiënten. Daarna werden maximale Case Report Forms gebruikt om aanvullende 
informatie te verzamelen over een representatieve subgroep. Om het gebuik van 
oxaliplatin in de dagelijkse, klinische praktijk te onderzoeken werden de toepassing van 
behandelschema’s, dosis aanpassingen en behandelinggerelateerde toxiciteiten 
bestudeerd. Overlevingscurves werden ontwikkeld met behulp van de Kaplan-Meier 
methode om de effecten van oxaliplatin op ziektevrije overleving (stadium III) en totale 
overleving (stadium IV) te analyseren. Behandelkosten werden berekend vanuit het 
ziekenhuisperspectief. Kosten werden per individuele patiënt bepaald met behulp van van 
micro-costing. Resultaten van de stadium III colon kanker pilot studie werden vergeleken 
met de klinische registratie trial (MOSAIC trial). Resultaten van de stadium IV colorectaal 
kanker pilot studie werden vergeleken met de post-registratie trial (CAIRO trial) die plaats 
vond in Nederland gedurende dezelfde periode als de pilot studie. Het retrospectieve 
onderzoeksdesign maakte het onmogelijk om data te verzamelen over de 
gezondheidsgerelateerde kwaliteit van leven. Echter, de CAIRO trial onderzocht de 
ziektespecifieke kwaliteit van leven gebruikmakend van de QLQ-C30 vragenlijst van de 
Europese Organisatie voor Onderzoek en Behandeling van Kanker (EORTC). Met behulp 
van een recent ontworpen model zijn de QLQ-C30 waarden omgezet in utiliteiten om een 
vergelijking te kunnen maken in voor kwaliteit van leven gecorrigeerde levensjaren 
(QALYs) tussen verschillende behandelingen voor gemetastaseerd colorectaal kanker. Tot 
slot is de incrementele kosten-effectiviteit van oxaliplatin in stadium III colon kanker 
vastgesteld met behulp van een probabilistisch Markov model, waarin resultaten van de 
pilot studie en MOSAIC trial werden samengevoegd.  
 
Resultaten 
Oxaliplatin in stadium III colon kanker 
In totaal werden 463 patiënten behandeld in 19 geselecteerde ziekenhuizen. Van deze 
patiënten werden er 391 geïncludeerd. De meest frequent toegepaste behandelschema’s 
in Nederland gedurende de studie waren capecitabine gecombineerd met oxaliplatin 
(CAPOX, 37%), 5FU/LV gecombineerd met oxaliplatin (FOLFOX, 35%), capecitabine 
monotherapie (24%) en verschillende 5-FU/LV schema’s (4%). Er was een snelle 
verspreiding van oxaliplatin in de bestudeerde tijdsperiode van de pilot studie. De 
geplande dosering voor elk schema was gelijk aan de doseringsaanbevelingen in de 
Nederlandse richtlijnen. De gemiddelde toegediende dosering per week gedurende alle 
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kuren was slechts iets lager dan de geplande dosering. Oxaliplatin lijkt echter minder goed 
getolereerd te worden in het CAPOX schema dan in het FOLFOX schema. Patiënten die 
geen oxaliplatin kregen waren significant ouder en hadden meer comorbiditeiten dan de 
patiënten die wel behandeld werden met oxaliplatin. Er waren duidelijke redenen waarom 
patiënten niet met oxaliplatin behandeld werden. Het bleek dat de prognose van patiënten 
die met oxaliplatin behandeld werden niet vergelijkbaar was met de prognose van andere 
patiënten, en dat directe vergelijking met betrekking tot ziektevrije overleving niet mogelijk 
was. Daarentegen was het wel mogelijk om de bevindingen te vergelijkingen met de 
resultaten van de MOSAIC trial. In totaal voldeden 82% van de pilot patiënten die met 
oxaliplatin behandeld werden aan de inclusiecriteria van de MOSAIC trial. 
Basiskarakteristieken, FOLFOX schema’s, totale cumulatieve doseringen en uitkomsten 
met betrekking tot ziektevrije overleving waren vergelijkbaar tussen de MOSAIC trial 
patiënten en de pilot studie patiënten die behandeld werden met oxaliplatin en voldeden 
aan de inclusiecriteria van de MOSAIC trial. De gemiddelde kosten per patiënt waren 
€9.114 voor 5FU/LV, €9.220 voor capecitabine monotherapie, €30.873 voor FOLFOX en 
€17.212 voor CAPOX. Verschillen in basiskarakteristieken leken niet in verband te staan 
met de totale kosten. De incrementele kosten-effectiviteit per gewonnen QALY varieerde 
van €15.491 tot €22.836, afhankelijk van de gekozen populatie en het scenario.  
 
Oxaliplatin in gemetastaseerd colorectaal kanker 
In totaal werden 433 patiënten met stadium IV colorectaal kanker behandeld in 29 
geselecteerde ziekenhuizen; 312 patiënten werden geïncludeerd voor verdere analyse. 
Drieënzestig procent van deze patiënten kreeg eerstelijns monotherapie met 
fluoropyrimidines en 37% kreeg combinatietherapie met oxaliplatin of irinotecan. 
Eenenzeventig procent (224/314) van de pilot studie populatie vervulde de inclusiecriteria 
van de CAIRO trial. Minstens de helft van de patiënten die monotherapie als eerstelijns 
behandeling kreeg, kreeg combinatietherapie met oxaliplatin of irinotecan in de tweede lijn. 
In de derde lijn werd 22% van de patiënten nog steeds met chemotherapie behandeld. 
Deze resultaten kwamen overeen met het type tweedelijns en derdelijns behandeling dat 
aan patiënten werd gegeven die in de eerste lijn met combinatietherapie behandeld 
werden, alhoewel een groter deel van deze patiënten oxaliplatin en irinotecan kregen 
gedurende hun ziekte in vergelijking met patiënten die monotherapie kregen als eerstelijns 
behandeling. Over het algemeen komen de bevindingen overeen met de aanbevelingen in 
de Nederlandse richtlijnen. De prognose van de pilot studie patiënten die voldeden aan de 
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inclusiecriteria van de CAIRO trial was vergelijkbaar met de prognose van de patiënten in 
de CAIRO trial. Dit werd ook zichtbaar in resultaten met betrekking tot totale overleving. 
De mediane totale overleving van de ‘eligible’ pilot studie patiënten; i.e. de patiënten die 
voldeden aan de inclusiecriteria was 15,1 (95% BI 12,8 – 19,0) maanden voor de 
patiënten die combinatietherapie in de eerste lijn kregen en 11,2 (95% BI 9,5 – 13,3) 
maanden voor patiënten die monotherapie in de eerste lijn kregen. In de CAIRO studie 
was de mediane totale overleving 15,9 (95% BI 14,3 – 18,0) maanden voor patiënten die 
combinatietherapie in de eerste lijn kregen en 13,4 (95% BI 11,5 – 15,2) maanden voor 
patiënten die monotherapie in de eerste lijn kregen. Er werd geen significant verschil 
gevonden in de totale overleving van de patiënten in de CAIRO trial en de pilot patiënten 
die werden behandeld in dagelijkse, klinische praktijk. Echter, patiënten die monotherapie 
kregen in de pilot studie leken een iets slechtere uitkomst te hebben vergeleken met de 
CAIRO patiënten die eerstelijns monotherapie kregen en vergeleken met patiënten die 
combinatietherapie kregen. Dit verschil kan worden verklaard door de niet-random 
toewijzing van behandelingen in de pilot populatie. Het aantal patiënten dat ouder was dan 
70 jaar was groter bij de patiënten in de pilot studie die monotherapie kregen dan bij de 
patiënten in de pilot studie die combinatietherapie kregen en bij de CAIRO trial patiënten. 
Ook kregen deze patiënten significant minder vaak een derdelijns behandeling dan 
patiënten in de CAIRO studie (eerstelijns monotherapie). Dit wijst wellicht op een neiging 
tot een grotere motivatie voor het behandelen van trial versus non-trial patiënten. 
Betreffende kwaliteit van leven was één van de conclusies van de CAIRO trial dat 
patiënten die eerstelijns monotherapie kregen en patiënten die combinatietherapie kregen 
een vergelijkbare gemiddelde utiliteit hadden (0,77 vs. 0,76). De gemiddelde totale kosten 
voor de ‘eligible’ pilot patiënten bedroegen € 19.812 voor monotherapie, € 28.200 voor 
oxaliplatin combinatietherapie en € 44.664 voor irinotecan combinatietherapie. De 
gemiddelde totale kosten voor monotherapie en oxaliplatin combinatietherapie waren 
significant verschillend. Een substantiële variatie in kosten werd gevonden in de totale 
kosten van individuele patiënten binnen behandelgroepen, als ook voor individuele 
kostencomponenten. Kosten van verpleegdagen en chemotherapie (leucovorin, 
capecitabine, oxaliplatine en irinotecan) waren de belangrijkste kostenposten.  
 
Discussie 
Uitkomstenonderzoek voorziet in belangrijke informatie over het gebruik van oxaliplatin in 
de dagelijkse, klinische praktijk. In stadium III colon kanker, inzicht in de 
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basiskarakteristieken van patiënten, het gebruik van oxaliplatin, de effectiviteit en 
toxiciteiten liet zien dat de behandeling met oxaliplatin in de praktijk overeenkomt met de 
vereisten voor de registratie van oxaliplatin op T = 0. Een goede vergelijking tussen 
patiënten die wel en niet met oxaliplatin behandeld werden was echter onmogelijk. Ter 
vergelijking werden daarom MOSAIC patiënten gebruikt die de controlebehandeling 
kregen voor het berekenen van de incrementele kosteneffectiviteit van oxaliplatin. Naar 
onze mening heeft deze benadering geleid tot een voldoende precieze en valide schatting 
van de kosteneffectiviteit van oxaliplatin in de dagelijkse, klinische praktijk.  
Zowel de kosteneffectiviteit als het juiste gebruik van oxaliplatin bij de behandeling van 
stadium III colon kanker in de dagelijkse, klinische praktijk is voldoende onderbouwd. Bij 
gemetastaseerd colorectaal kanker kon gebruik gemaakt worden van de CAIRO post-
registratie trial. De pilot studie patiënten werden geselecteerd uit dezelfde populatie, 
waardoor valide vergelijkingen gemaakt konden worden tussen de ‘eligible’ pilot studie 
patiënten en de CAIRO trial patiënten. De resultaten van de studies waren vergelijkbaar, 
waaruit bleek dat het mogelijk was om een voldoende precieze en valide schatting te 
maken van de kosten-effectiviteit van oxaliplatin. Bovendien kon het juiste gebruik van 
oxaliplatin voor de indicatie gemetastaseerd colorectaal kanker voldoende worden 
onderbouwd.  
Het is belangrijk om te realiseren dat een cruciale factor in deze pilot studie de 
mogelijkheid was om data en resultaten van trials, zoals de MOSAIC en CAIRO trial te 
gebruiken, gecombineerd met de beperkte dynamiek in de dagelijkse, klinische praktijk, 
met andere woorden de beperkte behandelvariatie. Het combineren van databronnen 
bevestigt dat bij het vaststellen van de effectiviteit en kosteneffectiviteit van een medicijn in 
de dagelijkse, klinische praktijk alle beschikbare data gebruikt dient te worden. Deze 
benadering is afhankelijk van het type data en het type bewijs dat aanwezig is op moment 
T = 3. 
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Background 
Policy regulation 
At the request of the Minister of Health, Welfare and Sport, the Dutch Healthcare Authority 
(NZa) amended the existing ‘expensive medicines’ policy regulation as of 1st January 2006. 
Provisional inclusion in this policy regulation makes it obligatory for the applying party to 
perform outcomes research. Outcomes research is described as the collection and analysis 
of data from daily clinical practice that are useful to assess the degree of appropriate use and 
determine the degree of cost-effectiveness of expensive hospital medicines within the 
framework of the additional financing of hospital based medicines.1 
 
Research 
At the request of the College voor zorgverzekeringen (CVZ, Health Care Insurance Board), 
the institute for Medical Technology Assessment (iMTA) conducted research into the 
methodological aspects that are important when carrying out outcomes research. An initial 
report relating to a literature study has already been issued. The present study is a study of 
daily practice in which two pilot studies take a central position. In addition to the literature 
study, the results of the pilot studies will contribute valuable information for the Guidance on 
outcomes research. The methodological problems brought to light by the two pilot studies will 
be described in a separate report. The present report discusses the content of the results of 
the outcomes research on one of the pilot studies: oxaliplatin. This drug is available in the 
Netherlands for the treatment of high-risk stage II, stage III, and metastatic colorectal cancer.  
 
Colorectal cancer 
Each year about 10,000 new patients are diagnosed with colorectal carcinoma. In the 
Netherlands, the incidence of colorectal carcinoma among men, with 14% of the total number 
of tumours, takes third place after prostate (21%) and long cancer (16%), and with 13% 
among women, it takes second place after breast cancer (33%). The number of patients 
diagnosed with colorectal carcinoma is expected to rise to about 14,000 in 2015 due to a 
slowly increasing incidence (particularly among men), the growing population and the ageing 
population.2, 3 
 
Colorectal carcinoma usually develops from a polyp. Such a polyp, which is a growth or 
thickening of the mucous membrane that lines the intestines, is usually benign, but some 
develop into cancer over time. Stage I and II invasive colorectal cancers confined to the wall 
of the colorectum comprise 40% of all cases of colorectal cancer. In stage III, occurring in 
37% of the patients, the carcinoma extends to the regional lymphatic glands. In stage IV 
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patients, which comprise 19% of all colorectal cancer patients at diagnosis, the cancer has 
already spread to distant sites. 
 
The stage of disease plays an important role in treatment options. In stage I, II and III 
patients, surgery is the recommended treatment option and is performed with curative intent. 
However, nearly half of the patients who undergo curative surgery will ultimately relapse and 
die of metastatic disease.4, 5 In patients with stage III colon cancer, 6 months of adjuvant 
chemotherapy decreases the risk of recurrence and has become part of the standard 
treatment. Stage IV patients have advanced or metastatic disease which is usually not 
curable. Chemotherapy is part of the standard treatment of metastatic colorectal cancer, 
since it has clearly been shown to lengthen the progression free and overall survival. 
 
Oxaliplatin 
For a long time, treatment with intravenous 5-fluorouracil and leucovorin (5FU/LV) was the 
only effective chemotherapy for patients with colorectal cancer.67, 8 However, during the past 
decade clinical trials have shown the efficacy of new products that are either equivalent in 
efficacy but less toxic or superior in efficacy to 5FU/LV. Oxaliplatin is a third-generation 
oncolytic, derived from platinum. In 2002 the drug was included in the list of ‘expensive 
medicines’ for metastatic colorectal cancer. Since 2005 oxaliplatin has also been eligible for 
additional reimbursement in stage III colon cancer after obtaining a positive advice from the 
CVZ on including it in the NZa policy regulation.  
 
Objectives 
The questions that are addressed in the present study are:  
 
Stage III colon cancer (section 1) 
1) How is oxaliplatin used in daily practice for the treatment of stage III colon cancer?  
2) What are the real-world effects and costs of oxaliplatin in stage III colon cancer?  
3) What is the cost-effectiveness of oxaliplatin in stage III colon cancer? 
 
Metastatic colorectal cancer (section 2) 
1) How is oxaliplatin used in daily practice for the first-line treatment of metastatic 
colorectal cancer?  
2) What are the real-world effects and costs of oxaliplatin in metastatic colorectal 
cancer?  
3) What is the cost-effectiveness of oxaliplatin as first-line treatment in metastatic 
colorectal cancer? 
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These items will be discussed in two different sections. In section 1, we describe a 
retrospective analysis of population-based data for patients treated with adjuvant 
chemotherapy following diagnosis of stage III colon cancer in 2005 and 2006. In section 2, 
we describe a retrospective analysis of population-based data of patients receiving 
chemotherapy for metastatic colorectal cancer. Here a cohort of stage IV patients diagnosed 
in 2003 and 2004 was selected, since oxaliplatin was already available by that time for 
metastatic colorectal cancer.  
 
For this study, iMTA worked in close collaboration with the Radboud University Nijmegen 
Medical Centre, the core institution of the Dutch Colorectal Cancer Group (DCCG). Annex I 
contains a specification of this collaboration. 
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Section 1 Oxaliplatin in stage III colon cancer 
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1. Introduction 
The initial treatment for about 80% of the patients with stage III colon carcinoma is a 
complete resection of the primary tumour. Almost half of these patients will eventually 
relapse.5 As adjuvant chemotherapy has clearly been shown to lengthen disease-free and 
overall survival, it has become part of the standard treatment.9 For a long time, treatment 
with intravenous 5-fluorouracil and leucovorin (5FU/LV), with a 3-years survival of 65% was 
the only available effective adjuvant chemotherapy for patients with stage III colon 
carcinoma.7, 8 However, during the past decade clinical trials have shown that new products 
are either equivalent in efficacy but less toxic or even superior in efficacy.  
 
Capecitabine 
Capecitabine is the oral pro-drug of fluorouracil. The X-ACT trial compared treatment using 
oral capecitabine with the Mayo clinic 5FU/LV schedule.10, 11 The primary endpoint of this 
study was non-inferiority with respect to disease-free survival. After a 7-year median follow-
up, no difference in disease-free and overall survival could be demonstrated between the two 
treatment groups. In addition, toxicities required comparable dose reductions in both 
treatment groups (5FU/LV 52% versus capecitabine 57%). In comparison with 5FU/LV, the 
incidence of stomatitis, alopecia and neutropenia was lower and the incidence of hand-foot 
syndrome higher in the capecitabine group. Overall, capecitabine was better tolerated 
compared to 5FU/LV. Based on these results and the fact that these data are supported by 
comparable findings relating to metastatic colorectal carcinoma, current advice is to 
prescribe capecitabine as standard adjuvant therapy in situations where 5FU/LV was 
previously used.  
 
Economic evaluations based on the X-ACT trial have estimated that the costs of 
capecitabine are about € 5,400 lower than those of 5FU/LV.12-1415 This cost saving in 
comparison with 5FU/LV was particularly due to a reduction in inpatient hospital days and 
adverse effects.  
 
Oxaliplatin 
A systematic literature study was carried out regarding the clinical efficacy and cost-
effectiveness of oxaliplatin for the adjuvant treatment of colon carcinoma. The study relates 
to literature published between January 2005 and February 2009 (between T=0 and T=3). 
Annexes II and III provide a complete review of this literature study. The most important 
findings are described below.  
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Oxaliplatin combined with 5FU/LV 
The literature review revealed seven publications, 4 publications based on the MOSAIC trial 
and 3 based on the NSABP C-07 trial. None of the publications relating to the NSABP C-07 
trial reported specifically on the sub-group of stage III patients with colon carcinoma. Dutch 
guidelines on oxaliplatin for the adjuvant treatment of stage III colon carcinoma are 
exclusively based on the MOSAIC trial. This trial is discussed here separately. 5, 16 17, 18 
        
The MOSAIC trial compared 5FU/LV with the combination therapy of 5FU/LV and oxaliplatin 
(FOLFOX). Table 1.1.1 provides a summary of the trial results after a median 6-year follow-
up. Treatment with FOLFOX led to a significantly better disease-free (p = 0.005) and overall 
survival (p = 0.046) than 5FU/LV alone. Neurotoxicity was the most important adverse event 
of oxaliplatin. However, this side effect decreased in most patients within 1 year. At 18 
months after treatment, about 25% of the patients still had some degree of neurological 
symptoms. In addition, FOLFOX was associated with more neutropenia, diarrhoea, nausea 
and vomiting than 5FU/LV alone. 16, 17  
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Table 1.1.1 Summary MOSAIC trial, limited to stage III colon carcinoma 
Study design Phase III randomized controlled trial
TNM tumour stage stage III after complete resection of primary tumour
Intervention/ treatment arms 5‐FU/LV 5‐FU/LV with oxaliplatin
Number of patients randomized n=675 n=672
Planned cumulative dose
Oxaliplatin NA 1,020 mg/m2
Fluorouracil (5‐FU) 12,000 mg/m2 12,000 mg/m2
Leucovorin (LV) 2,400 mg/m2 2,400 mg/m2
Primary endpoint Disease free survival (DFS)
DFS defined Time to progression or death, whichever comes first
Primary analyses cut‐off
Secondary endpoints Safety, overall survival (OS), long‐term adverse events
Statistical power 90% to detect a 6% increase in DFS at 3 years
Clinical effects
Disease free survival 58.9% 66.4%
Hazard Ratio (95% CI) 0.78 (0.65 tot 0.93)
Overall survival 68.7% 72.9%
Hazard Ratio (95% CI) 0.80 (0.65 tot 0.97)
Safety Oxaliplatin is associated with a 20% mortality reduction
Oxaliplatin increases the risk of severe neutropenia and diarrhea
Long‐term adverse events Neurotoxicity is present in  >85% of the oxaliplatin patients
NA = not applicable 
André T, et al. (2009). Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant 
Treatment in Stage II or III Colon Cancer in the MOSAIC Trial. J Clin Oncol 27:3109-3116
3 years from enrollment of last patiënt or 303 events 
(relapse or death) in test arm, whichever comes later
 
 
 
With respect to disease-free and overall survival, the relative advantage of 5FU/LV with 
oxaliplatin in comparison with 5FU/LV alone was not age-related. Although severe 
neutropenia and/or thrombocytopenia were observed more often in patients of at least 70 
years of age (p = 0.040), no difference could be demonstrated in patients younger than 70 
years with respect to other grade ≥ 3 adverse effects.19 
 
Various economic evaluations were carried out based on the MOSAIC trial.12, 20-22 All 
economic evaluations revealed lower costs for 5FU/LV in comparison with FOLFOX, 
although to a varying degree, depending in part on perspective of the study. Compared with 
5FU/LV, the life-time costs of the FOLFOX were estimated to be € 5,000 more expensive 
from the NHS perspective in the United Kingdom and € 16,000 more expensive from the 
perspective of Medicare in the United States.20, 21 
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Oxaliplatin combined with capecitabine 
Within the timeframe of our study (2005-2009), no data were available regarding prospective 
studies demonstrating the efficacy of the combination therapy with capecitabine and 
oxaliplatin (CAPOX) for use in the adjuvant setting.  
 
National guidelines 
Based on the results of these randomized controlled trials (RCTs), national guidelines in the 
Netherlands have recommended the use of FOLFOX as the primary treatment option for 
stage III colon cancer since the beginning of 2005.  These guidelines do not routinely support 
the use of adjuvant chemotherapy in stage III rectal cancer. For patients who are not eligible 
or who refuse treatment with oxaliplatin, adjuvant treatment with capecitabine is indicated. 23, 
24 The Dutch Society of Medical Oncology (NVMO) at that time also supported the use of 
CAPOX as an alternative to FOLFOX, as these treatments had shown comparable efficacy in 
metastatic colorectal cancer. 25 
 
Oxaliplatin in daily practice 
Economic evaluations piggy-backed on a randomized clinical trial are generally regarded as 
the most scientific substantiation of the cost-effectiveness of pharmacotherapeutic 
treatments. Data based on clinical trials may not be representative of daily practice, as 
clinical trials are conducted under controlled conditions. 
 
Outcomes research collects data from daily clinical practice that are useful for determining 
appropriate use and cost-effectiveness of pharmacotherapeutic treatments. This section 
describes the results of outcomes research that investigated the appropriate use and cost-
effectiveness of oxaliplatin for the treatment of stage III colon carcinoma. The economic 
burden of colorectal carcinoma is expected to increase in the next few years due to the 
increasing incidence of colon carcinoma and the increasing use and high costs of oxaliplatin. 
This makes it important to obtain answers to the following subquestions: 
 
• How is oxaliplatin used in daily practice? (sections 2.3 and 3.3) 
• What clinical effects does the use of oxaliplatin involve? (sections 2.4 and 3.4) 
• What costs are involved in the use of oxaliplatin? (sections 2.5 and 3.5) 
• What is the relationship between the results of this outcomes research and the 
results of clinical trials? (sections 2.6 and 3.6) 
• What is the cost-effectiveness of oxaliplatin? (2.7 and 3.7) 
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2 Methods  
2.1 Patient population 
 
All patients newly diagnosed with stage III colon carcinoma (pTanyN1,2M0, ICD-O C18-
C19.9) in 2005 or 2006 were eligible for this outcomes research provided that they received 
adjuvant chemotherapy. Firstly, patients were identified retrospectively in June 2007 via the 
database of the Dutch Cancer Registry. This databank registers the data of all cancer 
patients who were admitted to a hospital or whose disease was diagnosed by means of 
tissue examination. This amounts to more than 95% of all cancer patients in the Netherlands. 
Subsequently, using ‘minimal’ case record forms (CRFs), additional information was 
collected from the medical records of all patients identified in 19 selected hospitals. 
Afterwards, further selection of patients took place based on the information obtained via the 
‘minimal’ CRFs.  
 
Patients were excluded from the analyses if their medical records revealed that they had 
evidence of distant metastases, did not receive any chemotherapy, or did not start 
chemotherapy at the selected hospitals. Moreover, patients receiving pre-operative 
radiotherapy were excluded because their tumours were clinically considered to be rectal 
carcinoma. Three patients receiving bevacizumab (<1%) and 2 patients receiving UFT (<1%) 
were excluded from the analyses. Lastly, patients were excluded if they had been diagnosed 
with a second malignancy in the past five years - with the exception of adequately treated 
carcinoma in situ of the cervix or squamous or basal cell carcinoma of the skin.   
 
A randomly selected representative sub-group was selected from the patient population as 
defined. From this subgroup extra detailed data was collected from patients medical records 
by making use of ‘maximal’ CRFs.  
 
2.2 Data collection 
 
The data collection took place via three sources.  
 
Firstly, information was obtained via the databank of the Dutch Cancer Registry. This 
databank contains information about, among other things, age, gender, date of diagnosis, 
hospital where the diagnosis was made, tumour location, number of lymph glands 
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examined/found to be positive, the size and/or degree of dissemination of the tumour, stage, 
initial treatment data and survival.  
 
A second data source was formed by additional ‘minimal’ information obtained via the 
‘minimal’ CRFs, which could be completed based on medical records. This minimal data 
source contained information on co-morbidity, tumour characteristics, type of adjuvant 
chemotherapy, and data relating to disease-free and overall survival.  
 
Patients could be included or excluded from the pilot study based on the information 
obtained from the database of the Dutch Cancer Registry and the minimal dataset. This 
dataset also contained sufficient information for carrying out analyses relating to: 
 
• Baseline characteristics (section 2.3) 
• The diffusion of oxaliplatin (section 2.3) 
• Considerations regarding choice of treatment regimen (section 2.3) 
• Clinical effects of oxaliplatin (section 2.4) 
 
A third data source was obtained by collecting extra, more detailed data for a sub-group of 
patients, also based on patient files. The completion of a ‘maximal’ CRF provided additional 
data relating to exact dose schedules, adverse effects and resource use. This additional 
dataset facilitated extra analyses relating to: 
 
• Dose schedules (section 2.3) 
• Toxicity (section 2.3) 
• Costs (section 2.5) 
 
Between July 2008 and March 2009, all ‘minimal’ and ‘maximal’ data were collected by 
medical students under the supervision of the researchers. A detailed overview of the data 
obtained from the Dutch Cancer Registry and via the minimal and maximal CRFs can be 
found in Annex IV. The original versions of the minimal and maximal CRFs are also enclosed 
in Annexes V and VI.  
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2.3 Use of oxaliplatin 
 
The use of oxaliplatin in daily practice was examined by considering five different 
parameters. Each of those parameters provides an indication of who received 
oxaliplatin or how much oxaliplatin they received.  
 
Baseline characteristics 
The baseline patient and tumour characteristics provide a pointer for the ‘profile’ 
fulfilled by a patient being treated with oxaliplatin in daily practice. Among other 
things, the effect of age distribution was examined in order to explain significant 
differences between the treatment groups. We recorded established prognostic 
factors related to comorbid conditions from the medical records using a slightly 
adapted version of the Charlson index, which classifies all serious comorbid 
conditions based on possible prognostic impact into eight groups (i.e. previous 
malignancies, chronic obstructive pulmonary diseases, cardiovascular diseases, 
cerebrovascular diseases, hypertension, diabetes mellitus, digestive tract diseases 
and other). In the analyses we classified comorbidity as zero to one comorbid 
condition versus two or more comorbid conditions.26 27 
 
Diffusion of oxaliplatin 
The first moment that oxaliplatin was prescribed for stage III colon carcinoma was 
established for each hospital. In addition, the cumulative diffusion of oxaliplatin and 
the distribution of 5FU/LV, capecitabine and oxaliplatin were charted for the period 
2005 and 2006.  
 
Considerations in choice of treatment regimen 
Possible predictors for receiving a certain treatment were analysed. Reasons for not 
prescribing oxaliplatin were also analysed.   
 
Dose schedules 
The planned and actual dose schedules and reasons for dose reductions were 
recorded per individual patient and compared between the treatment groups. 
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Toxicity 
Toxicity was registered if it led to dose modification. Distinctions were made between 
haematological toxicity, gastrointestinal toxicity, neurological toxicity and toxicity as a 
result of the hand-foot syndrome.  
 
2.4 Clinical efficacy of oxaliplatin 
 
The clinical efficacy of oxaliplatin in daily practice was assessed by means of the 
following outcome parameters: 
 
Disease-free survival 
Disease-free survival was defined as the time to relapse or death. A relapse was 
determined based on diagnostic examination and, where necessary, cytology or 
biopsy. An increased carcinoembryonic antigen (CEA)-value as sole finding was not 
accepted as proof of a relapse. 
 
Statistical analyses of clinical data 
We first assessed the frequency of administration of treatment. To compare baseline 
characteristics, the administered regimens were grouped into “oxaliplatin-containing 
regimens” and “regimens without oxaliplatin”. Continuous data were expressed in 
terms of the mean value and categorical data as a percentage, unless otherwise 
denoted. The Student’s t-test and the chi-square test with the Fisher’s exact 
correction for frequencies less than five were used for continuous and categorical 
variables, respectively. To better explore the reasons for significant findings, we 
evaluated the effect of age distribution on the comparison of baseline characteristics 
between the different treatment groups. Additionally, we investigated the diffusion of 
new treatments as recommended by the new guidelines by the hospitals. We used 
the Cochran-Armitage trend test to examine the change in use of different treatment 
regimens over time. Reasons for not prescribing oxaliplatin were explored using 
descriptive statistics.  A multivariate logistic regression analysis was performed to 
identify independent predictors of non-prescription of oxaliplatin. Survival curves 
were visualised according to the Kaplan-Meier methods. A multivariate Cox 
regression was carried out on all expected prognostic factors in order to correct for 
differences in baseline characteristics. Approximately 100 patients who received 
treatment with oxaliplatin and 100 patients who received treatment without oxaliplatin 
were selected for the population of representative patients. This selection took place 
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at random, stratified for hospital and oxaliplatin use. This number is based on 
practicability in terms of time and finance and on experience with previous iMTA 
studies. An evaluation of dose schedules and modifications per treatment regimen 
was performed in this selected subset of patients. For this evaluation, the tests for 
continuous and categorical variables mentioned above were used.  Significant 
variables are reported with their respective p-value. In all analyses, statistical 
significance was assumed if the two-tailed probability value was <0.05.  The SAS 
computer package (version 8.2) was used for all statistical analyses (SAS Institute 
Inc., Cary, NC, USA, 1999). 
 
2.5 Costs of oxaliplatin 
 
Limitations in time and information meant that it was impossible to collect 
retrospective data on all types of societal costs. We therefore conducted the cost 
analysis using the hospital perspective (i.e., a health care sector perspective limited 
to hospital activities). Use of this perspective meant that some cost categories like 
productivity costs and costs associated to informal care were not taken into account. 
However, the inclusion of productivity costs is unlikely to have any major impact on 
the results, since most of the patients in this study were near or beyond retirement 
age. While inclusion of costs of informal care would increase total costs, there was 
no reason to expect any difference in costs of informal care between treatments. As 
a consequence, the inclusion of these costs would therefore have no impact on the 
difference in total costs. Given these arguments, we believe that the exclusion of 
those cost components from the analyses had no important impact on the estimate of 
the real-world cost-effectiveness of oxaliplatin.  
 
Total costs for individual patients were determined by the identification of resource 
use and unit costs of the following cost components: inpatient hospital days, 
intensive care days, outpatient visits, consultations by telephone, daycare 
treatments, emergency room visits, radiotherapy, surgical procedures, laboratory 
services, medical imaging services, chemotherapy and concomitant medications. 
 
Resource use was divided into two time periods. Period 1 began on day 1 of the first 
administration of adjuvant chemotherapy. To capture resource use resulting from 
treatment related toxicity, period 1 ended one month after the last administration of 
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chemotherapy. Period 2 started one month after the last administration of 
chemotherapy and lasted until disease progression (or end of follow up).  
 
Table 1.2.1 presents the unit costs of inpatient hospital days, intensive care days, 
outpatient visits, consultations by telephone, daycare treatments and emergency 
room visits. The unit cost calculations were based on detailed microcosting studies 
reflecting full hospital costs, including overhead costs.28, 29 We conducted this 
microcosting study to compute oncological specific unit prices since they are known 
to be slightly higher compared to the average prices in the Dutch Costing Manual 
2004. Some unit costs were weighted for their origin: 67% of the unit costs were 
based on data from the general hospitals and 33% on those from university hospitals. 
These shares reflect the distribution of patients among hospitals in Dutch daily 
practice. 
 
Table 1.2.1 Unit costs (Euro 2009) 
Oncological inpatient hospital day * € 490
general hospital € 408
university hospital € 657
Intensive care day € 2,080
Oncological outpatient visit * € 98
general hospital € 84
university hospital € 125
Consultation by telephone € 13
Oncological day-care treatment * € 167
general hospital € 140
university hospital € 222
Emergency room visit € 174
* weighting factor of 67:33 for general and university hospitals  
 
The resource use of surgical procedures, laboratory services and medical imaging 
services was valued using the fees as issued by the NZa.30 Unit costs of 
chemotherapy are shown in table 1.2.2. Unit costs of chemotherapy were acquired 
from the Committee Pharmacotherapeutic Aid.23 Unit costs of concomitant 
medications were also acquired from the Committee Pharmacotherapeutic Aid; those 
costs were based on costs per unit, for example grams or milligrams.  
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Table 1.2.2 Unit costs (Euro 2009) 
5-Fluorouracil (mg) € 0.01
Leucoforin (mg) € 0.28
Capecitabine (mg) € 0.01
Oxaliplatin (mg) € 4.35
Uracil/tegafur (mg) € 0.05
mg = milligram  
 
To determine the uncertainty of the obtained cost estimates, one-way sensitivity 
analyses were carried out by varying the unit cost values of inpatient hospital day, 
outpatient visit and daycare treatment unit costs between 50% and 150%. Unit costs 
other than those of hospital days were considered to be fairly stable or of less 
influence and were therefore not subjected to sensitivity analyses.  
 
Statistical analysis of cost data 
Statistical analyses were conducted with the statistical software programmes SPSS 
for Windows version 15.0 (SPSS Inc., Chicago, IL). In addition to descriptive 
statistics, differences between the four treatment groups were assessed by means of 
the one-way analysis of variance (ANOVA) test for variables showing a normal 
distribution, the Kruskal-Wallis test for variables not normally distributed and the 
Pearson Chi-square test for variable fractions. To adjust for multiple testing, one way 
analyses of variance with post hoc testing (type Bonferroni) were additionally 
performed. In all cases p < 0.05 was taken as statistically significant. All costs were 
based on Euro 2009 cost data. Where necessary, costs were adjusted to 2009 using 
the general price index from Statistics Netherlands.31 
2.6 Daily practice versus clinical trials 
 
We examined the similarities and differences between the results of our outcomes 
research and the results of the MOSAIC trial by comparing the baseline 
characteristics of the two populations, how patients were treated, and the effects and 
costs of oxaliplatin. This was achieved by comparing results in the following 
categories: baseline characteristics, dose schedules, clinical effects of oxaliplatin, 
and costs of oxaliplatin. 
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2.7 Cost-effectiveness of oxaliplatin 
 
A Markov model was developed in order to assess the cost-effectiveness of 
oxaliplatin plus standard adjuvant treatment versus standard adjuvant treatment 
alone in the treatment of stage III colon cancer. The cost-effectiveness estimate is 
based on two main sources of evidence: 
 
1. Results from the outcomes research investigating costs and effects of the use 
of oxaliplatin in daily clinical Dutch practice (sections 3.1 - 3.6) 
2. Results from the MOSAIC trial16, 17  
 
Model overview 
 
Target population 
The target population in the model is based on the populations from both the PILOT 
and the MOSAIC study. Figure 1.2.1 shows the possible populations to be used in 
the cost-effectiveness model. In order to make proper comparisons, demographic 
and baseline clinical characteristics need to be similar between patients treated with 
oxaliplatin and those treated without oxaliplatin. The oxaliplatin arm and control arm 
of the MOSAIC study are comparable since this trial was randomised. As shown in 
section 3.6, the oxaliplatin patients in the PILOT study who fulfilled the MOSAIC 
eligibility criteria (82%), were similar to the MOSAIC patient population. However, 
eligible control patients in the PILOT study were not comparable with the eligible 
oxaliplatin patients. Even correction for differences in baseline characteristics 
between oxaliplatin patients and control patients in the pilot study did not result in 
comparable patient groups (see section 3.4). Furthermore, ineligible patients were 
not comparable with eligible patients regarding their baseline prognostic factors.  
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Figure 1.2.1 Overview of target populations 
MOSAIC trial oxaliplatin group
N = 672
MOSAIC trial control group
N = 675
Adjuvant chemotherapy 
in stage III colon cancer
PILOT study oxaliplatin group patients fulfilling MOSAIC eligibility criteria
N = 200
patients ineligible for MOSAIC trial
PILOT study control group N = 43
patients fulfilling MOSAIC eligibility criteria
N = 54
patients ineligible for MOSAIC trial
N = 32
 
 
Because of the incomparability of the control group and the ineligible patients of the 
pilot study, we decided to use only the comparable populations (MOSAIC population 
and PILOT eligibles) in the base case analyses. The possible impact of the remaining 
patient groups in the PILOT study were explored via scenario analyses.  
 
The patient population in the model was based on: 
1. MOSAIC trial, stage III patients 
2. PILOT study, eligible patients receiving oxaliplatin 
 
Different treatment arms in the model were: 
1. MOSAIC study, control arm (n = 675) 
2. MOSAIC study, oxaliplatin arm (n = 672) 
3. PILOT study, oxaliplatin arm (n = 200) 
4. Oxaliplatin arm, PILOT and MOSAIC studies combined (n = 872) 
 
All patients in the model were diagnosed with stage III colon cancer and received 
adjuvant chemotherapy following radical surgery of the primary tumour. None of the 
patients participated in both the PILOT and MOSAIC studies, which enabled us to 
sum the PILOT and MOSAIC oxaliplatin populations (4th arm).  
 
Regimens without oxaliplatin given in control arm 
o 5FU/LV 
o Capecitabine 
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Regimens with oxaliplatin given in oxaliplatin arm 
o 5FU/LV + oxaliplatin 
o Capecitabine + oxaliplatin 
 
In both arms the regimens were given for 6 months or until serious adverse events, 
relapse of disease or death occurred. After 6 months, the patients were followed until 
relapse of disease, death or censoring.  
 
Endpoints 
The endpoints used in the model were: 
o incremental costs per life-year gained 
o incremental costs per quality-adjusted life-year (QALY) gained 
 
Disease-free survival estimates were directly derived from the MOSAIC trial (both 
oxaliplatin and control arms) and PILOT study (oxaliplatin treatment in eligibles). 
Overall survival estimates were derived from both the MOSAIC study and published 
literature. The utility (quality of life) component was derived from published literature.  
 
Direct costs such as drug, drug administration, adverse events (AE), and follow-up 
costs were included. All cost data (both control and oxaliplatin arms) were taken from 
the PILOT study.  
 
The cost-effectiveness analysis was conducted using TreeAge Pro Suite 2009 to 
compare the clinical and economic benefits of the treatment versus alternative 
treatments.  
 
Model structure 
 
A Markov model was developed to simulate the transition of patients receiving 
adjuvant treatment for stage III colon cancer through clinical states that are typically 
observed in a clinical setting. Each state is mutually exclusive, meaning that a patient 
can only be in one state at one time. 
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Figure 1.2.2 Conceptual model stage III colon cancer 
 
 
Figure 1.2.2 shows the conceptual model used in the cost-effectiveness model. The 
clinical states incorporated in the model were: (i) disease-free health state (DFS), (ii) 
relapsed health state and (iii) death. A similar model was used by Pandor et al., 
2006.12 In their analysis, a comparable cost-effectiveness analysis was used based 
on the MOSAIC trial. In our present cost-effectiveness analysis, we used a slightly 
simplified version of this conceptual model as is shown in Figure 1.2.3.  
 
Figure 1.2.3 Model used in this cost-effectiveness analysis 
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Model overview 
The Markov model shown in Figure 1.2.3 calculates the incremental costs per 
disease-free life-year gained over a 5-year time horizon. After a 5-year period, the 
Markov process halts. The health state of death was not included in this model, since 
the overall survival of patients receiving adjuvant treatment for stage III colon cancer 
is limited. Instead, we included life expectancy in the model and we assumed that the 
life expectancy after a relapse was not associated with the type of treatment. We also 
assumed that the average life expectancy of patients who have no relapse after 5 
years was equal for all treatment alternatives. The estimation of the incremental 
costs per life-year and QALY are deducted from the average life-expectancy of 
patients who are disease-free and patients who relapsed in the modelled time period.  
 
Model features 
o Patients with stage III colon cancer receiving control treatment are treated 
with either 5FU/LV or capecitabine. Patients who receive regimens that 
include oxaliplatin receive either oxaliplatin combined with 5FU/LV (FOLFOX) 
or oxaliplatin combined with capecitabine (CAPOX).  
o Patients can be in only one of the two states (DFS or relapse) at any point in 
time. 
o All patients start in the DFS state.  
o Patients who are disease-free in the current cycle can remain disease-free in 
the next cycle (stay in DFS state) or transition to the relapse state, which is an 
absorbing state (see Figure 1.2.3). 
o The cycle length is 6 months.  
o The Markov process stops after 10 cycles, which corresponds with a 5-year 
time horizon. 
o It is assumed that after 5 years of follow-up, the probability of relapse is 
negligible and equal for all treatment alternatives. 
o Total direct medical costs of adjuvant treatment, costs of follow-up, and costs 
of relapse are calculated for each therapy. 
o The average life-expectancy of disease-free patients is assumed to be equal 
for all treatment alternatives beyond 5 years of follow-up 
o The average life-expectancy of relapsed patients is assumed to be equal for 
all treatment alternatives 
o Utility estimates from published literature are attributed to the different health 
states. 
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o The calculated incremental costs per life-year and QALY gained reflect a 
lifetime time horizon. 
o Advice and feedback from a clinical expert were frequently sought during the 
development of the model.   
 
Parameter estimates – clinical inputs 
 
Probability of staying disease-free 
The probability of staying disease-free at 6-month interval until the last time points 
available was obtained from the MOSAIC trial (oxaliplatin and control arms) and the 
PILOT study (eligible oxaliplatin group). Data from 672 patients in the oxaliplatin arm 
and 675 patients in the control arm obtained from the MOSAIC trial were used in the 
model.17 Furthermore, use was made of data from 200 eligible oxaliplatin patients 
obtained from the PILOT study.  
 
The transition probabilities related to relapse are time-related variables in which 
transitions take place every six months. In the Markov model, patients in the DFS 
state may either stay in that phase [Prob(stay DFS)] or relapse [1- Prob(stay DFS)]. 
These probabilities were obtained from Kaplan-Meier curves obtained from both the 
MOSAIC trial and the PILOT study (Annex IX).  
 
Table 1.2.3 shows the cumulative probabilities that were derived directly from the 
Kaplan-Meier curves. However, these probabilities are cumulative probabilities. In 
order to use these in the Markov Model it was necessary to convert the cumulative 
probabilities into transition probabilities.  
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Table 1.2.3 Oxaliplatin PILOT versus Oxaliplatin MOSAIC versus Control MOSAIC 
cumulative probabilities of staying disease-free 
Time since start adjuvant PILOT Study
treatment (months) Oxaliplatin (n = 200) Oxaliplatin (n = 672) Control (n = 675)
0 1.000 1.000 1.000
6 0.965 0.970 0.955
12 0.889 0.900 0.880
18 0.837 0.825 0.785
24 0.779 0.795 0.725
30 0.743 0.755 0.685
36  0.718* 0.730 0.665
42  0.698* 0.710 0.645
48  0.694* 0.705 0.630
54  0.684* 0.695 0.610
60  0.653* 0.664 0.589
Cumulative probability of staying disease free (DFS)
MOSAIC Trial
 
*Follow-up time limited in pilot study. From 30 up to 60 months the hazard of relapsing was assumed to 
be equal to the hazard of relapsing in the oxaliplatin arm of the MOSAIC trial.  
 
Prob(stay DFS)  
The cumulative disease-free survival data were converted to transition probabilities 
using the following formula: 
Pt
Pt‐1
pt
          
 
Where Pt and Pt-1 denote the cumulative probability of surviving at the end of time t 
and t-1, respectively; pt denotes the transition probability for time t. For example, the 
MOSAIC oxaliplatin transitional prob(stay DFS) at 24 months is 0.795/0.825 
(=0.9636, see table 1.2.3).  
 
Follow-up time is limited in the PILOT study. In order to obtain transition probabilities 
for DFS up to 5 years, estimates from 30 up to 60 months were derived from the 
MOSAIC oxaliplatin arm. The hazard of relapsing in the PILOT oxaliplatin group was 
assumed to be equal to the hazard of relapsing in the oxaliplatin group of the 
MOSAIC trial (gray shaded area in table 1.2.4).  
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Table 1.2.4 Transition probabilities used in the Markov Model 
Time Initial state Ending state PILOT Study
Oxaliplatin Oxaliplatin Control
6 months DFS DFS 0.9650 0.9700 0.9550
Relapse 0.0350 0.0300 0.0450
12 months DFS DFS 0.9212 0.9278 0.9215
Relapse 0.0788 0.0722 0.0785
18 months DFS DFS 0.9416 0.9167 0.8920
Relapse 0.0584 0.0833 0.1080
24 months DFS DFS 0.9301 0.9636 0.9236
Relapse 0.0699 0.0364 0.0764
30 months DFS DFS 0.9539 0.9497 0.9448
Relapse 0.0461 0.0503 0.0552
36 months DFS DFS 0.9669 0.9669 0.9708
Relapse 0.0331 0.0331 0.0292
42 months DFS DFS 0.9726 0.9726 0.9699
Relapse 0.0274 0.0274 0.0301
48 months DFS DFS 0.9930 0.9930 0.9767
Relapse 0.0070 0.0070 0.0233
54 months DFS DFS 0.9858 0.9858 0.9683
Relapse 0.0142 0.0142 0.0317
60 months DFS DFS 0.9554 0.9554 0.9656
Relapse 0.0446 0.0446 0.0344
* Gray area reflects projected data. Transitional probabilities equal to MOSAIC oxaliplatin arm transitional probabilities
Transitional probabilities
MOSAIC Trial
 
Transition probabilities for oxaliplatin arm, PILOT and MOSAIC studies combined 
None of the patients participated in both the PILOT and MOSAIC studies. The similar 
baseline characteristics and similar probability of relapsing in both the PILOT and 
MOSAIC oxaliplatin populations enabled us to combine the two populations in order 
to create a larger sample size. Prob(stay DFS) for the combined oxaliplatin arm were 
directly derived from the separate transition probabilities of the oxaliplatin PILOT 
group and the oxaliplatin MOSAIC group. The separate probabilities were weighted 
by the number of patients at risk at each time point.  
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For example, the MOSAIC oxaliplatin transition prob(stay DFS) at 24 months is 
0.9636 (see table 1.2.4). The PILOT oxaliplatin transition prob(stay DFS) at 24 
months is 0.9301. The numbers of patients at risk at 24 months are 521 for the 
MOSAIC study and 111 for the PILOT study (see table 1.2.5). Consequently, the 
combined transition probability at 24 months = ((0.9636*521) + (0.9301*111))/ 
(521+111). Table 1.2.5 shows the number of patients at risk at each time point.  
 
Table 1.2.5 Number of patients at risk in DFS model 
PILOT study 
Months oxaliplatin oxaliplatin control
0 200 672 675
6 192 642 633
12 174 595 573
18 155 543 511
24 111 521 472
30 72 493 445
36 35 475 429
42 7 462 411
48 1 453 395
54 0 439 377
60 0 347 283
MOSAIC trial
 
 
Clinical inputs regarding patients’ prognosis after 5 years 
After 10 cycles, i.e., 5 years, the Markov process stopped. We added the patients’ 
average life-expectancy (after the 5-year period) in both the DFS and the relapse 
health states in order to calculate the life-years and QALYs over a lifetime horizon. 
 
Life-expectancy for disease-free patients 
We assumed that after 5 years of follow-up the probability of relapse is negligible and 
equal for all treatment alternatives. Furthermore, ages were similar between arms. As 
a result, we assumed the life-expectancy of disease-free patients to be equal for all 
treatment alternatives. At the start of the model period (beginning of adjuvant 
chemotherapy, first cycle), the average age is 61 years across all patient populations. 
In 2000, the life-expectancy of 61-year olds was 18.0 years for men and 22.2 years 
for women.31 In accordance to the sex distributions shown in table 1.3.12, the 
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average life-expectancy of the total target population is 19.8 years. After 5 years of 
follow-up the remaining life-expectancy of disease-free patients is estimated at 14.8 
years. This estimation was used as an input in our model 
 
Life expectancy for patients post-relapse 
We assumed the average life expectancy of relapsed patients to be equal for all 
treatment alternatives. This assumption was based on the comparison of the 
disease-free and overall survival curves of the MOSAIC study. This study showed a 
similar difference in effect between the oxaliplatin and control arms in both curves. 
The remaining average life expectancy of patients after a relapse was assumed to be 
1.7 years. This was derived from the study of Tol et al., 2009, who compared two 
first-line chemotherapy treatments for advanced colorectal cancer in Dutch patients. 
The overall survival of the two treatment groups did not differ and was estimated to 
be an average of 20 months.32 However, one could argue that patients eligible to 
participate in a clinical trial would be expected to be healthier than patients in daily 
practice. Therefore, we performed a supplemental analysis to examine the impact of 
this assumption. In this worst-case scenario, we set the life expectancy after a 
relapse to zero in order to see how much this affected the ICER. However we 
expected that this would not influence our conclusions that much, since a reduction in 
the life expectancy would have an impact on both arms and because most patients 
do not experience a relapse.  
 
Parameter estimates – quality-adjusted survival benefits 
 
In order to derive QALY estimates for each treatment, the survival benefits seen 
within the studies need to be weighted by a patient’s quality of life over that period. A 
method to derive QALY estimates is to assign health utilities to the various health 
states. However, quality of life (QoL) data were not routinely collected in the PILOT 
study and MOSAIC trial. Therefore, another strategy had to be used to estimate the 
potential QALY gain from using oxaliplatin. In the report published by Pandor et.al., 
2006, a literature search relating to QoL in patients with colon cancer was carried out 
to determine appropriate utilities for the following health states: 
 
o Utility whilst on adjuvant chemotherapy (with no serious side effects) 
o Utility whilst on adjuvant chemotherapy (with serious side effects) 
o Utility whilst in remission (post-adjuvant treatment) 
o Utility whilst on palliative chemotherapy 
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Table 1.2.6 shows the utility parameters used in the cost-effectiveness model of 
Pandor et al.12, 33, 34 
 
Table 1.2.6 Utility parameters used in the Markov model 
Health state Utility Standard error Reference
On adjuvant chemotherapy without significant side-effects) 0.70 0.036 Ness et al., 1999
On adjuvant chemotherapy with significant side-effects) 0.63 0.036 Ness et al., 1999
In remission 0.92 0.050 Ramsey et al., 2000
On palliative chemotherapy 0.24 0.041 Ness et al., 1999
 
 
The frequencies of significant side effects during the MOSAIC study have not been 
reported in the published literature. In the PILOT study significant side effects were 
defined as: side effects requiring dose modification. Table 1.3.4 shows the 
percentage of patients requiring dose modifications. A weighted average for each 
treatment group (control versus oxaliplatin) was used in the DFS Markov model as is 
shown in table 1.2.7.  
 
Table 1.2.7 Percentages of significant side effects in PILOT study 
5FU/LV Capecitabine FOLFOX CAPOX
n = 17 n = 93 n = 136 n = 145
% of patients requiring 53% 57% 59% 70%
dose modifications
Weigthed average %
Treatment without oxaliplatin Treatment with oxaliplatin
56% 65%
 
For example, 65% of the patients in the oxaliplatin groups experienced significant 
side effects. As a consequence, 65% of the patients had a health utility value of 0.63 
assigned to the first cycle. 35% remained without significant side effects, so 35% had 
a utility value of 0.70 during the first cycle (divided by 0.5 since the first cycle reflects 
only 6 months). In subsequent cycles, the yearly utility value was 0.92 as long as the 
patient was disease-free. Patients experiencing relapse were considered to be on 
palliative therapy (utility value of 0.24) for the remainder of their life.  
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Parameter estimates – cost analyses 
 
All costs incorporated in the Markov model were based on the PILOT studies. Three 
costing periods can be distinguished. In the first period (period 1) patients are treated 
with adjuvant chemotherapy (see table 1.3.8). The second period (period 2) reflects 
costs of follow-up (see table 1.3.9). Patients are disease-free during this period. 
Period 3 starts when patients experience a relapse and reflects the costs post-
relapse. 
 
Period 1. Treatment costs 
Period 1 lasts for 6 months and its costs are encountered during the first cycle of the 
Markov model. Table 1.2.8 contains an overview of the total treatment costs per 
treatment group (control versus oxaliplatin). The weighted means were used in the 
model.  
 
Table 1.2.8 Total treatment costs period 1 (Euro 2009) 
Costs per treatment regimen Mean SD
costs costs
5FU/LV (1) 15% 5,802           2,895     
Capecitabine (2) 85% 4,944           3,238     
FOLFOX (3) 48% 25,839        11,239  
CAPOX (4) 52% 13,888        5,582     
Costs per treatment group Weighted Pooled 
 Mean SD
Control group (1+2) 5,073           2,790     
Oxaliplatin group (3+4) 19,624        6,128     
 
Period 2. Follow-up costs 
The follow-up period lasts as long as patients are in remission, for a maximum 
duration of 5 years. Since the follow-up time of the pilot study was limited to 
approximately 2 years, the total follow-up costs shown in table 1.3.9 are censored 
and only reflect costs made during the first two years of follow-up. Table 1.2.9 
contains an overview of the total follow-up costs per treatment group (control versus 
oxaliplatin). The weighted mean costs of the treatment groups were similar (€ 4,132 
versus € 4,145). These total costs of follow-up reflect costs of monitoring (actual 
follow-up costs), costs of surgeries (mainly related to closure of ileostomy) and other 
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costs unrelated to colon cancer. Because the costs of follow-up were found to be 
independent of adjuvant treatment, a 6-monthly cost of € 1,140 was applied over the 
first two years of follow-up in both treatment arms of the DFS Markov model. For the 
remainder of the follow-up period a 6-monthly cost of € 257 was assumed. This was 
based on expected resource use according to current Dutch guidelines: monitoring 
visits and laboratory testing each 6 months, yearly assessments of thorax and liver, 
and 1 colonoscopy.34 
 
Table 1.2.9 Total costs of follow-up period 2 (Euro 2009)  
Mean follow Mean SD
duration costs costs
5FU/LV (1) 15% 25.0 3,312          3,637       
Capecitabine (2) 85% 22.1 4,276          7,598       
FOLFOX (3) 48% 22.7 5,034          7,071       
CAPOX (4) 52% 19.4 3,324          4,013       
Costs per treatment group Weighted Pooled 
 Mean SD
Control group (1+2) 4,132          
Oxaliplatin group (3+4) 4,145          
Costs per 6 months, first 2 years of follow‐up 1,140          1,428       
Costs per 6 months, remainder of follow‐up 257             
Costs of follow‐up per treatment regimen
 
Period 3. Post-relapse costs 
The costs of period 3 reflect the cost of metastatic disease until death.  These costs 
were not measured for the stage III colon cancer pilot. As a proxy for the total costs 
of period three, the treatment costs of the oxaliplatin arm (period 1 € 19,624, table 
1.2.8) were used. We assumed the costs of period 3 three to be equal in both 
treatment arms (with and without oxaliplatin). Total costs per treatment arm are 
shown both with and without the costs of period 3. 
 
Time horizon and discounting 
 
The time horizon of the DFS Markov model was limited to 5 years regarding the 
disease-free survival estimate. It was assumed that the probability of relapse after 5 
years of follow-up is negligible and equal in the whole target population. This 
assumption has often been used in the past.9 Implementation of remaining life-
expectancies for both disease-free and relapsed patient groups into the model made 
it possible to model costs and benefits over a lifetime horizon. 
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Cost and benefits incurred after the first year in the model were discounted at 4% 
and 1.5% per annum respectively, consistent with current Dutch guidelines. 
 
Half-cycle correction 
 
The half-cycle correction technique was applied to more accurately reflect the 
continuous nature of state transitions.  
 
Model assumptions 
 
Certain assumptions were made to simplify the Markov model, yet to best reflect the 
clinical practice. The clinical assumptions critical to the modelling approach are listed 
below: 
 
A1.  Disease-free survival data of the PILOT oxaliplatin population beyond the 
PILOT study follow-up period were derived from the probabilities of the 
MOSAIC oxaliplatin patients. The hazard of relapsing was assumed to be 
equal to the hazard of relapsing in the oxaliplatin arm of the MOSAIC trial.  
A2.  It was assumed that all adverse events that resulted in dose modifications 
were significant and had an impact on the patient’s quality of life.  
A3.  Deaths due to adverse events or background mortality were assumed not to 
influence the results during the first 5 years. 
A4. After 5 years of follow-up the probability of relapse is negligible and equal in 
the whole target population. 
A5. The average life expectancy of patients after a relapse is equal for all 
treatment alternatives. 
A6.  The average life expectancy of patients who have no relapse after 5 years is 
equal for all treatment alternatives. 
 
 
Base case analysis 
 
Incremental cost-effectiveness analyses were conducted. Total costs (with and 
without the post-relapse costs of period 3) were estimated for all treatment groups. 
Overall survival and disease-free survival were calculated in each cycle based on the 
number of patients in each health state (i.e., the total – disease-free – life-years 
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accumulated by the cohort in that cycle). Utility values were applied to each life-year 
in each cycle and were summed to determine the total quality-adjusted life-years. 
The incremental costs, incremental health gain, and incremental cost-effectiveness 
ratio (ICER, calculated by dividing the incremental costs by the incremental health 
gain) were then calculated. 
 
The base case results incorporated the following endpoints: 
 
Costs per life-years (LY) gained 
o MOSAIC oxaliplatin versus MOSAIC control treatment 
o PILOT oxaliplatin versus MOSAIC control treatment 
o MOSAIC + PILOT oxaliplatin combined versus MOSAIC control treatment 
 
Costs per quality-adjusted life-years (QALY) gained 
o MOSAIC oxaliplatin versus MOSAIC control treatment 
o PILOT oxaliplatin versus MOSAIC control treatment 
o MOSAIC + PILOT oxaliplatin combined versus MOSAIC control treatment. 
 
Discounting 
In order to see the effect of discounting, the base case results are first shown without 
discounting, followed by the results with discounting.  
 
Sensitivity analysis 
 
Probabilistic sensitivity analysis was conducted. This approach involves specifying 
distributions for the model’s input parameters that quantify the uncertainty about their 
values and employing Monte Carlo simulation to select values randomly from those 
distributions. In this way, probabilistic models allow the effects of joint uncertainty 
across all of the model’s input parameters to be included in a single analysis.  
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Probability Distributions 
Table 1.2.10 contains an overview of all distributions used in the DFS Markov model.  
 
Transition probability parameters 
The transition probabilities in the model reflecting Prop(stay DFS) were based on 
Kaplan-Meier curves (from the PILOT and MOSAIC studies, Annex IX). They express 
the observed proportions of the event of interest. The beta distribution is 
recommended and commonly used to describe uncertainty around proportions (e.g., 
transition probabilities).35 The beta distribution incorporates the number of 
observations (or patients) that were actually studied. The initial total study population 
of patients from the MOSAIC study consisted of 675 (control arm) + 672 (oxaliplatin 
arm) = 1347 patients. The initial total study population of eligible oxaliplatin patients 
in the PILOT study consisted of 200 patients. Table 1.2.5 shows the number of 
patients at risk of relapse at each time point. With known probabilities and population 
numbers, the inputs for beta distribution, α and β, could be estimated.  
 
Cost parameters 
All costs in period 1 followed a normal distribution. Normal distributions were 
therefore used to reflect the variation in costs in periods 1 and 3. Table 1.2.8 and 
shows the mean values and standard deviations used in the normal distributions. 
Due to the skewed cost of period 2 (first 2 years), a gamma distribution was used to 
accurately reflect the variation.  
 
Utility values 
Normal distributions were used to reflect the variation in the utility values. Table 1.2.6 
shows the mean values and standard deviations that were used in the normal 
distributions.  
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Table 1.2.10 Probability distributions of parameters included in sensitivity analyses 
Transitional probability parameters
Distribution alpha beta
Prob(stay DFS) Control treatment MOSAIC Beta Derived from table 3 and 5
Prob(stay DFS) Oxaliplatin treatment MOSAIC Beta Derived from table 3 and 5
Prob(stay DFS) Oxaliplatin treatment PILOT Beta Derived from table 3 and 5
Prob(stay DFS) Oxaliplatin treatment combined Beta Derived from table 3 and 5
cost parameters
Distribution mean SD
Total costs period 1 Control group Normal 5,073            2,790              
Total costs period 1 Oxaliplatin group Normal 19,624          6,128              
Total costs period 3 Normal 19,624          6,128              
alpha labda
Total costs period 2, first 2 years Gamma 0.6369 0.0006
Utility  values
Distribution mean SD
Utility of being on Oxaliplatin treatment normal 0.65 0.036
Utility of being on Control treatment normal 0.66 0.036
Utility of being disease free normal 0.92 0.050
Utility of being relaped normal 0.24 0.041
 
Monte Carlo simulation 
Monte Carlo simulations were performed to estimate the costs per QALY gained.  
 
Costs per QALY gained 
o MOSAIC oxaliplatin versus MOSAIC control treatment 
o PILOT oxaliplatin versus MOSAIC control treatment 
o MOSAIC + PILOT oxaliplatin combined versus MOSAIC control treatment 
 
Parameters were randomly selected from all distributions. This procedure was 
repeated 10,000 times. These 10,000 iterations generated 10,000 estimates of costs 
and DFS/OS/QALY for each treatment. By comparing the estimates for the two 
treatments, scatter plots on a cost-effectiveness plane were created to explore the 
degree of uncertainty regarding the differences in costs and health. In addition, a 
cost-effectiveness acceptability curve (CEAC) could be created to quantify the 
probability of cost-effectiveness of oxaliplatin vs. alternative treatment over a range of 
willingness-to-pay thresholds.  
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Scenario analyses 
 
In order to gain a complete view of the cost-effectiveness in the Dutch population, we 
modelled two scenarios.  
 
Scenario 1: FOLFOX versus CAPOX 
In this scenario the same values for almost all of the model parameters were used as 
in the base case. The only exception relates to the costs of the oxaliplatin treatment, 
which were entirely based on the costs of FOLFOX and CAPOX separately rather 
than being integrated in a weighted mean costs.  
 
Scenario 2: Ineligible patients integrated 
In the base case analyses, ineligible patients (i.e., patients ineligible for oxaliplatin) 
(Figure 1.2.1) were ignored because the PILOT population was not comparable to 
the MOSAIC populations. However, 18% of the PILOT patients receiving oxaliplatin 
were ineligible and it remains questionable whether this population has the same 
benefit from the oxaliplatin treatment as the eligible patients. Scenario 2 examined 
ineligible patients in order to investigate the possible impact of their inclusion on the 
incremental costs, effectiveness and ICER.  
Cumulative probabilities, transition probabilities and number of patients at risk were 
derived from the disease-free survival KM curve of ineligible PILOT patients. When 
comparing the 6-monthly probabilities of relapse of the first 30 months of follow-up, 
we observed the hazard of relapse to be on average 2.5 times larger in the ineligible 
oxaliplatin patient group (PILOT study) than in the eligible oxaliplatin patient groups 
(both PILOT and MOSAIC studies). The extrapolated transition probabilities from 30 
up to 60 months were taken from the MOSAIC oxaliplatin arm, multiplied by 2.5, 
assuming a constant hazard rate of relapse. Next, an ‘ineligible’ control arm had to 
be simulated. This was performed in two ways.  
 
1. Assuming an equal HR of effect (control vs oxaliplatin) as seen in eligible patients 
(full treatment effect) 
The 6-monthly hazard of relapse as found in the eligible control population was 
multiplied by 2.5 to reflect a simulated ineligible control population. 
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2. Assuming no treatment effect of oxaliplatin 
The 6-monthly hazard of relapse was set equal to the hazard of relapse in the 
ineligible oxaliplatin population. 
Because there were only 43 ineligible patients in the PILOT study, the number of 
patients at risk in the simulated populations was also adapted to 43, in order to 
accurately reflect the degree of uncertainty.  
Tables 1.2.11, 1.2.12 and 1.2.13 show the cumulative probabilities of staying 
disease-free, transitional probabilities and number of patients at risk for the ineligible 
oxaliplatin PILOT population and the two simulated ineligible control populations (‘full’ 
effect and ‘no’ effect).  
 
Table 1.2.11 Cumulative probabilities of staying disease-free 
Time since start adjuvant PILOT Study
treatment (months) Oxaliplatin ineligibles Control ineligibles Control ineligibles 
Full effect No effect
0 1.000 1.000 1.000
6 0.954 0.888 0.954
12 0.744 0.713 0.744
18 0.624 0.521 0.624
24 0.567 0.421 0.567
30 0.473 0.363 0.473
36 0.433 0.337 0.433
42 0.404 0.311 0.404
48 0.397 0.293 0.397
54 0.383 0.270 0.383
60 0.340 0.247 0.340
Cumulative probability of staying disease free (DFS)
Simulated control groups
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Table 1.2.12 Transition probabilities used in the Markov Model 
Time Initial state Ending state PILOT Study
Oxaliplatin
ineligibles Full effect No effect
6 months DFS DFS 0.954 0.888 0.954
Relapse 0.047 0.113 0.047
12 months DFS DFS 0.780 0.804 0.780
Relapse 0.220 0.196 0.220
18 months DFS DFS 0.839 0.730 0.839
Relapse 0.161 0.270 0.161
24 months DFS DFS 0.909 0.809 0.909
Relapse 0.091 0.191 0.091
30 months DFS DFS 0.833 0.862 0.833
Relapse 0.167 0.138 0.167
36 months DFS DFS 0.917 0.927 0.917
Relapse 0.083 0.073 0.083
42 months DFS DFS 0.932 0.925 0.932
Relapse 0.068 0.075 0.068
48 months DFS DFS 0.982 0.942 0.982
Relapse 0.018 0.058 0.018
54 months DFS DFS 0.965 0.921 0.965
Relapse 0.035 0.079 0.035
60 months DFS DFS 0.888 0.914 0.888
Relapse 0.112 0.086 0.112
Transitional probabilities
Simulated control groups
control ineligibles
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Table 1.2.13 Number of patients at risk  
Patients at risk DFS
PILOT study 
oxaliplatin
Months ineligibles Full effect No effect
0 43 43 43
6 41 38 41
12 31 30 31
18 23 19 23
24 18 12 18
30 11 6 11
36 2 2 2
42 1 0 1
48 0 0 0
54 0 0 0
60 0 0 0
Simulated control groups
control ineligibles
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3 Results 
3.1 Patient population 
 
A patient flowchart is shown in Figure 1.3.1. Between January 2005 and December 2006, 
4031 patients were diagnosed with stage III colon cancer, of whom 2284 (57%) were treated 
with adjuvant chemotherapy.  A total of 463 patients were treated at one of the 19 hospitals 
included in our study, of which 427 met our initial inclusion criteria. As to the administered 
chemotherapy regimens, the four most common regimens were: 5FU/LV (N = 17), 
capecitabine (N = 99), FOLFOX (N = 147), and CAPOX (N = 152). A total of 391 patients 
were included based on the minimal CRF. Subsequently 206 patients were selected for more 
extensive data collection from the medical records. This selection occurred at random but 
was stratified by hospital and oxaliplatin use with the aim of balancing the number of patients 
that received oxaliplatin with that of those who did not.  
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Figure 1.3.1 Patient distribution 
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3.2 Data collection 
 
Data collection took place via the database of the Dutch Cancer Registry and via patient files 
from 19 hospitals; ‘minimal’ data were collected for 391 included patients, which were 
supplemented with ‘maximal’ data for 206 patients.  
 
Cancer registry 
In October 2007 an application for data was submitted to the Dutch Cancer Registry with the 
aim of obtaining the data available on all patients diagnosed with stage III colon carcinoma in 
2005 and 2006. Although the application was honoured in December 2007, the data were not 
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released until July 2008. This was partly due to the merger of the regional databases into 1 
national database. Furthermore, the permission of the doctors treating the patients was 
necessary before insight could be granted into privacy-sensitive data.  
 
Hospitals 
Close collaboration with the DCCG in Nijmegen made it possible to make use of their 
relationships with oncologists in more than 80 hospitals in the Netherlands. As a result, 
permission was granted immediately for the collection of data from 40 hospitals. For logistical 
and pragmatic reasons, 19 hospitals were selected that would reflect the variety of clinical 
practice. Annex X provides an overview of the hospitals that participated. Participating 
centres included both academic and general hospitals, and thereby reflect the diversity of 
clinical practice in the Netherlands. 
 
Additional data collection: minimum CRF 
At each hospital, ‘minimal’ data were collected for all patients (identified via the Dutch Cancer 
Registry). As the minimal CRF data collection was limited to the information that could often 
be retrieved from a single patient letter, data on a maximum of 25 patients could be 
processed per day.  
 
Additional data collection: maximum CRF 
Per hospital, ‘maximal’ data were collected for a sub-group of patients. As maximal CRF data 
collection was extensive and required a detailed exploration of patient files, on average no 
more than 6 patients could be processed per day.  
 
 
3.3 Use of oxaliplatin 
 
Baseline characteristics 
The baseline patient characteristics of the total population fulfilling the eligibility criteria (N = 
391), as well as those of the four treatment groups, are summarised in Table 1.3.1. Patients 
receiving oxaliplatin were significantly younger (p < 0.0001) and had fewer comorbidities (p = 
0.0011) than patients who did not receive oxaliplatin. Furthermore, patients receiving 
oxaliplatin more often had well-differentiated tumour histology (p = 0.0073), and higher serum 
carcinoembryonic antigen (CEA) levels (p = 0.0282). Additional stratification by age (older 
versus younger than 70 years of age) revealed that differences in tumour differentiation and 
CEA levels between those patients receiving oxaliplatin and those patients not receiving 
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oxaliplatin could be explained by the different age distribution in the two groups. Patients 
receiving FOLFOX were comparable to patients receiving CAPOX.  
 
 
Table 1.3.1 Baseline Characteristics of Patients receiving chemotherapy in Dutch practice 
 
Total population 5FUL/LV Capecitabine 5FU/LV + Capecitabine +
Oxaliplatin Oxaliplatin
Baseline Characteristics N = 391 N = 17 N = 93 N = 136 N = 145 P-values
Age - yr
      Median 64 71 73 61 62 < 0.0001
      Range 22-85 41-80 46-85 30-78 22-82
Age group - no. (%)
      < 70 279 (71.4) 7 (41.2) 31 (33.3) 118 (86.8) 123 (84.8) < 0.0001
      ≥ 70 112 (28.6) 10 (58.8) 62 (66.7) 18 (13.2) 22 (15.2)
No. of comorbid conditions - no. (%)
      0 - 1 332 (84.9) 12 (70.6) 71 (76.3) 115 (84.6) 134 (92.4) 0.0011
      2+ 59 (15.1) 5 (29.4) 22 (23.7) 21 (15.4) 11 (7.6)
Sex - no. (%)
      male 209 (53.5) 9 (52.9) 47 (50.5) 72 (52.9) 81 (55.9) 0.5281
      female 182 (46.5) 8 (47.1) 46 (49.5) 64 (47.1) 64 (44.1)
Depth of invasion - no. (%)
      T2 -T3 336 (86.2) 15 (88.2) 82 (89.1) 116 (85.3) 123 (84.8) 0.3130
      T4 54 (13.8) 2 (11.8) 10 (10.9) 20 (14.7) 22 (15.2)
      Unknown 1
No of nodes involved - no (%)
      N1 242 (61.9) 11 (64.7) 62 (66.7) 84 (61.8) 85 (58.6) 0.2553
      N2 149 (38.1) 6 (35.3) 31 (33.3) 52 (38.2) 60 (41.4)
Histologic appearance - no (%)
      Well differentiated 322 (86.3) 11 (64.7) 75 (81.5) 111 (86.7) 125 (91.9) 0.0073
      poorly differentiated 51 (13.7) 6 (35.3) 17 (18.5) 17 (13.3) 11 (8.1)
      Unknown 18 1 8 9
CEA level  - no.
     < 5 ng/ml (ULN) 278 (84.5) 10 (83.3) 69 (93.2) 94 (83.2) 105 (80.8) 0.0282
     ≥ 5 ng/ml (ULN) 51 (15.5) 2 (16.7) 5 (6.8) 19 (16.8) 25 (19.2)
      Unknown 62 5 19 23 15
CEA = carcinoembryonic antigen
ULN = upper limit of normal
Regimens without oxaliplatin Oxaliplatin containing regimens
 
 
 
Diffusion of oxaliplatin 
After the inclusion of oxaliplatin for the adjuvant treatment of colon cancer in the National 
Guidelines, we observed a quick diffusion rate of oxaliplatin in the hospitals. Of the 19 
hospitals included in our survey, 8 were already using oxaliplatin in the first quarter of 2005, 
followed by a total of 16 hospitals that started to use oxaliplatin during the second quarter of 
2005. In January 2006, oxaliplatin was standard therapy in all 19 hospitals (Figure 1.3.2). 
However, even after their implementation, a substantial proportion of the patients did not 
receive oxaliplatin-based regimens. The percentage of patients not receiving oxaliplatin was 
28% and this percentage did not change over time (P trend = 0.5). In contrast, the use of 
different regimens changed between January 2005 and December 2006 (Figure 1.3.3).  The 
former standard therapy 5-FU/LV was prescribed to only 4% of the patients and was 
replaced by the FOLFOX or CAPOX regimens. Between January 2005 and December 2006, 
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a trend towards a shift from the use of FOLFOX to CAPOX was observed (test for trend, p < 
0.05). In the second quarter of 2005, 82% of the patients receiving oxaliplatin were treated 
with FOLFOX versus 18% with CAPOX. During the course of 2005-2006, FOLFOX was 
gradually replaced by CAPOX, resulting in only 27% being treated with FOLFOX versus 73% 
with CAPOX at the beginning of 2007. Between the second quartile of 2005 and the 
beginning of 2007, the proportion of patients who received CAPOX increased from 19% to 
73%.  
 
 
Figure 1.3.2 Cumulative Diffusion of oxaliplatin in 19 hospitals 
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Figure 1.3.3 Distribution of treatments schedules used in 2005-2006 
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Considerations in choice of treatment regimen 
We next explored reasons for non-prescription of oxaliplatin in all patients who did not 
receive this drug (N = 111). This is shown in table 1.3.2 The reasons for non-prescription 
were: advanced age (21%), comorbidity or poor health status (10%), specific contra-
indications for oxaliplatin (2%), patient refusal (18%), not in line with hospital policy (23%), 
combination of these factors (7%), and unknown (23%).  To assess independent predictors 
of non-prescription of oxaliplatin, we performed a multivariate logistic regression on baseline 
characteristics and included the variables age, presence of comorbid conditions, gender, 
depth of invasion of primary tumour (T-stage), lymph node involvement (N-stage), 
differentiation and serum CEA level. The multivariate analysis identified only age and 
comorbidity as being independent predictors of non-prescription of oxaliplatin (OR [95 CI] of 
0.765 [0.708-0,826] and 0.426 [0.169-1.075], respectively).  
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Table 1.3.2 Reasons for not prescribing oxaliplatin (N = 111) 
Reasons No of patients (%)
Advanced age 23 (21)
Comorbidity or poor health state 11 (10)
Specific contra-indication for oxaliplatin 2  (2)
Patient declined treatment 21 (19)
Prescription of oxaliplatin is no hospital policy 20 (18)
Combination of reasons 8  (7)
Unknown 25 (23)
 
 
Dose schedules 
The most frequently used treatment regimens in the Netherlands during the study period are 
presented in Table 1.3.3. In total, 37% of patients received CAPOX, 35% received FOLFOX-
4, 24% received capecitabine monotherapy, and 4% received different 5-FU/LV regimens. 
The use of these regimens in clinical practice is presented in Table 1.3.4. With six months of 
chemotherapy being accepted as the standard duration of adjuvant treatment, and duration 
of the treatment cycle of 2 weeks for FOLFOX and 3 weeks for CAPOX and capecitabine 
monotherapy, the number of planned cycles is 12 and 8, respectively.  The median number 
of cycles received equals the planned number of cycles in FOLFOX and capecitabine 
monotherapy, indicating that at least 50% of the patients were able to complete the number 
of cycles according to protocol. The median number of oxaliplatin cycles for patients 
receiving the CAPOX regimen was 7. The planned dose for each regimen is equal to the 
dosing recommendations as advised by the national guidelines. The mean dosages in 
milligrams per square metre per week across all cycles administered were slightly lower than 
the planned dosage. However, regarding mean dose over all planned cycles, we found that 
the mean dose of oxaliplatin in CAPOX was significantly lower than that in FOLFOX, with 30 
mg/m2/wk versus 36 mg/m2/wk, respectively (p = 0.00213). Furthermore, 70% of patients 
receiving CAPOX required dose modification and 71% of the total planned dose were 
administered versus 59% and 84%, respectively, in patients receiving FOLFOX (p = 0.2661 
and p = 0.0896, respectively), suggesting that oxaliplatin may be less well tolerated when 
administered in the CAPOX regimen.  
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Table 1.3.3   Dose schedules observed in Dutch clinical practice 
% of patients Duration of treatment
Regimen receiving regimen Oxaliplatin Capecitabine Fluorouracil leucovorin cycle (weeks)
CAPOX 37% 130 mg/m2 day 1 1000 mg/m2 bid days 
1-14 (ie, 28 doses)
FOLFOX-4 35% 85 mg/m2 day 1 400 mg/m2/d bolus 200 mg/m2/d bolus
days 1,2; 600 mg/ days 1,2
m2/d CI days 1,2 
Capecitabine 24% 1250 mg/m2 bid days 
1-14 (ie, 28 doses)
Aio/Ardalan 2% 2600 mg/m2 CI 500 mg/m2 
Mayo 1% 370 mg/m2/d bolus 20 mg/m2/d bolus
days 1-5 days 1-5
Other 5FU/LV 1%
Abbreviations: CI, continuous infusion for 24 hours; 
− − not reported not reported not reported
− − 1 wk
− − 4 wk
− − − 3 wk
Dose-Schedule
− − 3 wk
− 2 wk
 
 
Table 1.3.4 Planned and actually delivered dose in clinical practice 
5FUL/LV Capecitabine 5FU/LV Oxaliplatin Capecitabine Oxaliplatin
All regimens
(1)
N = 15 N = 89
Median nr of cycles received ** 8 (8) 12 (12) 12 (12) 8 (8) 7 (8)
(planned nr of cycles)
Dose according to schedules ** 11666 1000 / 200 43 9333 43
in mg/m2/wk 
Mean dose over all cycles given ** 9659 890 / 178 42 8049 42
in mg/m2/wk 
Mean dose over all planned cycles ** 8250 800 / 160 36*1 7052 30*1
in mg/m2/wk 
% of patients requiring modification 53% 57% 54% 59%*2 50% 70%*2
(for dose reduction or interrupation)
% of planned dose given 72% 83% 84% 84%*3 79% 71%*3
** Not reported because of diversity of dose schedules and low patient numbers
*1 p - value  = 0.0213, *2 p - value = 0.2661, *3 p - value = 0.0896,   Oxaliplatin in FOLFOX versus CAPOX
Regimens without oxaliplatin Oxaliplatin containing regimens
FOLFOX CAPOX
N = 37 N = 65
(2) (3)
 
 
Toxicity 
Haematological toxicity and neurotoxicity are the most frequent reasons for dose adjustment 
and/or interrupting treatment with oxaliplatin (Table 1.3.5). The hand-foot syndrome is a 
toxicity that occurs only in schedules involving capecitabine. The hand-foot syndrome also 
usually plays a role when “combination” is quoted as the reason for a dose adjustment and/or 
interruption of a schedule with capecitabine. Treatment with CAPOX seems to result more 
often into toxicities necessitating a dose adjustment and/or interruption than FOLFOX 
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(respectively 56% versus 35% for dose adjustments, P = 0.059; 42% versus 24% for 
interruption, P =0.072).  
 
Table 1.3.5 Toxicities 
5FU/LV Capecitabine
5FU/LV oxaliplatin capecitabine oxaliplatin
Adverse events (N =15 ) (N=89 )
Requiring dose reduction - nr (%)
Hematological toxicity 0 (0) 2 (2) 3 (8) 3 (8) 7 (11) 8 (13)
Gastrointestinal toxicity 0 (0) 8 (9) 2 (5) 0 (0) 4 (6) 4 (6)
Neurological toxicity 0 (0) 2 (2) 2 (5) 3 (8) 3 (5) 9 (14)
Hand‐Foot syndrome 0 (0) 8 (9) 0 (0) 0 (0) 2 (3) 3 (5)
Combination 0 (0) 3 (3) 2 (5) 1 (3) 3 (5) 6 (10)
Other 1 (7) 8 (9) 2 (5) 3 (8) 4 (6) 5 (8)
Unknown 0 (0) 5 (6) 2 (5) 3 (8) 0 (0) 0 (0)
Any 1 (7) 36 (40) 13 (35) 13 (35)* 23 (36) 35 (54)*
1
Requiring interrupation - nr (%)
Hematological toxicity 0 (0) 0 (0) 1 (3) 1 (3) 4 (6) 6 (9)
Gastrointestinal toxicity 1 (7) 1 (1) 0 (0) 0 (0) 2 (3) 3 (5)
Neurological toxicity 0 (0) 0 (0) 0 (0) 1 (3) 3 (5) 7 (11)
Hand‐Foot syndrome 0 (0) 3 (3) 0 (0) 1 (3) 1 (2) 2 (3)
combination 0 (0) 4 (4) 4 (11) 3 (8) 3 (5) 5 (8)
Other 2 (0) 6 (7) 1 (3) 3 (8) 1 (2) 4 (6)
Unknown 0 (0) 1 (1) 0 (0) 0 (0) 0 (0) 0 (0)
Any 3 (20,0) 15 (17) 6 (16) 9 (24)** 14 (22) 27 (42)**
requiring hospitalisation
Any 1 (7) 6 (7)
* chi‐square p‐value = 0.059
** chi‐square p‐value = 0.072
FOLFOX CAPOX
(N=37) (N=65)
2 (5) 4 (6)
 
 
3.4 Clinical efficacy of oxaliplatin 
 
 
Disease-free survival 
We found that patients who did not receive oxaliplatin were significantly older and had more 
comorbidities than patients who did receive oxaliplatin. We also found a quick diffusion of 
oxaliplatin and clear reasons why patients did not receive oxaliplatin. From this we can 
conclude that patients who did and did not receive oxaliplatin are not comparable in terms of 
their prognosis. Therefore, a direct comparison of the disease-free survivals of the two 
patient groups would not be valid. For this reason, we present the DFS survival curves of the 
two treatment groups separately.  The median duration of the follow-up exceeds 2 years for 
 46 
 
all treatment groups (table 1.3.6). The chance of remaining disease-free varies amongst all 
treatment groups from 72% to 88%, but this variation is not statistically significant.  
 
Table 1.3.6 Follow-up and disease free survival (DFS), unadjusted 
5FU/LV Capecitabine FOLFOX CAPOX
(N =17 ) (N=93) (N=136) (N = 145)
Follow-up - mo
      median 29.6 27.4 26.7 23.2
      Range 5.2 - 44.1 2.1 - 47.6 2.1 - 46.6 0.95 - 50.9
Probability  of DFS
      at 2 year - % (95% CI) 88.2 (72.9 - 103.5) 80.8 (72.5 - 89.0) 72.0 (64.3 - 79.7) 72.8 (65.1 - 80.5)
Event - no. (%)
      Relapse 2 (11.7) 17 (18.2) 37 (27.2) 36 (24.8)
      Death without relapse 0 4 (4) 1 (0.7) 1 (0.7)
 
 
Figure 1.3.4 shows the Kaplan Meier curve of the disease-free survival of patients treated 
without oxaliplatin (5FU/LV or capecitabine monotherapy). Figure 1.3.5 shows the Kaplan 
Meier curve of the disease-free survival of patients treated with oxaliplatin (FOLFOX of 
CAPOX). 
 
Figure 1.3.4 Kaplan Meier disease-free survival curve of patients treated without oxaliplatin 
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Figure 1.3.5 Kaplan Meier disease-free survival curve of patients treated with oxaliplatin 
 
Multivariate analysis 
Although we realised beforehand that an adequate adjustment for the baseline prognostic 
differences of the treatment groups would not be feasible, making it therefore by definition 
impossible to obtain an internally valid estimate of the treatment effect of oxaliplatin, we 
nevertheless performed a multivariate Cox regression analysis to identify prognostic factors 
and illustrate the problem of precision. Table 1.3.7 shows the results of the multivariate Cox 
regression, which included correction for differences in baseline characteristics. Disease-free 
survival was significantly shorter for patients younger than 70 years, patients with abnormal 
CEA values, patients with a T2-T3, and patients with N2-staging of the tumour. There was no 
significant association between survival and treatment with capecitabine or treatment with 
5FU/LV (HR[CI] = 0.998 [0.631-1.578]).  
 
Table 1.3.7 Multivariate analysis of factors associated with disease free survival 
Variables Hazard Ratio Lower Limit Upper Limit P
Treated with capecitabine 0.998 0.631 1.578 0.9921
Age younger than 70 years 2.006 1.085 3.706 0.0263
Elevated CEA levels 2.706 1.677 4.367 <.0001
Dept of invasion,  T2-T3 1.946 1.130 3.351 0.0164
Spread to lymph nodes, N2 2.135 1.341 3.400 0.0014
Several comorbidities 1.464 0.808 2.651 0.2084
poorly differentiated tumour 1.234 0.648 2.350 0.5215
Model characteristics: lilelihood ratio, χ2 (7) = 50.2181; probability >  χ2 = <0.0001; -2 log likelihood = 815.128
Risk ratios adjusted for all covariates; Total N = 314, number of events 79, 74.8% censored
95% CI
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3.5 Costs of oxaliplatin 
 
The mean costs per patient were determined for four treatment groups: 
• 5FU/LV (n=15) 
• Capecitabine (n=89) 
• FOLFOX (n=37) 
• CAPOX (n=65) 
 
 
Period 1: from the first administration of chemotherapy until one month after the last 
administration of chemotherapy  
The mean follow up durations for period 1 for the four treatment groups were as follows: 
• 5.8 ± 2.3 months for patients receiving 5FU/LV (range: 5.2 to 44.2 months)  
• 6.0 ± 1.3 months for patients receiving capecitabine (range: 1.0 to 47.6 months)  
• 5.9 ± 1.0 months for patients receiving FOLFOX (range: 7.3 to 46.6 months)  
• 6.4 ± 1.4 months for patients receiving CAPOX (range: 3.6 to 44.2 months)  
 
Table 1.3.8 presents the total mean treatment costs per patient in period 1 for the four 
treatment groups. Mean costs per patient amounted to € 5,802 for 5FU/LV, € 4,944 for 
capecitabine, € 25,839 for FOLFOX and € 13,888 for CAPOX (Kruskal Wallis test: p < 
0.001). Mean costs for FOLFOX and CAPOX were significantly different (p < 0.001), while 
mean costs for 5FU/LV and capecitabine were not significantly different (p = 0.060). A 
substantial cost variation was found in the total costs obtained for individual patients within 
treatment groups as well as in each individual cost component. Inpatient hospital days, 
daycare treatments, outpatient visits and chemotherapy (leucovorin, capecitabine and 
oxaliplatin) were the most important cost drivers. 
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Table 1.3.8 Total mean treatment costs per patient ~ period 1 (Euro 2009) 
5-FU/LV Capecitabine FOLFOX CAPOX
n=15 n=89 n=37 n=65
Inpatient hospital days 1,013 886 10,250 2,359
Intensive care unit days 0 23 0 0
Outpatient visits 1,065 830 985 783
Consultations by telephone 10 18 13 25
Day-care treatments 1,692 152 1,174 938
Emergency room visits 371 100 24 67
Radiotherapy 0 0 0 26
Intravenous access 0 0 150 7
Colonoscopy 119 65 60 112
Other surgical procedures 180 0 32 57
Laboratory 535 290 422 398
X ray 21 23 38 26
CT scan 16 45 70 63
PET scan 94 48 0 23
Ultrasound 17 35 26 53
Other radiological procedures 0 13 9 16
Other procedures 51 5 12 11
5-Fluorouracil (bolus) 5 0 101 3
5-Fluorouracil (infusion) 94 2 143 4
Leucovorin 376 19 2,075 84
Capecitabine 0 2,184 103 1,989
Oxaliplatin 0 88 8,351 6,486
Uracil/tegafur 0 9 0 26
Concomitant medication 142 108 1,800 330
Total costs 5,802 4,944 25,839 13,888
Median 6,235 4,173 27,182 13,814
Minimum 1,070 316 2,611 1,708
Maximum 12,127 19,231 60,149 33,567
CT = Computed Tomography
PET = Positron Emission Tomography  
 
Inpatient stay costs were € 1,013 in 5FU/LV, € 909 in capecitabine, € 10,250 in FOLFOX and 
€ 2,359 in CAPOX. Of the inpatient admissions, 3% were to a ward other than an oncology 
ward, such as a surgery or pulmonary ward. Inpatient hospital days were especially 
important in the FOLFOX group, as the administration of 5FU/LV involved a 48-hour 
continuous infusion in this schedule and frequent admissions. Patients treated with FOLFOX 
were admitted for an average of 20.3 (SD 16.9) inpatient days, compared to 2.1 (SD 4.7), 4,1 
(SD 20.2) and 4.3 (SD 9.4) days in the other three treatment groups (ANOVA test: p < 
0.001). It should be noted that these admissions regarding the administration of FOLFOX 
might not have been necessary since we found hospitals where the 48-hour infusion was 
given via day-care treatment or outpatient visits only. Only one patient was admitted to the 
intensive care unit. This patient was treated with capecitabine and developed sepsis during 
her admission following dehydration from diarrhoea.  
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There was a significant difference in costs of day-care treatment between the four treatments 
(Kruskal Wallis test: p < 0.001). Daycare treatments were of minor importance in the 
capecitabine treatment group (€ 152; SD 374), because capecitabine is administered orally 
during outpatient visits. Costs for day-care treatments were much higher in the other three 
treatment groups (€ 1,692 for 5FU/LV, € 1,174 for FOLFOX and € 938 for CAPOX). There 
was also a significant difference in costs of day-care treatment between these three 
treatments (Kruskal Wallis test: p = 0.027). A substantial variation was found in number of 
day-care treatments per individual patient (range: 0-46). 
 
The number of outpatient visits was of the same magnitude in the four treatment groups 
(ANOVA test: p = 0.239). The proportion of outpatient visits in total treatment costs was 
responsible for 18% in 5FU/LV, 17% in capecitabine, 4% in FOLFOX and 6% CAPOX. 
 
Period 2: from one month after the last administration of chemotherapy until progression or 
end of follow up 
The mean follow up durations in period 2 were as follows: 
• 25.0 ± 8.7 months for patients receiving 5FU/LV (n=15) 
• 22.1 ± 9.6 for patients receiving capecitabine (n=89) 
• 22.7 ± 12.4 months for patients receiving FOLFOX (n=37) 
• 19.4 ± 8.8 months for patients receiving CAPOX (n=65)  
 
Table 1.3.9 presents the total mean treatment costs per patient in period 2 for the four 
treatment groups (n=206). Mean costs per patient amounted to € 3,312 for 5FU/LV, € 4,276 
for capecitabine, € 5,034 for FOLFOX and € 3,324 for CAPOX (Kruskal Wallis test: p = 
0.517). Mean costs for patients whose resource use was collected until progression were not 
significantly different from patients whose resource use was collected until the end of follow 
up (p 5FU/LV = 0.167; p capecitabine = 0.691; p FOLFOX = 0.743; p CAPOX = 0.072). 
 
 
 
 
 
 
 
 
 
 
 51 
 
Table 1.3.9 Total mean treatment costs per patient ~ period 2 (Euro 2009) 
5-FU/LV Capecitabine FOLFOX CAPOX
n=15 n=89 n=37 n=65
Inpatient hospital days 1,143 1,316 2,159 882
Intensive care unit days 0 491 0 0
Outpatient visits 908 678 842 669
Consultations by telephone 7 7 8 8
Day-care treatments 56 68 42 58
Emergency room visits 23 77 39 15
Radiotherapy 0 0 0 26
Intravenous access 0 0 0 0
Colonoscopy 386 436 651 481
Other surgical procedures 0 222 477 355
Laboratory 287 363 288 277
X ray 97 76 78 64
CT scan 110 161 293 133
PET scan 94 128 0 134
Ultrasound 201 161 121 180
Other radiological procedures 0 83 27 35
Other procedures 0 10 10 7
Total costs 3,312 4,276 5,034 3,324
Median 1,813 2,156 2,235 1,976
Minimum 0 0 232 0
Maximum 10,084 62,737 38,645 20,018
CT = Computed Tomography
PET = Positron Emission Tomography  
 
 
Inpatient hospital days, outpatient visits and colonoscopies were the most important cost 
drivers. Patients receiving FOLFOX received more computed tomography scans (ANOVA 
test: p = 0.002) than patients in the other three groups. Only costs related to ‘other surgical 
site’ also reached statistical significance (Kruskal Wallis test: p = 0.040).  
 
Correction for baseline patient characteristics 
The total treatment costs per patient for periods 1 and 2 jointly amounted to € 9,114 for 
5FU/LV, € 9,220 for capecitabine, € 30,873 for 5FU/LV with oxaliplatin and € 17,211 for 
capecitabine with oxaliplatin. A multivariate linear regression on the logarithm of the total 
costs, involving the independent variables age, comorbidity, T-staging, N-staging, 
differentiation, CEA-values and the 4 treatment groups, revealed only a young age (and 
obviously treatment with oxaliplatin) as a possible predictor of higher costs (p ≈ 0,1). Table 
1.3.10 reflects the total costs over periods 1 and 2, stratified for age (younger than 70 years 
versus older than 70 years). There were no significant differences in costs between the 
treatment groups when the study population was stratified according to age group. This 
suggests that the costs incurred bear no relation to baseline characteristics.  
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Tabel 1.3.10 Total costs period 1+2 stratified according to age group (Euro 2009) 
5-FU/LV Capecitabine 5-FU/LV Capecitabine
Total population (n = 15) (n = 89) (n = 37) (n = 65)
     mean total costs 9,114 9,220 30,873 17,211
Population younger than 70 (n = 4) (n = 13) (n = 24) (n = 44)
     mean total costs 7,903 9,447 32,019 17,387
     standard deviation 768 6,024 14,918 7,232
Populatie older than 70 (n = 11) (n = 76) (n = 13) (n = 21)
     mean total costs 9,554 9,182 28,756 16,844
     standard deviation 7,903 8,776 13,347 7,716
p-value* 0.7940 0.6256 0.4451 0.8663
* Kruskal-Wallis Test
No oxaliplatin Oxaliplatin
 
 
Sensitivity analyses 
Varying the unit costs of inpatient hospital days, day-care treatments and outpatient visits 
between 50% and 150% appeared to have a rather modest influence on the total mean costs 
of period one and two with the greatest influence when varying the unit price for inpatient 
hospital days. For patients treated with oxaliplatin, total mean costs of period one and two 
varied from € 19,948 to € 27,590 when inpatient hospital day unit costs were varied, from € 
23,218 to € 24,320 when day-care treatment unit costs were varied and from € 22,953 to € 
24,585 when outpatient visit unit costs were varied. 
 
For patients in the control group, total mean costs of period one and two varied from € 8,107 
to € 10,302 when inpatient hospital day unit costs were varied, from € 8,979 to € 9,429 when 
day-care treatment unit costs were varied and from € 8,415 to € 9,993 when outpatient visit 
unit costs were varied. 
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3.6 Daily practice versus clinical trials 
 
Clinical effects: comparison with the MOSAIC trial 
Table 1.3.11 provides an overview of the inclusion criteria of our study compared with those 
of the MOSAIC trial. In total 82% of the pilot patients who received oxaliplatin and 63% of the 
pilot patients who did not receive oxaliplatin fulfilled the inclusion criteria of the MOSAIC trial. 
Table 1.3.12 provides an overview of the baseline characteristics of the different groups. The 
CEA-value, an important negative prognostic factor, had to be lower than 10 ng/ml in order 
for a patient to fulfil the inclusion criteria. With respect to the patients who did not fulfil the 
MOSAIC inclusion criteria, 39.5% of the patients who received oxaliplatin had a raised CEA-
value versus 9.4% in the group who did not receive oxaliplatin. Both ineligible and eligible 
pilot patients not receiving oxaliplatin were therefore not comparable to the MOSAIC control 
group. Therefore only pilot oxaliplatin patients were subject for further comparisons between 
the two studies.  
 
The FOLFOX schedules of the two studies are compared in table 1.3.13. There are no 
differences between the studies with respect to the planned doses. The percentage of 
patients that received the planned number of oxaliplatin cycles is lower in the Pilot Study 
than in the MOSAIC trial (respectively 62% versus 75%). On the other hand, the average 
dose of oxaliplatin over the cycles received was higher in the Pilot study (42 mg/m2/week 
versus 36 mg/m2/week in the MOSAIC trial). As a result, no substantial differences were 
seen between the percentages of the planned total doses that were actually given (84% and 
81% for the Pilot and the MOSAIC study respectively).  
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Table 1.3.11 Comparison eligibility criteria Pilot and MOSAIC studies 
 
>
>
> 
>
> 
>
>
>
> Histologically proven stage II or III coloncancer
> Coloncancer defined by presence of the inferior pole of the tumor above
the peritoneal reflection, that is at least 15 cm from the anal margin (C18) 
> Complete resection of the tumor required
> Treatment had to be started within seven weeks after surgery 
> Age of 18 to 75 years
> karnofsky performance score of at least 60
> Carcinoembryonic antigen level of less than 10 ng/ml
> Absence of prior chemotherapy, immunotherapy or radiotherapy
> Adequate blood counts and liver and kidney function
> Written informed consent
Absence of prior chemotherapy, immunotherapy or radiotherapy
Absence of treatment with Bevacizumab
Absence of 2nd tumor diagnosis < 5 years ago
PILOT Study
    MOSAIC trial
Histologically proven stage III coloncancer + clinical disease stage III
Coloncancer as defined by ICD-O-03 code C18 and C19
and described and treated as coloncancer by physician
Complete resection of the tumor required
Adjuvant treatment needs to start in included hospital
Not included in RCT
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Table 1.3.12 Baseline Characteristics of eligible versus ineligible patients 
 
MOSAIC patients
no oxaliplatin oxaliplatin no oxaliplatin oxaliplatin all
Baseline Characteristics N = 32 N = 43 N = 54 N = 200 N = 1347
Age - yr
      Median 77 62 70.5 61 61
      Range 59 - 85 32 - 82 55 - 75 22-75 19-75
Age group - no. (%)
      < 70 5 (15.6) 37 (86.1) 26 (48.2) 170 (85.0) (86)
      ≥ 70 27 (84.4) 6 (13.9) 28 (51.8) 30 (15.0) (14)
No. of comorbid conditions - no. (%)
      0 - 1 24 (75.0) 30 (69.8) 39 (72.2) 186 (93.0)
      2+ 8 (25.0) 13 (30.2) 15 (27.8) 14 (7.0)
Sex - no. (%)
      male 15 (46.9) 22 (51.2) 29 (53.7) 107 (53.5) (56.1)
      female 17 (53.1) 21 (48.8) 25 (46.3) 93 (46.5) (43.9)
Depth of invasion - no. (%)
      T2 -T3 27 (84.4) 32 (74.4) 49 (92.5) 174 (87.0) (80.5)
      T4 5 (15.6) 11 (25.6) 4 (7.5) 26 (13.0) (19)
      Unknown 1 (0.5)
No of nodes involved - no (%)
      N1 19 (59.4) 26 (60.5) 36 (66.7) 123 (61.5) (76.2)
      N2 13 (40.9) 17 (39.5) 18 (33.3) 77 (38.5) (23.8)
Histologic appearance - no (%)
      Well differentiated 25 (78.1) 34 (85.0) 41 (77.4) 176 (92.6) (83.2)
      poorly differentiated 7 (21.9) 6 (15.0) 12 (22.6) 14 (7.4) (12.6)
      Unknown 10
CEA level  - no.
     < 5 ng/ml (ULN) 29 (90.6) 26 (60.5) 50 (92.6) 173 (86.5)
     ≥ 5 ng/ml (ULN) 3 (9.4) 17 (39.5) 4 (7.4) 27(13.5)
     < 10 ng/ml 54 (100) 200 (100) (100)
CEA = carcinoembryonic antigen
ULN = upper limit of normal
Ineligible pilot patients Eligible pilot patients 
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Table 1.3.13 Treatment Characteristics Pilot and MOSAIC studies compared 
5FU/LV Oxaliplatin 5FU/LV Oxaliplatin
Median nr of cycles received 12 (12) 12 (12) 12 (12) 12 (12)
(planned nr of cycles)
Dose according to schedules 1000 / 200 43 1000/200 43
in mg/m2/wk
Mean dose over all cycles given 890 / 178 42 not reported 36
in mg/m2/wk
Mean dose over all planned cycles 800 / 160 36 not reported 34
in mg/m2/wk
% of patients receiving planned 68% 62% not reported 75%
nr of cycles
% of planned dose given 84% 84% 84% 81%
N = 37 N = 672
PILOT study MOSAIC Trial
FOLFOX FOLFOX
 
 
Table 1.3.14 provides an overview of the chance of disease-free survival at 24 months. After 
24 months 79% of the patients who received oxaliplatin in the MOSAIC trial were disease-
free. Table 1.3.6 already showed that the disease-free survival of patients who received 
oxaliplatin in the pilot study amounted to 72% at 24 months. After applying the inclusion 
criteria of the MOSAIC study to the pilot patients (treated with oxaliplatin), it appears that the 
selected group had a disease-free survival of 78.4% at 24 months.  
 
What is noticeable with respect to the pilot patients treated without oxaliplatin, is that the 
difference in disease-free survival at 24 months is very small (83.7% for patients who did not 
fulfil the MOSAIC inclusion criteria versus 82.8% for patients who did). However, due to the 
low number of patients, the confidence intervals are extremely wide. Figure 1.3.6 shows the 
Kaplan Meier curves of those pilot patients who received oxaliplatin, divided according to 
whether or not they fulfilled the inclusion criteria.  
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Table 1.3.14 Disease-free survival, Pilot versus MOSAIC oxaliplatin patients 
 
MOSAIC patients
ineligibles eligibles
(N=42) (N = 200) (N = 672)
Probability  of DFS 56.7 78.4 79.5
      at 2 year - % (95% CI) (41.5 - 72.0) (72.5 - 84.3)
PILOT patients
All patients treated with oxaliplatin
 
 
Figure 1.3.6 Disease-free survival curve of pilot patients treated with oxaliplatin 
stratified by eligibility for MOSAIC  
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Costs: comparison with existing literature 
The combination of 5FU/LV and oxaliplatin was observed to be the most expensive 
treatment option. Treatment with FOLFOX in periods 1 and 2 was € 21,759 more 
expensive than 5FU/LV without oxaliplatin (Kruskal Wallis test: p < 0.001), 
predominantly owing to hospitalisation and chemotherapy costs. Earlier studies, most 
of them based on the MOSAIC trial, have also demonstrated lower costs for 5FU/LV 
without oxaliplatin over FOLFOX, although to a varying degree. In comparison with 
5FU/LV, the life-time costs of the combination 5FU/LV and oxaliplatin were estimated 
to be about € 5,000 more expensive from the perspective of the NHS in the United 
Kingdom (€ 28,500 versus € 23,500) 20 and about € 16,000 more expensive from the 
perspective of Medicare in the United States (€ 52,850 versus € 36,900).21 
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Furthermore, treatment with FOLFOX in periods 1 and 2 was € 13,662 more 
expensive than treatment with CAPOX (Kruskal Wallis test: p < 0.001). Maniadakis et 
al. (2009), whose study was carried out in Greece, determined the total treatment 
cost of FOLFOX as an adjuvant treatment for high risk colon cancer patients to be 
about € 5,000 greater than that of CAPOX (p < 0.001; follow up duration: ≈ 13 
months). The higher costs for FOLFOX were almost entirely due to higher 
hospitalisation costs. The FOLFOX group was hospitalised for an average of 10.7 
inpatient days (versus 20.3 in our study) where the CAPOX group was hospitalised 
for an average of 2.2 inpatient days (versus 4.3 in our study).36 
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3.7 Cost-effectiveness of oxaliplatin 
Base case results 
 
The Markov model simulated the transitions of a hypothetical colon cancer stage III 
patient cohort through the clinical states.  
 
The undiscounted ICER results, using LY gained and QALY gained as effectiveness 
measures, are presented in table 1.3.15 (oxaliplatin MOSAIC/PILOT/combined 
versus control MOSAIC). For example, the incremental costs were € 13,316 for 
oxaliplatin combined versus control treatment. Oxaliplatin combined resulted in a 
QALY gained of 1.18 compared to the control treatment. The ICER of oxaliplatin 
combined was €11,266 per QALY gained compared with control treatment, meaning 
that € 11,266 would have to be spent to gain an additional QALY with oxaliplatin 
treatment combined.  
 
In general, the control treatment without oxaliplatin leads to the lowest costs (€ 
17,142 for periods 1+2+3) and lowest effectiveness (13.12 LY and 11.56 QALY). 
Treatment with oxaliplatin results in higher costs (varying from € 30,415 in MOSAIC 
patients to € 30,606 in PILOT patients) and greater effects (varying from 14.19 LY 
and 12.60 QALY in PILOT patients to 14.37 LY and 12.78 QALY in MOSAIC 
patients). Essentially there is no big difference between MOSAIC oxaliplatin and 
PILOT oxaliplatin patients. Moreover, ICER results based on QALYs are very similar 
to ICER results based on LYs. Table 1.3.16 shows the discounted base case results. 
Discounting leads to ICERs that are € 4,629 to € 5,659 higher than undiscounted 
ICERs.  
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Table 1.3.15 Base Case results, Not Discounted 
Base case results over a lifetime horizon
Incremental cost per life year gained
Total Costs Total Costs Life Years LY ICER per LY ICER per LY
period 1+2 period 1+2+3 (LY) (1+2) (1+2+3) gained gained (1+2) gained (1+2+3)
1 Control treatment MOSAIC € 9,077 € 17,142 13.12
2 Oxaliplatin treatment MOSAIC € 23,825 € 30,415 14.37 2 vs 1 € 14,748 € 13,273 1.26 € 11,723 € 10,551
3 Oxaliplatin treatment PILOT € 23,800 € 30,606 14.19 3 vs 1 € 14,723 € 13,464 1.07 € 13,747 € 12,571
4 Oxaliplatin treatment combined € 23,819 € 30,458 14.33 4 vs 1 € 14,742 € 13,316 1.22 € 12,123 € 10,951
Incremental costs per QALY gained
Total costs Total Costs Quality Adjusted QALY ICER per QALY ICER per QALY
period 1+2 period 1+2+3 (LY) (1+2) (1+2+3) gained gained (1+2) gained (1+2+3)
1 Control treatment MOSAIC € 9,077 € 17,142 11.56
2 Oxaliplatin treatment MOSAIC € 23,825 € 30,415 12.78 2 vs 1 € 14,748 € 13,273 1.22 € 12,069 € 10,862
3 Oxaliplatin treatment PILOT € 23,800 € 30,606 12.60 3 vs 1 € 14,723 € 13,464 1.04 € 14,157 € 12,946
4 Oxaliplatin treatment combined € 23,819 € 30,458 12.74 4 vs 1 € 14,742 € 13,316 1.18 € 12,472 € 11,266
Incremental costs
Incremental costs
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Table 1.3.16 Base Case results, Discounted 
 
 
 
 
 
 
Base case results over lifetime horizon 
Incremental cost per life year gained 
Total Costs Total Costs Life Years LY ICER per LY ICER per LY 
period 1+2 period 1+2+3 (LY) (1+2) (1+2+3) gained gained (1+2) gained (1+2+3) 
1 Control treatment MOSAIC € 8,893 € 16,350 9.95
2 Oxaliplatin treatment MOSAIC € 23,626 € 29,719 10.82 2 vs 1 € 14,733 € 13,369 0.87 € 16,857 € 15,296 
3 Oxaliplatin treatment PILOT € 23,603 € 29,895 10.69 3 vs 1 € 14,710 € 13,545 0.74 € 19,798 € 18,230 
4 Oxaliplatin treatment combined € 23,620 € 29,758 10.80 4 vs 1 € 14,727 € 13,408 0.85 € 17,428 € 15,867 
Incremental costs per QALY gained
Total costs Total Costs Quality Adjusted QALY ICER per QALY ICER per QALY 
period 1+2 period 1+2+3 (LY) (1+2) (1+2+3) gained gained (1+2) gained (1+2+3) 
1 Control treatment MOSAIC € 8,893 € 16,350 8.69
2 Oxaliplatin treatment MOSAIC € 23,626 € 29,719 9.55 2 vs 1 € 14,733 € 13,369 0.86 € 17,072 € 15,491 
3 Oxaliplatin treatment PILOT € 23,603 € 29,895 9.42 3 vs 1 € 14,710 € 13,545 0.73 € 20,068 € 18,479 
4 Oxaliplatin treatment combined € 23,620 € 29,758 9.52 4 vs 1 € 14,727 € 13,408 0.83 € 17,658 € 16,077 
Incremental costs
Incremental costs
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Sensitivity analyses 
 
In the base case the average life-expectancy of relapsed patients was assumed to be 
1.7 years for all treatment alternatives. The effect of a lower life-expectancy was 
tested, using a worst case scenario, i.e. life-expectancy is equal to zero. Life years 
gained has increased by changing the life-expectancy. As a consequence the ICER 
per LY gained decreased somewhat, varying from € 1,792 to € 2,105 compared to 
the base case results. We therefore concluded that a lower life-expectancy has no 
major impact on our result, since we used the worst case scenario which is not very 
likely to occur in reality.  
 
Probabilistic sensitivity analyses were conducted for the outcome measure of QALY 
gained (oxaliplatin MOSAIC, oxaliplatin PILOT, and oxaliplatin combined, all versus 
control treatment). The uncertainty surrounding the ICER is related to the uncertainty 
surrounding the costs and effects used in the model. Table 1.3.17 shows the mean 
difference in costs and QALYs as well as their 95% confidence intervals.  
 
Table 1.3.17 Mean (95% CI) values of the total ∆ Costs and ∆ QALYs of the sensitivity 
analysis 
Δ Costs Δ QALY ICER
Mean Min Max Mean Min Max Median
1 Control treatment MOSAIC
2 Oxaliplatin treatment MOSAIC 2 vs 1 13,369 2,175‐     28,984  0.86 0.26 1.45 € 15,491
3 Oxaliplatin treatment PILOT 3 vs 1 13,545 2,648‐     30,229  0.73 ‐1.78 2.79 € 18,479
4 Oxaliplatin treatment combined 4 vs 1 13,408 2,400‐     29,168  0.83 0.26 1.28 € 16,077
95% CI 95% CI
 
The 95% confidence interval of the difference in costs between control treatment and 
oxaliplatin treatment (MOSAIC and PILOT patients combined) varied from - € 2,400 
to € 29,168. The 95% confidence interval of the difference in QALYs between control 
treatment and oxaliplatin treatment varied from 0.26 to 1.45 when the MOSAIC 
oxaliplatin patients were used. However, when using only PILOT oxaliplatin patients, 
the 95% confidence interval was much wider (from -1.78 to 2.79). 
 
Furthermore, the results of the simulations are shown in the three scatter plots below, 
where the simulated estimates in incremental costs and effects (i.e., QALYs) are 
plotted on a cost-effectiveness plane. Each dot on the scatter plot represents one 
estimate of the incremental costs and effectiveness of oxaliplatin vs. control 
treatment. The graphs illustrate again the much wider 95% confidence interval 
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regarding the effectiveness of only PILOT oxaliplatin patients. The 95% confidence 
ellipse of the PILOT patients is much wider, covering three quadrants of the cost-
effectiveness plane. The ICER of only PILOT oxaliplatin patients is less robust. 
 
Figure 1.3.7 Scatter plot of MOSAIC oxaliplatin versus control treatment based on 
Monte Carlo results (10,000 simulations) 
 
 
Figure 1.3.8 Scatter plot of PILOT oxaliplatin (eligibles) versus control treatment based 
on Monte Carlo results (10,000 simulations) 
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Figure 1.3.9 Scatter plot of combined oxaliplatin versus control treatment based on 
Monte Carlo results (10,000 simulations) 
 
 
Since oxaliplatin was associated with both increased costs and increased 
effectiveness vs. control therapy, it is important to consider whether or not the 
additional costs are worth incurring in order to gain the additional effectiveness. Cost-
effectiveness threshold curves (CEACs) show the probability that a treatment will be 
cost-effective at any given willingness-to-pay threshold. Figs. 1.3.7, 1.3.8 and 1.3.9 
show the three CEACs from the base-case analyses. 
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Figure 1.3.10 cost-effectiveness acceptability curve for MOSAIC oxaliplatin versus 
control treatment 
 
 
Figure 1.3.10 shows that for oxaliplatin MOSAIC vs. control treatment, there was a 
98% probability that oxaliplatin would be cost-effective at a willingness-to-pay 
threshold of € 65,000.  
 
Figure 1.3.11 Cost-effectiveness acceptability curve for PILOT oxaliplatin (eligibles) 
versus control treatment 
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Figure 1.3.11 shows that for oxaliplatin PILOT vs. control treatment, there was a 85% 
probability that oxaliplatin would be cost-effective at a willingness-to-pay threshold of 
€ 65,000.  
 
Figure 1.3.12 Cost-effectiveness acceptability curve for combined oxaliplatin versus 
control treatment 
 
 
 
Figure 1.3.12 shows that for oxaliplatin PILOT vs. control treatment, there was a 98% 
probability that oxaliplatin would be cost-effective at a willingness-to-pay threshold of 
€ 65,000.  
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Scenario analyses 
 
Scenario 1: FOLFOX versus CAPOX’ 
Table 1.3.18 shows the impact of regimen choice. When oxaliplatin was combined 
with 5FU/LV (FOLFOX), the total costs were € 11,951 higher (PILOT oxaliplatin 
versus MOSAIC control) compared to the combination treatment with capecitabine 
(CAPOX). The resulting incremental costs per QALY gained are € 26,958, more than 
twice as high as the ICER of € 10,653 seen for scenario FOLFOX versus CAPOX.  
 
Scenario 2: Ineligible patients integrated 
Table 1.3.19 shows the impact of incorporating into the model the 18% of PILOT 
oxaliplatin patients who did not fulfil the MOSAIC eligibility criteria. Different 
scenarios can be made about the actual treatment benefit of oxaliplatin for these 
patients. One scenario is to assume that oxaliplatin is just as beneficial for these 
patients as it is for patients who fulfil the MOSAIC eligibility criteria. Another scenario 
is to assume that oxaliplatin has absolutely no treatment effect of oxaliplatin in this 
ineligible subpopulation. Although this would be viewed as an extremely unlikely 
scenario, we nevertheless examined the impact that this assumption would have on 
the ICER. Table 1.3.19 shows that the impact of these assumptions about benefit to 
ineligible patients is limited. For example, the incremental costs per QALY gained for 
the total population (eligible + ineligible patients) are € 22,836 in the worst-case 
scenario, only slightly higher than the ICER found in the base case scenario. 
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Table 1.3.18 FOLFOX versus CAPOX treatment 
Discounted results over lifetime horizon
All oxaliplatin patients receive FOLFOX
Total Costs Life Years Quality Adjusted LY QALY ICER per LY ICER per QALY
period 1+2+3 (LY) (LY) (1+2+3) gained gained gained gained
1 Control treatment MOSAIC € 16,350 9.95 8.69
2 Oxaliplatin treatment MOSAIC € 35,934 10.82 9.55 2 vs 1 € 19,584 0.87 0.86 € 22,407 € 22,693
3 Oxaliplatin treatment PILOT € 36,110 10.69 9.42 3 vs 1 € 19,760 0.74 0.73 € 26,595 € 26,958
4 Oxaliplatin treatment combined € 35,973 10.80 9.52 4 vs 1 € 19,623 0.85 0.83 € 23,222 € 23,529
All oxaliplatin patients receive CAPOX
Total Costs Life Years Quality Adjusted LY QALY ICER per LY ICER per QALY
period 1+2+3 (LY) (LY) (1+2+3) gained gained gained gained
1 Control treatment MOSAIC € 16,350 9.95 8.69
2 Oxaliplatin treatment MOSAIC € 23,983 10.82 9.55 2 vs 1 € 7,633 0.87 0.86 € 8,733 € 8,845
3 Oxaliplatin treatment PILOT € 24,159 10.69 9.42 3 vs 1 € 7,809 0.74 0.73 € 10,510 € 10,653
4 Oxaliplatin treatment combined € 24,022 10.80 9.52 4 vs 1 € 7,672 0.85 0.83 € 9,079 € 9,199
Incremental costs
Incremental costs
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Table 1.3.19 Impact of including patients not fulfilling the MOSAIC eligibility criteria 
Discounted results over lifetime horizon
Incremental cost per life year and QALY gained
Total Costs Life Years Quality Adjusted LY QALY ICER per LY ICER per QALY
period 1+2+3 (LY) (LY) (1+2+3) gained gained gained gained
1 Control treatment MOSAIC € 16,350 9.95 8.69
2 Oxaliplatin treatment MOSAIC € 29,719 10.82 9.55 2 vs 1 € 13,369 0.87 0.86 € 15,296 € 15,491
3 Oxaliplatin treatment PILOT € 29,895 10.69 9.42 3 vs 1 € 13,545 0.74 0.73 € 18,230 € 18,479
4 Oxaliplatin treatment combined € 29,758 10.80 9.52 4 vs 1 € 13,408 0.85 0.83 € 15,867 € 16,077
5 Control ineligibles  Full effect € 21,562 5.89 4.66 7 vs 5 € 13,233 1.20 1.18 € 11,055 € 11,205
6 Control ineligibles  Zero effect € 20,244 7.09 5.84 7 vs 6 € 14,551 0.00 0.00 ∞ ∞
7 Oxaliplatin  ineligibles PILOT € 34,795 7.09 5.84
8 Control el (82%) + inel (18%) Full € 17,288 9.22 7.96 10 vs 8 € 13,489 0.82 0.81 € 16,356 € 16,578
9 Control el (82%)+ inel (18%) Zero € 17,051 9.44 8.18 10 vs 9 € 13,726 0.61 0.60 € 22,529 € 22,836
10 Oxaliplatin PILOT el + inel € 30,777 10.04 8.78
Incremental costs
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4 Discussion 
4.1 Data collection 
 
Data collection was based on three sources: data obtained via the Dutch Cancer Registry, 
data obtained via the ‘minimal’ CRF and data obtained via the ‘maximal’ CRF.  
 
Dutch Cancer registry 
The Dutch Cancer Registry (NKR) is a registry that provides important data for 
epidemiological research, clinical studies, evaluation of preventive programmes and health 
care policy. The NKR collects data of all cancer patients who are admitted to a hospital or 
whose disease has been confirmed by means of tissue examination. This amounts to more 
than 95% of all cases of cancer in the Netherlands.  
 
Information from the NKR formed the basis for the data collection and was used to identify 
patients with stage III colon carcinoma. This guaranteed that a representative sample of the 
population was included which contributes to the external validity of the study. Furthermore, 
using this existing database allowed a simple method of supplying data on large numbers of 
patients. However, a disadvantage was the time-lag because of regular updates of the NKR 
database: new patients are often entered in the database a couple of months after their 
treatment has started. This is a problem particularly when a study is set up prospectively. 
Since our pilot study had a retrospective study design, this disadvantage was less important 
in our study. Nevertheless, it did take seven months before the data became available. We 
expect this to be much quicker in the future. Furthermore, it turned out that the database of 
the NKR contains insufficient data to form a complete basis for outcomes research. Firstly, 
extra information was needed for further patient selection. For the outcomes research on 
oxaliplatin it was important to know which type of chemotherapy patients had received. The 
NKR database does not contain this information. Secondly, for more detailed information, for 
example, on clinical effects and costs, additional data had to be collected from hospitals.  
 
Minimal versus maximal CRF 
It was possible to screen a large number of patients (in total 463) effectively via ‘minimal’ 
data collection (minimal CRF). This method is particularly effective when one does not know 
in advance whether all patients are relevant to the study. A disadvantage is that the collected 
data provide insufficient details to be able to assess dose schedules, toxicity and costs of 
treatments. This required a form of ‘maximal’ data collection (maximal CRF). This type of 
data collection was extremely time-consuming.  
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Prospective versus retrospective data collection 
The set-up for data collection in this pilot study was retrospective. This means that at the 
moment of data collection the entire follow-up period was already in the past. In this pilot 
study we followed patients from 2005 up to the moment of inspecting the patient files. With 
prospective studies the follow-up time begins at the moment that data collection begins. The 
researcher subsequently follows the patients during the follow-up period. Both types of 
studies have advantages and disadvantages.37 The advantage of using retrospective data 
collection in this pilot study was the possibility of making use of the NKR. Furthermore, data 
could be collected in a relatively short period of time, as each patient file only needed to be 
examined once. A major disadvantage was that we were utterly dependent on what could be 
found in the patient files. For example, an important prognostic factor, the WHO performance 
score, was often not recorded. In addition it was sometimes difficult to determine the 
chemotherapy dose schedules and doctors’ considerations in choosing a particular therapy. 
Nor was there any information about quality of life, which is often only available in 
prospective studies. However, the price of this advantage is loss of efficiency: repeated 
measurements have to be made over a number of years.  
4.2 Use of oxalilatin 
 
This study has shown that, since 2005, the conventional treatment with 5FU/LV has been 
almost fully replaced by either capecitabine monotherapy (24%) or a combination therapy 
with oxaliplatin (72%). Over the time period 2005-2006 a preference started to develop for a 
combination therapy with CAPOX rather than FOLFOX. This is probably closely linked to 
implantable devices required by long-term intravenous administration of 5FU/LV, whilst 
capecitabine is given orally.  
 
The prescription of oxaliplatin was significantly lower for elderly patients and patients with 
comorbidities. The negative impact of age and comorbidity on the prescription of adjuvant 
therapy for stage III colon carcinoma has been described earlier.26 During 2005 and 2006 
the prescription pattern of doctors was reasonably stable. This is probably a result of the 
extensive experience with both capecitabine and oxaliplatin in the treatment of metastatic 
colorectal carcinoma.38 
 
The observed dose schedules correspond with current guidelines. The results, both of dose 
modifications and toxicities, suggest that oxaliplatin may be less well tolerated when given in 
the CAPOX schedule than in the FOLFOX schedule. A direct comparison of these two 
schedules for the treatment of stage III colon carcinoma had never been done before. There 
was only one study published on the use of CAPOX for stage III colon carcinoma, and it 
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reported that oxaliplatin dose had to be reduced for 35% of the patients and that on average 
87% of the planned doses were received.39 This differs considerably from the results in this 
pilot study (70% and 71%, respectively). Comparing the FOLFOX schedules in the pilot and 
MOSAIC studies shows that in Dutch daily practice dose adjustments are less frequently 
performed, but treatment is discontinued earlier. This difference may be explained by strict 
instructions for dose adjustments and treatment continuation within the trial protocol. 
4.3 Clinical efficacy 
Patients treated with oxaliplatin 
In our study, after 2 years 72% of all the patients treated with oxaliplatin were still disease-
free. 78.4% of the pilot patients who fulfilled the inclusion criteria of the MOSAIC trial were 
still disease-free after 2 years. This percentage is comparable to the percentage of patients 
being disease-free in the MOSAIC trial (79%). This outcome, which is supported by the 
finding that the baseline characteristics and the FOLFOX dosages are comparable in the 
pilot and MOSAIC patients, can be interpreted as a positive sign for the generalisability of 
the results of the MOSAIC trial to Dutch daily practice. However, these results obviously 
apply only for the 82% of the pilot oxaliplatin patients who fulfilled the MOSAIC eligibility 
criteria. The prognosis of the patients who did not fulfil these inclusion criteria was 
considerably poorer. This can be explained by the fact that these patients had significantly 
higher CEA-values, which is a strongly negative prognostic factor. 
 
Patients treated without oxaliplatin 
Patients who did not receive oxaliplatin were significantly older and had more comorbidities 
than patients who were treated with oxaliplatin. Patients who did not receive oxaliplatin were 
also significantly older than the patients in the MOSAIC trial, resulting in incomparability of 
the pilot and MOSAIC populations regarding the control treatment. This may be explained by 
the fact that oxaliplatin adds toxicity to treatment, and elderly patients and patients with 
comorbidities are therefore often considered to be poor candidates for this treatment. 
 
Incremental efficacy of treatment with oxaliplatin versus treatment without oxaliplatin  
Due to limitations in study design, caution is required when interpreting the results on 
incremental efficacy. The retrospective, observational nature of the pilot study is 
fundamentally different from a prospective, randomized design. In our study, the treating 
physicians determined which patients would be treated with oxaliplatin and which would not. 
This resulted in patients who did not receive oxaliplatin being older and having more 
comorbidities. For this reason, the uncorrected disease-free survival curves of the patients 
with and without oxaliplatin cannot be directly compared. Even after correction for baseline 
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characteristics, it is uncertain whether a valid estimate of the hazard ratio (HR) of the 
treatment effect of oxaliplatin was calculated. This is because it is uncertain whether the 
model has taken all relevant factors into account. For example, no information was available 
on the state of health of the patients (WHO performance score or Karnofsky index). It is not 
a standard  procedure to record this in the medical files. However, we know that a poor state 
of health is a prognostic factor for a poor outcome, irrespective of comorbidity.40 Apart from 
this, other factors may have played a role in the decision-making between doctors and 
patients, which have not been documented and therefore cannot be incorporated into the 
analysis. The selection of historical control patients diagnosed in 2004, before the rapid 
uptake of oxaliplatin had taken place, could result in more comparable groups of patients.  
 
The median duration of the follow-up in our study approximated 2 years. This was 1 year 
less than what is usual in adjuvant colon carcinoma trials. Nevertheless, the literature 
indicates that extending from 2 to 3 years has only a limited effect on the outcomes of 
studies in this setting.9 
4.4 Costs 
 
In 2005 and 2006, 2,284 newly diagnosed patients with stage III colon cancer in the 
Netherlands received adjuvant chemotherapy. Of these, 4% received 5FU/LV, 24% received 
capecitabine, 35% received FOLFOX and 37% received CAPOX. In general, the diversity of 
treatment agents and regimens applied in daily practice results in a wide cost variation 
between patients.41 Especially new expensive drugs, such as oxaliplatin, have placed a 
serious economic burden on the health care system, not only because of higher costs per 
drug but also because of their expanded use.41, 42 The lower costs of CAPOX in comparison 
with FOLFOX may relieve the economic burden of stage III colon cancer in the future. 
 
Costs are preferably determined from a societal perspective in which all relevant costs are 
included.43. However, considering limited time and information, it was impossible to collect 
retrospective data on societal costs for our cost analyses. Therefore, our cost analyses were 
conducted from the hospital perspective. As stage III colon carcinoma often occurs in the 
elderly unemployed population, productivity losses are expected to only have a minor impact 
on the results. Ignoring patients’ out-of-pocket expenses may have affected the relative cost 
difference in favour of patients treated with oxaliplatin. In comparison with patients treated 
with capecitabine, more inpatient days and daycare treatments were registered for the 
FOLFOX group because the administration of 5FU/LV with oxaliplatin is an inpatient 
procedure. However, it should be noted that these admissions regarding the administration 
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of FOLFOX might not have been necessary since we found hospitals where the 48-hour 
infusion was given via day-care treatment or outpatient visits only. 
 
Previous studies examining the costs of stage III colon cancer treatment based their cost 
assessment on resource use obtained from RCTs. However, the potentially limited 
generalisability of RCT-based economic evaluations may seriously restrict their relevance to 
policy-making. On the other hand, RCTs guarantee comparability between treatment groups, 
which was not the case in our observational study. Patients who received oxaliplatin were 
significantly younger and had fewer comorbidities than patients who did not receive 
oxaliplatin. This has a substantial impact when calculating the incremental cost-effectiveness 
of oxaliplatin. However, on the cost side, we have shown that differences in baseline 
characteristics do not have a significant impact on the total costs. This makes it considerably 
easier to arrive at a valid estimate of the incremental costs. 
4.5 Cost-effectiveness model 
 
The cost-effectiveness of oxaliplatin as an adjuvant treatment in stage III colon cancer was 
determined using a probabilistic Markov model. In order to evaluate the cost-effectiveness of 
oxaliplatin, the two arms (oxaliplatin containing regimens versus regimens without 
oxaliplatin) were evaluated separately. The model contains three Markov states for each 
arm: disease-free state, relapsed state and death. The Markov model simulated the 
transitions of a hypothetical cohort through the clinical states. Three categories of 
parameters are used as inputs to the model: transition probabilities between the Markov 
states, costs and utility values. 
 
The process of model development and parameterisation requires making choices and 
assumptions. Each of these choices introduces additional uncertainty. Assumption 1 states 
that the disease-free survival data of the PILOT oxaliplatin population beyond the PILOT 
study follow-up period can be derived from the probabilities of the MOSAIC oxaliplatin 
patients. The hazard of relapsing was assumed to be equal to the hazard of relapsing in the 
oxaliplatin arm of the MOSAIC trial. This assumption is realistic since the hazard of relapsing 
was similar during the first 30 months as well. Furthermore, a large uncertainty surrounding 
the 6-monthly hazard is incorporated in the sensitivity analyses via the beta distributions.  
 
Secondly it is assumed that all adverse events resulting in dose modifications are significant 
and have an impact on the patient’s quality of life. This assumption might lead to an 
overestimation of the impact of dose modifications on quality of life, which would lead to a 
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conservative estimate of the cost-effectiveness of oxaliplatin, since patients receiving 
oxaliplatin experienced a higher number of dose modifications.  
 
Thirdly it is assumed that deaths due to adverse events did not influence the results during 
the first 5 years following treatment. This assumption was based on the results of the 
MOSAIC trial that the number of deaths (possibly) due to adverse events was similar in both 
control and oxaliplatin arms (0.5% in each group). Furthermore, background mortality was 
assumed not to influence the incremental effectiveness results. This is plausible because 
ages were similar between the groups and the number of deaths was expected not to be 
higher than 5% during the first 5 years5.  
 
Assumption 5 says that the average life-expectancy of relapsed patients is equal for all 
treatment alternatives. This assumption was based on the findings of the MOSAIC trial that 
disease-free survival turned out to be an excellent predictor of overall survival. This finding 
supports the use of DFS not only as a surrogate endpoint for survival, but also as a full 
endpoint in colon cancer adjuvant studies.9, 16  
 
In the MOSAIC study, adjuvant treatment with additional oxaliplatin was demonstrated to be 
more effective than adjuvant treatment with 5FU/LV or capecitabine alone, resulting in 0.863 
QALY gain over a lifetime horizon. The oxaliplatin patients in the PILOT study show similar 
results, resulting in 0.733 QALY gained when compared with the MOSAIC control patients. 
The costs of treatment with oxaliplatin were higher than treatment with 5FU/LV or 
capecitabine alone, resulting in a lifetime incremental cost/QALY gained of € 15,491 and € 
18,479 for MOSAIC and PILOT oxaliplatin patients respectively. When combining both 
MOSAIC and PILOT oxaliplatin patient groups, the incremental cost/QALY becomes € 
16,077. The base case results were expressed in costs per life-year gained and costs per 
QALY gained. The difference in ICER based on life-years versus QALYs is < € 300, showing 
only a limited impact of the inclusion of quality-of-life in the analyses.  
 
The impact of the model parameters was evaluated through probabilistic sensitivity 
analyses. The 95% confidence interval of the difference in costs between control treatment 
and oxaliplatin treatment (MOSAIC and PILOT patients combined) varied from - € 2,400 to € 
29,168. The 95% confidence interval of the difference in QALYs between control treatment 
and oxaliplatin treatment varied from 0.26 to 1.45 when the MOSAIC oxaliplatin patients 
were used. However, when only PILOT oxaliplatin patients were used, the 95% confidence 
interval was much wider (from -1.78 to 2.79). The reason for this increased uncertainty 
surrounding the incremental QALY estimate is the lower number of patients and the limited 
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follow-up time in the PILOT study (200 patients and median follow-up of 24 months in the 
PILOT study versus 672 patients and median follow-up of 60 months in the MOSAIC study).  
 
Sensitivity analyses were performed using different sources of cost and effectiveness data. 
Overall we found only minimal differences in the estimated incremental cost-effectiveness in 
our analyses, showing the robustness of the model results. The CEAC for MOSAIC 
oxaliplatin versus control treatment showed that in 98% of the 10,000 iterations, the 
incremental cost per QALY was < € 65,000. The CEAC for PILOT oxaliplatin versus control 
treatment showed that in 85% of the 10,000 iterations, the incremental cost per QALY was < 
€ 65,000.  
 
Two scenario analyses were performed to evaluate the cost-effectiveness of oxaliplatin in 
settings that better reflect the current Dutch daily practice setting. In the first scenario the 
cost of FOLFOX was compared to that of CAPOX. If all patients use CAPOX rather than 
FOLFOX, the incremental cost per QALY gained would decrease by € 16,305 (ICER of € 
26,958 for FOLFOX versus € 10,653 for CAPOX). Figure 1.3.3 shows a trend towards the 
use of CAPOX rather than FOLFOX during the course of 2005-2006. As a consequence the 
ICER decreased as well during the course of 2005-2006; this lower ICER might better reflect 
the cost-effectiveness of Dutch daily clinical practice from 2006 to the present. The second 
scenario also included patients who did not fulfil the MOSAIC trial eligibility criteria. The 
PILOT study showed that 18% of the patients receiving oxaliplatin did not fulfil these criteria. 
The prognosis of these patients was worse than the prognosis of patients who fulfilled the 
criteria. Since the ineligible patients were not included in the MOSAIC trial at all, no 
information was available regarding ineligible patients receiving control treatment. Two 
additional options were explored: one option assumed that oxaliplatin is just as beneficial for 
these patients as it is for patients who fulfil the MOSAIC eligibility criteria, and one option 
assumed no effect of oxaliplatin at all. The latter forms the most conservative assumption. 
The scenario analyses showed that if there is no treatment effect of oxaliplatin in the 
ineligible patient group (18%), the resulting incremental cost per QALY gained is € 22,836. 
 
A similar cost-effectiveness model was used by Pandor et al., 2006.12 In their analysis a 
comparable cost-effectiveness analysis was used based on the MOSAIC trial. In our cost-
effectiveness analysis we used a slightly simplified version of their model. Pandor et. al 
reported 1.61 undiscounted QALYs (1.33 discounted) gained in the base case analysis. Our 
study found 1.22 undiscounted QALYs (0.86 discounted) gained when considering only 
MOSAIC patients. The difference between these two estimates is probably caused by our 
more conservative estimate regarding the overall survival of the patients. Furthermore, 
Pandor et al. (2006) only reported discounted incremental costs of £ 3,941 where this is € 
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13,369 (Euro 2009) in our study (€ 13,273 discounted). This difference is due to the higher 
costs of the control treatment in the study of Pandor et al. In current Dutch daily practice, 
capecitabine is indicated rather than 5FU/LV. Therefore the costs of the control treatment 
are mainly based on the cost of capecitabine, which is a less costly alternative compared to 
5FU/LV.  
 
4.6 Cost-effectiveness in daily clinical practice 
 
Figure 1.4.1 reflects the passage of time in relation to treatment of stage III colon carcinoma 
with oxaliplatin. Based on the knowledge at T = 0 oxaliplatin was accepted into the policy 
regulation ‘expensive medicines’. A first indication of its cost-effectiveness was provided at 
that moment. At T = 3 knowledge will have to be obtained on the cost-effectiveness of 
oxaliplatin in daily practice. 
 
Figure 1.4.1 Time-plan for oxaliplatin 
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Knowledge at T = 0 
 
Knowledge relating to clinical efficacy 
Oxaliplatin was included in the policy regulation based on the results of the MOSAIC trial. 
This trial found a significantly lengthened disease-free survival when using FOLFOX in 
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comparison with 5FU/LV alone. There are no data available relating to overall survival and 
quality of life. 
 
Knowledge relating to costs 
Based on the costs of the new medicine itself, the extra costs that would be involved in using 
oxaliplatin were estimated at T = 0. The duration of treatment, as agreed by protocol, and 
the expected dose schedules were taken into account. 
Provisional inclusion in the policy regulation takes place in the event of positive advice which 
follows if a medicine has a therapeutic added value, it achieves the cost threshold and the 
research protocol for cost-effectiveness has been sufficiently elaborated. The latter means 
that the provisional data regarding cost-effectiveness provide an indication of efficiency (t=0) 
and that a properly substantiated proposal for outcomes research is submitted.1  As 
oxaliplatin was accepted into the policy regulation before this new policy was implemented, 
no such CVZ-report was available at T=0.  
 
Knowledge via outcomes research at T = 3 
 
Knowledge relating to clinical efficacy 
Oxaliplatin is used both in combination with 5FU/LV (FOLFOX) and in combination with 
capecitabine (CAPOX). There was no difference in efficacy between these two 
combinations. Based on their baseline characteristics, a large majority (82%) would have 
been eligible for the MOSAIC trial. Furthermore, the entire group of oxaliplatin-users show a 
similar disease-free survival to the MOSAIC trial. These similarities can be regarded as a 
positive sign of the generalisability of the results from the MOSAIC trial into daily practice. 
However, due to its rapid diffusion, most of the patients who were eligible for oxaliplatin, 
were actually treated with it, which has resulted in a control group that is not comparable 
with the group of patients that received oxaliplatin as far as baseline characteristics are 
concerned. In the meantime 5FU/LV has actually been replaced by capecitabine 
monotherapy. Correction for dissimilarities is hampered by the small numbers of patients 
(problems of precision) and possible “residual confounding” (problems with internal validity). 
As a result, there is a great deal of uncertainty regarding the estimated incremental disease-
free survival in daily practice. There are no data on overall survival and quality of life from 
daily practice in the Netherlands. 
 
Knowledge relating to costs 
The total costs of treatment and follow-up were calculated per treatment group. However, 
there was considerable variation in these costs. This was due to the large variation in costs 
and the small numbers of patients. The patients from the various treatment groups did differ 
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with regard to baseline characteristics, but this had no impact on the total costs. This finding 
suggests there is no threat to the internal validity of incremental cost estimation in daily 
practice.  
 
Knowledge via literature study at T = 3 
 
Knowledge relating to clinical efficacy 
Various publications were available at T=3. The results of a 6-year follow-up of the MOSAIC 
study show that the use of oxaliplatin leads to a significantly improved overall survival (83). 
No data are available involving a comparison with capecitabine monotherapy. There are no 
publications on the efficacy of CAPOX in stage III colon carcinoma available at T = 3. Nor is 
any information available relating to quality of life. 
 
Knowledge relating to costs 
Various publications were available at T = 3. These were mainly cost studies that had piggy-
backed on the MOSAIC trial. There are no publications on Dutch costs.12, 20, 21 
 
Cost-effectiveness at T =3 
 
Knowledge on clinical effectiveness from outcomes research alone does not supply a valid 
and reliable estimate of the incremental cost-effectiveness of oxaliplatin. We have described 
how the oxaliplatin patients who fulfilled the inclusion criteria of the MOSAIC study with 
respect to baseline characteristics and disease-free survival correlate highly with the 
MOSAIC patients who received oxaliplatin. Furthermore, new results of the MOSAIC study 
had been published at T = 3. In order to arrive at the best possible valid and reliable 
estimate of cost-effectiveness, a model study of clinical effectiveness and knowledge was 
carried out that combined knowledge at T = 0, knowledge at T = 3 obtained from outcomes 
research, and knowledge at T = 3 from the literature. Only data from the outcomes research 
was used for calculating the incremental costs.  
 
Cost-effectiveness model of oxaliplatin 
The aim of the cost-effectiveness model was to establish the cost-effectiveness of oxaliplatin 
in the treatment of stage III colon carcinoma. The base case results showed an incremental 
cost-effectiveness per QALY gained that varied from € 15,491 for patients from the MOSAIC 
trial to € 18,479 when only the pilot oxaliplatin patients were taken into account. Sensitivity 
and scenario analyses were subsequently carried out using various sources of cost and 
effectiveness data. Overall we found only minimal differences in the estimated ICERs in our 
analyses, showing the robustness of the model results. In the most conservative scenario, 
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i.e., incorporating PILOT patients who were not eligible for the MOSAIC study and assuming 
no treatment effect of oxaliplatin in this subpopulation, the incremental cost per QALY gained 
was estimated to be € 22,836. We feel confident that the effects of the model’s assumptions 
are limited. Based on our results, one can conclude that the addition of oxaliplatin 
combination therapy as adjuvant treatment of stage III colon carcinoma is a cost-effective 
alternative.  
 
General conclusion on cost-effectiveness 
 
The model makes use of both the results of the outcomes research and the published 
literature. All cost data used in the model were based entirely on the outcomes research. 
Data relating to clinical efficacy on patients treated with oxaliplatin were based both on the 
outcomes research and on the MOSAIC study. Due to the impossibility of comparing 
patients who received oxaliplatin treatment in daily practice and those who did not, with 
respect to clinical cost-effectiveness, we were forced to limit ourselves to the control arm of 
the MOSAIC study as sole comparator in the model. We feel that this choice provides a 
sufficiently precise and accurate estimate of the cost-effectiveness of oxaliplatin in daily 
practice. The claim is justified that the cost-effectiveness of oxaliplatin has been sufficiently 
substantiated in daily practice.  
4.7 Appropriate use in daily clinical practice 
This pilot outcomes research studied the appropriate use of oxaliplatin. The aim was to 
provide insight into the dynamics of clinical practice. Dynamics of clinical practice is defined 
as the differences between the requirements for registering oxaliplatin and the information 
on its use in daily practice. These differences may result from differences in the use of 
oxaliplatin or differences in the observed effectiveness or adverse events.1 The following is a 
short summary of the aspects relevant to the dynamics of clinical practice.  
 
Population treated in clinical practice versus population from the MOSAIC study 
A large proportion of the patients (82%) treated with oxaliplatin in daily practice were similar 
to the population from the MOSAIC study. The patients who did not fulfil the MOSAIC 
eligibility criteria (18%) had significantly higher CEA-values, which is a strongly negative 
prognostic factor.  
 
Selective prescription 
As a result of the rapid diffusion of oxaliplatin, the baseline characteristics of patients who 
received oxaliplatin and those who did not remained unaltered during 2005 and 2006. 
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Therefore we do expect that the patients groups studied are representative of the total 
patient populations for whom oxaliplatin was prescribed after 2006.  
 
Prescribing outside the registered indication 
Oxaliplatin is registered for the indication adjuvant treatment of stage III colon carcinoma. 
This is the indication examined in this pilot study. The professionals involved have already 
indicated that oxaliplatin can also be considered for high-risk stage II patients. We did not 
investigate this shift in indication and the degree to which this existed during the timeframe 
of this pilot study is unclear. 
 
The use of oxaliplatin in practice versus use in the MOSAIC study 
The observed dose schedules in daily practice demonstrated a good adherence to existing 
guidelines which, with respect to FOLFOX, are based on the MOSAIC study. Regarding 
FOLFOX, the total cumulative dose of oxaliplatin received by patients in daily practice was 
also similar to the dosages reported in the MOSAIC study. In daily practice, in addition to the 
FOLFOX, the CAPOX regimen was also often prescribed. The observed CAPOX dose 
schedules are also consistent with existing guidelines. In daily practice, however, dose 
modifications were seen more frequently. On average patients in daily practice received 71% 
of the planned dose, whilst the literature reports this to be 87%. In there Netherlands, 
extensive experience has been obtained with the use of CAPOX for treating metastatic 
colorectal carcinoma.  
 
Effectiveness of oxaliplatin in practice versus effectiveness in the MOSAIC study 
The 82% oxaliplatin patients from daily practice who fulfilled the inclusion criteria of the 
MOSAIC study show a similar disease-free survival to that of the oxaliplatin patients in the 
MOSAIC study. Although on the basis of the pilot study no conclusions can be drawn with 
regard to overall survival, due to the short follow-up (median 24 months), the outcome, with 
a median 2-year follow-up, appears to be a good predictor for overall survival.9 No 
comparative trial data are available on the patients who did not fulfil the inclusion criteria of 
the MOSAIC study (18%). Daily practice shows that these patients have a less favourable 
prognosis. This is mainly explained by the significantly higher CEA-values of these patients. 
Although it is uncertain whether adjuvant therapy with oxaliplatin might have an added value 
here, it is unlikely that oxaliplatin would be unfavourable for this group of patients as 
oxaliplatin also plays an important role in the treatment of metastatic colon carcinoma.  
 
Toxicity of oxaliplatin in practice versus toxicity in the MOSAIC study 
The adverse events of FOLFOX in daily practice are similar to the pattern of side effects 
described in the MOSAIC study. Side effects seem to occur more frequently with CAPOX. 
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The hand-foot syndrome often plays a role in adjustments in the CAPOX dose. This side 
effect occurs frequently in patients treated with capecitabine (such as CAPOX). Although the 
hand-foot syndrome is burdensome for patients, this side effect is not life-threatening. 
 
General conclusion on appropriate use 
 
It is difficult to compare patients who have been treated in daily practice without oxaliplatin 
with patients who have been treated with oxaliplatin. It has proven impossible to correct 
satisfactorily for differences in baseline characteristics. Nevertheless, proper correction is 
essential for calculating the incremental cost-effectiveness based only on data from daily 
practice.  
 
Providing insight into the dynamics of clinical actions makes it clear that patients who are 
treated with oxaliplatin in daily practice, with respect baseline characteristics, use of 
oxaliplatin, efficacy and toxicity, comply well with the requirements for registering oxaliplatin 
at T = 0. Lastly, one can say that oxaliplatin, when prescribed within the registered 
indication, is used appropriately in daily practice.  
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Section 2 Oxaliplatin in metastatic colorectal cancer 
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1 Introduction 
For patients with distant irresectable metastatic CRC there are no curative treatment options 
and palliative systemic treatment is the treatment of choice, with the goal to prolong overall 
survival and maintain quality of life for as long as possible. The median overall survival of 
patients with metastatic colorectal cancer (mCRC) is significantly increased by the use of 
chemotherapy.  
 
The paper of Miriam Koopman and Cornelis JA Punt, titled “Chemotherapy, which drugs and 
when”, published in the European Journal of Cancer 200944, gives an overview of the most 
relevant data concerning, among others, the efficacy of each of these drugs, their use in 
combination chemotherapy, their sequential versus combined use as well as their preferred 
sequence. Parts of the findings are mentioned in this introduction.  
 
For this pilot study a cohort of metastatic CRC patients diagnosed in 2003 and 2004 was 
used. Consequently, the data collection of this retrospective pilot study went back to January 
2003.  In order to focus on published literature relevant for the timeframe of the pilot study, 
we used different time periods; 1) Published literature until January 2003, since this was the 
only information available at T=0, 2) published literature until January 2006, since this was 
the information available at T=3, and 3) Results of the CAIRO and FOCUS studies.45, 46 
Furthermore, a summary of the cost-effectiveness of different chemotherapy regimens will be 
provided and drugs that became available more recently will be mentioned briefly.  
 
Published literature until January 2003 (T=0) 
 
Fluoropyrimidines (FL) 
For many decades, 5-FU with or without leucovorin (LV) was the only available treatment for 
patients with mCRC, which resulted in a median overall survival of approximately 11-12 
months.47 Its main toxicities are diarrhoea, stomatitis, neutropenia, and hand-foot syndrome, 
depending on the type of schedule used. Since 2001, oral fluoropyrimidines have become 
available of which capecitabine and UFT have been tested in mCRC. In comparison to  bolus 
5FU/LV, both oral agents have shown comparable results in overall and progression-free 
survival but an improved tolerability. 48-53   
 
 
 
 85 
 
Irinotecan 
Irinotecan, available since 2000, is a topo-isomerase I inhibitor, and its main toxicities are 
nausea/vomiting, diarrhoea, alopecia, myelosuppression, and a cholinergic syndrome. It first 
showed efficacy in second-line treatment in 5-FU refractory mCRC patients.54, 55 
Subsequently two studies with irinotecan plus either bolus or infusional 5FU/LV compared to 
5FU/LV alone showed a significant absolute benefit in median overall survival of 2.2 and 3.3 
months, respectively.56 57 However, these studies have been criticised for the fact that 
effective second-line treatment with irinotecan in the control arm was not a prospective part 
of the study design.58 
 
Oxaliplatin 
Oxaliplatin is an alkylating agent of the platinum family, and its main toxicities are a (often 
reversible) sensory neuropathy, nausea/vomiting, diarrhoea, and myelosuppression. Given 
its synergistic activity with fluoropyrimidines (FL) it is usually administered in combination 
with a fluoropyrimidine.59 Two studies, published in 2000, in which the addition of oxaliplatin 
to 5FU/LV was compared to 5FU/LV alone in first-line treatment did show a benefit in 
response rate and progression-free survival for the combination, but not in overall survival as 
these studies were not designed to demonstrate a benefit in overall survival.60, 61  
  
In conclusion, newer chemotherapy agents such as irinotecan and oxaliplatin already 
became available in 2000, both showing a benefit over the use of monotherapy with FL. 
However, in 2003 there were no good data on the optimal strategy to use these drugs. 
 
Table 2.1.1 Possible (equivalent) treatment combinations 
first-line second-line third-line
FL FL+ oxaliplatin (FL+) irinotecan
FL (Fl +) irinotecan FL+ oxaliplatin
FL+ oxaliplatin (Fl +) irinotecan
(FL +) irinotecan FL+ oxaliplatin
 
 
The first two treatment combinations can be referred to as “sequential treatment” since both 
treatments start with fluoropyrimidines only, followed by either oxaliplatin or irinotecan in 
second- and third-line. The latter two are “combination treatments” as they directly start with 
a combination of fluoropyrimidines and oxaliplatin or irinotecan in the first-line treatment.  
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Published literature until January 2006 (T=3) 
 
 In 2003 it became apparent that the combination of fluoropyrimidines with oxaliplatin had 
efficacy as a second-line treatment after failure on 5-FU and irinotecan.62. In 2004, a 
combination of infusional 5FU/LV and oxaliplatin (FOLFOX) was shown to significantly 
prolong the median overall survival compared with a bolus 5FU/LV/irinotecan (IFL)63. In many 
countries these results have shifted the preference to FOLFOX as first-line regimen. 
However, as with studies on first-line irinotecan-based combination therapy, second-line 
treatment was not a prospective part of the study design. In this study there was an 
imbalance in the use of salvage treatment, since 60% of patients received second-line 
irinotecan after failure on FOLFOX, but, due to its limited availability at the time this study 
was conducted, only 24% of the patients failing IFL received oxaliplatin. The finding that the 
absolute difference in medial overall survival (4.5 months) was greater compared to the 
absolute difference in median time to progression (1.8 months) also suggests that salvage 
treatment had a significant impact on survival outcome.58 Furthermore, the different modes of 
5FU administration between the two treatment arms (continuous versus bolus infusion) may 
have been responsible for the higher incidence of severe toxicities as well as the decreased 
efficacy in the IFL arm. This latter view is supported by the results of another randomised 
study in which FOLFOX and infusional 5FU/LV plus irinotecan (FOLFIRI) had comparable 
overall survival results, although it should be noted that overall survival was not the primary 
endpoint of this study.64. Regarding toxicities, this study showed that the incidence of serious 
adverse events was higher in patients treated with FOLFIRI (14% versus 5%), but the overall 
incidence of grade 3-4 toxicities as well as the percentage of patients that had to discontinue 
treatment for reasons of toxicities was greater upon treatment with FOLFOX (74% versus 
53%, and 11% versus 6%, respectively). Based on this and other comparative studies it 
could be concluded that there is no preference for irinotecan or oxaliplatin in the first-line 
treatment in terms of efficacy, and that the choice can be made on individual patient 
preferences.65 However, despite the fact that combination treatment of 5FU with either 
irinotecan or oxaliplatin was widely accepted as the new standard in first-line treatment of 
mCRC, the question whether its benefit would have been maintained if patients would have 
received appropriate salvage treatment in the control arm of these studies was left 
unanswered. The validity of this question first came from a retrospective analysis that 
showed a correlation between survival and the number of effective drugs to which patients 
had been exposed.66 In other words, it may be more important that patients are exposed to 
these drugs during the course of their disease, rather than receiving these drugs in first-line. 
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Two important studies with a novel design have provided a better insight in this issue: the 
CAIRO and FOCUS studies.  
 
CAIRO and FOCUS studies 
 
Although not published before 2007, we will discuss the CAIRO and FOCUS studies as they 
were already conducted during the timeframe of our pilot study. The results of the CAIRO 
study are particularly of interest because its study population was selected from the same 
source population as the pilot study. The CAIRO study of the DCCG was the only study that 
prospectively evaluated the sequential versus concomitant use of all three effective cytotoxic 
drugs, i.e. a fluoropyrimidine, irinotecan and oxaliplatin.6745 In this study the treatment with 
first-line capecitabine, second-line irinotecan and third-line capecitabine plus oxaliplatin was 
compared with first-line capecitabine plus irinotecan, and second-line capecitabine plus 
oxaliplatin. Upfront combination treatment did not result in a significant overall survival 
benefit compared to sequential treatment. The FOCUS study of the Medical Research 
Council UK confirmed this finding.46 In this study the sequential versus concomitant use of 
either irinotecan or oxaliplatin with infusional 5FU/LV was tested in separate treatment arms, 
and no advantage was demonstrated for combination therapy. Therefore, the CAIRO and 
FOCUS studies demonstrate that the sequential use of cytotoxic agents remains a valid 
treatment option in mCRC patients.  
 
Cost-effectiveness 
 
The paper of Marieke Krol, Miriam Koopman, Carin Uyl-de Groot and Cornelis JA Punt, 
published in Expert Opinion 2007, presents a systematic review of economic analyses of 
pharmaceutical therapies for advanced colorectal cancer.42 The selected publication date 
limit was from 01 January 2000 to 15 May 2006, which reflects literature until T = 3. The main 
cost-effectiveness findings of this paper will be summarized here. 
 
Cost-effectiveness of orally versus intravenously administered fluoropyrimidine 
Two selected articles have compared the cost (-effectiveness) of capecitabine with traditional 
5FU/LV regimes. One study analysed 89 fee-listings from 26 patients with advanced 
colorectal cancer treated with 5FU/LV.68 Projected quarterly costs for capecitabine were € 
2,338. The potential savings of replacing 5FU/LV with capecitabine were € 310 – 
10,500/quarter depending on the treatment setting and the 5FU/LV regimen. Another study 
examined the files of 33 patients who were treated with 5FU/LV for metastatic disease. 
Capecitabine costs were projected in this study as well resulting in a mean total cost of 
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capecitabine treatment of € 4,004 and a mean total cost of 5FU/LV of € 5,614.69 Both studies 
used projections to calculate costs of capecitabine treatment and have limited sample sizes. 
 
Cost-effectiveness of irinotecan 
Three selected articles studied the cost and cost-effectiveness of irinotecan in the treatment 
of advanced colorectal cancer. The first compared the economic implications of differences 
in clinical benefit between irinotecan plus 5-FU/LV versus 5-FU/LV as first-line therapy 
among 385 patients.54. The analyses resulted in an incremental cost-effectiveness ratio of £ 
14,794/life year gained. Based on these findings, the authors conclude that the use of 
irinotecan plus 5-FU/LV in the first-line is strongly supported. Another study compared 
irinotecan to infusional 5-FU regimens when given as second-line treatment among 256 
patients.70 The cost-effectiveness ratios varied from $ 9344 – 10,137/life year gained 
(depending on the infusional 5-FU regimen chosen). The authors concluded that the 
additional costs of irinotecan were balanced by the added months of survival, with a cost-
effectiveness ratio close to that of other cancer treatments. Lastly, a study compared 2 
schedules of second-line irinotecan: a weekly and a 3-weekly schedule.71 The results show a 
cost–utility ratio associated with the 3-weekl arm of $ 78,627/QALY. Because of the large 
uncertainty of this study, no conclusion could be drawn on the incremental cost-
effectiveness.  
 
 
Cost-effectiveness of oxaliplatin 
No studies of the cost-effectiveness of oxaliplatin plus fluoropyrimidines versus 
fluoropyrimidines alone could be found. Two articles reported on the cost-effectiveness of 
oxaliplatin versus irinotecan. Hillner et al.72 calculated the costs and effects of oxaliplatin plus 
infusional fluorouracil (FOLFOX) compared to irinotecan plus bolus fluorouracil (IFL) in first-
line therapy. Total costs were $ 94,693 for FOLFOX and $ 66,231 for IFL at a 5-year end 
point. Their baseline results indicate that FOLFOX would provide a survival benefit of 4.4 
months at an incremental cost-effectiveness ratio of $ 80,410/life year gained and $ 
111,890/QALY gained. Limat et al.73 undertook a cost-minimisation analysis to compare the 
costs related to the standard de Gramont regimen and to the simplified de Gramont regimen 
combined with oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) as first-line treatment.  
Overall costs appeared to be similar between FOLFOX and FOLFIRI, with the exception of 
hospital admissions related to adverse effects (these admission were more expensive for 
FOLFIRI within the standard regimen and in the simplified regimen for FOLFOX). For now, it 
seems that similar to the clinical viewpoint, there is no clear preference for either irinotecan 
or oxaliplatin as first-line treatment from an economical point of view.  
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No cost-effectiveness analysis was performed piggy-backed on the CAIRO trial. For this 
reason it is impossible to comment on the cost-effectiveness of fluoropyrmidines, irinotecan 
and oxaliplatin when consequently used in either sequential or combination therapy.  
 
Newer targeted therapies 
 
The median overall survival of the treatment of advanced colorectal cancer has been further 
improved by the addition of a new class of drugs (targeted therapy) to chemotherapy, which 
include the inhibitors of signal transduction through VEGF or EGFR. Currently available 
drugs are bevacizumab, cetuximab and panitumumab. Adding bevacizumab to a 
fluoropyrimidine-containing chemotherapy regimen is considered the standard of care in first-
line treatment for patients with advanced colorectal cancer, at present.  
 
Bevacizumab, cetuximab and panitumumab are relatively new drugs in the treatment of 
colorectal cancer. It is clear that these drugs will greatly increase the costs of treatment for 
advanced colorectal cancer.  To be able to assess the cost-effectiveness of these therapies 
results of ongoing research needs to be awaited. 
 
 
Oxaliplatin in daily practice 
Economic evaluations piggy-backed on a randomized clinical trial are generally regarded as 
the most scientific basis to determine the cost-effectiveness of pharmaceutical treatments. 
Data based on clinical trials may not be representative of daily practice, as clinical trials are 
conducted under controlled conditions. 
 
Outcomes research collects data from daily clinical practice that are useful for determining 
appropriate use and cost-effectiveness of pharmaceutical treatments. This section describes 
the results of outcomes research that investigated the appropriate use and cost-effectiveness 
of oxaliplatin as first-line treatment of metastatic colorectal cancer.  
 
• How is oxaliplatin used in daily practice? (sections 2.2 and 3.2) 
• What clinical effects does the use of oxaliplatin involve? (sections 2.3 and 3.3) 
• What costs are involved in the use of oxaliplatin? (sections 2.4 and 3.4) 
• What is the relationship between the results of this outcomes research and the 
results of clinical trials? (sections 2.5 and 3.5) 
• What is the cost-effectiveness of oxaliplatin? (2.6 and 3.6) 
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2 Methods 
2.1 Patient population and data collection 
 
All patients newly diagnosed with stage IV colorectal cancer (pTany,Nany,M1, ICD-O C18 
C20) in 2003 or 2004 were eligible for this outcomes research provided that they received 
palliative chemotherapy. Similar to the stage III colon cancer pilot study, patients were 
identified retrospectively in June 2007 via the database of the Dutch Cancer Registry. 
Subsequently, using ‘minimal’ case record forms (CRFs), additional information was 
collected from the medical records of all patients identified in 29 selected hospitals. 
Afterwards, further selection of patients took place based on the information obtained via the 
‘minimal’ CRFs.  
 
Patients were excluded from the analyses if their medical records revealed that they did not 
have colorectal cancer, had clinical disease stage III, did not receive any chemotherapy, or 
did not start chemotherapy at the selected hospitals. Moreover, patients included in trials and 
patients whose medical file was not available were excluded. Lastly patients were excluded if 
their tumour could not be evaluated or if the patients received bevacizumab as first-line 
therapy.   
 
A randomly selected representative sub-group was selected from the patient population thus 
defined. Additional data regarding this subgroup of patients were collected from medical 
records by means of ‘maximal’ CRFs.  
 
Some of the patients identified via the Dutch Cancer Registry participated in the CAIRO 
trial.45 In the CAIRO study 820 patients were included between January 1st 2003 and  
December 31st 2004 in 74 hospitals in the Netherlands. They were randomly allocated to one 
of the following treatment strategies: 1) first-line capecitabine, second-line irinotecan, and 
third-line capecitabine + oxaliplatin (sequential treatment arm); or 2) first line capecitabine + 
irinotecan and second-line capecitabine + oxaliplatin (combination treatment arm). 
 
All patients included in the CAIRO trial fulfilled certain eligibility criteria. The patients included 
in the PILOT study were categorized according to these CAIRO eligibility criteria in order to 
facilitate comparisons between the CAIRO and PILOT studies. Tables 2.2.1 and 2.2.2 give 
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an overview of the inclusion and exclusion criteria of the CAIRO trial. Subsequently patients 
were categorized according to administered chemotherapy regimens.  
 
 
Table 2.2.1 Inclusion criteria CAIRO study 
Histological proven Colorectal Cancer; advanced disease, not amenable to curative surgery
In case of a single metastasis, hystological or cytological proof should be obtained prior to randomization
Measurable or evaluable disease
Serum CEA as only parameter for disease activity is not allowed
Adequate bone marrow function
WBC ≥ 3.0 x 109 / L
Platelets ≥ 100 x 109 / L
Hb ≥ 6.0 mmol /L 
Adequate hepatic function
Tot. Bilirubin ≤ 1.5 x ULN
ASAT ≤ 3 x ULN (in case of liver mets's ≤ 5 x ULN)
ALAT ≤ 3 x ULN (in case of liver mets's ≤ 5 x ULN)
Adequate renal function: creat clearance (Cockroft) ≥ 50 ml /min
Age ≥ 18  
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Table 2.2.2 Exclusion criteria CAIRO study 
Any prior chemotherapy for advanced disease; prior adjuvant therapy completed
 ≤ 6 months prior randomisation
Serious concomitant disease preventing the safe administration of chemotherapy
or likely to interfere with the study assessment
Central nervous system metastases (in asymptomatic patients no screening required)
Serious active infections
Inflammatory bowel disease or other disease associated with chronic diarrhoea
Previous radiation of the pelvis or abdomen (excl. 5x5 Gy in case of rectal carcinoma)
Other malignancies in the past 5 years with the exception of adequately treated carcinoma
in situ of the cervix or squamous or basal cell carcinoma of the skin
Concomitan (or within 4 weeks of randomisation) administration of any other experimental
drug under investigation
pregnancy or lactation
Patients with reproductive potential not implementing adequate contraceptive measurses  
 
 
Data collection of both stage III and metastatic colorectal cancer pilots took place in a similar 
way.  An extensive description of the data collection methodology can be found in section 1, 
2.2. The data collection took place via three sources: the Dutch Cancer Registry, the 
‘minimal CRF’, and the ‘maximal CRF’. A detailed overview of the data obtained from the 
Dutch Cancer Registry and via the minimal and maximal CRFs can be found in Annex IV. 
The original versions of the minimal and maximal CRFs are also enclosed in Annexes VII 
and VIII.  
2.2 Use of oxaliplatin 
The use of oxaliplatin in daily practice was examined by considering five different 
parameters. Each of those parameters provides an indication of who received oxaliplatin or 
how much oxaliplatin they received.  
 
Treatment patterns 
All treatments observed in Dutch clinical practice were illustrated for each line, per separate 
first-line treatment group.  
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CAIRO eligibility status 
Reasons for not being eligible for the CAIRO trial were analysed 
 
Baseline characteristics 
The baseline patient and tumour characteristics provide a pointer for the ‘profile’ fulfilled by a 
patient being treated with oxaliplatin in daily practice. Among other things, the effect of age 
distribution and WHO performance score were examined in order to explain significant 
differences between the different treatment groups as well as between CAIRO eligible versus 
non eligible patients.   
 
Considerations in choice of treatment regimen 
Possible predictors for receiving combination therapy in first-line were analysed.  
 
Dose schedules 
The number of patients receiving specific drugs, median number of cycles and total 
cumulative dosages were recorded and compared between the treatment groups. 
 
2.3 Clinical efficacy of oxaliplatin 
 
The clinical efficacy of oxaliplatin in daily practice was assessed by examining its impact on 
overall survival, since this was also the primary endpoint in the CAIRO trial. Overall survival 
was calculated as the interval from the date of start of the first treatment line until date of 
death from any cause or until the date of last follow-up. 
 
Statistical analyses of clinical data 
We first assessed the frequency of administration of treatment. To compare baseline 
characteristics, the administered regimens were firstly grouped into “patients receiving first-
line monotherapy” and “patients receiving first-line combination therapy”. Subsequently 
baseline characteristics were compared in patients grouped according to CAIRO eligibility 
status. Continuous data were expressed in terms of the mean value and categorical data as 
a percentage, unless otherwise denoted. The Student’s t-test and the chi-square test with the 
Fisher’s exact correction for frequencies less than five were used for continuous and 
categorical variables, respectively. Reasons for not being eligible for the CAIRO trial were 
explored using descriptive statistics. A multivariate logistic regression analysis was 
performed to identify independent predictors of non-prescription of first-line combination 
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therapy. Survival curves were visualised according to the Kaplan-Meier methods, including 
comparisons by means of the log rank test. A total of 130 patients were selected for further 
more extensive analyses. For patients eligible for inclusion in the CAIRO study, this selection 
took place at random. Only 11 patients ineligible for CAIRO were evaluated. These numbers 
were based on practical limitations in terms of time and finance and on experience with 
previous iMTA studies. An evaluation of dose schedules per treatment regimen was 
performed in this selected subset of patients. For this evaluation, the tests for continuous and 
categorical variables mentioned above were used.  Significant variables are reported with 
their respective p-value. In all analyses, statistical significance was assumed if the two-tailed 
probability value was < 0.05.  The SAS computer package (version 8.2) was used for all 
statistical analyses (SAS Institute Inc., Cary, NC, USA, 1999). 
 
2.4 Costs of oxaliplatin  
 
This section describes the methods of the cost analyses which were conducted from the 
hospital perspective. Use of this perspective meant that some cost categories like 
productivity costs and costs associated to informal care were not taken into account. 
However, as explained before, we believe that the exclusion of those cost components from 
the analyses had no important impact on the estimate of the real-world cost-effectiveness of 
oxaliplatin. The following costs were calculated separately for: 
o patients receiving monotherapy (n=57) 
o patients receiving oxaliplatin combination therapy (n=51) 
o patients receiving irinotecan combination therapy (n=11)  
o patients who did not meet the CAIRO eligibility criteria (see section 2.1) (n=11) 
For the interpretation of results, one should keep in mind that patients who did not meet the 
CAIRO eligibility criteria could either have received monotherapy (n=7), oxaliplatin 
combination therapy (n=2) or irinotecan combination therapy (n=2).  
 
Total costs for individual patients were determined by the identification of resource use and 
unit costs of the following cost components: inpatient hospital days, intensive care days, 
outpatient visits, consultations by telephone, daycare treatments, emergency room visits, 
radiotherapy, surgical procedures, laboratory services, medical imaging services, 
chemotherapy and concomitant medications. 
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Table 2.2.3 Unit costs (Euro 2009) 
5-Fluorouracil (mg) € 0.01
Leucoforin (mg) € 0.28
Capecitabine (mg) € 0.01
Oxaliplatin (mg) € 4.35
Irinotecan (mg) € 1.83
Bevacizumab (mg) € 3.78
Cetuximab (mg) € 2.15
Uracil/tegafur (mg) € 0.05
mg = milligram  
 
Table 2.2.3 presents the unit costs per milligram for chemotherapy. Methods on the unit cost 
calculation of other cost components as well as methods on sensitivity and statistical 
analyses are identical to those of stage III colon cancer (see section 1, 2.5). 
 
2.5 Daily practice versus clinical trials 
 
We examined the relationship between the results of our outcomes research and the results 
of the CAIRO trial by comparing results in the following categories: baseline characteristics, 
treatment patterns, dose schedules, and the clinical effects of oxaliplatin. These subjects 
were chosen to determine whether the patients treated in the CAIRO trial were similar to 
those in the pilot population, whether oxaliplatin use in the CAIRO study was similar to the 
oxaliplatin use in the pilot population and whether the clinical effects of oxaliplatin were 
similar in the two populations.  
 
 2.6 Quality of life 
 
Our retrospective study design made it impossible to use Health Related Quality of Life 
(HRQOL) as an outcome measure. As a consequence, we did not collect real-world HRQOL 
data of pilot patients. However, the CAIRO trial provided disease specific quality of life data 
on Dutch patients, which meant that there was little need to collect real-world quality of life 
data. The CAIRO study measured the disease specific quality of life by means of the QLQ-
C30 questionnaire of the European Organisation for Research and Treatment of Cancer 
(EORTC). A model to convert QLQ-C30 values into utilities in haematological cancers has 
recently been developed, but has not yet been validated.74 To enable us to compare Quality 
adjusted life years (QALYs) rather than life years between the mono and combination 
 96 
 
therapy treatment groups, we applied this model on patient-level CAIRO disease specific 
quality of life data. The validity of such a model for use across diseases has the attention of 
researchers in this field as it needs further exploration. However, due to the characteristics of 
the QLQ-C30, which is a generic quality of life questionnaire, the specific influences of 
disease type are assumed to be small. The model applied is the only model capable of 
estimating Dutch EQ-5D utility values at this moment. 
 
Quality of life measurement in the CAIRO study 
The QLQ-C30 questionnaire was used to assess the patients’ wellbeing during the study. 
Participation in this part of the study was proposed to the first 620 patients entered in the 
study. Questionnaires were to be completed within 1 week before randomisation and at 
every 9 weeks thereafter until the end of study treatment. 
 
Model converting QLQ-C30 values into utilities 
The 30 items of the QLQ-C30 can be divided in three categories: Functional scales (physical, 
role, emotional, cognitive and social functional, total of 15 items), symptom scales (fatigue, 
nausea/vomiting, pain, dyspnoea, sleep, appetite, constipation, diarrhea and financial 
difficulties, total of 13 items) and a global health status scale (two items). The regression 
coefficients of the model we used to convert these QLQ-C30 values into utilities are: 
 
EQ-5D index (Dutch tariff)= 0.985 + (1*-.037)+ (2*-.025) + (3*-.059) +  
(4*-.033) + (5*-.134) + (6_level2*-.033) + (6_level3*-.067) +  
(6_level4*-.180) + (7_level2*-.013) + (7_level3*-.037) +  
(7_level4*-.012) + (9_level2*-.065) + (9_level3*-.053) +  
(9_level4*-.189) + (16_level2*-.038) + (16_level3*-.045) +  
(16_level4*-.126) + (23_level2*-.028) + (23_level3*-.049) +  
(23_level4*-.456) + (24_level2*-.053) + (24_level3*-.140) +  
(24_level4*-.232) + (27_level2*-.027) + (27_level3*-.091) +  
(27_level4*-.110). 
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3 Results 
3.1 Patient population 
 
A patient flowchart is shown in Figure 2.3.1. Between January 2003 and December 2004, 
4201 patients were diagnosed with stage IV colon cancer, of whom 1962 (47%) were treated 
with palliative chemotherapy.  Of these identified patients, 400 were included in the CAIRO 
trial and 1562 patients were treated outside the CAIRO trial. A total of 433 patients were 
treated at one of the 29 hospitals included in our study; 314 of these patients met our initial 
inclusion criteria. After evaluation of the CAIRO eligibility criteria in the PILOT population, 
224 patients would and 90 patients would not have been eligible for the CAIRO trial. Figure 
2.3.2 shows the different first-line treatment combinations found in Dutch practice. A total of 
312 patients were included for further analyses. As to the administered first-line 
chemotherapy regimens, 197 patients (63%) received first-line monotherapy with 
fluoropyrimidines, of which 64% fulfilled the CAIRO eligibility criteria. The remaining 116 
patients (37%) received combination therapy with either oxaliplatin (N = 91) or irinotecan (N 
= 24) in first-line. In total, 84% of the patients receiving combination therapy would have been 
eligible for the CAIRO trial (87% in the oxaliplatin group and 72% in the irinotecan group), 
which is significantly higher compared to patients receiving first-line monotherapy (p <0.001).  
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Figure 2.3.1 Patient flowchart 
 
Stage IV 
Colorectal Cancer
N = 4201
Chemotherapy
N = 1962
CAIRO
N = 400
Chemotherapy outside 
CAIRO
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Chemotherapy in 
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N = 119
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N = 224
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Chemotherapy  in other 
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No Chemotherapy
N = 2239
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Figure 2.3.2 Flowchart of first-line treatment combinations found in Dutch practice 
 
Patients in present 
study N = 314
Patients included 
for further analyses 
N = 312
Monotherapy in 
first line N = 197 
(63%) 
Eligible
N = 127 (64%) 
Ineligible
N = 70 (36%) 
Combination 
therapy with 
oxaliplatin in first 
line N = 91 (29%) 
Eligible
N = 79 (87%) 
Ineligible
N = 12  (13%) 
Therapy with 
irinotecan in first 
line N = 24 (8%)  
Eligible
N = 17 (72%) 
Ineligible
N = 7 (28%) 
Patients receiving 
bevacizumab in first 
line excluded N = 2
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3.2 Use of oxaliplatin 
 
CAIRO eligibility status 
We explored the reasons why patients in the PILOT study would not have been eligible for 
the CAIRO trial. These reasons, shown in Table 2.3.1, included: poor patient condition 
(32%), comorbidity (17%), second tumour (11%), abnormal lab values (13%), brain 
metastases (3%), no evaluable disease (8%), unclear histology (7%) and other factors (9%).  
 
Table 2.3.1 Reasons for not being eligible for CAIRO (N = 90) 
 
Reasons for not being eligible for CAIRO study Number of patients (%)
Patient condition 29 ( 32% )
Comorbidity 15 ( 17% )
Second tumor diagnosed < 5 years ago 10 ( 11% )
Abnormal liver/renal function 12 ( 13% )
Brainmetastases 3 ( 3% )
No evaluable disease 7 ( 8% )
Histology of tumor unclear 6 ( 7% )
Other 8 ( 9% )
 
 
 
Baseline characteristics 
 
The baseline patient characteristics of the total included PILOT population, categorized by 
first-line chemotherapy regimen and CAIRO eligibility status, are summarized in table 2.3.2a. 
Subsequently, table 2.3.2b presents the results of the statistical comparisons of baseline 
characteristics. Statistically significant findings are highlighted in this table. Patients receiving 
combination therapy with either oxaliplatin or irinotecan were significantly younger than 
patients who did receive first-line monotherapy ( p < 0.0001). This is also illustrated by the 
percentages of patients older than 70 years old (32% in mono therapy patients versus 13% 
in patients receiving combination therapy, p = 0.0002). However, there was no difference in 
age between patients who would have been eligible for the CAIRO study and patients who 
would not have been eligible. This seems logical considering that age was not a selection 
criterion in the CAIRO study. Regarding performance score, a significant difference is 
observed in both comparisons. Firstly, 90% of the patients receiving combination therapy has 
a good performance score (WHO PS 0-1), versus 78% in the group of patients receiving 
mono therapy (p = 0.0426). The non-randomised assignment of treatments in the pilot 
patients can explain this finding, since combination therapy is generally associated with an 
increased risk of toxicity. Therefore, patients having a worse performance score (WHO 2-3) 
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might be less likely to receive the more aggressive combination treatment regimen. 
Furthermore, we found a significant difference in WHO performance scores between CAIRO-
eligible patients versus CAIRO-ineligible patients as well (WHO PS 0-1: 92% versus 60%, 
respectively, p < 0.0001). This difference can be explained by the CAIRO selection criteria, 
since patients having a poor performance score (WHO 3) and severe comorbidities were 
excluded. However, it should be noted that up to 62% of this variable was missing, since 
physicians do not routinely document a patients’ performance status.  No other differences in 
baseline characteristics were found when comparing the mono and the combination therapy 
groups. Regarding eligible versus ineligible patients we found that eligible patients more 
often had a resection of their primary tumour (65% versus 52% p = 0.0255). No other 
statistically significant differences were found although there was a trend towards a higher 
frequency of extrahepatic metastases and white blood count abnormalities in ineligible 
patients.  
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Table 2.3.2a Baseline characteristics of patients receiving chemotherapy in Dutch practice 
 
Eligible Ineligible Eligible Ineligible Eligible Ineligibe
Baseline Characteristics N = 127 (64%) N = 70 (36%) N = 79 (87%) N = 12 (13%) N = 18 (72%) N = 7 (28%)
Age - yr
      Median 64 64 59 61 58 59
      Range 39-84 30-92 29-81 35-75 39-70 41-73
Age group - no. (%)
      ≥ 70 42 (33%) 21 (30%) 12 (15%) 1 (8%) 1 (6%) 1 (14%)
Performance status
      PS 0-1 71 (91%) 23 (55%) 41 (91%) 6 (75%) 11 (100%) 4 (80%)
      PS 2-3 7 (9%) 19 (45%) 4 (9%) 2 (25%) 0 (0%) 1 (20%)
      Missing 50 (39%) 28 (40%) 34 (43%) 4 (33%) 7 (39%) 2 (29%)
Sex - no. (%)
      male 72 (57%) 43 (61%) 55 (70%) 7 (58%) 5 (28%) 5 (71%)
      female 55 (43%) 27 (39%) 24 (30%) 5(42%) 13 (72%) 2 (29%)
Predominant localisation
of metastases
      Liver 111 (93%) 54 (86%) 65 (93%) 9 (82%) 15 (94%) 5 (100%)
      Extrahepatic 8 (7%) 9 (14%) 5 (7%) 2 (18%) 1 (6%) 0 (0%)
      Missing 8 (6%) 7 (10%) 9 (11%) 1 (8%) 2 (11%) 2 (29%)
LDH at randomisation
      Normal 51 (49%) 26 (47%) 36 (54%) 7 (58%) 9 (60%) 2 (40%)
      Abnormal 53 (51%) 29 (53%) 31 (46%) 5 (42%) 6 (40%) 3 (60%)
      Missing 23 (18%) 15 (21%) 12 (15%) 3 (17%) 2 (29%)
 WBC at randomisation
      Normal 79 (68%) 35 (57%) 49 (70%) 8 (67%) 17 (94%) 3 (60%)
      Abnormal 38 (32%) 26 (43%) 21 (30%) 4 (33%) 1 (6%) 2 (40%)
      Missing 10 (8%) 9 (13%) 9 (11%) 2 (29%)
AF at randomisation
      Normal 47 (44%) 12 (26%) 23 (36%) 4 (36%) 6 (38%) 2 (40%)
      Abnormal 59 (56%) 34 (74%) 41 (64%) 7 (64%) 10 (62%) 3 (60%)
      Missing 21 (17%) 24 (34%) 15 (19%) 1 (8%) 2 (11%) 2 (29%)
Site of primary tumor
      Rectosigmoid 10 (8%) 9 (13%) 10 (13%) 1 (8%) 0 (0%) 3 (43%)
      Rectum 27 (21%) 19 (27%) 2 (30%) 3 (25%) 5 (28%) 2 (29%)
      Colon 90 (71%) 42 (60%) 45 (57%) 8 (67%) 13 (72%) 2 (29%)
Resection of primary tumor
      Yes 79 (65%) 33 (47%) 451(67%) 7 (58%) 10 (63%) 2 (29%)
      No 43 (35%) 37 (53%) 25 (33%) 5 (42%) 6 (38%) 5 (71%)
      Missing 5 (4%) 3 (4%) 2 (11%)
N = 197 N = 91 N = 25
First-line chemotherapy
Monotherapy Combinationtherapy with oxaliplatin Combinationtherapy with irinotecan
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Table 2.3.2b Comparison of baseline characteristics of patients receiving chemotherapy in 
Dutch practice  
 
T or X2 tests T or X2 tests
mono therapy combi therapy p-value Eligible Ineligible p-value
Baseline Characteristics N = 197 (63%) N = 116 (37%) m vs c N = 224 (72%) N = 89 (28%) el vs inel
Age - yr
      Median 64 59 <0.0001 61 63 0.96
      Range 30-92 29-81 29-84 30-92
Age group - no. (%)
      ≥ 70 63 (32%) 15 (13%) 0.0002 23 (26%) 55 (25%) 0.8123
Performance status
      PS 0-1 93 (78%) 62 (90%) 0.0426 122 (92%) 33 (60%) <0.0001
      PS 2-3 26 (22%) 7 (10%) 11 (8%) 22 (40%)
      Missing 78 (40%) 69 (41%) 91 (41%) 55 (62%)
Sex - no. (%)
      male 115 (58%) 72 (62%) 0.5206 132 (59%) 55 (62%) 0.6411
      female 82 (42%) 44 (38%) 92 (41%) 34 (38%)
Predominant localisation
of metastases
      Liver 165 (91%) 94 (92%) 0.6697 191 (93%) 68 (86%) 0.0591
      Extrahepatic 17 (9%) 8 (8%) 14 (7%) 11 (14%)
      Missing 15 (8%) 14 (12%) 19 (8%) 10 (11%)
LDH at randomisation
      Normal 77 (48%) 54 (55%) 0.3401 96 (52%) 35 (49%) 0.6659
      Abnormal 82 (52%) 45 (45%) 90 (48%) 37 (51%)
      Missing 38 (19%) 17 (15%) 38 (17%) 38 (43%)
 WBC at randomisation
      Normal 114 (64%) 77 (73%) 0.1077 145 (71%) 46 (59%) 0.0596
      Abnormal 64 (36%) 28 (27%) 60 (29%) 32 (41%)
      Missing 19 (10%) 11 (9%) 19 (8%) 11 (12%)
AF at randomisation
      Normal 59 (39%) 35 (36%) 0.7099 76 (41%) 18 (29%) 0.0971
      Abnormal 93 (61%) 61 (64%) 110 (59%) 44 (71%)
      Missing 45 (23%) 20 (17%) 38 (17%) 27 (30%)
Site of primary tumor
      Rectosigmoid 19 (10%) 14 (12%) 0.157 20 (9%) 13 (15%) 0.3758
      Rectum 46 (23%) 34 (29%) 56 (25%) 24 (27%)
      Colon 132 (67%) 68 (59%) 148 (66%) 52 (58%)
Resection of primary tumor
      Yes 116 (60%) 70 (63%) 0.649 140 (65%) 46 (52%) 0.0255
      No 76 (40%) 41 (37%) 74 (35%) 43 (48%)
      Missing 5 (3%) 5 (5%) 10 (5%)
All patients 
N = 313
First-line chemotherapy
All therapies
N = 313
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Considerations in choice of treatment regimen 
We next tried to identify independent predictors of non-prescription of combination therapy. 
We performed a multivariate logistic regression on baseline characteristics and initially 
included all variables present in the baseline characteristics table. The multivariate analysis 
identified only age and eligibility status as being independent predictors of non-prescription of 
combination therapy (OR [95CI] of 0.956 [0.932 – 0.980] and 3.269 [1.632 – 6.548] for age 
and eligibility, respectively).  
 
 
Treatment patterns 
Since several chemotherapies were available at the time this study was conducted, we 
expected that patients in daily practice might receive one of several different treatment 
regimens. Therefore, chemotherapy treatments during the course of different treatment lines 
were explored for each first-line therapy group (mono versus oxaliplatin versus irinotecan). 
Table 2.3.3a, describes the numbers of patients who received available treatments by line for 
patients receiving first-line monotherapy. Table 2.3.3b, describes the same for patients 
receiving first line combination therapy with oxaliplatin and Table 2.3.3c for patients receiving 
first-line irinotecan. Fifty-two percent of the patients receiving first-line monotherapy received 
chemotherapy in second-line as well; most of these patients received either oxaliplatin or 
irinotecan. In the third line, 22% of the patients still received chemotherapy. It is very likely 
that the patients who did not receive oxaliplatin in previous lines receive it in third line, and 
likewise this also applies to irinotecan.  
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Table 2.3.3a Treatments given to pilot patients who received first-line monotherapy 
Treatment Line 1 Line 2 Line 3 Line 4 Line 5 
Number of patients 197 103 44 12 5
(% of patients) (100%) (52%) (22%) (6%) (3%)
5FU/LV 83 18 9 ‐ ‐
capecitabine 109 36 21 3 3
UFT 5 1 ‐ ‐ ‐
Raltitrexed ‐ ‐ ‐ ‐ ‐
oxaliplatin ‐ 43 26 2 3
irinotecan ‐ 49 14 4 1
bevacizumab ‐ ‐ 1 ‐ ‐
cetuximab ‐ ‐ 2 2 ‐
experimental ‐ ‐ ‐ 5 1
patients receiving first line monotherapy
 
 
Regarding patients receiving oxaliplatin combination therapy in the first-line, all patients 
received the oxaliplatin in combination with either 5FU/LV or capecitabine. There was no 
clear preference for either fluoropyrimidine. In second-line therapy the majority of the patients 
received irinotecan, but bevacizumab was also administered to some patients. Patients 
receiving irinotecan combination therapy in the first line who received a second-line therapy 
were mostly treated with oxaliplatin in the second line. In general, 20-22% of the patients in 
all groups received at least three treatment lines.  
 
Table 2.3.3b Treatments given to pilot patients who received first-line oxaliplatin combination 
therapy 
Treatment Line 1 Line 2 Line 3 Line 4 Line 5 
Number of patients 91 53 20 4 0
(% of patients) (100%) (57%) (22%) (4%) (0%)
5FU/LV 40 4 1 ‐ ‐
capecitabine 51 17 9 3 ‐
UFT ‐ ‐ ‐ ‐ ‐
Raltitrexed 1
oxaliplatin 91 10 5 1 ‐
irinotecan ‐ 36 10 1 ‐
bevacizumab ‐ 6 2 1 ‐
cetuximab ‐ ‐ 4 ‐ ‐
experimental ‐ ‐ 1 1 ‐
patients receiving first line oxaliplatin
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Table 2.3.3c Treatments given to pilot patients who received first-line irinotecan combination 
therapy 
Treatment Line 1 Line 2 Line 3 Line 4 Line 5 
Number of patients 24 18 5 1 1
(% of patients) (100%) (32%) (20%) (4%) (4%)
5FU/LV 11 4 ‐ ‐ ‐
capecitabine 9 11 1 1 ‐
UFT ‐ ‐ ‐ ‐ ‐
Raltitrexed ‐ ‐ ‐ ‐ ‐
oxaliplatin ‐ 16 2 1 ‐
irinotecan 24 2 ‐ ‐ ‐
bevacizumab ‐ ‐ 1 ‐ ‐
cetuximab ‐ ‐ ‐ ‐ ‐
experimental ‐ ‐ 2 ‐ 1
patients receiving first line irinotecan
 
 
 
Dose schedules 
Treatment details of the most frequently used treatment regimens in the Netherlands during 
the study period are presented in table 2.3.4, where eligible patients receiving first-line 
monotherapy were compared to eligible patients receiving first-line combination therapy. 
Most (98%) of the eligible combination therapy patients were treated with oxaliplatin at one 
time or another; 54% of them received irinotecan. In the monotherapy group the percentages 
were significantly lower (44% for oxaliplatin and 30% for irinotecan) than those seen in the 
monotherapy group (p < 0.001 for both oxaliplatin and irinotecan). This is easily explained by 
the fact that in monotherapy, both irinotecan and oxaliplatin are being administered only after 
first line treartment, and after each treatment line a subgroup of patients are not able to 
receive further treatment. No significant differences were found in the percentages of 
patients receiving fluoropyrimidines, which corresponds to the inclusion of fluoropyrimidines 
as part of the standard first line treatment. Regarding the mean total cumulative dosages, a 
significant difference was only found for the fluorouracil regimen (p < 0.05). This can be 
explained by the large variety in administration schedules of fluorouracil. We also compared 
the median numbers of cycles of the different treatment regimens and found no significant 
differences between the monotherapy and combination therapy groups. We also found no 
differences in the median number of cycles (of any treatment) per line. The median total time 
on therapy was 6 months (range 1-37) for the monotherapy group versus 8 months (range 1-
44) in the combination therapy group. Since we had only limited detailed treatment data of 
ineligible patients, comparisons by treatment group in ineligible patients were not feasible. In 
general, the ineligible patients received less chemotherapy than eligible patients.  
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Table 2.3.4 cycles and dosages received in clinical practice 
Ineligibles
 monotherapy combination therapy All
N = 57 N = 62 N = 11
5FU/LV 
     patients receiving drug - nr (%) 34 (60%) 39 (62%) 3 (27%)
     Median nr of cycles 9 10 3
     Fluorouracil
     Mean total cumulative dose - mg 18901* 35971* 8000
     Leucovorin
     Mean total cumulative dose - mg 7848 4729 299
Capecitabine
     patients receiving drug - nr (%) 39 (68%) 36 (57%) 8 (73%)
     Median nr of cycles 6 6 6
     Mean total cumulative dose - mg 352910 319450 363688
Oxaliplatin
     patients receiving drug - nr (%) 25 (44%)** 62 (98%)** 3 (27%)
     Median nr of cycles 5 6 4
     Mean total cumulative dose - mg 1176 1274 661
Irinotecan
     patients receiving drug - nr (%) 17 (30%)** 33 (53%)** 3 (27%)
     Median nr of cycles 2 6 4
     Mean total cumulative dose -mg 2866 3277 1950
Median nr of cylcles per line
     Line 1 6 6 3
     Line 2 6 5 4
     Line 3 3 3 2
Total time on therapy (months)
     Median 6 8 3
     Range 1 - 37 1 - 44 1 - 22
First-line therapy, Eligibles only
 
3.3 Clinical efficacy of oxaliplatin 
 
Overall survival of patients eligible for CAIRO versus ineligible patients 
We found that pilot patients who would have been eligible for the CAIRO study were different 
from ineligible patients regarding certain baseline characteristics. Based on this, ineligible 
patients are expected to have a worse prognosis compared to eligible patients. Possible 
unfavourable parameters that can be present in ineligible patients include: worse 
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performance score, no resection of primary tumour, inadequate organ functions, presence of 
brainmetastases, comorbidities, or presence of second tumours.  
 
Median overall survival was 13.1 (95% CI 10.8 – 14.4) months for the patients who would 
have been eligible for the CAIRO trial and, as expected much lower, 7.3 (95% CI 6.0 – 9.4) 
months for the ineligible patients. Figure 2.3.3 shows the Kaplan Meier overall survival 
curves of both eligible and ineligible patient groups.  
 
Figure 2.3.3 Overall survival by CAIRO eligibility status 
 
 
Overall survival of patients receiving first-line mono therapy versus first-line combination  
Next we compared the overall survival of patients receiving first-line monotherapy with 
fluoropyrimidines to patients receiving combination therapy with either oxaliplatin or 
irinotecan.Figure 2.3.4 shows the Kaplan Meier overall survival curves of monotherapy 
versus combination therapy in eligible patients. Median overall survival was 15.1 (95% CI 
12.8 – 19.0) months for the patients who received first-line combination therapy and 11.2 
(95% CI 9.5 – 13.3) months for patients receiving first-line monotherapy. 
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Figure 2.3.4 Overall survival by treatment group, eligible patients 
 
 
It should be noted that the assignment of these treatments was not randomized. We found 
that patients who received monotherapy were significantly older than patients receiving first-
line combination therapy. From this we can conclude that the patients in the two treatment 
groups are not comparable in terms of their prognosis. In order to able to comment on the 
efficacy of the combination treatment a randomized study like the CAIRO trial is needed. In 
section 3.5 our results will be compared to the CAIRO study.  
 
Regarding ineligible patients, we have shown they have a worse overall survival than eligible 
patients. The small patient numbers in this subgroup, the differences in baseline 
characteristics between the monotherapy and combination therapy groups, and the inability 
to make comparisons with the CAIRO trial, where all patients were obviously eligible, made 
direct comparisons between the mono- and combination therapy inappropriate. However, we 
did observe trends in the ineligible patient population that were similar to the eligible 
population.   
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3.4 Costs of oxaliplatin  
 
Table 2.3.5 presents the total mean costs per patient for the four treatment groups. Mean 
costs amounted to € 19,812 (SD 14,679) for monotherapy, € 28,200 (SD 19,470) for 
oxaliplatin combination therapy, € 44,664 (SD 24,367) for irinotecan combination therapy and 
€ 13,899 (SD 11,860) for ineligible patients (Kruskal Wallis test: p < 0.001). Mean costs for 
monotherapy and oxaliplatin combination therapy were significantly different (Mann-Whitney 
U test: p = 0.014). A substantial cost variation was found in the total costs obtained for 
individual patients within treatment groups as well as in each individual cost component. 
Inpatient hospital days and chemotherapy (leucovorin, capecitabine, oxaliplatin and 
irinotecan) were the most important cost drivers. 
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Table 2.3.5 Total mean treatment costs for monotherapy, oxaliplatin combination therapy, 
irinotecan combination therapy and ineligibles  
Monotherapy
Oxaliplatin 
combination 
Irinotecan 
combination Ineligibles
n=57 n=51 n=11 n=11
Costs (Euro 2009)
Inpatient hospital days 6,241 9,387 14,878 4,455
Intensive care unit days 0 0 0 378
Outpatient visits 1,154 1,355 2,013 1,007
Consultations by telephone 32 26 22 8
Day-care treatments 1,620 959 2,885 501
Emergency room visits 89 133 174 127
Radiotherapy 89 165 0 153
Intravenous access 0 70 216 36
Colonoscopy 101 244 283 162
Other surgical procedures 293 689 1,215 1,497
Laboratory 968 782 1,701 671
X ray 103 114 289 138
CT scan 613 870 815 493
PET scan 25 249 128 0
Ultrasound 76 79 282 102
Other radiological procedures 121 169 241 138
Other procedures 70 225 146 143
5-Fluorouracil (bolus) 28 18 97 8
5-Fluorouracil (infusion) 43 96 172 5
Leucovorin 1,237 576 2,210 28
Capecitabine 1,458 1,111 1,155 1,593
Oxaliplatin 2,440 6,123 5,946 928
Irinotecan 1,575 2,651 6,553 1,000
Bevacizumab 0 244 1,716 0
Cetuximab 860 1,396 0 0
Uracil/tegafur 264 0 0 71
Other chemotherapy 41 32 279 40
Concomitant medication 272 438 1,247 218
Costs (Euro 2009) 19,812 28,200 44,664 13,899
Median 17,650 23,172 40,039 10,327
Minimum 2,052 2,200 18,016 462
Maximum 65,288 95,118 109,139 40,305
CT = Computed Tomography
PET = Positron Emission Tomography
 
Inpatient stay costs were € 6,241 (SD 7,861) for monotherapy, € 9,387 (SD 9,971) for 
oxaliplatin combination therapy, € 14,878 (SD 12,756) for irinotecan combination therapy and 
€ 4,455 (SD 5,602) for ineligible patients (Kruskal Wallis test: p = 0.014). Inpatient stay costs 
for monotherapy and oxaliplatin combination therapy were not significantly different (Mann-
Whitney U test: p = 0.069). Of the inpatient admissions, 33% related to the administration of 
chemotherapy. Inpatient hospital days were especially important in irinotecan combination 
therapy, particularly owing to one patient whose inpatient stay was relatively long (97 days of 
which 87 days for the administration of 5FU/LV). 25% of the patients in the irinotecan 
combination therapy group had an inpatient stay of at least 30 days, compared to 9%, 10% 
and 9% of the patients in the other three treatment groups. Only one patient was admitted to 
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the intensive care unit. This patient did not meet the CAIRO eligibility criteria and was 
admitted for pneumonia, shock and wound infection following a low anterior resection.  
 
Chemotherapy costs were € 7,946 (SD 9,459) for monotherapy, € 12,246 (SD 12,591) for 
oxaliplatin combination therapy, € 18,128 (SD 12,484) for irinotecan combination therapy and 
€ 3,672 (SD 3,808) for ineligible patients (Kruskal Wallis test: p < 0.001). Mean costs for 
monotherapy and oxaliplatin combination therapy were significantly different (Mann-Whitney 
U test: p = 0.003). For oxaliplatin combination therapy, oxaliplatin alone accounted for 50% of 
the chemotherapy costs (compared to 31%, 33% and 25% for the other treatment groups) 
and 22% of the total treatment costs (compared to 12%, 13% and 7% for the other treatment 
groups). For irinotecan combination therapy, irinotecan alone accounted for 36% of the 
chemotherapy costs (compared to 20%, 22% and 27% for the other treatment groups) and 
15% of the total treatment costs (compared to 8%, 9% and 7% for the other treatment 
groups).  
 
Significant differences between the treatment groups were further observed in the costs of 
outpatient visits (Kruskal Wallis test: p = 0.033) day-care treatments (Kruskal Wallis test: p = 
0.006), intravenous accesses (p < 0.001), colonoscopies (p = 0.031), laboratory services (p = 
0.005), X ray (Kruskal Wallis test: p = 0.027), PET scans (p = 0.039), ultrasounds (p = 
0.001), other procedures (Kruskal Wallis test: p = 0.002) and concomitant medications (p = 
0.001). Significant differences between monotherapy and oxaliplatin combination therapy 
were observed in the costs of intravenous accesses (Mann-Whitney U test: p = 0.001), CT 
scans (p = 0.018) and PET scans (p = 0.009). 
 
For patients receiving monotherapy, treatment costs ranged from € 2,052 to € 65,288, with 
the most expensive patient receiving 6 cycles of uracil/tegafur (€ 5,014), 4 cycles of 
irinotecan (€ 5,115), 6 cycles of capecitabine with oxaliplatin (€ 8,882) and 6 cycles of 
cetuximab with irinotecan (€ 28,959).  
 
For patients receiving oxaliplatin combination therapy, treatment costs ranged from € 2,200 
to € 95,118, with the most expensive patient receiving 6 cycles of capecitabine with 
oxaliplatin (€ 7,905), 8 cycles of irinotecan (€ 6,868) and 23 cycles of cetuximab with 
irinotecan (€ 64,572).  
 
For patients receiving irinotecan combination therapy, treatment costs ranged from € 18,016 
to € 109,139, with the most expensive patient receiving 15 cycles of 5FU/LV with irinotecan 
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(€ 15,102) and 14 cycles of 5FU/LV and bevacizumab with oxaliplatin (€ 34,392). 5FU/LV 
was administered to this patient during 87 inpatient days (€ 42,630). 
 
Sensitivity analyses 
Varying the unit costs of inpatient hospital days, day-care treatments and outpatient visits 
between 50% and 150% appeared to have a rather modest influence on the total mean costs 
with the greatest influence when varying the unit price for inpatient hospital days. Total mean 
costs varied from € 16,692 to € 22,933 for patients treated with monotherapy, from € 23,507 
to € 32,893 for patients treated with oxaliplatin combination therapy and from € 37,225 to € 
52,103 for patients treated with irinotecan combination therapy when inpatient hospital day 
unit costs were varied. Total mean costs varied from € 19,002 to € 20,623 for patients treated 
with monotherapy, from € 27,720 to € 28,680 for patients treated with oxaliplatin combination 
therapy and from € 43,222 to € 46,106 for patients treated with irinotecan combination 
therapy when day-care treatment unit costs were varied. Total mean costs varied from € 
19,236 to € 20,389 for patients treated with monotherapy, from € 27,523 to € 28,877 for 
patients treated with oxaliplatin combination therapy and from € 43,657 to € 45,671 for 
patients treated with irinotecan combination when outpatient visit unit costs were varied. 
3.5 Daily practice versus clinical trials 
 
In the CAIRO study 820 patients with metastatic colorectal cancer were included between 
January 1st 2003 and December 31st 2004 in 74 hospitals in the Netherlands. They were 
randomized between first-line capecitabine, second-line irinotecan, and third-line 
capecitabine + oxaliplatin (sequential treatment arm) versus first line capecitabine + 
irinotecan and second-line capecitabine + oxaliplatin (combination treatment arm). It should 
be noted that the trial population consisted of patients with both synchronous and  
metachronous metatastases, which subgroups differ in their prognosis. Synchronous disease 
was defined as distant metastases occurring within 6 months of diagnosing CRC. In our pilot 
population, all patients were diagnosed with metastases and therefore having synchronous 
disease. Also the 400 CAIRO patients who were identified via the Dutch Cancer Registry 
(Figure 2.3.1) had synchronous disease. The result of the CAIRO study involving all included 
patients was published by Koopman et al, Lancet 2007.45 This section shows the results of 
the comparison of our pilot study with the CAIRO trial. In this comparison we only included 
the 394 CAIRO patients who were part of the same source population as the pilot patients, 
i.e. patients diagnosed with stage IV colorectal cancer in 2003 or 2004, in the Netherlands, 
by making use of patient level data of this CAIRO subpopulation.  
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Comparison of baseline characteristics 
A total 224 PILOT patients fulfilled the CAIRO eligibility criteria and were included in the 
comparison. Table 2.3.6 provides an overview of the baseline characteristics of the CAIRO 
and Pilot patients, the latter grouped by therapy choice.  
Statistically significant findings are highlighted in gray in this table. Pilot study patients 
receiving monotherapy were significantly older than CAIRO patients (p = 0.0002). On the 
other hand, pilot patients receiving combination therapy were significantly younger than 
CAIRO patients (p = 0.0258). This is explained by the non-randomised assignment of 
treatments in the pilot patients. No other differences in baseline characteristics between the 
CAIRO and pilot patients were found, except for the earlier mentioned difference in 
synchronous/metachronous metastases.  
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Table 2.3.6 Baseline characteristics CAIRO and Pilot studies compared 
CAIRO study, eligibles
N = 394 T or X2 tests T or X2 tests
mono therapy combi therapy randomised patients p-value p-value
Baseline Characteristics N = 127 (57%) N = 97(43%) mono vs CAIROCombi vs CAIRO
Age - yr
      Median 64 59 61 0.0002 0.0258
      Range 39-84 29-81 27-82
Age group - no. (%)
      ≥ 70 42 (33%) 13 (13%) 73 (19%) 0.0006 0.2346
Performance status
      PS 0-1 71 (91%) 52 (93%) 373 (95%) 0.2023 0.5799
      PS 2-3 7 (9%) 4 (7%) 21 (5%)
      Missing 50 (39%) 41 (42%) 0 (0%)
Sex - no. (%)
      male 72 (57%) 60 (62%) 256 (65%) 0.0931 0.5660
      female 55 (43%) 37 (38%) 138 (35%)
Predominant localisation
of metastases
      Liver 111 (93%) 80 (93%) 345 (88%) 0.1048 0.1804
      Extrahepatic 8 (7%) 6 (7%) 47 (12%)
      Missing 8 (6%) 11 (11%) 2 (0.5%)
LDH at randomisation
      Normal 51 (49%) 45 (55%) 208 (53%) 0.4960 0.7308
      Abnormal 53 (51%) 37 (45%) 186 (47%)
      Missing 23 (18%) 15 (15%) 0 (0%)
 WBC at randomisation
      Normal 79 (68%) 66 (75%) 227 (72%) 0.3566 0.5851
      Abnormal 38 (32%) 22 (25%) 88 (28%)
      Missing 10 (8%) 9 (9%) 79 (20%)
AF at randomisation
      Normal 47 (44%) 29 (36%) 139 (44%) 0.9298 0.2196
      Abnormal 59 (56%) 51 (64%) 178 (56%)
      Missing 21 (17%) 17 (18%) 77 (20%)
Site of primary tumor
      Rectosigmoid 10 (8%) 10 (10%) 38 (10%) 0.4523 0.1740
      Rectum 27 (21%) 29 (30%) 93 (23%)
      Colon 90 (71%) 58 (60%) 263 (67%)
Resection of primary tumor
      Yes 79 (65%) 31 (34%) 140 (36%) 0.9539 0.7399
      No 43 (35%) 61 (66%) 254 (64%)
      Missing 5 (4%) 5 (5%) 0 (0%)
N = 224
First-line chemotherapy
Pilot study, eligibles
 
 
Comparison of treatment characteristics 
 
A comparison of the treatment details is presented in table 2.3.7. Regarding the percentage 
of patients receiving subsequent lines, the results show that approximately 60% of all eligible 
patients receive second-line chemotherapy treatment. In third-line however, a larger 
percentage of the CAIRO patients who were randomised to the sequential (monotherapy 
first-line) arm is still on therapy (39% of CAIRO patients versus 28% of pilot patients, p < 
0.05). The CAIRO patients receiving first-line combination therapy went off-protocol after two 
lines of therapy, making comparisons regarding the third line impossible in this group.  
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Table 2.3.7 Treatment characteristics CAIRO and Pilot studies compared 
mono therapy combi therapy mono therapy combi therapy
Treatment Characteristics N = 127 (57%) N = 97(43%) N = 193 (49%) N = 201 (51%)
      % of patients receiving line 1 100% 100% 100% 99%
      % of patients receiving line 2 60% 59% 60% 58%
      % of patients receiving line 3 28%* NA 39%* NA
* p < 0.05
First-line chemotherapy
Pilot study, eligibles
N = 224
CAIRO study, eligibles
N = 394
 
 
Overall survival of CAIRO patients; sequential versus combination therapy 
First the results of the CAIRO study are presented here. Figure 2.3.5 shows the Kaplan 
Meier overall survival curves for the sequential (first-line monotherapy) versus combination 
therapy arms. Median overall survival was 13.4 (95% CI 11.5 – 15.2) months for the patients 
who received first-line monotherapy and 15.9 (95% CI 14.3 – 18.0) months for patients 
receiving first-line combination therapy. Comparison of the curves by the log-rank test 
showed that the difference was not significant (p = 0.0897). The corresponding hazard ratio 
was 0.84 (95% CI 0.68 – 1.029). Again, it should be noted that these survival curves reflect a 
CAIRO subpopulation with synchronous metastases only. The survival curves as presented 
in the paper of Koopman et al, 200745, reflect the total CAIRO population including 
metachronous patients as well (N = 820 in total versus N = 394 in our comparison). The 
median overall survival of the total CAIRO population is 16.3 months in patients receiving 
first-line monotherapy versus 17.4 months in patients receiving first-line combination therapy 
(HR 0.92 (95% CI 0.79 – 1.08) Log-rank statistics (p = 0.3281)).  
 
Overall survival of CAIRO patients versus eligible pilot patients; first-line monotherapy 
Figure 2.3.6 shows the Kaplan Meier overall survival curves of pilot versus CAIRO patients, 
all receiving first-line mono therapy. Median overall survival was 13.4 (95% CI 11.5 – 15.2) 
months for CAIRO patients receiving first-line monotherapy and 11.2 (95% CI 9.5 – 13.3) 
months for the Pilot patients who received first-line monotherapy. Comparison of the curves 
by the log-rank test showed that the difference was not significant (p = 0.2772). The 
corresponding hazard ratio was 0.88 (95% CI 0.70 – 1.11). 
 
Overall survival of CAIRO patients versus eligible pilot patients; first-line combination therapy 
Figure 2.3.7 shows the Kaplan Meier overall survival curves of pilot versus CAIRO patients, 
all receiving first-line combination therapy. Median overall survival was 15.9 (95% CI 14.3 – 
18.0) months for CAIRO patients receiving first-line combination therapy and 15.1 (95% CI 
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12.8 – 18.9) months for the Pilot patients who received first-line combination. Comparison of 
the curves by the log-rank test showed that the difference was not significant (p = 0.5737). 
The corresponding hazard ratio was 1.077 (95% CI 0.83 – 1.34). 
  
Figure 2.3.5 Overall survival by treatment group, CAIRO patients 
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Figure 2.3.6 Overall survival by study, patients receiving first-line monotherapy only 
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Figure 2.3.7 Overall survival by study, patients receiving first-line combination therapy only 
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We conclude that the eligible Pilot study patients are comparable to the patients included in 
the CAIRO study. This is reflected in the overall survival outcomes. No significant differences 
were found between the CAIRO study and the pilot patients treated in Dutch clinical practice. 
However, patients receiving monotherapy in the pilot study tend to have a slightly worse 
outcome compared to the CAIRO patients receiving first-line monotherapy and compared to 
patients receiving combination therapy. This can be explained by the non-random 
assignment of treatments in the pilot population. A significantly larger part of the pilot 
population receiving monotherapy was over 70 years of age (compared to pilot patients 
receiving combination therapy and compared to CAIRO patients). Besides this we found that 
these patients were significantly less often treated with a third-line therapy than were patients 
in the CAIRO sequential treatment arm. This may reflect a tendency towards a higher 
motivation for treatment in trial versus non-trial patients. 
 
 
Costs: comparison with existing literature 
From the systematic review of Krol et al. (2007)42 on the cost (-effectiveness) of 
pharmaceutical therapies for advanced colorectal cancer, 5 papers discussed the cost-
effectiveness of irinotecan.54, 70-73 Of these, 2 made a comparison with oxaliplatin 
combinations.72, 73 
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Table 2.3.8 The cost assessment of Hillner et al. (2005) (Euro 2009) 
 
FOLFOX IFL FOLFOX FOLFIRI
Initial semipermanent venous access 1,648 502
First-line treatment 47,076 26,860
First-line toxic deaths 317 566
Nonfatal toxicities 3,342 4,380
Second-line treatment 7,467 5,682
Palliative care for advanced disease  23,907 20,591
Total treatment costs 83,757 58,582 28,533 50,166
Hillner et al. (2005) Our outcomes study
 
Hillner et al (2005). 72compared the total treatment costs for patients receiving FOLFOX in 
the first treatment line to those of patients receiving 5FU (bolus) with irinotecan (IFL) in the 
first treatment line from the perspective of an American third party payer. Resource use was 
collected during 5 years and included hospitalisation for chemotherapy or adverse events, 
chemotherapy, concomitant medications, surgical procedures and some laboratory services 
(e.g. prothrombin time, complete blood count). Table 2.3.8 presents the cost assessment of 
Hillner et al. (2005). Total treatment costs were € 83,757 for FOLFOX and € 58,582 for IFL.  
 
Total treatment costs for patients receiving IFL were comparable to those found for patients 
receiving FOLFIRI in our outcomes study. 7/12 patients of our irinotecan combination therapy 
group received FOLFIRI in the first treatment line; their total cost were € 50,166 (SD 27,390).  
Total treatment costs for patients receiving FOLFOX were much higher compared to those 
found in our outcomes study. 27/51 patients of our oxaliplatin combination therapy group 
received FOLFOX in the first treatment line; their total cost were € 28,533 (SD 18,257). 
There may be 3 explanations for this cost difference. Firstly, Hillner et al. (2005) used a unit 
cost price of € 14.95 per mg (versus € 4.35 in our outcomes study; table 2.2.3). Secondly, 
Hillner et al. (2005) made use of a model to simulate the observations and consequences of 
care over a 5-year period after initiating therapy with either FOLFOX or IFL. However, this 
Markov process model was based on various assumptions and projections (verified by expert 
opinion), while our outcomes study was based on actual patient level data. Thirdly, Hillner et 
al. (2005) included palliative care costs (at palliative care centers) because their study was 
conducted from the third party payer perspective. In contrast, our outcomes study excluded 
these palliative costs, because our study was conducted from the perspective of the hospital.  
 
Limat et al. (2006)73 compared the first treatment line costs for patients receiving FOLFOX to 
those for patients receiving FOLFIRI from the perspective of the French Health System. 
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Resource use included hospitalisation for chemotherapy or adverse events, chemotherapy, 
concomitant medications (including blood products), medical devices (e.g. disposal pumps) 
and patients’ travel expenses. Laboratory services and radiological procedures were 
assumed to be identical in both treatment groups and therefore excluded from the cost 
analysis. Using standard de Gramont regimens, the per diem approach resulted in first 
treatment line costs of about € 14,000 for FOLFOX and € 15,500 for FOLFIRI. The DRG 
approach resulted in first treatment line costs of about € 21,000 for FOLFOX and € 21,500 
for FOLFIRI. These results are fairly in agreement with the results of our outcomes study.  
 
 3.6 Quality of life 
Table 2.3.9 gives an overview of the generated mean utility values per 9 week interval in 
CAIRO study patients. The overall mean utility value 0.77 in patients randomised to 
sequential therapy and 0.76 in patients randomised to combination therapy (p = 0.2599). In 
conclusion, the quality of life in patients treated with sequential therapy and combination 
therapy is comparable. This is in line with the conclusions of the CAIRO study based on the 
disease specific QLQ-C30 values, where only one significant difference in change between 
the two treatment arms was seen: 20 points for sequential versus 28 points for combination 
treatment change in the score for diarrhoea (p = 0.002).   
 
Table 2.3.9 health utility values  
Sequential therapy Combination therapy
Mean ± sd ( N ) Mean ± sd ( N )
Baseline 0.76 ± 0.20 ( 385 ) 0.75 ± 0.22 ( 362 )
Wk 9 0.76 ± 0.21 ( 208 ) 0.74 ± 0.22 ( 199 )
Wk 18 0.79 ± 0.18 ( 188 ) 0.74 ± 0.20 ( 194 )
Wk 27 0.81 ± 0.17 ( 149 ) 0.80 ± 0.15 ( 135 )
Wk 36 0.75 ± 0.22 ( 132 ) 0.75 ± 0.24 ( 102 )
Wk 45 0.78 ± 0.22 ( 105 ) 0.76 ± 0.21 ( 84 )
Wk 54 0.78 ± 0.17 ( 98 ) 0.76 ± 0.17 ( 76 )
Wk 63 0.76 ± 0.19 ( 68 ) 0.77 ± 0.19 ( 58 )
Wk 72 0.77 ± 0.18 ( 61 ) 0.82 ± 0.15 ( 49 )
Wk 81 0.75 ± 0.22 ( 33 ) 0.83 ± 0.12 ( 33 )
Wk 90 0.71 ± 0.21 ( 32 ) 0.76 ± 0.16 ( 30 )
Wk 99 0.73 ± 0.20 ( 27 ) 0.81 ± 0.22 ( 19 )
Wk 108 0.80 ± 0.22 ( 15 ) 0.89 ± 0.10 ( 8 )
p-value
Totals 0.77 ± 0.20 ( 1501 ) 0.76 ± 0.20 ( 1349 ) 0.2599
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4 Discussion 
4.1 Use of oxaliplatin 
This study has shown that patients who started first-line chemotherapy treatment for 
metastatic colorectal cancer between January 2003 and January 2005 were treated with 
either monotherapy using fluoropyrimidines (63%) or combination therapy including 
oxaliplatin (29%) or irinotecan (8%). According to professional guidelines, these three options 
were all appropriate in the first-line treatment of metastatic colorectal cancer. No 
recommendations in regard to the choice and sequence of chemotherapy were available. In 
the CAIRO study, all patients randomised to first-line combination therapy received 
irinotecan. Therefore, the total percentage of patients receiving irinotecan as first-line 
chemotherapy in the Netherlands between January 2003 and January 2005 was actually 
higher than the 8% we found.  
 
After evaluation of the CAIRO eligibility criteria in the PILOT population, 71% of the patients 
would have been eligible for the CAIRO study. Possible unfavourable parameters that can be 
present in ineligible patients include: poorer performance score, no resection of primary 
tumour, inadequate organ functions, presence of brain metastases, comorbidities, or 
presence of second tumours. Patients receiving first-line combination therapy were more 
likely to be eligible for the CAIRO study than patients receiving first-line monotherapy. This 
was to be expected since first-line combination therapy is considered to be associated with a 
slightly higher degree of side effects. Therefore, patients who would have been excluded 
from the CAIRO study because of patient condition, comorbidity or inadequate organ 
functions, would also have been less eligible to receive a more toxic chemotherapy regimen 
as first choice since the assignment of treatments was not randomised in our pilot study.  
 
Physicians were less likely to prescribe combination therapy to patients with advanced age 
or decreased performance status. This finding was in line with the results of the stage III 
colon cancer pilot study (section 1) where physicians were less likely to prescribe oxaliplatin 
to patients with advanced age or serious comorbidities. However, in metastatic colorectal 
cancer most patients receive several treatment lines. Our results showed that at least half of 
the patients receiving monotherapy as first-line treatment received combination therapy with 
either oxaliplatin or irinotecan in second-line. In the third line 22% of the patients are still 
receiving chemotherapy. These percentages are in line with patients receiving first-line 
combination therapy although a larger part of these patients received both oxaliplatin and 
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irinotecan during the course of their disease compared to patients receiving first-line 
monotherapy. Furthermore, patients receiving first-line combination therapy were more often 
treated with other therapies such as bevacizumab or cetuximab during the course of their 
disease. This difference between the mono and combination therapy groups might be 
explained by the difference in baseline characteristics where elderly patients with a worse 
performance status will be less able to receive a long series of aggressive chemotherapies, 
especially when they start with monotherapy.  
4.2 Clinical efficacy 
 
In the pilot study, eligible patient population, the median overall survival was 15.1 (95% CI 
12.8 – 19.0) months for the patients who received first-line combination therapy and 11.2 
(95% CI 9.5 – 13.3) months for patients receiving first-line monotherapy. These results are 
comparable to the results of the CAIRO study where the median overall survival was 15.9 
(95% CI 14.3 – 18.0) months for patients receiving first-line combination therapy and 13.4 
(95% CI 11.5 – 15.2) months for the patients who received first-line monotherapy. This 
outcome, which is supported by the finding that the baseline characteristics and treatment 
patterns are comparable between eligible pilot and CAIRO patients, can be interpreted as a 
positive sign for the generalisability of the results of the CAIRO trial to Dutch daily practice.  
However, patients receiving monotherapy in the pilot study tend to have a slightly worse 
outcome compared to the CAIRO patients receiving first-line monotherapy and compared to 
patients receiving combination therapy. This can be explained by the non-random 
assignment of treatments in the pilot population. A significantly larger part of the pilot 
population receiving monotherapy was over 70 years old (compared to pilot patients 
receiving combination therapy and compared to CAIRO patients). Besides this we found that 
these patients were significantly less often treated with a third-line therapy than were patients 
in the CAIRO sequential (first-line monotherapy) treatment arm. This may reflect a tendency 
towards a higher motivation for treatment in trial versus non-trial patients. These results 
obviously only apply for the eligible pilot patients. The prognosis of the patients who did not 
fulfil these inclusion criteria was considerably poorer. 
 
Due to limitations in study design, caution is required when interpreting the results on 
incremental efficacy. The retrospective, observational nature of the pilot study is 
fundamentally different from a prospective, randomized design. In our study, the treating 
physicians determined which patients would be treated with first-line monotherapy and which 
would receive combination therapy. This resulted in an older population receiving 
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monotherapy. For this reason, the uncorrected disease-free survival curves of the patients 
with and without oxaliplatin are not directly comparable. Even after correction for baseline 
characteristics, it remains uncertain whether a valid estimate of the hazard ratio (HR) of the 
treatment effect can be calculated. This is because it is uncertain whether the model has 
taken all relevant factors into account. For example, up to 62% of the information on the 
health state of the patients was missing since physicians do not routinely document a 
patients’ performance status. Apart from this, other factors may have played a role in the 
decision-making between doctors and patients, which have not been documented and 
therefore cannot be incorporated into the analysis. 
4.3 Costs 
 
Mean costs amounted to € 19,812 (SD 14,679) for monotherapy, € 28,200 (SD 19,470) for 
oxaliplatin combination therapy, € 44,664 (SD 24,367) for irinotecan combination therapy and 
€ 13,899 (SD 11,860) for ineligible patients. In general the diversity of treatment agents and 
regimens applied in daily practice results in a wide cost variation between patients.41 Another 
consequence of the diversity is the difficulty in comparing results to those of existing 
literature, as was partly demonstrated in section 3.5. 
 
Costs are preferably determined from a societal perspective in which all relevant costs are 
included.1, 43 However, considering limited time and information, it was impossible to collect 
retrospective data on societal costs for our cost analyses. Therefore, our cost analyses were 
conducted from the hospital perspective. As stage IV colon carcinoma often occurs in the 
elderly unemployed population, productivity losses are expected to only have a minor impact 
on the results. Inclusion of costs of informal care would increase total costs. However, there 
was no reason to expect any difference in costs of informal care between treatments. As a 
consequence, the inclusion of these costs would therefore have no impact on the difference 
in total costs. Given these arguments, we believe that the exclusion of those cost 
components from the analyses had no important impact on the estimate of the real-world 
cost-effectiveness of oxaliplatin. 
4.4 Quality of life 
 
Our retrospective study design made it impossible to use Health Related Quality of Life 
(HRQOL) as an outcome measure. However, The CAIRO study measured the disease 
 124 
 
specific quality of life by means of the QLQ-C30 questionnaire of the European Organisation 
for Research and Treatment of Cancer (EORTC). We used a recently developed model to 
convert these QLQ-C30 values into utilities to allow comparisons of Quality adjusted life 
years (QALYs) rather than life years between the treatment groups in metastatic colorectal 
cancer. This approach however has an important limitation. The model was developed and 
validated in patients having haematological cancers. The extent to which the model applies 
to colorectal cancer patients is uncertain. For this reason the validation of this model to 
colorectal cancer is currently under investigation by the institute for Medical Technology 
Assessment. 
4.5 Cost-effectiveness in daily clinical practice 
 
Knowledge at T = 0 
Knowledge relating to clinical efficacy 
Chemotherapy with a fluoropyrimidine was the only available treatment option for patients 
with metastatic colorectal cancer for many decades. In 2000 however, two novel 
chemotherapeutic agents, oxaliplatin and irinotecan were approved for the treatment of 
metastatic colorectal cancer as well. In 2003, which is the T=0 moment of this pilot study, 
both agents were completely diffused and used in first-, second- and third-line chemotherapy 
treatment. However, no recommendations from professional guidelines in regard to which 
chemotherapy to use when were available. At T = 0 it was unclear whether a combination 
therapy with either oxaliplatin or irinotecan should be preferred over monotherapy with 
fluoropyrimidines as first-line treatment option.  
 
Knowledge relating to the costs 
In 2003, no publications regarding costs of oxaliplatin in the treatment of metastatic 
colorectal cancer were available. Based on the costs of the new medicine itself, the extra 
costs that would be involved in using oxaliplatin were estimated at T = 0. The duration of 
treatment, as agreed by protocol and the expected dose schedules were taken into account. 
 
The cost-effectiveness indication and a T = 0 model were not available for the 
reimbursement decision body due to the year of registration.  
 
Knowledge via outcomes research at T = 3 
Knowledge relating to clinical efficacy 
See section 4.2 
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Knowledge relating to costs 
The total costs of treatment and follow-up were calculated per treatment group. However, 
only limited information regarding costs from ineligible patients was available.  
 
Knowledge via literature study at T = 3 
Knowledge relating to clinical efficacy 
Various new publications regarding were available at T=3. Based on these publications, 
combination therapy with either irinotecan or oxaliplatin had been widely accepted as the 
new standard in first-line treatment of mCRC. However, the question of whether the benefit 
of fist-line combination therapy with oxaliplatin or irinotecan would have been maintained if 
patients would have received appropriate salvage treatment in the control arm of these 
studies was left unanswered. In other words, it may be more important that patients are 
exposed to these drugs during the course of their disease, rather than receiving the drugs in 
the first-line. The CAIRO and the FOCUS studies were designed to provide a better insight in 
this issue. However their results were not available until T = 4.  
 
Knowledge relating to costs 
Various publications were available at T = 3.  However, related to clinical efficacy, no results 
were known regarding the cost-effectiveness of fluoropyrimidines, irinotecan or oxaliplatin 
when consequently used in either sequential or combination therapy.  
 
 
Cost-effectiveness at T =3 
Knowledge of clinical effectiveness solely obtained via outcomes research was not sufficient 
to produce a valid estimate of the incremental effectiveness of oxaliplatin. The assignment of 
the treatments was not randomised. We found that patients who received monotherapy were 
significant older than patients receiving first-line combination therapy. From this we can 
conclude that the patients in the two treatment groups might not be comparable in terms of 
their prognosis. Randomised studies that are applicable to the daily practice setting are 
needed to compare the results from outcomes research with. The comparability between the 
pilot study and the CAIRO trial can be interpreted as a positive sign in support of the 
generalisability of the results of the CAIRO trial to Dutch daily practice. The hazard ratios 
regarding the treatment effect of combination therapy of the two studies were comparable. 
Therefore, both estimates could be used for the cost-effectiveness analysis. Similarly, we 
also feel confident in using the cost estimates obtained via outcomes research.  
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General conclusion on cost-effectiveness 
Both the results of outcomes research and the CAIRO study could be used in the cost-
effectiveness analyses. All cost data would be based entirely on outcomes research. In our 
opinion it would be possible to obtain a sufficiently precise and valid estimate of the cost-
effectiveness of oxaliplatin in daily practice. However we should realise that the ability to 
compare our results to the CAIRO study has been of crucial importance in this pilot study. It 
remains questionable how often such trials will be available in other expensive drugs. 
Furthermore, the results of the CAIRO study were not available until T = 4.  
 
4.6 Appropriate use in daily clinical practice 
 
This section focused on the appropriate use of oxaliplatin as first-line treatment in metastatic 
colorectal cancer. The aim was to provide insight into the dynamics of clinical practice. 
Dynamics of clinical practice is defined as the differences between the requirements for 
registering oxaliplatin and the information on its use in daily practice. These differences may 
result from differences in the use of oxaliplatin or differences in the observed effectiveness or 
adverse events.1 The following is a short summary of the aspects relevant to the dynamics of 
clinical practice.  
 
Population treated in clinical practice versus population from the CAIRO study 
A large proportion of the patients (71%) treated with oxaliplatin in daily practice were similar 
to the population from the CAIRO study with respect to their baseline characteristics. The 
patients who did not fulfil the CAIRO eligibility criteria (29%) had a significantly worse 
performance status.  
 
Selective prescription 
During the timeframe of this pilot study which started in 2003, oxaliplatin was completely 
diffused in clinical daily practice because this regimen was already registered for the 
indication of metastatic colorectal cancer since 2000. Moreover, professional guidelines 
approved the use of oxaliplatin in first-, second- and third-line treatment, without 
recommendation for one specific treatment line. In general, patients receiving oxaliplatin as a 
first-line treatment option were significantly younger and had a better performance score than 
patients receiving monotherapy with fluoropyrimidines as first-line therapy.  
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Prescribing outside the registered indication 
In metastatic colorectal cancer, oxaliplatin is registered for first-, second- and third-line 
treatment. Given this broad registration, the problem of possible prescription outside the 
registered indication does not exist here.  
 
The use of oxaliplatin in practice versus use in the CAIRO study 
In the CAIRO study, patients were randomised to receive first-line chemotherapy with either 
capecitabine monotherapy or capecitabine + irinotecan combination therapy. In the pilot 
study, patients receiving combination therapy mostly received a combination with oxaliplatin 
as first-line treatment regimen. This is not surprising since professional guidelines did not 
recommend the use of a specific regimen as first-line treatment. We can conclude that the 
observed regimens as well as the observed dose schedules in daily practice demonstrated a 
good adherence to existing guidelines.  
 
Effectiveness in practice versus effectiveness in the CAIRO study 
Those patients from daily practice (71% of pilot study population) who fulfilled the inclusion 
criteria of the CAIRO study showed a similar overall survival to that of the patients in the 
CAIRO study. No comparative trial data are available on the patients who did not fulfil the 
inclusion criteria of the CAIRO study (29%). Daily practice shows that these patients have a 
less favourable prognosis. This is as expected since the exclusion criteria of the CAIRO trial 
mainly consisted of factors that would exclude patients with an unfavourable prognosis like 
patient condition, comorbidity, presence of a second tumour, abnormal organ function and 
brain metastases.  
 
General conclusion on appropriate use 
In regard to the insights gained from the dynamics in clinical practice, we observe that the 
pilot patients, with respect to baseline characteristics, use of oxaliplatin and efficacy comply 
well with the findings of the CAIRO study. We can conclude that oxaliplatin is used 
appropriately in metastatic colorectal cancer.  
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Conclusions 
Oxaliplatin is an expensive medicine that was admitted under the Dutch policy regulation 
‘expensive medicines’ in order to allow hospitals to obtain additional funding for this drug. 
Since 2006, the Dutch policy regulations for expensive hospital medicines require evidence 
from outcomes research for the assessment of appropriate use and real-world cost-
effectiveness of expensive medicines after three years of temporary additional funding. 
Outcomes research in this particular context is new in Dutch policy making and therefore 
experience in the application of outcomes research is lacking. This report investigated how 
oxaliplatin is used in daily practice and explored real-world treatment effects and costs in 
stage III colon and metastatic colorectal cancer in Dutch daily practice. This pilot outcomes 
research study was conducted as part of a comprehensive study of methodological issues 
related to outcomes research. We conclude that outcomes research provides valuable 
information on the utilisation of oxaliplatin in daily practice. Via outcomes research we were 
able to obtain insight into the appropriate use of oxaliplatin. Results were comparable to the 
MOSAIC and CAIRO trials, allowing us to use these trials to obtain a valid and precise 
estimate of the incremental effectiveness. However it is important to note that the ability to 
use data from trials such as the MOSAIC and CAIRO was of crucial importance in this pilot 
study, along with a limited dynamics in daily practice (i.e., a limited amount of treatment 
variation). The combination of data sources used in this study is a cogent reminder that the 
assessment of the real-world effectiveness and cost-effectiveness of a medicine will make 
use of all available data. The actual approach to be taken will have to depend on the types of 
data and evidence available at the time of the final assessment (i.e., 3-4 years of use in daily 
practice). 
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Annex I Collaboration with the DCCG in Nijmegen 
 
For this outcomes research, the iMTA worked very closely with, in particular, the UMC St 
Radboud in Nijmegen, the core centre of the Dutch Colorectal Cancer Group (DCCG). In the 
DCCG a large number of hospitals work together in the field of clinical research on patients 
with a colorectal carcinoma. At the end of 2002 the ‘CAIRO 1’ study was initiated. In this 
study 820 patients with metastatic colorectal cancer were included between 1 January 2003 
and 31 December 2004 in 74 hospitals in the Netherlands. They were randomized between 
first-line capecitabine, second-line irinotecan, and third-line capecitabine + oxaliplatin 
(sequential treatment arm) versus first line capecitabine + irinotecan and second-line 
capecitabine + oxaliplatin (combination treatment arm). Subsequently the ‘CAIRO 2’ and 
‘CAIRO 3’ studies were initiated, of which the latter is still ongoing. Due to the national 
connections of the DCCG, permission for participation in the pilot study has been obtained in 
a large number of hospitals. 
 
Prof. dr. C.J.A. Punt, chairman of the DCCG, and Dr. M. Koopman have been involved in the 
oxaliplatin pilot study since it’s design. Furthermore, during the course of the pilot study, 
close collaboration took place with drs. L. Mol who is performing research into the quality of 
medical oncologic care and local data management. Efficiency gains were possible because 
this quality research and the pilot study were able to make use of the same patient 
population.  
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Annex II Systematic review of the clinical effectiveness of 
oxaliplatin for the adjuvant treatment of colon cancer 
 
Identification of studies  
A systematic literature search was performed to identify randomised controlled trials (RCTs) 
of oxaliplatin as adjuvant therapy in the treatment of colon cancer.  
 
Sources searched  
Pandor et al. published results of an extensive systematic review regarding the clinical 
effectiveness and cost-effectiveness of oxaliplatin, covering the literature until January 2005 
(Pandor et al. 2006). In this literature review the publication date limit was set from January 
2005 until February 2009 to cover the recent literature. A total of eight electronic databases 
were searched: Medline, Embase, Pubmed, Cochrane, Central, Dare-nhs eed-hta, Cinahl, 
and Web of science. In the searches of MEDLINE, EMBASE and Web of Science, search 
results were restricted to RCTs. Following Pandor et al. (2006), the search of PUBMED was 
restricted to the last 180 days to capture recent and unindexed MEDLINE references.  
 
Key word strategies 
Key word strategies were used similar to the ones reported by Pandor et al, Annex 3. These 
key word strategies were slightly adapted to fit other versions of the same databases.  
 
Inclusion and exclusion criteria 
The relevance of the studies was assessed according to the criteria set out below, largely 
identical to the criteria formulated by Pandor et al. (2006). Only English-language articles that 
were not incorporated in Pandor et al. (2006) were considered. All titles were screened and, 
when considered possibly relevant, abstracts were evaluated. Based on the abstracts, full 
copies of relevant papers were obtained.  
 
Population Patients (either gender at any age) with Stage III colon cancer after complete 
surgical resection of the primary tumour. 
Interventions Oxaliplatin (Eloxatin®, Sanofi-Aventis) used in combination with 5FU/LV, 
within its licensed indication. 
Comparator Chemotherapy as adjuvant therapy with an established FU-containing 
regimen. 
Outcomes Data on the following outcomes were included (as defined by Pandor, 2006): 
 138 
 
 
Outcome Definition 
Overall survival The interval from randomisation to death from any cause. 
Disease‐free survival The time from trial entry or randomisation until recurrence of colorectal 
cancer or death from any cause. 
Relapse‐free survival The time from trial entry or randomisation until recurrence of colorectal 
cancer or death from any cause, excluding deaths unrelated to disease 
progression or treatment. 
Time to treatment failure The interval from randomisation to discontinuation of treatment for any 
reason (including treatment toxicity and death). 
Adverse effects of 
treatment/toxicity 
Abstracted as reported, however defined. 
Health‐related QoL Abstracted as reported, however defined. 
 
Articles primarily focussing on safety/adverse events and/or drug 
administration were excluded. 
Study design  RCTs  
 
Data abstraction and critical appraisal strategy 
Since, no new studies were conducted from 2005 onwards, meeting the above-mentioned 
criteria, data relating to study design and quality, could be obtained from Pandor et al. 
(2006). New publications, mainly of extended follow-up results, were identified, data were 
extracted and incorporated into the initial outcomes reported by Pandor et al. (2006). 
 
Results of clinical effectiveness review  
 
Number and type of studies identified 
A total of 1531 titles and abstracts were screened for inclusion. Based on this screening, 88 
full papers were retrieved and assessed in detail. Three studies were identified, 2 of which 
covered the clinical effectiveness of oxaliplatin (MOSAIC and NSABP C-07). In our limited 
time period, 7 new and relevant publications on these studies were published (Kuebler, 2007; 
Wolmark, 2008; André, 2009; de Gramont 2007a; de Gramont, 2007b; Sargent, 2006; 
Goldberg, 2006).  
 
Number and type of studies included 
Between 2005 and February 2009, no new studies were conducted comparing the efficacy of 
adjuvant therapy with oxaliplatin with the efficacy of adjuvant therapy with an established FU-
containing regimen. However, while former results of the NSABP C-07 trial were only 
published in abstract-form, in 2007 the first full-text report of this study appeared (Kuebler, 
2007). In 2008 these results were updated with overall survival results in an ASCO Annual 
Meeting Proceedings (Wolmark, 2008). Furthermore, in 2007 abstracts with updated results 
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from the MOSAIC study were presented, providing a median follow-up of six years for this 
trial (de Gramont 2007a; de Gramont, 2007b). Very recently, the MOSAIC 6-year overall 
survival was also published in a full-text article (André, 2009). Although this paper was 
published after the end of our search period, we included it since it elaborates on the limited 
information provided in the included abstracts. Two other articles, partly based on results 
from the MOSAIC trial, report the safety and efficacy of the FOLFOX4 regimen when given to 
elderly compared to younger patients with colorectal cancer (Sargent, 2006; Goldberg, 
2006).  
 
Number and type of studies excluded 
A total of 80 papers were excluded. The main reason for exclusion was that the study 
presented no new data relating to efficacy. Most of the excluded articles were non-systematic 
reviews. A couple of these reviews did provide interesting comparisons between the 
MOSAIC and NSABP C-07 trial data. The review of Sharif et al. (2008) is quoted on various 
occasions for this reason. Several articles were excluded because they solely or primarily 
focussed on safety/adverse events. 
 
Potentially relevant citations 
Identified, screened and inspected
 n = 1531 
n = 1443
Full papers retrieved  and
assessed 
n = 88 
Papers rejected at the title stage
n = 81
  
n = 7
Papers rejected at the abstract/ 
full text stage 
Publications meeting inclusion
criteria  
Publications of MOSAIC trial Publications of NSABP C-07 trial
n = 4 n = 3
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Description of included studies 
Tables 1 and 2 below – derived from Sharif et al. (2008) – provide a summary of the main 
characteristics of the MOSAIC trial and the NSABP C-07 trial. See Pandor et al. (2006) for 
more extensive information on study characteristics, including a quality assessment. 
 
Table 1 Summary of design and study characteristics – MOSAIC trial and NSABP C-07 trial 
(Shardif, 2008). 
 
 141 
 
Table 2 Summary of patient characteristics – MOSAIC trial and NSABP C-07 trial (Shardif, 
2008). 
    
 
Efficacy of oxaliplatin 
Disease-free survival (DFS) and overall survival (OS) data of the MOSAIC trial were 
published before, with a median follow-up of 37.9 months and 48.6 months (Pandor, 2006). 
In 2007, these OS results were updated for a median follow-up of six years, reported in 
abstract form (de Gramont 2007a; de Gramont, 2007b). In 2009 these abstracts were 
followed by a full-text article (André, 2009). MOSAIC trial results were reported for the patient 
group as a whole, as well as for subgroups based on disease stage. Since we are 
particularly interested in patients with stage III colon cancer, outcomes for this group are 
reported separately here as well. For the NSABP C-07 study, outcomes for the stage III 
patient subgroup were limited: they were available online, only for DFS at 4 years. The 
recent publications did extend formerly reported DFS-results for the whole patient group, 
whereby the DFS and OS results had a median follow-up of 42.5 (Kuebler, 2007) and 67 
months (Wolmark, 2008). The following table shows that the MOSAIC trial and the NSABP 
C-07 trial both demonstrate the superiority of oxaliplatin-containing regimens (FOLFOX and 
FLOX) compared to FL and FULV, respectively. Adding oxaliplatin to 5FU/LV improves the 
DFS and OS of patients with resected colon cancer. 
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Table 3 Disease-free and overall survival for the MOSAICa and NSABP C-07b trial. 
Study/outcome Median 
follow-up 
(months) 
Event rate Hazard ratiod 
(95% CI) 
p-value for 
superiority 
  Oxaliplatin (plus 
5FU/LV)c 
5FU/LVc   
Disease-free survival 
All patients (Stage II and III colon cancer) 
MOSAIC * 37.9 237/1123 
(21.1%) 
293/1123 
(26.1%) 
0.77 (0.65 to 0.91) p = 0.002 
MOSAIC + 48.6 267/1123 
(23.8%) 
332/1123 
(29.6%) 
0.76 (0.65 to 0.90) p = 0.0008 
MOSAIC # 72.0 Not reported Not reported Not reported Not 
reported 
MOSAIC % 73.4 304/1123 
(27.1%) 
360/1123 
(32.1%) 
Not reported Not 
reported 
NSABP C‐07 & 34.0 272/1200 
(22.7%) 
332/1207 
(27.5%) 
0.79 (0.67 to 0.93) p = 0.004 
NSABP C‐07 @ 42.5 308/1200 
(25.7%) 
369/1207 
(30.6%) 
0.80 (0.69 to 0.93) p = 0.0034 
NSABP C‐07 ^ 67.0 Not reported Not reported Not reported Not 
reported 
      
Patients with stage III colon cancer only 
MOSAIC * 37.9 181/672 (26.9%) 226/675 
(33.5%) 
0.76 (0.62 to 0.92) Not 
reported 
MOSAIC + 48.6 200/672 (29.8%) 252/675 
(37.3%) 
0.75 (0.62 to 0.90) p = 0.002 
MOSAIC # 72.0 Not reported Not reported Not reported Not 
reported 
MOSAIC % 73.4 226/672 (33.6%) 271/675 
(40.1%) 
Not reported Not 
reported 
NSABP C‐07 & 34.0 Not reported Not reported Not reported Not 
reported 
NSABP C‐07 @ 42.5 Not reported Not reported Not reported Not 
reported 
NSABP C‐07 ^ 67.0 Not reported Not reported Not reported Not 
reported 
      
Overall survival 
All patients (Stage II and III colon cancer) 
MOSAIC * 37.9 133/1123 
(11.8%) 
146/1123 
(13.0%) 
0.90 (0.71 to 1.13) Not 
significant 
MOSAIC + 48.6 176/1123 
(15.7%) 
194/1123 
(17.3%) 
0.89 (0.72 to 1.09) p = 0.236 
MOSAIC # 72.0 241/1123 
(21.5%) 
272/1123 
(24.2%) 
0.85 (0.71 to 1.01) Not 
reported 
MOSAIC % 81.9 245/1123 
(21.8%) 
283/1123 
(25.2%) 
Not reported Not 
reported 
NSABP C‐07 & 34.0 Not reported Not reported Not reported Not 
reported 
NSABP C‐07 @ 42.5 187/1200 
(15.6%) 
198/1207 
(16.4%) 
Not reported Not 
reported 
NSABP C‐07 ^ e 67.0 259/1200 
(21.6%) 
301/1209 
(24.9%) 
0.853 (0.723 to 
1.008) 
p = 0.061  
      
Patients with Stage III colon cancer only 
MOSAIC * 37.9 104/672 (15.5%) 119/675 0.86 (0.66 to 1.11) Not 
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(17.6%) significant 
MOSAIC (ad hoc 
analysis) + 
48.6 Not reported Not reported 0.86 (0.68 to 1.08) p = 0.196 
MOSAIC # 72.0 182/672 (27.1%) 214/675 
(31.7%) 
0.80 (0.66 to 0.98) Not 
reported 
MOSAIC % 81.9 182/672 (27.1%) 220/675 
(32.6%) 
Not reported Not 
reported 
NSABP C‐07 & 34.0 Not reported Not reported Not reported Not 
reported 
NSABP C‐07 @ 42.5 Not reported Not reported Not reported Not 
reported 
NSABP C‐07 ^ 67.0 Not reported Not reported Not reported Not 
reported 
      
* André T, Boni C, Mounedji‐Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant 
treatment for colon cancer. N Engl J Med. 2004 Jun 3;350(23):2343‐51. 
+ Gramont Ad, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II 
and stage III colon cancer: Efficacy results with a median follow‐up of 4 years. Journal of Clinical Oncology. 2005;23(16S):3501. 
# Gramont Ad, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated 
efficacy results of the MOSAIC trial, including survival, with median follow‐up of six years. Journal of Clinical Oncology. 
2007;25(18S):4007. 
% André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved Overall Survival With Oxaliplatin, Fluorouracil, and 
Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial. J Clin Oncol. 2009 May 18. 
& Wolmark N, Wieand S, Kuebler J, Colangelo L, Smith R. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III 
carcinoma of the colon: Results of NSABP Protocol C‐07. Journal of Clinical Oncology. 2005;23(16S). 
@ Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, et al. Oxaliplatin combined with weekly bolus fluorouracil 
and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C‐07. J Clin Oncol. 2007 Jun 
1;25(16):2198‐204. 
^ Wolmark N, Wieand S, Kuebler P, Colangelo L, O'Connel M, Yothers G. A phase III trial comparing FULV to FULV+oxaliplatin in stage 
II or III carcinoma of the colon: Survival results of NSABP C‐07. Journal of Clinical Oncology. [2008 ASCO Annual Meeting 
Proceedings]. 2008;26(15S). 
a ITT analysis. 
b Per protocol analysis. 
c MOSAIC trial, infusional 5FU/LV (de Gramont regimen); NSABP C‐07 trial, bolus 5FU/LV (Roswell Park regimen). 
d Hazard ration <1.0 favors oxaliplatin (plus 5FU/LV). 
e Because the number of deaths (560) was fewer than anticipated (700), the power to detect de protocol specified effect size was 
reduced from 0.89 to 0.81. 
 
Disease-free survival 
The DFS-estimates of the MOSAIC trial and the NSABP C-07 trial do not differ greatly. 
Adding oxaliplatin to the 5FU/LV regimens significantly reduces a patient’s risk of relapse or 
death by about 20%. The DFS at 3 years in the MOSAIC trial was 78.2% for FOLFOX 
compared to 72.9% for FL. Treatment with FOLFOX reduced the relative hazard of relapse 
or death by 23% (HR 0.77, 95% CI, 0.65-0.91, p=0.002). The DFS at 3 years in the NSABP 
C-07 trial was 76.1% for FLOX versus 71.8% for FULV. Treatment with FLOX reduced the 
relative hazard of relapse or death by 20% (HR 0.80, 95% CI 0.69-0.93, p=0.0034) (Shardif, 
2008). Four-year en five-year DFS rates are similar. The MOSAIC trial shows five-year DFS 
rates of 73.3% and 67.4% in the FOLFOX4 and LV5FU2 groups respectively (HR=0.80, 95% 
CI 0.68-0.93, p=0.003) (André, 2009). The NSABP C-07 trial shows four-year DFS rates of 
73.2% and 67.0% in the FLOX and FULV groups respectively: an absolute difference of 
6.2% (Kuebler, 2007). The impact of oxaliplatin on DFS is even better for the subgroup of 
patients with stage III disease only. In this case, the absolute difference in four-year DFS 
rates between the FLOX and FULV groups is 7.8% (68.9% with FLOX, 61.1% with FULV). 
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The MOSAIC trial shows us the probabilities of DFS events at 5 years for this subgroup: 
66.4% with FOLFOX4 and 58.9% with LV5FU2 (André, 2009). 
 
Overall survival 
While former results of the MOSAIC trial already showed a (non-significant) survival benefit 
with the addition of oxaliplatin, longer follow-up confirms this. At a median follow-up of six 
years, 24.2% of the patients in the LV5FU2 group died, versus 21.5% of the patients in the 
FOLFOX4 group (HR 0.85, 95% CI 0.71-1.01). When looking at stage III patients only, at a 
median follow-up of six years, 31.7% of the patients in the LV5FU2 group died, versus 27.1% 
of the patients in the FOLFOX4 group (HR 0.80, 95% CI 0.66-0.98). Adding oxaliplatin to 
adjuvant treatment significantly increases the probability that these patients will survive at 6 
years by reducing their risk of death by 20% (de Gramont, 2007a; de Gramont, 2007b). The 
NSABP C-07 results do not provide survival information about the stage III subgroup of 
patients. For the total patient group, however, results are quite similar to the MOSAIC results. 
At a follow-up of 67 months, 24.9% of the patients on FULV died, versus 21.6% of the 
patients treated with FLOX (HR 0.85, 95% CI 0.72-1.01, p = 0.06) (Wolmark, 2008). Although 
the difference is not yet significant, there seems to be a trend towards improved survival. 
 
Adverse events (toxicities)  
Although the efficacy of FL (infusion schedule) appears to be similar to the efficacy of FULV 
(bolus schedule), their toxicity profiles are different. The same is true for FOLFOX versus 
FLOX. The rate of severe diarrhoea is 7% with FL versus 32% with FULV. Addition of 
oxaliplatin increases these rates of severe diarrhoea to 11% with FOLFOX and 38% with 
FLOX. Thus, although oxaliplatin improves DFS, it also increases the rate of severe 
diarrhoea. Oxaliplatin is also associated with an increase in other side effects, the most 
important one being severe peripheral neuropathy. In the NSABP C-07 trial, severe 
neurosensory toxicity was noted in 8.2% of patients receiving FLOX and in 0.7% of those 
receiving FULV (P<0.001) (Kuebler, 2007). Different oxaliplatin-containing regimens have 
different toxicity profiles (Shardif, 2008). For example: more diarrhoea was reported with 
FLOX than with FOLFOX4, but more severe neurotoxicity was reported with FOLFOX4 
(12%) than with FLOX (8.2%) (Kuebler, 2007). The choice between FOLFOX and FLOX 
(and/or other oxaliplatin-containing regimens) should be made for each patient individually, 
based on toxicity as well as practical considerations (André, 2004). André et al. show that in 
the MOSAIC trial, the majority of deaths were a result of relapse or recurrence, with six 
deaths in each group being a result of adverse events. The incidence of secondary cancers 
was 5.5% in the FOLFOX4 group and 6.1% in the LV5FU2 group (André, 2009). 
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Oxaliplatin for elderly patients with colorectal cancer 
The results of the MOSAIC trial and three other clinical trials were used to analyse the 
efficacy and safety of oxaliplatin plus FU/LV in elderly patients. Grade ≥3 adverse events, 
response rate, progression or relapse free survival, dose-intensity and OS were compared in 
patients aged younger than 70 years (n=3128) versus patients of at least 70 years old 
(n=614). Results demonstrate that FOLFOX4 maintains its efficacy and safety ratio in 
selected elderly patients with colorectal cancer. Old age was associated with slightly higher 
rates of neutropenia and thrombocytopenia but no other grade ≥3 adverse events. The 
relative benefit of FOLFOX4 versus control did not differ by age for response rate, 
progression or recurrence-free survival or OS. These results are not specific to FOLFOX4 in 
the adjuvant setting. Data from the MOSAIC trial were pooled with results from other clinical 
trials, testing FOLFOX4 in a combination of adjuvant, primary and secondary care settings 
(Sargent, 2006; Goldberg, 2006).  
 
Observational studies 
In the searches of MEDLINE, EMBASE and Web of Science, a methodological filter was 
used, aimed at restricting search results to RCTs. Since we were curious about observational 
research on the clinical effectiveness of oxaliplatin as well, we undertook another search to 
obtain these studies. PUBMED (including MEDLINE) was searched again for any citation 
(2005-2009, in English) concerning the clinical effectiveness of oxaliplatin, disregarding 
research type. 1126 titles were screened. Studies comparing oxaliplatin to (non-FU/LV) 
therapies, like irinotecan, were excluded. Studies focussing solely or primarily on 
safety/adverse events were also excluded. No additional, non-RCT studies on the clinical 
effectiveness of oxaliplatin were found. More specifically: we could not find any observational 
study on oxaliplatin fulfilling our criteria. Thus, this review provides a complete account of the 
recent literature on the efficacy of oxaliplatin. 
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Annex III Systematic review of the cost-effectiveness of 
oxaliplatin for the adjuvant treatment of colon cancer 
Identification of studies  
A systematic literature search was performed to identify economic evaluations of oxaliplatin 
in combination with 5FU/LV as adjuvant therapy in the treatment of completely resected 
stage III colon cancer. The comparator therapy was adjuvant chemotherapy with an 
established 5FU/LV-containing regimen. 
 
Sources searched  
Pandor et al. published results of an extensive systematic review regarding the clinical 
effectiveness and cost-effectiveness of oxaliplatin covering the literature until January 2005 
(Pandor et al. 2006). In this review publication date limit was set from January 2005 until the 
month our search was undertaken, April 2009. Six electronic databases were searched, 
providing coverage of the biomedical and health technology assessment literature: Medline, 
Embase, Pubmed, Dare-nhs eed-hta, Cinahl, and Web of science. Following Pandor et al. 
(2006), the search of PUBMED was restricted to the last 180 days to capture recent and 
unindexed MEDLINE references.  
 
Key word strategies 
As reported by Pandor et al. (2006), the key word strategies developed in the review of 
clinical effectiveness were used, with the RCT methodological filter being replaced by a filter 
aimed at restricting search results to economic and cost-related studies. The key word 
strategies used by Pandor et al. (2006) were slightly adapted to fit other versions of the same 
databases.  
 
Inclusion and exclusion criteria 
The relevance of the studies was assessed according to the criteria formulated by Pandor et 
al. (2006). Studies were included if they reported the cost-effectiveness of oxaliplatin in the 
adjuvant treatment of colon cancer. Only English-language articles that were not 
incorporated in Pandor et al. were considered. All titles were screened and, when considered 
possibly relevant, abstracts were evaluated. Based on the abstracts, full copies of relevant 
papers were obtained.  
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Results of the cost-effectiveness review  
 
Systematic searches of the various databases resulted in a total of 619 relevant titles, 
representing 489 unique publications. Based on screening of titles and abstracts, 39 studies 
were identified. Full papers of these studies were retrieved and assessed in detail. Eight 
studies met the review criteria and were included. These 8 publications reported on the cost-
effectiveness of oxaliplatin. First, an overview of the methods and results of the identified 
studies is presented. The subsequent section highlights important conclusions and compares 
the results to the findings of Pandor et al. (2006). 
 
Two of the eight included publications on oxaliplatin were meeting-abstracts of economic 
evaluations which were later reported in more detail. Both the meeting-abstracts and the 
more recent full-text articles of the same analyses were included in the review. An overview 
of the methods and results of all included economic evaluations on oxaliplatin is presented 
below. 
 
One full-text article, written by Maniadakis et al. (2009), is included in the review, despite the 
fact that it would formally be excluded according to our inclusion/exclusion guidelines. 
Maniadakis et al. report on a trial comparing XELOX (capecitabine/oxaliplatin) with 
FOLFOX6 (5FU/LV/oxaliplatin) in the adjuvant treatment of colorectal cancer patients in 
Greece. We do report the results of the economic analysis, since it provides an interesting 
addition to the rest of our review’s results.  
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Potentially relevant citations 
identified through electronic
searches
n = 619
Papers rejected because they
appeared in more than one
database
n = 489
Titles screened and inspected
n = 130
Papers rejected at the title stage
n = 91
  
Abstracts and/ or full copies
screened and inspected
n = 39
Papers rejected at the abstract/
full text stage
n = 16
Publications meeting inclusion
criteria
n = 8
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Aballea and colleagues (2007). An economic evaluation of oxaliplatin 
for the adjuvant treatment of colon cancer in the United Kingdom 
(UK). 
 
1. Overview 
This article evaluates the long-term cost-effectiveness of oxaliplatin in 
combination with 5FU/LV. It uses patient level data from the MOSAIC trial, 
which compared oxaliplatin/5FU/LV (FOLFOX4) to 5FU/LV alone in the 
adjuvant treatment of stage II and III colon cancer. Aballea et al. restricted 
their analysis to stage III colon cancer. The primary outcome they 
estimated was the cost of adjuvant treatment with FOLFOX4 per QALY 
gained over a lifetime. The perspective of the analysis was that of the UK 
NHS. 
 
2. Effectiveness analysis 
DFS and OS in the first 4 years following randomisation were derived from 
the MOSAIC trial. As the trial data were not mature, survival in the 5th year 
was extrapolated from the first four using Weibull distributions. No further 
relapses were assumed to occur beyond 5 years from diagnosis and 
survival in subsequent years was assumed to match the general mortality 
of the UK as observed in standard life tables. The lifetime analyses were 
curtailed after 50 years. 
Utility estimates were obtained from literature. QALYs, DFYs and LY 
gained were calculated and discounted at 3.5% per annum.  
 
3. Cost analysis 
Resource utilisation data were derived from the MOSAIC trial, 
supplemented with data from the literature and validated by UK clinical 
experts. Unit costs were sourced from the literature. Costs were for the 
year 2003. The perspective considered was direct costs to the UK NHS. 
Costs were discounted at 3.5% per annum. 
 
4. Results and conclusion 
See table 4.  
Total unit cost per relapse was estimated to be £12.687. 
 
5. Comments 
- Analyses were reported for a time horizon of 4 years as well as for a time 
horizon of 50 years. 
- Aballea et al. reported that the availability of relevant values for the 
calculation of QALYs was limited. Sensitivity analysis suggest that the 
impact of this parameter on long-term results is modest. 
- Eleven sensitivity analyses were carried out to explore the effect of 
conceivable changes in some of the assumptions and data inputs. Ten of 
these analyses produced results similar to the base case scenario. One 
analysis, limiting benefits and costs to short term follow-up, resulted in 
substantially higher ICERs.  
- Uncertainty surrounding efficacy data was explored using a bootstrapping 
approach. 
 
 
Aballea and colleagues (2005). Cost-effectiveness analysis of 
oxaliplatin/5FU/LV in adjuvant treatment of stage III colon cancer in 
the UK. 
 
1. Overview 
This meeting abstract outlines a cost-effectiveness analysis of oxaliplatin in 
combination with 5FU/LV. It uses patient level data from the MOSAIC trial, 
which compared oxaliplatin/5–FU/LV (FOLFOX4) to 5FU/LV alone in the 
adjuvant treatment of stage II and III colon cancer. Aballea et al. restricted 
their analysis to stage III colon cancer. They estimated the cost of adjuvant 
treatment with FOLFOX4 per QALY gained over a lifetime. The 
perspective of the analysis was that of the UK NHS. 
 
2. Effectiveness analysis 
The median follow-up of the used MOSAIC trial data was 44.2 months. 
DFS and OS were estimated up to 4 years from randomisation. A Weibull 
function was fitted to the DSF-curve and extrapolated to 5 years post-
randomisation, with no further relapses assumed to occur beyond this 
time. A life table was used for survival of the UK general population, 
adjusting for age and gender. OS beyond 4 years was predicted using the 
extrapolated DSF-estimates and data on observed survival in relapsing 
patients.  
To estimate QALYs, life-years accrued in both arms were assigned 
weights depending on occurrence of chemotherapy-related toxicities, 
disease status, and age. The number of QALYs were discounted at 3.5% 
per annum. 
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3. Cost analysis 
Costs were calculated from trial data up to relapse, accounting for 
censoring. Costs for periods after relapse or 4 years were estimated using 
literature. The cost analysis was performed from a UK NHS perspective. 
Costs were discounted as well, probably at 3.5% per annum (not reported). 
 
4. Results and conclusion 
See table 4.  
Expected cost of treatment following relapse was under £11.000. 
 
5. Comments 
- Uncertainty was explored using a bootstrapping approach.  
- No breakdown of the costs is given.  
- A full text article on the analyses outlined in this abstract was published in 
2007 and has been discussed previously (37).  
 
 
Aballea and colleagues (2005). Cost-effectiveness analysis of 
oxaliplatin/5FU/LV in adjuvant treatment of stage III colon cancer in 
Germany. 
 
1. Overview 
This meeting abstract outlines a cost-effectiveness analysis of oxaliplatin in 
combination with 5FU/LV. It uses patient level data from the MOSAIC trial, 
which compared oxaliplatin/5–FU/LV (FOLFOX4) to 5FU/LV alone in the 
adjuvant treatment of stage II and III colon cancer. Aballea et al. restricted 
their analysis to stage III colon cancer. They estimated the cost of adjuvant 
treatment with FOLFOX4 per LY gained over a lifetime. The perspective of 
the analysis was that of the German public health payer. 
 
2. Effectiveness analysis 
The median follow-up of the used MOSAIC trial data was 44.2 months. 
DFS and OS were estimated up to 4 years from randomisation. A Weibull 
function was fitted to the DSF-curve and extrapolated to 5 years post-
randomisation, with no further relapses assumed to occur beyond this 
time. A life table was used for the US general population. OS beyond 4 
years was predicted using the extrapolated DSF-estimates and data on 
observed survival in relapsing patients. Outcomes were discounted at 5% 
per annum. 
 
3. Cost analysis 
Costs were calculated from trial data up to relapse, accounting for 
censoring. Costs for periods after relapse or 4 years were estimated using 
literature. The cost analysis was performed from a German public health 
payer perspective. Costs were discounted at 5% per annum. 
 
4. Results and conclusion 
See table 4.  
Expected cost of treatment following relapse was close to *21.000 in both 
arms. 
 
5. Comments 
- Uncertainty was explored using a bootstrapping approach.  
- No breakdown of the costs is given.  
- The analysis is presented only in abstract form, hence it is difficult to 
comment upon the specific methodologies and the appropriateness of their 
use. 
 
 
Aballea and colleagues (2007). Cost-Effectiveness Analysis of 
Oxaliplatin Compared With 5-Fluorouracil/Leucovorin in Adjuvant 
Treatment of Stage III Colon Cancer in the US. 
 
1. Overview 
This article evaluates the long-term cost-effectiveness of oxaliplatin in 
combination with 5FU/LV. It uses patient level data from the MOSAIC trial, 
which compared oxaliplatin/5–FU/LV (FOLFOX4) to 5FU/LV alone in the 
adjuvant treatment of stage II and III colon cancer. Aballea et al. restricted 
their analysis to stage III colon cancer. The outcome measures they 
estimated were the cost of adjuvant treatment with FOLFOX4 per LY, DFY 
and QALY gained over a lifetime. The perspective of the analysis was that 
of the US Medicare system. 
 
2. Effectiveness analysis 
The median follow-up of the used MOSAIC trial data was 44.2 months. 
DFS and OS were estimated up to 4 years from randomisation. A Weibull 
function was fitted to the DSF-curve and extrapolated to 5 years post-
randomisation. No further relapses were assumed to occur beyond 5 years 
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from diagnosis and subsequent survival was estimated from life tables, 
adjusting for age and sex. OS beyond 4 years was predicted from the 
extrapolated DSF-estimates and observed survival after recurrence. 
QALYs, DFYs and LYs gained were calculated and discounted at 3% per 
annum. Utility estimates were obtained from literature. 
 
3. Cost analysis 
Lifetime costs of colon cancer-related healthcare resources were 
estimated from a US Medicare perspective, discounted to present values 
at a rate of 3% per annum. Costs were calculated from trial data, 
accounting for censoring. Costs for periods after relapse or 4 years were 
estimated using literature. 2003 cost data has been used. 
 
4. Results and conclusion 
See table 4. 
Average standard cost of a recurrence was $61.200 for patients receiving 
adjuvant 5FU/LV as treatment and $58.800 for patients on adjuvant 
FOLFOX4. 
 
5. Comments 
- ICERs were also calculated for three alternative scenarios, resulting in 
modest variations in the outcomes. 
- A probabilistic analysis was conducted using the bootstrap method to 
estimate the level of confidence in the cost-effectiveness results, given the 
sampling variability in the MOSAIC trial data. FOLFOX4 has a 91% to 96% 
probability of being cost-effective, assuming a willingness-to-pay of 
$50.000 to $100.000 per QALY gained. 
 
 
Aballea and colleagues (2005). Cost-effectiveness analysis of 
oxaliplatin/5FU/LV in adjuvant treatment of stage III colon cancer in 
the UK and Germany. 
 
1. Overview 
This meeting abstract outlines a cost-effectiveness analysis of oxaliplatin in 
combination with 5FU/LV. It uses patient level data from the MOSAIC trial, 
which compared oxaliplatin/5–FU/LV (FOLFOX4) to 5FU/LV alone in the 
adjuvant treatment of stage II and III colon cancer. Aballea et al. restricted 
their analysis to stage III colon cancer. They estimated the cost of adjuvant 
treatment with FOLFOX4 per QALY gained over a lifetime. A payer 
perspective was used. 
 
2. Effectiveness analysis 
DFS and OS were estimated up to 4 years from randomisation. A Weibull 
function was fitted to the DSF-curve and extrapolated to 5 years post-
randomisation. No further relapses were assumed to occur beyond 5 years 
from diagnosis and subsequent survival was estimated from life tables, 
adjusting for age and gender. Lifetime OS was predicted using DSF and 
data on observed survival in relapsing patients.  
Life-years accrued were assigned weights according to chemotherapy-
related toxicities, recurrence and age, to estimate QALYs. 
QALYs were discounted at 3.5% and 5% per annum for the UK and 
Germany respectively. 
 
3. Cost analysis 
Costs were estimated from trial data, accounting for censoring; while costs 
of relapse and subsequent management were estimated from literature. 
The cost analysis was performed from a payer perspective. Costs were 
discounted at 3.5% and 5% per annum for the UK and Germany 
respectively. 
 
4. Results and conclusion 
See table 4. 
 
5. Comments 
- If the willingness to pay for additional QALYs were £20.000 in the UK and 
€50.000 in Germany, FOLFOX4 would be cost-effective with probabilities 
of 95% and 96% in these countries respectively. 
- Uncertainty was explored using a bootstrapping approach.  
- No breakdown of the costs is given.  
- The analysis is presented only in abstract form, hence it is difficult to 
comment upon the specific methodologies and the appropriateness of their 
use. 
 
Aballea and colleagues (2005). Cost-effectiveness analysis of 
oxaliplatin/5FU/LV in adjuvant treatment of stage III colon cancer in 
the U.S. 
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1. Overview 
This ASCO (American Society of Clinical Oncology) Annual Meeting 
Abstract outlines a cost-effectiveness analysis of oxaliplatin in combination 
with 5FU/LV. It uses patient level data from the MOSAIC trial, which 
compared oxaliplatin/5–FU/LV (FOLFOX4) to 5FU/LV alone in the adjuvant 
treatment of stage II and III colon cancer. Aballea et al. restricted their 
analysis to stage III colon cancer. They estimated the cost of adjuvant 
treatment with FOLFOX4 per LYG over a lifetime. The perspective of the 
analysis was that of the US Medicare system. 
 
2. Effectiveness analysis 
The median follow-up of the used MOSAIC trial data was 44.2 months. 
DFS and OS were estimated up to 4 years from randomisation. A Weibull 
function was fitted to the DSF-curve and extrapolated to 5 years post-
randomisation, with no further relapses assumed to occur beyond this 
time. A life table was used for survival of the US general population. OS 
beyond 4 years was predicted using the extrapolated DSF-estimates and 
data on observed survival in relapsing patients. Health benefits were 
discounted at 3%. 
 
3. Cost analysis 
Costs were calculated from trial data up to relapse, accounting for 
censoring. Costs for periods after relapse or 4 years were estimated using 
literature. The cost analysis was performed from a US Medicare 
perspective, with a discount rate of 3% applied to both costs and health 
benefits. 
 
4. Results and conclusion 
See table 4.  
Expected cost of treatment following relapse was estimated at $54.000. 
 
5. Comments 
- Uncertainty was explored using a bootstrapping approach.  
- No breakdown of the costs is given.  
- The analysis is presented only in abstract form, hence it is difficult to 
comment upon the specific methodologies and the appropriateness of their 
use. 
 
 
Muszbek and Odhiambo (2007). Cost-utility analysis of oxaliplatin in 
the adjuvant treatment of colon cancer in Hungary. 
 
1. Overview 
This meeting abstract outlines a cost-utility analysis of oxaliplatin in 
combination with 5FU/LV. It uses data from the MOSAIC trial, which 
compared oxaliplatin/5–FU/LV (FOLFOX4) to 5FU/LV alone in the adjuvant 
treatment of stage II and III colon cancer. Muszbek and Odhiambo 
restricted their analysis to stage III colon cancer. They estimated the 
incremental cost of adjuvant treatment with FOLFOX4 per QALY, DFY and 
LY saved over a lifetime. The analysis was accomplished from a 
Hungarian payer perspective. 
 
2. Effectiveness analysis 
The efficacy data of the MOSAIC trial was extrapolated for lifetime. Utilities 
values were incorporated from published sources. Age and gender specific 
general mortality rates and utilities were derived from epidemiology data of 
the Hungarian population and published utilities based on the EQ-5D 
questionnaire. Outcomes were discounted at 5%. 
 
3. Cost analysis 
The analysis was performed from a payer perspective thus, only direct 
medical costs were taken into account. Resource use was based on 
Hungarian treatment patterns and unit costs. Costs were discounted at 
5%. 
 
4. Results and conclusion 
See table 4.  
Expected cost of treatment following relapse was close to *21.000 in both 
arms. 
 
5. Comments 
- One-way sensitivity analysis was employed. The results were most 
sensitive to discount rate, general population data and the cost of 
chemotherapy. 
- No breakdown of the costs is given.  
- The analysis is presented only in abstract form, hence it is difficult to 
comment upon the specific methodologies and the appropriateness of their 
use. 
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Maniadadakis and colleagues (2009)(22). XELOX versus FOLFOX6 as 
an adjuvant treatment in colorectal cancer: an economic analysis. 
 
1. Overview 
In this economic analysis, XELOX (capecitabine/oxaliplatin) is compared to 
FOLFOX6 (5FU/LV/oxaliplatin) as adjuvant treatment for operated high risk 
stage B2 or stage C colorectal cancer patients in Greece. Interim data from 
a long-term, randomised, multi-centre, controlled, phase III, clinical trial 
were used. Treatment effectiveness was measured in terms of mean 
survival in each treatment group. Since survival rate was the same in the 
two arms, a cost-minimisation analysis was carried out. It was undertaken 
at a median trial follow-up of over a year, from the perspectives of the 
National Health Service (NHS), Social Insurance Funds (SIF) and patients 
in Greece.  
 
2. Effectiveness analysis 
Survival was calculated as the time from randomisation to death or loss to 
follow-up. The Kaplan-Meier method was used to analyse the survival 
data. The survival rate was 91.9% in the FOLFOX6 arm and 97.6% in the 
XELOX arm (p = 0.20) and the median survival for the follow up period 
time was 1.17 and 1.00 years respectively (p = 0.62). It was concluded that 
there was no difference in the survival rate and the mean survival for the 
follow up period in the two trial arms. 
 
3. Cost analysis 
Patient data were combined with 2008 unit prices to estimate the total cost 
of patient care, the patients’ travelling expenditure and their productivity 
losses. 
 
4. Results and conclusion 
See table 4.  
From a NHS as well as from a SIF perspective, mean chemotherapy costs 
are higher for XELOX than for FOLFOX6, while costs of administration and 
hospitalisations are higher for FOLFOX6 compared to XELOX. In result, 
total treatment costs were lower for XELOX compared to FOLFOX6, 
irrespective of the perspective of the analysis. From patients’ perspective, 
XELOX resulted in a reduction of travelling expenditures and productivity 
losses.  
 
5. Comments 
- Raw data were bootstrapped 5000 times in order to allow statistical 
testing. 
- Quality of life data were not considered. 
- The analysis is presented in abstract form, hence it is difficult to comment 
upon the specific methodologies and the appropriateness of their use. 
 
 
Cost-effectiveness oxaliplatin: comments 
New cost-effectiveness information on adjuvant treatment with oxaliplatin 
published between 2005 and 2009 is limited. MOSAIC trial results were 
extrapolated and projected on various countries to estimate national cost-
effectiveness of FOLFOX4 compared to 5FU/LV alone. Six of the eight 
articles included in this review were published by Aballea et al.. They were 
meeting abstracts published in 2005 and full text articles presenting results 
similar to the results of these 2005-meeting abstracts. The results of 
Aballea et al. are closely related to the estimates in the manufacturer’s 
submission to the appraisal, already covered in Pandor et al. (2006). Since 
2005, NSABP C-07 results have not been used to contribute to the 
reported MOSAIC-trial based estimates. 
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Table 4 - Results of the oxaliplatin cost-effectiveness review. 
Effectiveness  Treatment Comparator Stage Perspective 
Treatment Comparator 
Cost Cost-effectiveness Conclusion 
Number of LYs gained*:  Cost of relapses occurring in 
year 5 (treatment+follow‐up)*: 
11.739 10.971 £205 £300 
LY difference: 0.768. Costs of follow‐up for patients 
relapsing during years 1‐4*: 
Number of DFYs gained*: £408 £547 
11.153 9.906 
DFY difference: 1.247. 
Costs of follow‐up for patients 
with no relapse*: 
Number of QALYs gained*: £740 £644 
9.257 8.577 Total*: 
£1352 £1491 
Aballea et 
al. 2007  
FOLFOX4 
(oxaliplatin/
5FU/LV) 
5FU/LV 
 
III UK NHS 
QALY difference: 0.680 
Incremental costs*: ‐£140. 
ICER:  
£4254 per LYG (dominant‐
dominated) 
£2620 per DFY gained 
(dominant‐£8108) 
£4.805 per QALY gained 
(dominant‐£45.658) 
FOLFOX4 compares favourable 
with other accepted interventions 
in oncology. 
Extrapolated overall life‐
expectancy: 
Total lifetime disease‐ related 
costs: 
17.6 years 16.2 years £18.548 £15.281 
Overall life‐expectancy 
difference: 1.4 years (95% CI 
unknown). 
Lifetime extrapolated 
incremental DFS: 1.99 years 
(0.63‐3.36). 
Number of QALYs gained: 
9.26  8.58 
Aballea et 
al. 2005  
FOLFOX4 
(oxaliplatin/
5FU/LV) 
5FU/LV III UK NHS 
QALY difference: 0.68 (0.08‐
1.31) 
Cost difference: £3.267. 
ICER:  
£4.805 per QALY gained 
(dominant‐£45.658) 
 
FOLFOX4 compares favourable 
with other accepted interventions 
in oncology. 
Extrapolated overall life‐
expectancy: 
Total lifetime disease‐ related 
costs: 
17.51 years 16.18 years *23.129 *17.285 
Overall life‐expectancy 
difference: 1.3 years (‐0.01‐
2.68). 
Aballea et 
al. 2005  
FOLFOX4 
(oxaliplatin/
5FU/LV) 
5FU/LV III German 
public health 
payer 
Lifetime extrapolated 
incremental DFS: 1.98 years 
(0.65‐3.31). 
Cost difference: *5.844. 
ICER: 
*9.328 per LYG 
FOLFOX4 compares favourable 
with other accepted interventions 
in oncology. 
Number of LYs gained:  Mean estimated costs: 
12.34 11.52 $56.300 $39.300 
Aballea et 
al. 2007  
FOLFOX4 
(oxaliplatin/
5FU/LV) 
5FU/LV III US Medicare 
LY difference: 0.83. Cost difference: $17.000. 
ICER:  
$20.603 per LYG (95% CI 
unknown) 
FOLFOX4 compares favourable 
with other accepted interventions 
in oncology. 
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Number of DFYs gained: 
11.75 10.42 
DFY difference: 1.32 
Number of QALYs gained: 
9.94 9.20 
QALY difference: 0.75. 
$12.873 per DFY gained 
(95% CI unknown) 
$22.804 per QALY gained 
(95% CI unknown) 
Aballea et 
al. 2005  
FOLFOX4 
(oxaliplatin/
5FU/LV) 
5FU/LV III Payer (UK 
and 
Germany) 
QALY difference UK: 0.68 (0.08‐
1.31). 
QALY difference Germany: 0.57 
(0.04‐1.10). 
Cost difference UK: £3267. 
Cost difference Germany: 
£5844. 
 
ICER: 
UK: £4805 per QALY gained. 
Germany: €10.199 per QALY 
gained. 
 
‐ FOLFOX4 compares favourable 
with other accepted interventions 
in oncology. 
‐ The difference between countries 
was largely attributable to the 
discount rates used rather than 
differences in organisation of 
health care. 
Extrapolated overall life‐
expectancy: 
Total lifetime disease‐related 
costs: 
19.99 years 18.33 years $55.525 $38.093 
Aballea et 
al. 2005  
FOLFOX4 
(oxaliplatin/
5FU/LV) 
5FU/LV III US Medicare 
Overall life‐expectancy 
difference: 1.66 years (0.10‐
3.22). 
Lifetime extrapolated DFS: 2.31 
years (0.72‐3.89). 
Cost difference: $17.432. 
ICER: 
$17.900 per LYG 
FOLFOX4 compares favourable 
with other accepted interventions 
in oncology. 
Muszbek 
and 
Odhiambo 
2007  
FOLFOX4 
(oxaliplatin/
5FU/LV) 
5FU/LV III Payer 
(Hungary) 
LY difference: 0.531. 
DFY difference: 0.958. 
QALY difference: 0.455. 
 
Cost difference: HUF 1.310.064 
(€5.240). 
ICER: 
HUF 2.468.660 (€9.875) per 
LYG. 
HUF 1.367.712 (€5.471) per 
DFY gained. 
HUF 2.889.342 (€11.521) 
per QALY gained. 
FOLFOX4 is a cost‐effective 
strategy in Hungary for the 
postoperative adjuvant treatment 
of patients with stage III colon 
cancer compared to the De 
Gramont protocol. 
Maniadakis 
et al. 2009 
(22) 
XELOX FOLFOX6 High 
risk 
B2 
and C 
NHS, SIF and 
patients in 
Greece 
Survival rate: 
97.6%         91.9% 
(p=0.20) 
Median survival for the follow 
up period time: 
1.17 years      1.00 years 
(p=0.62) 
Total cost to the NHS: 
€12525          €17480 
Cost savings: €4955  
(95% CI €2423‐€6524, 
p<0.001) 
Total cost to the SIF: 
€12617          €16240 
Cost savings: €3623 (95% CI 
€1467‐5439, p<0.001) 
‘Comparable’ effectiveness, 
lower cost. 
XELOX may be a cost‐effective 
treatment approach for the 
management of colorectal cancer 
patients who had surgery in 
Greece. 
FOLFOX4: 2‐h infusion of 85 mg/m2 oxaliplatin simultaneously with 200 mg/m2 FA followed by a 400 mg/m2 bolus of 5‐FU day 1 followed by a 22‐h protracted infusion of 600 mg/m2 5‐FU days 1‐2, every 
14 days for 12 cycles. 
5FU/LV: 2‐h infusion of 200 mg/m2 FA followed by a 22‐h protracted infusion of 600 mg/m2 FU days 1‐2, every 14 days for 12 cycles. 
* Predicted beyond 4 years, discounted by 3.5% per annum. 
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Annex IV Summary of collected data 
 Data from the cancer registry
Demographics
  Patient identification number
  Date of birth
  Gender
Data source
  Hospital where patient was diagnosed
Diagnosis / tumor characteristics
  Date of diagnosis
  Location of the tumor
  Differentiation of the tumor
  Number of lymph nodes assessed/ positive
  Disease stage, metastasis stage
Treatment characteristics 
  Surgery (yes/no)
  Chemotherapy (yes/no)
  Radiotherapy (yes/no)
  Hospital where patient was treated
Follow-up data
  Survival status
  Date of death or date last known to be alive  
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Additional data Minimal CRF
Patient characteristics
  Co‐morbidity
   
Tumor characteristics
  Number of lymph nodes assessed
  Differentiation of the tumor
  Perforation of the intestine
  Pre‐operative carcinoembryonic antigen (CEA) level
  Post‐operative CEA level
Treatment characteristics
  Date of adjuvant chemotherapy administration
  Type of chemotherapy given
  Reason for not giving oxaliplatin
Follow-up data
  Survival status
  Date last known to be alive or date of death
  Disease status
  In case of progression, date of progression
  In case of death, main cause of death
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Additional data Maximal CRF
Patient characteristics
  Height
  Weight at start every treatment cycle
  Body Surface Area (BSA) at start every treatment cycle
   WHO performance status at start every treatment cycle
Treatment characteristics
  Prior radiotherapy
  Type of chemotherapy given
  Planned daily dose
  Actual dose received
  Dose reduction/ reason for dose reduction
  Delay of treatment/ reasons for delay 
  Total number of cycles given
  Major reason for discontinuation chemotherapy
Follow-up data
  CEA level/ date of CEA laboratory test
  Basis on which progression was diagnosed
Resource use
  Number of visits to outpatient clinic
  Hospital admissions
  Laboratory tests
  Radiology
  Surgery
  Radiotherapy
  Other procedures
  Concomitant medication  
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Annex V Summary of minimal CRF Stage III 
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Annex VI Summary of maximal CRF Stage III 
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Annex VII Summary of minimal CRF Stage IV 
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Annex VIII Summary of maximal CRF Stage IV 
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Annex IX Kaplan Meier curves derived from MOSAIC trial 
and PILOT study 
Kaplan Meier curves derived from MOSAIC trial. 
 
Kaplan-Meier estimates of disease-free survival by treatment arm and by stage 2 
 
  
 
Kaplan Meier curves derived from PILOT study. 
 
Kaplan-Meier estimates of disease-free survival of eligible oxaliplatin patients 
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Annex X Summary of the hospitals that participated 
The following hospitals participated in the pilot study: 
 
 
UMC St Radboud ‐ Nijmegen
Erasmus MC ‐ Rotterdam
LUMC ‐ Leiden
Catharina ziekenhuis ‐ Eindhoven
Mesos Medisch Centrum ‐ Utrecht
Groene Hart ziekenhuis ‐ Gouda
Diakonessenhuis ‐ Utrecht
Gelderse Vallei ‐ Ede
Martini ziekenhuis ‐ Groningen
Reinier de Graaf Gasthuis ‐ Delft
Medisch Centrum Alkmaar ‐ Alkmaar
 't Lange Land ziekenhuis ‐ Zoetermeer
Ikazia ziekenhuis ‐ Rotterdam
Nij Smellinghe ‐ Drachten
Slotervaart ziekenhuis ‐ Amsterdam
MC Haaglanden ‐ Den Haag
Isala klinieken ‐ Zwolle
Spaarne ziekenhuis ‐ Hoofddorp
Jeroen Bosch ‐'s Hertogenbosch  
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Summary 
Introduction 
The Dutch policy regulations for expensive hospital medicines require evidence from 
outcomes research for the assessment of appropriate use and real-world cost-
effectiveness of expensive medicines after three years of temporary additional funding. 
Outcomes research in this particular context is new in Dutch policy making and therefore 
experience in the application of outcomes research is lacking. The Dutch Health Care 
Insurance Board published the Guidance for Outcomes Research in collaboration with a 
working party of experts from relevant disciplines. This report is a practical addendum to 
this Guidance and provides empirical evidence about methodological issues related to 
outcomes research. 
 
Method 
We investigated methodological issues related to performing outcomes research. These 
issues can be classified into three categories: 1) study design and data collection; 2) 
appropriate use and dynamics in daily clinical practice; 3) ability to obtain valid and precise 
cost-effectiveness estimates. We explored recommendations from the Guidance for 
Outcomes Research and applied them in two pilot outcomes research studies. Both pilot 
studies investigated the appropriate use and cost-effectiveness of two expensive hospital 
drugs (i.e., oxaliplatin and bortezomib) in real-world clinical practice in the Netherlands. 
Despite the strong recommendations in the Guidance to use a prospective research 
design, both pilot studies adopted a retrospective study design because they needed to be 
completed within a short time period. 
 
Results 
In both pilot studies, it was possible to collect data on the diffusion of the drug, baseline 
patient characteristics, application of treatment regimes, dose modifications, treatment 
related toxicities and direct medical costs. The feasibility of collecting data in an efficient 
way was challenged by our retrospective research design and by the fact that detailed 
data were retrieved from hospital medical records. We were able to obtain information on 
appropriate use of drugs and dynamics of treatment in daily practice. A high degree of 
treatment variation was revealed in the bortezomib pilot study, whereas the oxaliplatin pilot 
study (in both stage III colon cancer and metastatic colorectal cancer) showed that 
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patients were treated in a way that was reasonably similar to the treatment of patients in 
clinical studies. Subsequently, evidence synthesis using modelling techniques of evidence 
from outcomes research and evidence from the literature enabled the estimation of a valid 
and precise incremental outcome measure in the oxaliplatin pilot study for stage III colon 
cancer. Evidence synthesis was not performed in the oxaliplatin pilot study for metastatic 
colorectal cancer, but we concluded that synthesis would not result in an important change 
in the incremental cost-effectiveness ratio. Although evidence synthesis was not 
performed in the bortezomib study, it is debatable as to whether any synthesis would have 
led to a valid and precise estimate of the incremental cost-effectiveness of bortezomib 
versus other treatments. 
 
Discussion 
Taking into account the recommendations from the Guidance for Outcomes Research, our 
pilot studies had some limitations. Use of the retrospective study design resulted in three 
consequences: no data could be collected on Health Related Quality of Life, only direct 
healthcare costs were studied, and treatment randomisation was not possible. However, 
we believe that the retrospective design did not significantly affect the conclusions about 
the cost-effectiveness of oxaliplatin and bortezomib. In observational studies, irrespective 
of whether data are prospectively or retrospectively collected, patients are not randomly 
allocated to different therapies and there is no guarantee that patient groups are 
comparable. Although disease specific registries cannot resolve all of the drawbacks of 
data collection, they can help to obtain sufficient numbers of similarly treated patients, 
enable uniform response criteria, support data collection and thereby facilitate outcomes 
research. Based on the pilot studies, we conclude that it is feasible for an outcomes 
research study to provide relevant information about appropriate drug use (who gets it, 
and what do they receive) as well as the diffusion of the drug and the dynamics of 
treatment in daily practice. Furthermore, where appropriate, cost-effectiveness estimates 
should be based on a synthesis of real-world data and other available evidence.  
We believe that the findings from the pilot studies are reasonably generalisable to 
the situation with other drugs on the expensive drug list. However, if outcomes research is 
going to be used in an optimal way for different types of diseases and treatments, it is 
necessary to accept flexibility in study characteristics, including the evidence development 
time frame and the questions that outcomes research should answer.  
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KEY MESSAGES 
 
 
Critical success factors 
• Appropriate research design available at T=0 
• Clearly defined research question 
• Research question aims to reveal and/or reduce uncertainty at reappraisal 
• Collaboration between regulatory agency, medical field and HTA agencies  
• Flexibility and customisation  
 
 
Drawbacks 
• Outcomes research requires financial and time investments 
• Observational studies have important bias and confounding issues 
• Existing data sources do not provide sufficient data for outcome research 
requiring additional data collection 
• Medical records have important missing values on prognostic factors and 
outcome measures 
• Dynamics in daily practice can compromise the comparability with the clinical 
registration trial and hinder the ability to estimate a valid and precise cost-
effectiveness ratio 
 
 
Recommendations 
• Choice of research design should depend on type of disease, type of drug and 
expected dynamics in daily practice 
• Appropriate time frame depends on type of disease and drug 
• Disease specific registries can help to obtain sufficient numbers of similarly 
treated patients and enable uniform response criteria 
• Real-world evidence development on appropriate use should reveal who 
receives the drugs and how the drug is given in daily practice 
• Insight into who receives the drug requires a minimal real-world dataset 
• Insight into how the drug is given requires a detailed real-world dataset 
• Flexibility is needed regarding the objectives and subsequent requirements of 
outcomes research 
• Where appropriate, cost-effectiveness estimates should be based on a 
synthesis of real-world data and other evidence  
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1. Introduction 
Since 2006, Dutch policy regulations for expensive hospital drugs require outcomes 
research. Outcomes research (“uitkomstenonderzoek”) in this particular context is defined 
as the collection of data from daily clinical practice in order to assess appropriate use 
(“doeltreffende toepassing”) and real-world cost-effectiveness (“doelmatigheid”) of a drug. 
According to this policy regulation, hospitals are entitled to receive additional funding for 
enlisted expensive hospital or orphan drugs after regulatory approval for a limited period of 
time. After three years, a re-appraisal is conducted regarding the real-world therapeutic 
added value, actual budget impact, appropriate use and cost-effectiveness in daily 
practice. The decision whether or not to continue financial compensation for hospitals is 
based on the results of outcomes research. 
The outcomes research requirement in this context is new in Dutch policy making; 
therefore, experience in the application of outcomes research is lacking. Important 
questions arising in this particular context of outcomes research are: 1) which study design 
and outcome parameters should be used; 2) what kind of data can be collected; 3) which 
data sources are available and appropriate; 4) how should dynamics in daily clinical 
practice be dealt with; 5) in what way can outcomes research lead to valid, precise and 
generalisable results; 6) what is the impact of the decision to use a three-year time frame; 
and 7) how to set up outcomes research studies in an efficient and pragmatic way? 
The Health Care Insurance Board (CVZ) initiated several research activities to 
investigate how outcomes research should be conducted. In 2007, the institute for Medical 
Technology Assessment performed a literature search and, in parallel, experts from 
relevant disciplines cooperated in a working party with the aim to identify, elaborate and 
draw up relevant methodological issues. This resulted in the Guidance for Outcomes 
Research (“Leidraad voor uitkomstenonderzoek”) published in December 2008 by the 
Dutch Health Care Insurance Board (Delwel 2008). To evaluate this Guidance, the institute 
for Medical Technology Assessment conducted two outcomes research pilot studies. Two 
different existing databases for identifying eligible pilot patients and two different types of 
diseases were intentionally selected in order to assess methodological issues related to 
outcomes research from a broad perspective. The Guidance for Outcomes Research 
provides recommendations how to perform outcomes research based on literature and 
expert opinion, whereas the pilot studies present primary information on empirical findings 
of performing outcomes research while taking into account this Guidance.  
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The main objectives of this study were 1) to obtain experience with designing and 
executing outcomes research; 2) to generate knowledge with respect to methodological 
issues associated with dynamics in daily clinical practice; and 3) to examine the feasibility 
to obtain valid and precise incremental cost-effectiveness estimates. These objectives 
address the previously described seven questions that arise in the application of outcomes 
research in the context of the policy regulations for expensive hospital drugs. This report 
presents the findings regarding the methodological issues based on the pilot studies; the 
results of the pilot studies are described in separate reports. These empirical findings are a 
practical addendum to the Guidance for Outcomes Research.  
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2. Methods 
We investigated methodological issues related to performing outcomes research as 
required by Dutch policy regulations for expensive hospital medicines. Two pilot outcomes 
research studies were the core of this research. We choose a pragmatic research design 
for both pilot studies. Considering the research questions, methodological issues were 
investigated according to the following three categories: 1) study design and data 
collection; 2) appropriate use and dynamics in daily clinical practice; and 3) ability to obtain 
valid and precise cost-effectiveness estimates. For all three categories, we explored the 
recommendations from the Guidance for Outcomes Research and applied them in the two 
pilot outcomes research studies. 
The pilot studies investigated the appropriate use and cost-effectiveness of two 
expensive hospital drugs (i.e., bortezomib and oxaliplatin) in real-world clinical practice in 
the Netherlands. Two different data sources for identifying eligible pilot patients and two 
different types of drugs were intentionally selected in order to assess methodological 
issues of outcomes research from a broad perspective. The selection for bortezomib and 
oxaliplatin was based on factors such as type of drug, disease population (i.e., small 
versus large), indication, expectations regarding shift in indication, relevant outcome 
measures (i.e., intermediate endpoints versus final endpoints), expected way of treatment 
(i.e., trial based versus daily practice) and availability of data sources to identify eligible 
patients (i.e., trial database versus population based registry). 
 The bortezomib pilot study examined the appropriate use and cost-effectiveness of 
bortezomib by exploring how bortezomib was used in Dutch daily practice of relapsed or 
refractory multiple myeloma and by investigating real-world treatment effects and costs of 
bortezomib treatment. Pilot patients were selected from patients who relapsed from 
treatment protocol of a clinical trial (HOVON50) for upfront therapy of multiple myeloma. 
First, a minimal Case Report Form was obtained from the HOVON50 database in order to 
identify eligible patients. Second, detailed case reports were retrospectively completed 
using hospital medical records available from the time of first relapsed or refractory 
disease until end of follow-up. We investigated the diffusion of bortezomib, application of 
treatment regimes, dose modifications and treatment-related toxicities. Different 
adjustment techniques were compared in order to analyse the effect of bortezomib 
treatment on overall survival. Treatment costs were computed from a healthcare 
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perspective and costs for individual patients were determined by applying unit costs to 
individual resource use. 
 The oxaliplatin pilot study examined the appropriate use and cost-effectiveness of 
oxaliplatin by exploring how oxaliplatin was used in Dutch daily practice for a) the 
treatment of stage III colon cancer; and b) the treatment of metastatic colorectal cancer. 
Real-world effects and costs of oxaliplatin treatment were investigated. The pilot 
population was identified via the database of the Comprehensive Cancer Centres in the 
Netherlands and comprised patients diagnosed with stage III colon or stage IV colorectal 
cancer. First, minimal Case Report Forms were retrospectively completed using hospital 
medical records. Second, maximal Case Report Forms were used to collect further 
detailed data for a representative sub-group. We investigated how oxaliplatin was used in 
daily practice and analysed application of treatment regimes, dose modifications and 
treatment-related toxicities. Cox multivariate regression techniques were used to analyse 
the effect of oxaliplatin on disease-free survival (stage III) and overall survival (stage IV). 
Treatment costs were calculated using the hospital perspective and resource use was 
assessed per individual patient by means of micro-costing estimates. Additionally, the 
incremental cost-effectiveness of oxaliplatin in stage III colon cancer was determined using 
a probabilistic Markov model, synthesising evidence from the pilot study and the pivotal 
clinical registration trial (MOSAIC). 
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3. Results 
The empirical findings from the two pilot outcomes research studies are presented in three 
categories: experiences regarding study design and data collection; appropriate use and 
dynamics in daily clinical practice; and ability to obtain valid and precise of cost-
effectiveness estimates. 
 
 
3.1 Study design and data collection 
Study design 
The Guidance for Outcomes Research provides a flowchart describing how to set up a 
pragmatic outcomes research design (Figure 3.1). At time T=0 (i.e., time of the initial 
assessment), the availability of a T=0 model, Value of Information (VOI) analysis and the 
expectation for potential dynamics in daily practice determine what data needs to be 
collected (i.e., detailed data versus target specific data). The Guidance describes several 
potential data sources for outcomes research, such as ongoing clinical trials, existing 
patient registries, hospital medical records, and prospective observational patient registries 
(Delwel 2008). CVZ strongly recommends to use disease or indication specific patient 
registries in order to prospectively collect data useful for the assessment of both 
appropriate use and (incremental) cost-effectiveness of an expensive drug at time T=3 
(i.e., time for reappraisal after three years) in daily practice. For more detailed information 
on this flowchart and on pragmatic outcomes research designs, we refer to the Guidance 
for Outcomes Research (Delwel 2008).  
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Figure 3.1: Flowchart for a pragmatic research design for outcomes research 
 
Source: Delwel 2008 
 
The pilot studies conducted outcomes research of two expensive hospital drugs (i.e., 
bortezomib and oxaliplatin). For both studies, an initial cost-effectiveness indication and a 
T=0 model were not available for the reimbursement decision body due to the year of 
registration. For the bortezomib pilot study, we anticipated high variation in daily practice 
and the expected use of a VOI analysis, in order to establish which specific data should be 
collected, would have had limitations. In contrast, a VOI analysis might have been relevant 
for the oxaliplatin pilot study. Nevertheless, in both pilot studies a VOI analysis was not 
performed, but detailed data were collected for the assessment at time T=3 of outcomes 
research regarding the dynamics in daily practice, appropriate use and cost-effectiveness. 
In contrast to a prospective study design as recommended by the Guidance, both pilot 
studies applied a retrospective study design for pragmatic reasons (i.e., time restrictions 
due to the fact that the empirical evidence as addendum to the Guidance needed to be 
obtained within a short time period). 
In both pilot studies, an existing patient registry was used to identify eligible 
patients. First, the bortezomib pilot study obtained a minimal dataset from the HOVON50 
database in order to identify eligible patients. This is a database of a clinical trial performed 
in patients younger than 65 years for upfront therapy in multiple myeloma. It contains 
information on 543 Dutch patients and is a representative sample for younger multiple 
- 7 - 
myeloma patients in the Netherlands. Data from this database for all 543 Dutch patients 
could be retrieved immediately after granted permission from the principal investigator. 
The database provided sufficient information to identify eligible pilot patients. In addition, 
this database provided information such as the hospital where the patient was treated, 
age, gender, date of diagnosis, disease stage, treatments, response to treatment, adverse 
events, time to first progression and survival status. The database often lacked the 
previous year’s follow-up. Therefore, this data source not only restricted our pilot 
population to younger patients but also the available follow-up limited the ability to identify 
patients who were treated for relapsed or refractory disease in the last one to two years. 
Consequently, we were forced to apply lenient inclusion criteria in order to be able to 
include a sufficient number of patients. Detailed data for 139 pilot patients were 
retrospectively collected from hospital medical records. Since access to these records 
required consent from clinicians in each participating hospital, a short time delay (i.e., one 
to six weeks) before data collection could take place. 
 Second, the oxaliplatin pilot study used the database of the population based 
registry of the Comprehensive Cancer Centres in the Netherlands to identify pilot patients. 
After the request for data was submitted, it took two months to obtain data approval and 
another six months to receive the data from this registry on 4031 patients diagnosed with 
stage III colon cancer and 4201 patients diagnosed with stage IV colorectal cancer. The 
merging process of regional databases into one national database might have prolonged 
this process. Subsequently, granted permission of physicians was necessary before data 
could be collected from hospital medical records. The data from this registry offered 
sufficient information to identify eligible pilot patients and provided information such as 
hospital where patient was diagnosed, age, gender, date of diagnosis, disease stage, 
tumour location, degree of malignancy, initial treatment data and survival. This information 
is in itself not sufficient for outcomes research and extra information was needed for 
further patient selection, such as type of chemotherapy received. Detailed data (e.g. 
treatment, effects and costs) were completed using hospital medical records. The required 
hospital consent did not cause any time delay because we could make use of the network 
of our close collaboration partners (Dutch Colorectal Cancer Group Nijmegen) which 
resulted in immediate granted permission in 40 hospitals. 
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Detailed data collection 
In the Guidance for Outcomes Research, it is stated that a pragmatic approach for detailed 
data collection implies that all relevant data should be collected, such as data on costs, 
clinical outcomes, patient characteristics, patient reported outcomes and data on 
comparative treatments (Delwel 2008). The (re-)assessment of the therapeutic value of 
medicines is based on efficacy, effectiveness, side effects, experience, applicability and 
user-conveniences (Kuijpers and Toenders 2006). Therefore, relevant outcome measures 
in outcomes research of cancer treatments are amongst others life-years, quality adjusted 
life years (QALY), progression-free survival and disease-free survival. The assessment of 
appropriate use requires data on who receives the drug, how patients are treated and 
dynamics in daily practice. Real-world cost effectiveness estimations involve data on 
comparative treatments and the costs of resource use. Although a cost-utility analysis is 
preferred since quality of life is a relevant outcome measure, a cost-effectiveness analysis 
may provide essential additional decision making information (Drummond et al. 2005; CVZ 
2006; Delwel 2008). Reimbursement decisions are made for the entire population and 
therefore outcomes research should be conducted from a societal perspective (CVZ 2006; 
Delwel 2008).  
 Both pilot studies retrospectively collected detailed data from hospital medical 
records. The bortezomib study obtained detailed data on baseline patient characteristics, 
treatment application, treatment effects and resource use for all 139 included patients. 
Based on the information from the registry of the Comprehensive Cancer Centres on 463 
patients (in 19 hospitals) and 433 patients (in 29 hospitals) with stage III colon and 
metastatic colorectal cancer respectively, the oxaliplatin pilot study retrieved a minimal 
data set from hospital medical records for 391 and  312 patients respectively. This minimal 
dataset contained information on baseline characteristics, diffusion of oxaliplatin, 
considerations for choosing a treatment regime and clinical effects. Additionally, detailed 
data on dosage schemes, side effects and resource use was obtained for a representative 
subgroup of 206 and 130 patients with stage III colon and metastatic colorectal cancer 
respectively. 
It was possible to collect data on baseline patient characteristics. For patients 
treated for stage III colon cancer, we could obtain information on physicians’ motivation 
regarding the choice not to prescribe oxaliplatin in 77% of the patients. For example, age 
and co-morbidity were identified as independent predictors of non-prescription of 
oxaliplatin. Nevertheless, information on performance scores, which is thought to influence 
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both physician choice and prognosis, was missing in nearly half of the patients in both 
stage III colon and metastatic colorectal cancer. In the bortezomib pilot study, it was hardly 
ever possible to find information on physicians’ motivations regarding treatment choices for 
relapsed or refractory multiple myeloma disease. Besides that, essential information on 
prognostic factors was frequently missing. For both pilot studies, information on treatment 
details, such as received treatments and applied dosages, was usually reported in detailed 
chemotherapy lists.  
Regarding treatment outcomes, the availability of information on intermediate and 
final endpoints varied per pilot study. In the oxaliplatin study, progression free survival and 
overall survival were well described for stage III colon and metastatic colorectal cancer 
respectively. The median follow-up time in the oxaliplatin pilot study was approximately 
two years. In the bortezomib pilot study, treatment responses were often not reported 
according to universal standards and the reasons for starting a new treatment regime were 
not always transparent (i.e., progression, refractory or toxicity). However, effectiveness in 
life years could be estimated since the median follow-up available was approximately four 
years due to the fact that data were retrospectively collected for a drug already on the 
market before it was admitted on the policy list for expensive drugs. Information on 
treatment related toxicity was only moderate available for both pilot studies. Firstly, 
toxicities were hardly ever objectively recorded according to a standardised grading 
system. Secondly, it was not only time consuming to find data on toxicity in both pilot 
studies, but also difficult to find sufficient information on concomitant medication. 
Although treatment costs should be calculated from a societal perspective 
according to the Guidance for Outcomes Research and Guidelines for Pharmacoeconomic 
Research, both pilot studies only computed direct medical costs and thus used a 
healthcare perspective. A retrospective study design limits the feasibility and validity of 
using costs from a societal perspective. Data on individual resource use was available in 
patient medical records or in electronic databases. Unit costs (e.g. inpatient hospital days) 
were based on detailed micro-costing studies including full hospital costs (including 
overhead costs). It was possible to conduct these micro-costing studies by means of 
questionnaires for oncologists, haematologist and nurses involved in colon and colorectal 
cancer and multiple myeloma treatment. The costs of radiotherapy, surgical procedures 
and medical imaging were available by using tariffs issued by the Dutch Healthcare 
Authority. Finally, costs for medicines could be obtained from the Pharmaceutical 
Guideline of the Pharmaceutical Advisory Committee (“Farmacotherapeutisch Kompas”).  
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Feasibility of the study design and data collection 
Two different patient registries for recruiting pilot patients and two different types of 
diseases were used to assess methodological issues of outcomes research from a broad 
perspective. Table 3.1 presents the findings regarding study design and data collection for 
the bortezomib and oxaliplatin pilot studies in a summarised format. The study design and 
data collection were feasible for both pilot outcomes research studies. Both pilot studies 
applied a pragmatic research design set up with the aim to collect data in order to reduce 
uncertainty at the initial coverage decision and to evaluate appropriate use and real-world 
cost-effectiveness in Dutch daily practice. The oxaliplatin pilot study was able to examine 
two years of follow-up within the three year time frame of outcomes research for both 
stage III colon and metastatic colorectal cancer. The bortezomib pilot study was able to 
obtain approximately four years of follow-up due to a retrospective study design which 
assessed overall survival from start of diagnosis and included patients treated for multiple 
myeloma disease before bortezomib was added to the expensive drug list. 
 However, the feasibility to collect data in an efficient way was challenged by 
several reasons. First, our retrospective study design made it impossible to use Health 
Related Quality of Life (HRQOL) as an outcome measure. We did not collect real-world 
HRQOL data of pilot patients. Second, our retrospective study design resulted in missing 
values, such as important prognostic factors and intermediate outcome measures, since 
they were not always reported in medical records. Third, the existing data sources 
(HOVON50 database and the population based registry of the Comprehensive Cancer 
Centres) provided sufficient data to identify eligible pilot patients. However, it was 
necessary to collect additional data using hospital medical records. Data collection on 
treatment details and resource use was time consuming for both pilot studies. For 
example, the required time (up to four hours per patient) for obtaining information on 
concomitant medication in the bortezomib pilot study forced us to base concomitant 
medication resource use on detailed data of eighteen patients. For the remaining 121 
patients, data was collected in categories of concomitant medication use in set time 
periods and resource use costs involved were computed on costs per day treated. The 
oxaliplatin pilot study obtained minimal case report forms for 391 patients with stage III 
colon cancer in 19 hospitals, and for 312 patients with metastatic colorectal cancer in 29 
hospitals. It required one full day of work to collect minimal case reports forms for 
approximately 25 patients. Additionally, it was possible to retrieve approximately 6 and 4 
maximal case reports forms per day for a subsample of 206 patients with stage III colon 
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and 130 patients with metastatic colorectal cancer respectively. Fourth, many multiple 
myeloma patients (49%) were treated in more than one hospital. Consequently, over 1700 
hours were needed for data collection for the bortezomib pilot in 42 different hospitals in 
order to collect detailed data for a total of 139 patients.  
All data were collected by the principal investigators and medical students under 
the guidance of these investigators between April 2008 and May 2009. The retrospective 
study design enabled a relatively short time-period required for data collection. It is 
important to realise that the time frame to perform outcomes research not only includes the 
time needed for data collection, but also the time needed to design and implement the 
study and/or disease registry (including administrative steps such as approval by medical 
ethics committees) and the time needed for data analysis and reporting. Based on our 
experiences, we estimate that the study design and implementation phase would involve 
an average of three to six months (which could in theory be completed before time T=0), 
whereas the data analysis and reporting phase could require three to six months. 
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3.2 Appropriate use and dynamics in daily practice 
Appropriate use has two different aspects, namely who receives the drug and how the 
drug is used in daily practice. The Guidance advises collection of a minimal data set for 
investigating appropriate use and detailed data for examining dynamics in daily practice, 
both by means of an indication specific registry that prospectively follows patients (see 
Figure 3.1). The Guidance for Outcomes Research describes ‘dynamics in daily practice’ 
in terms of potential differences in a drug’s usage according to the registered indication 
and the actual application of this drug in daily practice. When assessing the potential for 
such difference, relevant aspects to be considered include the representativeness of the 
patient population, diffusion of drugs, patient compliance, shift in indication, off-label use, 
safety information and under-usage because of high costs (Delwel 2008). It is important 
that outcomes research reveals these dynamics in daily practice, not only by studying the 
appropriate use of a drug, but also by investigating treatment patterns, comparative 
treatments, treatment toxicities, diffusion of the drug and shifts in indication. 
 As mentioned before, both pilot studies retrospectively collected detailed data from 
hospital medical records on diffusion of both new drugs, application of treatment regimes, 
dose modifications, and treatment-related toxicities, effects and costs. It should be noted 
that the oxaliplatin pilot study only collected detailed data for a representative subgroup of 
patients regarding treatment details and resource use. Dynamics in daily practice could 
only be revealed from our detailed datasets. Appropriate use regarding the patient group 
who receive the drug could be retrieved from our minimal datasets, whereas appropriate 
use regarding the application of the drug could only be revealed from our detailed 
datasets. The findings on appropriate use and dynamics in daily practice are presented in 
two categories: diffusion of oxaliplatin and bortezomib and actual treatment in daily 
practice. Table 3.2 provides a summary of these results. Experiences regarding the 
estimation of a valid and precise incremental effectiveness, which is according to the 
Guidance for Outcomes Research also part of establishing appropriate use, are reported 
in section 3.3.  
 
Diffusion of oxaliplatin and bortezomib 
The degree of diffusion of new innovative hospital medicines can amongst others be 
influenced by professional guidelines or enlisting the drug under the policy regulations for 
expensive drugs. Bortezomib was initially recommended as third line therapy, but was 
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subsequently shifted to use in second line. It was possible to reveal this shift in indication, 
the majority of patients receiving bortezomib after the indication shift in 2007, received it in 
second line (56%). It was possible to show the diffusion of bortezomib with the minimal 
dataset retrieved from the HOVON50 database. Although additional data obtained from 
the national DBC registration system (DIS) was incomplete, it illustrated an increased 
usage over the years and showed that all different types of hospitals used bortezomib 
treatment. It was possible to reveal that physicians needed several years before 
bortezomib was common practice by means of exploring the diffusion of bortezomib in 
multiple myeloma patients in the Netherlands with national sales data provided by the 
manufacturer.  
 In stage III colon cancer, it was not possible to show a shift in indication towards 
high risk stage II patients, because we did not collect data for this population. Both pilot 
studies were not designed to retrieve data on off-label use. Subsequent to the inclusion of 
oxaliplatin in national guidelines, we observed rapid diffusion of oxaliplatin in stage III 
disease. Our data showed that oxaliplatin was already completely diffused to all involved 
hospitals of the metastatic colorectal cancer pilot study.  
  
Treatment in daily practice 
Generally, the patient population included in a clinical trial is a homogeneous group and 
may not be representative for a more heterogeneous patient group receiving the drug in 
daily practice. This potentially has an impact on the effectiveness and safety of the drug. 
Therefore, the oxaliplatin stage III colon cancer study compared the baseline 
characteristics of the pilot patients to the inclusion criteria of the pivotal clinical registration 
trial (MOSAIC trial). It could be concluded that the majority of patients (82%) receiving 
oxaliplatin fulfilled these inclusion criteria. Similarly, 71% of the patients included in the 
metastatic colorectal cancer pilot would have been eligible for the CAIRO-1 study and 
baseline patient characteristics of these patients were thus comparable. The bortezomib 
study found some small differences (e.g. age, previous treatment combinations) between 
the baseline characteristics of pilot patients and patients of the pivotal clinical registration 
trial (APEX trial). However, although only slight differences were observed in prognostic 
biomarkers, valid comparisons were difficult as a result of large missing values in the pilot 
study. 
Treatment effectiveness can also differ from the efficacy shown in a clinical trial 
because drugs can be used differently in daily practice. Therefore, it is important to collect 
- 15 - 
data on comparative treatments, treatment regimes, dosages schemes, dose modifications 
and treatment related toxicities. In the stage III oxaliplatin pilot, our data revealed that pilot 
patients were treated according to professional guidelines. Furthermore pilot patients and 
MOSAIC study patients showed similar patterns of dose reductions resulting in 
comparable total cumulative dosages received. We could reveal that haematological- and 
neurotoxicity were the most frequent reasons for dose modifications or treatment 
interruptions; however, reasons for lowering a dose or discontinue treatment were not 
always transparent from medical records. 
On the contrary, in the bortezomib pilot there was a high degree of treatment 
variation and thus the treatment in the comparator arm differed significantly from the 
clinical registration trial. The majority of multiple myeloma patients received similar 
bortezomib regimes. However, daily practice patients received on average lower 
bortezomib dosages (87%) and fewer treatment cycles (4 versus 6) compared to the 
clinical registration trial. In total, 53% of all bortezomib regimes required a dose 
modification. We could identify the most common reported toxicity which required a dose 
modification (i.e., neurotoxicity). However, the reasons for lowering a dose or discontinue 
treatment were not always transparent in medical records. It could indicate that pilot 
patients had lower tolerance or more frequently experienced side-effects. On the other 
hand, it can also mean that physicians are more reluctant to new novel pharmaceuticals. 
Both pilot studies concerned hospital drugs administered intravenously in 
ambulatory care. Therefore, compliance is not expected to be a major issue. Nevertheless, 
the burden of repetitive treatment boluses requiring ambulatory care could possibly have 
an impact on the treatment choice both by physician and patient. 
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3.3 Ability to obtain valid and precise cost-effectiveness estimates 
The decision to enlist bortezomib and oxaliplatin on the expensive drug list was based on 
data obtained in randomised controlled trials. Generally, randomised experiments are 
considered the gold standard for demonstrating clinical efficacy (Garrison et al. 2007). To 
demonstrate clinical efficacy, these trials are designed to be internally valid and to result in 
precise effect measures. Internal validity is the degree to which extent the effect measures 
represent the actual treatment effect in a comparable group of patients. The main threats 
to internal validity include confounding, selection bias and information bias. Furthermore, 
precision of the estimated effects are ensured by large sample sizes of homogeneous 
patient groups. Despite the fact that a randomised controlled trial provides results on the 
efficacy of a treatment obtained under ideal experimental conditions, the applicability of 
these results to the actual effectiveness in a real-world setting can be limited (Drummond 
et al. 2005). Although real-world observational studies can be subject to biases that 
threaten internal validity, the degree of heterogeneity in the study population is more 
representative to the patient population found in daily clinical practice. Consequently, real-
world data obtained from outcomes research can lead to a greater degree of external 
validity and the results are thus more generisable to daily practice compared to clinical trial 
results. This section describes experiences from the pilot studies regarding evidence 
obtained within the three-year time frame of outcomes research and elaborates on the 
precision, internal and external validity and generisability of our pilot outcome measures. 
 
Evidence at Time T=3 from outcomes research and literature 
During the three-year time frame of outcomes research (i.e., time T=3 is time for 
reappraisal after three years), new evidence is generated by outcomes research and by 
new evidence from literature. In the stage III colon cancer pilot study, we could obtain a 
median follow-up time of two years for 391 patients. All relevant data could be obtained in 
the three-year time frame of outcomes research, therefore, we did not experience any time 
restrictions. Information on essential parameters was available, however, the fast diffusion 
rate resulted in incomparable patient groups treated and not treated with oxaliplatin and 
insufficient possibilities to correct for confounding. As a consequence, our pilot study 
sample size (N=391) was not sufficient to obtain precise results as illustrated by large 
confidence intervals. In metastatic colorectal cancer, all relevant data could be obtained 
within the three-year time frame of outcomes research due to the shorter life expectancy of 
- 18 - 
this patient group. However, there was a large degree of missing data on essential 
parameters which limited the possibility to fully correct for confounding. On the other hand, 
considering trial eligible patients only, the oxaliplatin treatment arm and comparator arm 
seemed comparable regarding baseline patient characteristics, limiting the need for 
advanced adjustment methods.  
In the three year time frame for outcomes research more evidence became 
available in the literature. For stage III colon cancer, the pivotal clinical registration trial 
(MOSAIC) had a three years follow-up and provided intermediate endpoints; however, six 
years extended follow-up data provided information on disease free survival and overall 
survival estimates. The registration trial did not report on quality of life and only limited 
information regarding quality of life was published for stage III colon cancer. One study 
reported utility values for various colorectal cancer disease stages (Ness et al. 1999). In 
metastatic colorectal cancer, the post registration CAIRO study measured disease specific 
quality of life by means of the EORTC QLQ-C30 questionnaire. A model to convert these 
QLC-C30 values into utilities in haematological cancer has recently been developed 
(Versteegh et al. 2010). The influence of disease type is expected to be small, the 
validation to colorectal cancer is currently under investigation by the institute for Medical 
Technology Assessment. Furthermore, some new data regarding costs of oxaliplatin 
treatment were published. However, these studies only provided cost data of clinical trials 
and were not based on a Dutch setting. 
 In the bortezomib pilot study, we did experience time restrictions related to the 
three-year outcomes research time frame. In the last few years, there were many 
advances in treatment for multiple myeloma resulting in changes to the professional 
guidelines, which is reflected by the heterogeneity in our data. Consequently, comparisons 
that were relevant at time T=0 were less relevant at time T=3 in outcomes research. 
Overall survival depended on upfront therapy and on the line in which bortezomib was 
administered, resulting in small sample sizes. Furthermore, essential data on prognostic 
factors and treatment responses were often missing in medical records. Patient not treated 
with bortezomib differed in baseline characteristics compared to patients treated with 
bortezomib. Additionally, a high degree of treatment variation was observed, which made it 
impossible to identify a treatment comparator. Small patient numbers limited the ability to 
correct for confounding, and we presumed residual confounding to be present. 
Consequently, our pilot sample size (N=139) was not sufficient to estimate internally valid 
and precise outcome measures.  
- 19 - 
In the three year time frame for outcomes research more evidence became 
available in the literature. Extended follow-up from the clinical registration trial and from 
various ongoing studies provided new evidence on efficacy and effectiveness outcomes. 
Several publications reported more detailed data on toxicity of bortezomib. In contrast, no 
new information became available on costs of bortezomib treatment as well as no new 
information regarding treatment related quality of life.  
 
Modelling and evidence synthesis 
Randomised controlled trials and observational studies are important sources for 
economic evaluations. However, it is almost inevitable to synthesise evidence by means of 
modelling techniques (Buxton et al. 1998; Brennan and Akehurst 2000). The incremental 
cost-effectiveness of a drug depends amongst others on dosage schemes, indication, 
patient characteristics and the selected comparator. The Guidance for Outcomes 
Research suggests to base the real-world incremental cost-effectiveness measure on a 
reanalysis of the valid and if necessary adapted T=0 model (Delwel 2008). 
 We developed a probabilistic Markov model for stage III colon cancer by using a 
NICE model which we adapted and validated for the Dutch setting. Both the clinical 
registration trial (MOSAIC) and the pilot study assessed disease free survival as primary 
endpoint. We could use the overall survival from the extended follow-up data of the 
registration trial to extrapolate intermediate endpoints to life years gained. Furthermore, it 
was necessary to use the comparator arm of the registration trial in our model since pilot 
patients not treated with oxaliplatin were not comparable to pilot patients receiving 
oxaliplatin. The latter group, especially patients eligible for the registration trial, had similar 
baseline patient characteristics as patients from the registration trial. Evidence synthesis 
was not performed in the metastatic colon cancer pilot study; we concluded that synthesis 
would not result in an important change in the incremental cost-effectiveness ratio.  
We did not develop a model for the bortezomib pilot study to estimate an 
incremental cost-effectiveness measure. We only compared the results of the pilot study to 
the clinical registration trial. We assume that it would have been possible to develop a 
model, requiring evidence synthesis. Nevertheless, it is debatable as to whether any 
synthesis would have led to a valid and precise estimate of the incremental cost-
effectiveness of bortezomib versus other treatments. 
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Internal validity and precision of cost-effectiveness estimates 
As mentioned before, randomised clinical trials generally provide internally valid and 
precise outcome measures (such as clinical effectiveness), whereas heterogeneity in 
outcomes research (such as practice variation and rapid diffusion) can lead to biases that 
threaten internal validity and precision. We developed a model for stage III colon cancer 
which made it possible to extrapolate intermediate outcome measures and synthesise 
evidence from various sources. Therefore, we concluded that it was possible to obtain an 
internally valid incremental cost-effectiveness ratio of oxaliplatin in stage III disease. Our 
relatively small confidence intervals showed that we were able to estimate a precise 
estimate. As mentioned before, evidence synthesis was not performed in the oxaliplatin 
pilot study for metastatic colon cancer. The pilot patient population was similar to the trial 
patient population; we could therefore conclude that evidence synthesis would not result in 
an important change in the incremental cost-effectiveness ratio of oxaliplatin in metastatic 
colorectal cancer. 
 In contrast, in the bortezomib pilot study, patients treated with bortezomib were not 
comparable with patients not treated with bortezomib. Unfortunately, we were not able to 
correct for confounding and other biases, partly due to small sample sizes. The registration 
trial compared bortezomib with dexamethasone and many treatment crossovers occurred 
during the trial. A great deal of treatment variation was seen in our pilot study, and the 
different treatment combinations and thus the treatment comparator was not similar to the 
comparators used in the pivotal clinical registration trial or any other clinical trial. 
Consequently, we could not establish an internally valid and precise incremental cost-
effectiveness ratio for bortezomib, let alone produce an estimate that could be compared 
with a cost-effectiveness ratio based on the pivotal clinical trial results. Although we did not 
develop a model for this pilot, we suspect that a model would not guarantee the ability to 
establish a valid and precise estimate of the incremental cost-effectiveness of bortezomib 
versus other treatments. In future research, we aim to perform evidence synthesis and 
investigate the feasibility to establish an internally valid outcome measure. 
 
External validity and generisability of cost-effectiveness estimates 
In contrast to homogeneous patient groups included in randomised clinical trials, data from 
outcomes research better represents the heterogeneity found in daily clinical practice and 
can thus lead to a greater degree of external validity and generisability of the results to the 
disease population in daily practice. In stage III colon cancer, we could conclude that it 
- 21 - 
was possible to estimate an externally valid incremental cost-effectiveness ratio based on 
our representative population-based sample. It should be noted that we did not collect data 
on stage II disease and thus cannot guarantee an externally valid estimate of oxaliplatin if 
its usage is shifted to high risk stage II patients since this might affect the incremental cost-
effectiveness estimate of oxaliplatin. Furthermore, we were able to estimate an externally 
valid incremental cost-effectiveness ratio of oxaliplatin in metastatic colorectal cancer 
since also this pilot population was a representative sample. It is worth to mention that we 
only included stage IV patients and did not collect data on patients metastasising from 
stage I, II or III disease. However, we are confident that our study results are generalisable 
to the entire metastatic colorectal cancer population in the Netherlands based on 
published literature showing these groups generally to be comparable. 
In the bortezomib pilot study, we concluded that our cost-effectiveness estimates 
expressed in cost per month of survival are highly likely to be externally valid for younger 
multiple myeloma patients since the heterogeneity found in the pilot data is representative 
of that found in actual clinical practice of treatment for multiple myeloma. However, due to 
small sample sizes, incomparability of pilot patients and practice variation we could not 
estimate an incremental cost-effectiveness ratio of bortezomib compared to other 
treatments using the patient population included in this study and were therefore unable to 
estimate an externally valid incremental cost-effectiveness ratio of bortezomib.  
 
- 22 - 
 
Pi
lo
t b
or
te
zo
m
ib
 in
 M
M
Pi
lo
t o
xa
lip
la
tin
 in
 s
ta
ge
 II
I C
C
Pi
lo
t o
xa
lip
la
tin
 m
et
as
ta
tic
 C
R
C
K
no
w
le
dg
e 
at
 ti
m
e 
T=
3
D
at
a 
fr
om
 o
ut
co
m
es
 re
se
ar
ch
   
   
W
er
e 
m
is
si
ng
 v
al
ue
s 
on
 e
ss
en
tia
l p
ar
am
et
er
s
   
   
pr
es
en
t?
Ye
s,
 p
er
fo
rm
an
ce
 s
ta
tu
s 
an
d 
so
m
e 
ot
he
r p
ro
gn
os
tic
 
fa
ct
or
s,
 tr
ea
tm
en
t r
es
po
ns
e 
an
d 
du
ra
tio
n.
Y
es
, p
er
fo
rm
an
ce
 s
ta
tu
s.
Y
es
, p
er
fo
rm
an
ce
 s
ta
tu
s 
an
d 
so
m
e 
pr
og
no
st
ic
 la
bo
ra
to
ry
 
va
lu
es
.
   
   
W
er
e 
tre
at
m
en
t a
nd
 c
om
pa
ra
to
r a
rm
s 
   
   
co
m
pa
ra
bl
e 
re
ga
rd
in
g 
ba
se
lin
e 
ch
ar
ac
te
ris
tic
s?
N
o
N
o
Y
es
, r
ea
so
na
bl
e.
   
   
W
as
 th
e 
sa
m
pl
e 
po
pu
la
tio
n 
su
ffi
ci
en
t t
o 
ob
ta
in
 
   
   
st
at
is
tic
al
 p
ow
er
?
N
o
N
o,
 la
rg
e 
co
nf
id
en
ce
 in
te
rv
al
s.
Y
es
, r
ea
so
na
bl
e.
   
   
W
as
 it
 p
os
si
bl
e 
to
 c
or
re
ct
 fo
r c
on
fo
un
di
ng
?
N
o
N
o,
 d
ue
 to
 fa
st
 d
iff
us
io
n 
ra
te
 a
nd
 li
m
ite
d 
po
w
er
.
Li
m
ite
d 
co
nf
ou
nd
in
g,
 b
ut
 to
o 
m
an
y 
m
is
si
ng
 v
al
ue
s 
to
 
fu
lly
 c
or
re
ct
 fo
r c
on
fo
un
di
ng
.
D
at
a 
fr
om
 li
te
ra
tu
re
   
   
W
as
 it
 p
os
si
bl
e 
to
 o
bt
ai
n 
re
le
va
nt
 a
dd
iti
on
al
 d
at
a 
   
   
re
ga
rd
in
g:
   
   
   
  (
in
cr
em
en
ta
l) 
ef
fic
ac
y?
Ye
s,
 e
xt
en
de
d 
fo
llo
w
-u
p 
an
d 
va
rio
us
 n
ew
 (o
ng
oi
ng
) 
st
ud
ie
s.
Y
es
, e
xt
en
de
d 
fo
llo
w
-u
p 
an
d 
va
rio
us
 n
ew
 (o
ng
oi
ng
) 
st
ud
ie
s.
Y
es
, C
AI
R
O
 s
tu
dy
 s
im
ul
ta
ne
ou
sl
y 
in
 s
im
ila
r p
op
ul
at
io
n.
   
   
   
  (
in
cr
em
en
ta
l) 
ef
fe
ct
iv
en
es
s?
Ye
s
Y
es
Y
es
   
   
   
  (
in
cr
em
en
ta
l) 
Q
ua
lit
y 
A
dj
us
te
d 
Li
fe
 Y
ea
rs
?
N
o
M
od
er
at
e,
 m
ay
be
 n
ot
 re
pr
es
en
ta
tiv
e,
 u
til
ity
 v
al
ue
s 
av
ai
la
bl
e.
Y
es
, i
nd
ire
ct
 u
til
iti
es
 (Q
LC
-C
30
).
   
   
   
  t
ox
ic
ity
?
Ye
s
Y
es
Y
es
   
   
   
  (
in
cr
em
en
ta
l) 
co
st
s?
N
o
N
o
N
o
D
id
 th
e 
th
re
e-
ye
ar
 ti
m
e 
fr
am
e 
of
 o
ut
co
m
es
 re
se
ar
ch
 
le
ad
 to
 s
er
io
us
 re
st
ric
tio
ns
?
Ye
s,
 ra
pi
d 
ad
va
nc
es
 in
 tr
ea
tm
en
ts
.
N
o
N
o
M
od
el
lin
g 
an
d 
da
ta
 s
yn
th
es
is
   
   
W
as
 it
 n
ec
es
sa
ry
 to
 d
ev
el
op
 a
 m
od
el
?
Ye
s,
 b
ut
 n
ot
 c
on
du
ct
ed
.
Y
es
, e
xt
ra
po
la
tio
n 
fro
m
 in
te
rm
ed
ia
te
 e
nd
po
in
ts
.
N
o
   
   
W
as
 it
 p
os
si
bl
e 
to
 d
ev
el
op
 a
 m
od
el
?
Ye
s,
 w
ou
ld
 re
qu
ire
 d
at
a 
sy
nt
he
si
s,
 w
ou
ld
 n
ot
 g
ua
ra
nt
ee
 
su
ffi
ci
en
tly
 v
al
id
 a
nd
 p
re
ci
se
 e
st
im
at
es
.
Y
es
, a
da
pt
ed
 v
er
si
on
 o
f N
IC
E 
m
od
el
.
Y
es
, b
ut
 n
ot
 c
on
du
ct
ed
.
   
   
W
as
 it
 n
ec
es
sa
ry
 to
 c
om
bi
ne
 d
at
a 
so
ur
ce
s?
 
Ye
s,
 b
ut
 n
ot
 c
on
du
ct
ed
.
Y
es
, b
ec
au
se
 o
f i
nc
om
pa
ra
bl
e 
co
m
pa
ra
to
rs
.
N
o
   
   
W
as
 it
 p
os
si
bl
e 
to
 c
om
bi
ne
 d
at
a 
so
ur
ce
s?
N
ot
 e
xa
m
in
ed
.
Y
es
Y
es
, b
ut
 n
ot
 c
on
du
ct
ed
.
In
te
rn
al
 a
nd
 e
xt
er
na
l v
al
id
ity
   
   
W
as
 it
 p
os
si
bl
e 
to
 o
bt
ai
n 
an
 in
te
rn
al
ly
 v
al
id
 
   
   
in
cr
em
en
ta
l c
os
t-e
ffe
ct
iv
en
es
s 
m
ea
su
re
?
M
os
t l
ik
el
y 
N
o,
 b
ut
 n
ot
 e
xa
m
in
ed
.
Y
es
M
os
t l
ik
el
y 
Y
es
, b
ut
 n
ot
 e
xa
m
in
ed
.
   
   
W
as
 it
 p
os
si
bl
e 
to
 o
bt
ai
n 
a 
pr
ec
is
e 
in
cr
em
en
ta
l 
   
   
co
st
-e
ffe
ct
iv
en
es
s 
m
ea
su
re
?
M
os
t l
ik
el
y 
N
o,
 b
ut
 n
ot
 e
xa
m
in
ed
.
Y
es
M
os
t l
ik
el
y 
Y
es
, b
ut
 n
ot
 e
xa
m
in
ed
.
   
   
W
as
 it
 p
os
si
bl
e 
to
 o
bt
ai
n 
an
 e
xt
er
na
lly
 v
al
id
   
   
in
cr
em
en
ta
l c
os
t-e
ffe
ct
iv
en
es
s 
m
ea
su
re
?
M
os
t l
ik
el
y 
N
o,
 b
ut
 n
ot
 e
xa
m
in
ed
.
Y
es
M
os
t l
ik
el
y 
Y
es
, b
ut
 n
ot
 e
xa
m
in
ed
.
Ta
bl
e 
3.
3.
 E
xp
er
ie
nc
es
 re
ga
rd
in
g 
th
e 
ab
ili
ty
 to
 o
bt
ai
n 
va
lid
 a
nd
 p
re
ci
se
 c
os
t-e
ffe
ct
iv
en
es
s 
es
tim
at
es
- 23 - 
4. Discussion 
Although an early assessment of innovative drugs ensures access to promising drugs, it 
implies that policymakers face uncertainty when deciding on value for money. In the initial 
assessment phase, uncertainty may exist on actual clinical therapeutic value, real-world 
cost-effectiveness, and budget-impact. The Dutch policy regulation aims to reduce the 
uncertainties about promising but expensive hospital medicines but also ensures 
undelayed access by evaluating these medicines after a certain number of years of initial 
coverage. Initially, these policy regulations focused on a three-year time period before a 
reassessment would take place, but this has been changed to four years. The decision in 
the re-appraisal phase about whether or not to continue financial compensation for 
hospitals is based on the results of outcomes research regarding appropriate use and real-
world cost-effectiveness. Outcomes research in this particular context is new in Dutch 
policy making. Therefore, experience in the application of outcomes research is lacking. 
The Dutch Health Care Insurance Board published the Guidance for Outcomes Research 
in collaboration with a working party of experts from relevant disciplines. This report is a 
practical addendum to this Guidance and provides empirical evidence about 
methodological issues related to outcomes research. We investigated these 
methodological issues addressing three research categories: 1) study design and data 
collection; 2) appropriate use and dynamics in daily practice; 3) ability to obtain valid and 
precise cost-effectiveness estimates. Two pilot outcomes research studies formed the core 
of this research. These studies investigated the appropriate use and cost-effectiveness of 
two expensive hospital drugs (i.e., bortezomib and oxaliplatin) in real-world clinical practice 
in the Netherlands.  
 
Experiences from the pilot studies 
Two different data sources for recruiting pilot patients (i.e., trial database versus population 
based registry) and two different types of diseases (i.e., multiple myeloma and colon and 
colorectal cancer) were intentionally selected in order to assess methodological issues 
from a broad perspective. Despite the strong recommendations in the Guidance for 
Outcomes Research to use a prospective research design, both pilot studies adopted a 
retrospective study design because they needed to be completed within a short time 
period to obtain empirical evidence as addendum to the Guidance for Outcomes 
Research.  
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Both pilot studies retrospectively collected detailed data from hospital medical 
records. The studies were able to examine diffusion of the drugs, baseline patient 
characteristics, application of treatment regimes, dose modifications, treatment related 
toxicities and direct healthcare costs. A high degree of treatment variation was revealed in 
the bortezomib pilot study, whereas the oxaliplatin pilot study showed that patients were 
treated reasonably similar compared to clinical studies. In the oxaliplatin pilot study for 
stage III colon cancer, evidence synthesis using modelling techniques, evidence from 
outcomes research and evidence from the literature enabled the estimation of a valid and 
precise incremental cost-effectiveness ratio. Although evidence synthesis was not 
performed in the bortezomib study, it is questionable as to whether any synthesis would 
have led to a valid and precise estimate of the incremental cost-effectiveness of 
bortezomib versus other treatments due to small samples sizes, incomparability of 
patients, practice variation and frequent missing values. 
 
Limitations of the pilot studies and implications for outcomes research 
Taking into account the flowchart for a pragmatic research design and the 
recommendations from the Guidance for Outcomes Research, both pilot study designs 
have their limitations. To begin with, both pilot studies had to apply a retrospective study 
design because these studies had to be completed within a short time period. The use of a 
retrospective design meant that some of the techniques and strategies normally available 
in outcomes research were simply impossible to apply. First, we were unable to collect 
data on Health Related Quality of Life (HRQOL) since this is inherently impossible in a 
retrospective study design. Therefore, we cannot provide empirical conclusions about 
HRQOL data collection in outcomes research. Generally, quality of life is viewed by 
policymakers as an important factor in health outcomes and its use is also strongly 
recommended by the Guidance for Outcomes Research. Although we could not collect 
HRQOL data on Dutch stage III colon cancer patients, we were able to integrate utility data 
from the literature in our analyses and found that this did not change the conclusions about 
the cost-effectiveness of oxaliplatin use. Regarding oxaliplatin use for metastatic colorectal 
cancer, the post registration CAIRO study provided disease specific quality of life data 
(QLQ-C30) on Dutch patients, which meant that there was little need to collect real-world 
quality of life data. The situation with HRQOL in relapsed/refractory multiple myeloma 
patients was different: there is currently no evidence in the literature of any differences in 
HRQOL between treatment strategies. Evidence synthesis to produce a valid and precise 
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estimate of the incremental cost-effectiveness of a drug is only as good as the available 
data. Given the lack of good HRQOL data on multiple myeloma patients, it would have 
been valuable to have collected real-world HRQOL data to facilitate the assessment of 
bortezomib. 
 The Guidance for Outcomes Research includes the recommendation to use a 
societal perspective in the cost-effectiveness analysis. However, a retrospective study 
design limits the feasibility of collecting data on all costs, and this limitation may endanger 
the validity of the cost-effectiveness estimates of a drug. Since both pilot studies adopted a 
retrospective design, we cannot report any findings regarding the application of a societal 
perspective in outcomes research. A prospective study design would have made it 
possible to use health and labour questionnaires to assess costs of absence from work 
and productivity losses of paid and unpaid work. However, we expect that the inclusion of 
productivity costs would have had limited impact on the results of our pilot studies because 
multiple myeloma, colon and metastatic colorectal cancer most often occur in the elderly 
population. Although the bortezomib pilot study only included younger multiple myeloma 
patients, the majority of multiple myeloma patients do not work due to the disease severity 
and they will not return to work after treatment. We did not collect data on direct non-
medical costs (such as travel costs), even though this might have been possible by using 
postal codes. Although we realise that the exclusion of indirect healthcare costs and 
(in)direct non-medical costs might have affected our results somewhat, we believe that 
their exclusion did not significantly influence the conclusions about the cost-effectiveness 
of oxaliplatin and bortezomib. 
Another consequence of a retrospective study design is the inability to randomly 
allocate patients to receive a specific treatment. This meant that even though the flowchart 
in the Guidance for Outcomes Research refers to an option for a post registration RCT, 
this option was simply not possible in our pilot studies. Therefore, we can only speculate 
about its potential added value. If a prospective study design had been applied in the 
bortezomib study, it could have been theoretically possible to randomise multiple myeloma 
patients in daily practice to receive either bortezomib or lenalidomide (i.e., another 
expensive (orphan) drug for the same indication). We believe that RCTs should be 
seriously considered when there are new indications of a drug (e.g. the CAIRO post-
registration study for oxaliplatin in metastatic colorectal cancer). 
A retrospective design can result in greater problems with bias and confounding 
compared to a prospective design. However, selection bias was minimised by our use of 
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representative samples of the Dutch patient population (i.e., HOVON50 database and 
Comprehensive Cancer Centres registry) and information bias was addressed by 
additionally collecting detailed data from hospital medical records. Consequently, we 
believe that the retrospective research design did not significantly affect our conclusions 
about the real-world cost-effectiveness of oxaliplatin and bortezomib.  
Although a retrospective design has its shortcomings, it also has its advantages. It 
requires less time to retrospectively collect data because data can be retrieved at one time 
instead of many points in time. In addition, the time required to set up the outcomes 
research study (e.g. research design, permission from medical ethics committees, 
collaboration physicians) does not reduce the amount of time that is available for data 
collection. Both pilot studies revealed that a retrospective design already requires a 
significant amount of time for data collection. Additionally, the bortezomib study showed 
that if data is retrospectively collected, retrieved follow-up of patients can be extended 
beyond the three-year time frame. Although a prospective research design offers greater 
control over data collection, all observational designs rely on information that is provided 
by others (e.g. physicians). For example, the Population HAematological Registry for 
Observational Studies (PHAROS) is an observational population based registry for 
haematological diseases that was created to facilitate outcomes research. This registry 
aims to monitor dynamics in daily practice, treatment regimes and survival. Although the 
PHAROS registry prospectively collects patient level data, we expect that missing values 
(e.g. regarding essential prognostic factors, universal response criteria) are still present 
since data are collected from medical records by staff at the Comprehensive Cancer 
Centres. Consequently, it is not only necessary to set up an appropriate prospective 
registry collecting essential data but also to involve physicians who treat the patients and 
report in medical records. Nevertheless, registries may help to obtain information on a 
sufficient number of patients and ensure the usage of uniform response criteria and 
standardised toxicity grading systems.  
One other limitation about the pilot studies is that a value of information (VOI) 
analysis was not performed. A VOI analysis provides information on the costs forgone due 
to incorrect decision-making under uncertainty (Claxton et al. 2004). It was expected that 
dynamics in daily practice of multiple myeloma would have limited the use of a VOI 
analysis in the bortezomib pilot study. However, it is possible that a VOI analysis could 
have been relevant for the oxaliplatin pilot study, particularly in stage III disease. We are 
therefore currently investigating in another study if a VOI analysis in the stage III colon 
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cancer pilot study could have resulted in targeted data collection and thereby improved the 
efficiency of the cost-effectiveness analysis study. 
 
Other considerations regarding outcomes research 
It is generally acknowledged that an appropriate research design to reduce the uncertainty 
at the initial coverage decision should clearly define the specific aim of evidence 
development (Tunis and Pearson 2006; Carbonneil, Quentin, and Lee-Robin 2009; Towse 
and Garrison 2010; Menon et al. 2010; McCabe et al. 2010; MacLeod and Mitton 2010; 
Trueman, Grainger, and Downs 2010). Carbonneil et al. (2009) identified four critical 
success factors for access with evidence generation: coordination between decision-
makers, medical and HTA agencies; methodological guidance; funding; and an 
implemented regulatory framework. Our pilot studies provide empirical findings to 
strengthen the methodological guidance. Since we only conducted pilot studies for two 
expensive drugs, we can only base our conclusions on these two studies. There is no 
consensus in the literature on the time frame required for evidence collection (Hutton, 
Trueman, and Henshall 2007; Tunis and Chalkidou 2007; Drummond, Manca, and 
Sculpher 2005). The oxaliplatin pilot study showed that a three year frame was sufficient if 
extended follow-up from the pivotal registration trial was used in addition to our real-world 
pilot data. In contrast, the bortezomib pilot revealed that advances in treatment and shifts 
in indication limited the relevance of the uncertainty at T=0 for the decision to be made at 
T=3. As result, the degree of uncertainty about oxaliplatin at time T=0 was reduced by time 
T=3, whereas the degree of uncertainty about bortezomib possibly increased between T=0 
and T=3. This implies that both an appropriate research design for outcomes research and 
an appropriate time-frame can depend on the type of disease and the treatment under 
investigation. If this is the case, then the regulatory reimbursement agency will need to be 
more flexible regarding the quality of outcomes research study plans. It is important to 
realise that the time frame to perform outcomes research not only includes the time 
needed for data collection, but also the time needed to design and implement the study 
and/or disease registry (including administrative steps such as approval by medical ethics 
committees) and the time needed for data analysis and reporting. Based on our 
experiences, we estimate that the study design and implementation phase would involve 
an average of three to six months (which could in theory be completed before time T=0), 
whereas the data analysis and reporting phase could require three to six months. 
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Generalisability to other expensive hospital medicines 
We investigated methodological issues related to the outcomes research requirement of 
the policy regulations for expensive medicines addressing three research categories: 1) 
study design and data collection; 2) appropriate use and dynamics in daily practice; 3) 
ability to obtain valid and precise cost-effectiveness estimates. Although we only 
conducted pilot studies for two expensive drugs, we assume that our findings are most 
likely generalisable to other (orphan) drugs enlisted on the policy regulation for expensive 
hospital medicines. This is due to the fact that we intentionally selected two different types 
of diseases to assess these methodological issues from a broad perspective. Many of the 
enlisted expensive medicines are to be used for different types of cancer, but there are 
also other drugs on the list which are indicated for other diseases such as rheumatoid 
arthritis, macular degeneration, multiple sclerosis, severe asthma and multiple organ 
failure sepsis. We expect that the limitations of a retrospective research design can have a 
different impact on different diseases. In our pilot studies we believe that our retrospective 
research design did not significantly affect our research outcomes. However, survival is an 
essential outcome in haematological and colorectal cancer patients, whereas quality of life 
is a more appropriate primary outcome measure for other diseases such as rheumatoid 
arthritis. Consequently, appropriate outcome measures (e.g. intermediate versus final 
endpoints) are important decision factors for the study design (retrospective versus 
prospective). Additionally, we concluded that the use of a healthcare sector perspective 
did not significantly affect our results about the cost-effectiveness of oxaliplatin or 
bortezomib since we expected that treatment with these drugs would not have an 
important impact on indirect health care costs and (in)direct non-medical costs. However, it 
is possible that treatment with expensive hospital medicines could have an impact on 
indirect health care costs and (in)direct non-medical costs in other disease types (e.g. 
rheumatoid arthritis, multiple sclerosis). Therefore, it is important to have a comprehensive 
understanding of the disease and the treatment effect in order to design an appropriate 
outcomes research study. We believe that it is possible to collect real-world data that 
provides evidence on appropriate use and dynamics in daily practice for any of the listed 
drugs. However, the data needed for this type of evidence may include detailed data that 
need to be retrieved from hospital medical records. Regarding orphan drugs, it might be 
necessary to set up an international registry in order to obtain a sufficient amount of real-
world data. One example of such a registry is the Pompe Registry to track the natural 
course of Pompe disease. As mentioned before, we suggest that the most appropriate 
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time frame for evidence development will depend on the treatment and the treatment 
indication. Furthermore, it is essential to realise that it might not be feasible to estimate a 
valid and precise incremental cost-effectiveness ratio for some indications, even if data are 
combined from various sources. This necessitates flexibility from the regulatory decision 
authority when assessing the quality of outcomes research proposals. 
 
Recommendations 
In the context of Dutch policy regulations for expensive medicines, the aim of outcomes 
research is to reduce the uncertainty about the cost-effectiveness of a drug, which exists 
at the time of the initial coverage decision (i.e., T=0). Based on our findings in both pilot 
studies, we recommend that the study plan should include a clear statement of how the 
data collection will reduce uncertainty for decision makers at the reappraisal time. 
Comprehensive knowledge of the disease and the treatment, early modelling and/or VOI 
can assist in the identification of important knowledge gaps. This implies that policy 
regulations in outcomes research require flexibility. As both of our pilot studies revealed, 
there is not just one formula for evidence building when it comes to drugs for different 
diseases and indications; customisation is necessary. Furthermore, we recommend that 
the Guidance for Outcomes Research should further refine the definition of appropriate 
use. Establishing evidence on appropriate use should address two research questions: 
who receives the drug and how is the drug used in daily practice? It is important to realise 
that the first question (“the who”) can require a minimal data set whereas the second one 
(“the how”) will require detailed data. Although appropriate use of a drug influences the 
degree of effectiveness of that drug in daily practice, we suggest that an incremental cost-
effectiveness measure should be based on a synthesis of the evidence drawn from 
different sources, including real-world experiences with the drug, extended follow-up 
results from the pivotal clinical registration trial and other evidence available from the 
literature. Outcomes research studies provide valuable information about the application of 
the drug in daily practice and thereby enable assessments of appropriate use and 
dynamics in daily practice. However, in order to obtain a valid and precise incremental 
cost-effectiveness measure, real-world evidence should be synthesised with evidence 
from randomised controlled trials by using modelling and statistical techniques. It is 
essential to realise that some indications might have many treatment advances during the 
first three years that a drug can be used for a particular indication, and these advances will 
result in a high degree of dynamics (i.e., rapid changes in treatment) and practice 
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variation. We therefore suggest that it might be impossible to establish sufficiently valid 
and precise estimates of the incremental effectiveness and cost-effectiveness of a drug for 
some indications. As a consequence, we recommend that a more customised outcomes 
research design is required if a high level of dynamics in daily practice is expected in the 
first three years after a drug has been added to the expensive medicines list.  
Finally, active physician participation and patient registries can help to obtain 
sufficient numbers of similarly treated patients, enable uniform response criteria, support 
data collection and thereby facility outcomes research. Some registries may even contain 
patient-related outcomes such as HRQOL. However, while disease or indication specific 
registries can facilitate the collection of relevant data, they cannot resolve all of the 
drawbacks of data collection from medical records. This is another reason why the most 
appropriate outcomes research study plan for a particular drug requires a good 
understanding of the merits and shortcomings of the different data sources. 
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